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1 Introduction 
1.1 Biological roles of N- and O-glycosylation 
Protein glycosylation is regarded as one of the most complex post-translational 
modifications.[1-2] Glycans are found on diverse protein classes and are often located on the 
extracellular side of the cell-surface. Toxins, lectins, antibodies, hormones, viruses and 
bacteria are interacting with membrane bound glycoproteins and are thereby participating in 
various biological processes.[3-5] Glycoproteins are also involved in intracellular interactions, 
for instance O-GlcNAcylation play a major role in signal transduction. Protein glycosylation 
may further influence protein folding and controlling resistance to proteases.[6-7] 
Two major types of protein glycosylation exist, N-glycosylation and O-glycosylation. In 
N-glycosylation the glycans are attached to asparagine (Asn) through an amide bond and in 
O-glycosylation the glycan structure is linked through an O-glycosidic bond to serine (Ser), 
threonine (Thr) and sometimes to tyrosine (Tyr), hydroxylysine or hydroxyproline. The 
biosynthetic pathways of these modifications are significantly different. In N-glycan 
biosynthesis[8] a presynthesized triantennary tetradecasaccharide (Glc3Man9GlcNAc2) is 
transferred from dolichol pyrophosphate to an Asn residue of the newly produced protein 
employing the enzyme oligosaccharyl transferase (OST).[9] The terminal glucose residues are 
then enzymatically removed in a sophisticated process involving specific chaperones and are 
forming the common pentasaccharide core (Man3GlcNAc2). The pentasaccharide are then 
further extended to obtain high mannose-, hybrid- or complex type N-glycans (Figure 1 A). A 
consensus peptide sequence consisting of Asn-Xaa-Ser/Thr are usually found for recognition 
of sites that are modified with N-glycans, Xaa can be any of the 20 natural amino acids 
except proline. In O-glycoprotein biosynthesis single monosaccharides are directly attached 
to the Ser/Thr or Tyr, which usually are further extended by sequential enzymatic addition of 
up to 3-9 sugar residues. The mucin-type O-glycosylation is the most common modification, 
which is initiated with the attachment of an α-linked N-acetylgalactosaminyl (GalNAc) 
residue to Ser or Thr (Tn-antigen). The GalNAc residue is usually extended with GlcNAc, Gal 
or GalNAc in 3- or 6-position forming core 1-8 structures.[10] These core structures can be 
further extended and often carry terminal sialylation or fucosylation (Figure 1 B). In the 
recently discovered O-GlcNAcylation,[11] found on intracellular glycoproteins, a 
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INTRODUCTION 
 N-acetylglucosamine monosaccharide is usually β-linked to Ser/Thr without further 
extension (Figure 1 C). 
 
Figure 1．Examples of typical N- and O-linked glycans. 
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INTRODUCTION 
 1.2 General introduction to carbohydrate synthesis 
1.2.1 Common protecting groups 
An optimal protecting group strategy is essential during synthesis of complex 
oligosaccharides. By modulation of the protecting groups under different protection/ 
deprotection conditions, highly functionalized monosaccharide units could be designed and 
applied in coupling reactions forming larger oligosaccharides. [12] 
Starting from unprotected D-glucose, D-mannose or D-galactose monosaccharides, the first 
step often involves the protection of the anomeric center, since the cyclic hemiacetal can 
otherwise be ring opened, changing anomeric configuration or switch from hexose to 
furanose rings in solution. The conformation of the coupling product can be controlled by 
different methods (Scheme 1). In general, the α-anomer is thermodynamically more stable, 
due to the anomeric effect,[13-15] while the β-anomer is more reactive and typically generate 
kinetic products. 
 
Scheme 1. α/β anomers of the pyranose ring. 
An example is the synthesis of β-acetylated glucose under kinetic control, which is preformed 
by heating and refluxing glucose together with sodium acetate in acetic anhydride. The 
sodium acetate causes a rapid anomerization of the free sugar at high temperature resulting 
in acetylation of the more reactive β-anomer. Selective α-acetylation can perform under 
thermodynamic control by treatment of D-galactose with acetic anhydride and Lewis acid 
catalysis. Acetylation with acetic anhydride in pyridine usually gives the peracetylated 
product that retains the anomeric configuration found in the parent free sugar. 
The selective protection of remaining monosaccharide hydroxyl groups is then proceeding. 
The choice of protecting groups applied on the saccharide would influence the 
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 regioselectivity and reactivity in the next coming coupling reactions. In this thesis, several 
classes of common protecting groups are used for sugar ring protection. 
Ester protections: acetyl, benzoyl; 
Ether protections: benzyl, p-methoxybenzyl, trityl, allyl, tert-butyldimethylsilyl; 
Acetal protections: benzylidene acetal, and butane diacetal. 
The acetyl group is the most widely applied protection group in carbohydrate synthesis, 
which is easy to form[16] and remove[17] by mild acid or base hydrolysis. Acetylation or 
deacetylation reactions are usually not performed with a particular selectively within the 
sugar ring, with exception of the anomeric acetyl group that selectively react forming a 
desired donor or stable protection of the position. The acetyl groups may then be removed 
followed by more selective protection of the ring or the acetylated donor is directly applied 
in coupling reactions. When acetyl protection is combined with other protecting group 
functionalization, the order of protection and deprotection needs to be considered, acyl 
migration may otherwise be a problem since the acetyl protecting group have a tendency of 
moving towards the more reactive positions within the ring.[18] The benzoyl protecting group 
behaves rather similar to acetyl protection, but is more stable. 
Ether protection, is more stable than esters and in the case of benzyl (Bn) protection, which 
is the most common ether protection, it even survive strong acid/base conditions. The 
generation of benzyl ether protection often involves treatment with base (e.g. NaH) and 
halogenated reagents such as benzyl bromide.[19] By using dibutyltin oxide or tributyltin oxide 
regents, the benzyl ether protecting groups can be introduced with high selectively.[20] 
For removal of the benzyl group protection, catalytic hydrogenation with 10% palladium on 
carbon (Pd(C)) is commonly used.[21] In order to introduce a protecting group that can be 
removed under milder conditions p-methoxybenzyl protection might be an alternative, 
which can be cleaved by CAN/DDQ treatment or diluted TFA.[21] The trityl protecting group, is 
even less stable and can be removed using 80% acetic acid. The allyl group is another option, 
which is selectively removed using a Rh(I) or Ir(II) catalyst, e.g. Wilkinson’s/Baudry catalyst 
for double bond isomerization and followed by acid hydrolysis.[22] Further, 
tert-butyldimethylsilyl (TMS)[23] or similar reagents,[24] are commonly used in selective 6-OH 
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 protection of the primary hydroxyl and is removed by acid hydrolysis
[25-26] or by using a 
fluoride source.[27-28] 
To selectively protect two hydroxyl groups simultaneously, acetal protection can be 
introduced, for instance by treatment with ketones or aldehydes in weak acidic conditions. 
The Benzylidene acetal is often used for 4,6-O-protection and by selective ring opening the 
formation of 4-OH or 6-OH products can be controlled. The cleavage of the benzylidene 
acetal by using borane and TMSOTf would favor formation of a free hydroxyl on the less 
sterically hindered 6-position, alternatively LiAlH4, AlCl3 in ether can be used.
[29] On the other 
hand treatment with sodium cyanoborohydride in 2M HCl result in a free hydroxyl in 
4-position (Scheme 2).[30] 
 
Scheme 2. Selective benzylidene acetal ring opening. i) 1 M BH3 in THF, TMSOTf, DCM, 0 °C 30 min, r.t. 16 h; 
ii) sodium cyanoborohydride, 2N HCl in Et2O, THF, 0 °C 30 min. 
The choice of protecting group strategy on the donor and acceptor saccharide residues may 
further be important to increase or decrease the reactivity or influence the stereoselectivity 
during coupling of the saccharide building blocks. For instance glycan donors protected with 
acetate groups (in particular in C2), which are electron withdrawing groups, disfavor the 
build-up of positive charge in the anomeric center (C1) and stabilize the saccharide. In 
contrast benzyl groups are electronically passive and do not hinder the build-up of positive 
charge in the pyranose ring. Differences in stability of in particular the glycan donors can in 
this way be used to modulate the reactivity in coupling reactions. These differences in 
reactivity influenced by protecting groups was initially studied by Paulsen[31] and later the 
armed/disarmed concept was described by Fraiser-Reid. [32] 
In certain occasions it is better to skip protection of hydroxyl groups and instead make use of 
the individual OH group nucleophilicity within the pyranose ring. Thereby avoiding 
unnecessary protection and deprotection steps. The differences in hydroxyl group reactivity 
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 may further be used to selectively introduce protecting groups within the ring.  Some 
general rules describing OH group reactivity within the pyranose ring is summarized below 
(Scheme 3).[33] 
Reactivity of the hydroxyl groups in the pyranose ring: 
i) 1° OH > 2° OH; 
ii) Equatorial OH > axial OH; 
iii) Equatorial OH with vicinal axial OH (or OR) > Equatorial OH without vicinal axial OH (or 
OR). 
 
Scheme 3. Expected nucleophilicity of different monosaccharide residues. 
In conclusions, by combining different protecting group methods, selective protected 
monosaccharide units are obtained. The protecting group strategy should be well planned 
and reducing the number of protection and deprotection steps. In particular, a unified 
protection pattern, requiring less deprotection steps in the end of a complex synthesis route 
is preferable. Alternation of the protecting groups results in variation of reactivity and 
selectivity of the saccharide building blocks. Sometimes reactions without complete hydroxyl 
protection[34-35] should be considered, since shorter synthesis routes usually result in higher 
overall yields. 
1.2.2 Different glycosylation coupling methods and stereoselective control 
Glycosylation coupling steps are other key aspect to control during the synthesis of large 
oligosaccharides. The glycosylation coupling procedure typically involves activation of a 
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 leaving group on the donor saccharide to form an oxacarbenium ion intermediate. A 
nucleophile, the hydroxyl group on the acceptor, then attack the oxacarbenium ion in the 
anomeric center to form a glycosidic linkage (Scheme 4). 
 
Scheme 4. General procedure of chemical glycosylation. 
Several factors influence the glycosylation process,[36] which will be discussed below. 
1.2.2.1 The anomeric effect 
The propensity to favor axial configuration at the anomeric center (C1) with increased 
electronegativity of the substituent is called the anomeric effect.[15] To stabilize the formation 
of an oxacarbenium ion intermediate, an ion electron pair from the ring oxygen is preferably 
shared with the anomeric carbon. Since the electron density from the upper face is higher, 
nucleophile attack is favored from below, to form an α-glycosidic bond. Further, the two 
oxygen of the β-product will have unfavorable parallel dipole-dipole interactions, repelling 
each other, while the axial α-product have favorable dipole-dipole interactions resulting in a 
lower energy state. Another explanation of the anomeric effect is that the ion pair of 
electrons in an oxygen molecular orbital overlap with an anti-bonding molecular orbital of 
the α-glycosidic bond, which stabilize the α-anomer (Scheme 5). 
 
 
 
 
 
Scheme 5. Anomeric effect on α/β glycosylation. 
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 1.2.2.2 Neighboring group participation 
During synthesis of β-glycosylated products, neighboring group participation is often involved, 
for instance in presence of 2-O/N acetyl, benzoyl, 2,2,2-trichloroethoxycarbonyl (Troc) or 
phthalimido (Phth) protecting groups. Participation with acetyl and benzoyl groups involves 
formation of an orthoester ring intermediate, giving the opportunity of nucleophile attack 
from the equatorial site and thereby obtaining a β-glycosylated product (Scheme 6).[37-39] 
 
Scheme 6. Neighboring group participation during glycosylation. 
1.2.2.3 Protecting group effects 
As briefly described in section 1.2.1., protecting groups influence the reactivity of glycosyl 
donor/acceptor pairs. In general, the electron withdrawing acyl protecting groups, disfavor 
the build-up of positive charge in the anomeric center and will deactivate the glycan 
donor/acceptor. Alkyl groups or deoxy modifications will on the other hand increase the 
reactivity. To perform a specific glycosylation reaction, a donor with suitable reactivity should 
be used. For example two glycosyl donors were here evaluated for the synthesis of the 
GlcNAc-Man di- and trisaccharide building blocks. The reactions involved thioglycoside donor 
couplings to 2-OH or 2,4-OH mannose acceptors activated by NIS-TfOH in DCM. The 
benzylated donor, was far more reactive during coupling to 2-OH mannose, while the 
acetylated donor was not reacting at all. During coupling to a more reactive acceptor, a 
3,6-benzylated 2,4-OH mannose, the benzyl donor was too active resulting in multiple 
by-product formation and low yields. Instead, the less active acetylated donor, gave high 
yields of the desired product 2,4-glycosylated product (Scheme 7). 
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Scheme 7. Benzylated/acetylated donor compared in coupling reactions. 
1.2.2.4 Ion-pairs and solvent effects 
After glycosyl donor activation, the reactivity of the oxacarbenium-leaving group ion pair is 
influenced by the surrounding solvent molecules. In less polar solvents the cation and anion 
will still be in contact, which is described as a CIP: contact ion-pair or tight ion-pair. Similar to 
a SN2 mechanism, the nucleophile attack will be directed by the leaving group and cause 
inversion of the anomeric conformation.[40-41] Solvents with a high dielectric constant can 
stabilize positive charge very well and the oxacarbenium ion will be completely solvated and 
shielded from the counterion, described as a SSIP: solvent separated ion pair (Scheme 8). 
  
Scheme 8. An example of solvent effects on glycosylation. 
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 The SN1 resembled oxacarbenium cation can then be attacked by a nucleophile both from 
the upper and bottom side resulting in α/β mixtures.[42] In addition to the solvent, the kind of 
glycan residue, the neighboring protecting groups, conformation, acceptor and reagents are 
thus further influencing the ratio of the obtained anomeric mixture. For mannose, the 2-OR 
axial bond would for instance influence and often favor the formation of α-glycosylated 
products. 
When acetonitrile is used as solvent, the glycosylation mechanism will be slightly different. 
Under SN1-like conditions, the acetonitrile may coordinate to the anomeric center of the 
oxacarbenium ion, forming a nitrilium-nitrile on the α-face.[43] The acetonitrile SSIP effect will 
then result in a nucleophile attack from above leading to β-glycoside product formation. 
 
Scheme 9. Solvent effect on glycosylation performed in MeCN 
1.2.3 Common glycosylation reactions 
In coupling reactions, activation of the donor leaving group results in the formation of a 
oxacarbenium ion intermediate[44] followed by nucleophilic attack by an acceptor.[45-46] 
Dependent on the desired structure of the final product, stereochemistry in glycosidic bonds 
and applied protecting groups, different leaving group/activation reagent combinations can 
be applied in the synthesis strategy.[47-49] Glycosyl halides was employed in the very first 
glycosylation synthesis[50] and a few years later the Königs-Knorr method, was developed, 
which involved glycosyl halide donors reacting with alcohols in the presence of silver (I) 
carbonate.[51] The Königs-Knorr method had an enormus impact in the method development 
of carbohydrate synthesis and is still commonly used in a modern form. Lemieux devloped 
the halide ion catalyzed In situ anomerization method for selective formation of 1,2-cis 
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 glycosidic bonds.
[52] This method is based on that the α-glycosylbromide donor rapidly 
equilibrate with the β-bromide under catalysis of tetraalkylammonium halides. The more 
reactive β-bromide is constantly consumed in the glycosylation reaction forming the desired 
α-glycoside coupling product. The trichloroacetimidate method developed by Schmidt, are 
commonly used in coupling reactions and are described in detail below. Stable benzyl or allyl 
ethers or acetyl groups in the anomeric center of the glycan are here typically converted to 
trichloroacetimidate donors in two simple steps. The couplings proceed generally using Lewis 
acid promotors like borontrifluoride (BF3) etherate or catalytic amounts of trimethylsilyl 
triflate (TMSOTf). A great number of coupling reactions involving thioglycoside donors have 
further been developed. The thioglycosides are stable for storage and reactions involving 
protecting group modification steps or orthogonal glycosylations with other donor-activation 
systems. A few thioglycoside promoter systems employed in this work are described below. 
Other glycosyl donors employed in couplings are; n-pentenyl glycosides,[53-54] 
phenylselenoglycosides[55] and glycal donors.[56] 
1.2.3.1 Trichloroacetimidate method 
The trichloroacetimidate group is first activated by addition of a TMS group, the double 
bound is then transferred from a carboximidate into a carbonyl and is leaving meanwhile the 
glycan forms an oxacarbenium ion.[57-59] After nucleophilic attack by the acceptor, the TfO- 
group abstracts a hydrogen atom from the acceptor to form triflic acid. The Triflic acid is 
regenerated into TMSOTf and only catalytically amounts of TMSOTf[60] were required in this 
reaction (Scheme 10).  
 
  
 
Scheme 10. Trichloroacetimidate coupling mechanism. 
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 A major side-reaction upon activation of the glycosyl trichloroacetimidate is the Chapman 
rearrangement.[61-62] During trichloroacetimidate activation, a rearrangement into an inactive 
form can take place. This occurs particularly in slow coupling reactions, for instance by using 
large oligosaccharide donors (Scheme 11). 
 
Scheme 11. The trichloroacetimidate rearrangement reaction.  
1.2.3.2 Thioglycoside with NIS-TfOH coupling 
The thiol ethers (SEt/SPh) are good leaving groups[63] when activated with a bromine or 
iodine source e.g. NBS[64] or NIS.[65-66] Catalytic amounts of triflic acid are used, while equal 
amounts of the donor sugar and NIS would be required (Scheme 12). 
 
Scheme 12. NIS-TfOH assisted thioglycoside activation. 
1.2.3.3 DMTST coupling 
DMTST should be synthesized freshly prior to synthesis.[67] Upon activation with DMTST the 
thioglycoside donor form a positively charged methyl disulfide, which serves as a good 
leaving group generating a oxacarbenium ion available for coupling with the acceptor 
(Scheme 13). 
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Scheme 13. DMTST thioglycoside coupling mechanism. 
1.3 General introduction to glycopeptide synthesis[10, 68-70] 
1.3.1 Fmoc-Solid-Phase glycopeptide synthesis 
Fmoc-solid-phase synthesis (Fmoc-SPPS) is the most common method applied in peptide and 
glycopeptide synthesis. The Fmoc protecting group, can be removed under mild base 
treatment and is compatible with acid labile side-chain protecting groups such as the 
tert-butyl and trityl groups. In glycopeptide synthesis the use of mild conditions are in 
particular critical, since the glycosidic bond on the glycosylated amino acids are labile to 
strong acid such as HF, the other common peptide synthesis method, Boc-SPPS, is therefore 
not an option in glycopeptide synthesis. Harsh base treatment of O-glycopeptides may result 
in β-elimination, however the use of O-acetyl glycan protecting groups and the use of mild 
organic bases in the Fmoc peptide synthesis strategy, avoid that such undesired side 
reactions takes place. By using an automatic peptide synthesizer, the peptide assembly can 
perform in a stepwise fashion starting from a resin preloaded with the first C-terminal 
Fmoc-amino acid. The peptide assembly proceeds in coupling cycles, starting with Fmoc 
deprotection with 20% piperidine in DMF followed by amino acid (4-10 eq) coupling 
activated by HBTU/HOBt and DIPEA. For introducing a glycosylated amino acid (1.5-2 eq), the 
more reactive coupling reagent HATU/HOAt together with DIPEA are used instead (Scheme 
15).[71-72] To compensate for the lower excess of the valuable glycosylated amino acids, the 
couplings perform more concentrated and during longer reaction times. After the 
completion of the desired peptide sequence, a resin cleavage step follows by treatment with 
a mixture of TFA/TIPS/H2O (standard conditions, other TFA cleavage reagents are used if 
peptide contains oxidation sensitive amino acids). Simultaneously the acid sensitive amino 
acid side chain protecting groups are cleaved. The cleaved peptides are desalted on a C-18 
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 cartridge or purified by HPLC. For glycan deprotection, deacetylation is performed under 
mild basic conditions with NaOMe/MeOH at pH 9.5-10 to avoid β-elimination or for larger 
saccharides NaOH in MeOH/H2O is used. The final product is then typically purified by HPLC.  
 
Scheme 14. Procedure for solid phase peptide synthesis. 
 
Scheme 15. Reagents used for peptide synthesis coupling reactions. 
1.3.2 Glycopeptide synthesis by direct glycan coupling to the peptide backbone 
The use of peracetylated Fmoc glycosylated amino acids in stepwise peptide assembly, as 
described above, is the most common approach for glycopeptide synthesis. The formation of 
an O-glycosidic bond connecting the glycan to the amino acid side-chain (Thr/Ser) is 
preferably introduced in an early stage of the glycosylated amino acid synthesis using optimal 
protecting groups for desired reactivity, stereochemistry and regioselectivity in the coupling 
step. Direct coupling of a protected O-glycan donor to a fully assembled peptide forming an 
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 O-glycosidic bond is not desirable, since it often results in low yields and lack of 
stereoselectivity in the reaction. In contrast to O-glycopeptides, N-glycopeptides are 
connected through an amide bond to the peptide backbone and N-glycan attachment to a 
fully assembled peptide through a standard amide coupling is here an option. By using 
synthetic N-glyco-amino acid building blocks in stepwise Fmoc-SPPS, the yields for the 
glycosylated amino acid coupling step often drop as the size of the glycan structure increases. 
Due to sterical hindrance and slow amino acid reactivity, it might result in aspartimide 
formation on the N-glycan Asn (Scheme 16 A). Since the glycan acetyl protecting groups 
dramatically reduce the reactivity, unprotected N-glycosylated amino acids and modified 
coupling conditions, might be an option to achieve N-glycopeptides in acceptable yields.[73-75] 
 
Scheme 16. Formation of asparimide byproduct during peptide synthesis. A) asparimide formed on 
glycosylated amino acid during Fmoc-SPPS; B) asparimide formed on peptide backbone during Lansbury 
glycopeptides synthesis. 
In the alternative approach, a protected peptide backbone is synthesized with an 
unprotected aspartate side-chain, which later is employed in an amide coupling with a 1-NH2 
reactive unprotected N-glycan (the Lansbury method, Scheme 17).[76] Also in this method 
asparimide byproduct formation can take place during coupling of large and slowly reacting 
N-glycans (Scheme 16 B). Danishefsky and coworkers synthesized hybrid type N-glycopeptide 
gp120 fragments using the Lansbury method.[77-78] A synthetic Man7GlcNAc2 1-NH2 
oligosaccharide was conjugated to a pentapeptide in 30% yield and a 20 amino acid gp120 
fragment peptide in 20% yield. In another example by Danishefsky a homogeneous 
Erythropoietin N-glycopeptide fragment 1-28 was synthesized.[79] The 1-NH2 disaccharide, 
hexasaccharide, and dodecasaccharide, were conjugated to a 28 residue peptide by the 
Lansbury reaction, in yields of 70%, 30% and 0%, showing the influence of the N-glycan size. 
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 As it was not possible to join the biantenary dodecasaccharide to the long peptide directly, 
the glycan donor was first conjugated to a shorter 22-28 peptide fragment in 65% yield, 
which was then elongated by native chemical ligation[80-82] to give the desired 
N-glycopeptide.[83-84] 
 
Scheme 17. Principle of Lansbury method by amide coupling of glycan donors to the Asp side chain. 
1.3.3 Chemoenzymatic glycopeptide synthesis 
Another approach to synthesize N- and O-glycopeptides is to use chemoenzymatic 
methods.[85-86] Initially the peptide backbone is synthesized with one or a few glycans 
attached to the peptide backbone, and is then further glycosylated through enzyme 
catalysis.[87-88]  
Different glycosyl transferases are employed together with UDP, GDP or CMP activated 
monosaccharide donors to sequentially extend the O-glycopeptide acceptors. However, if the 
enzymatic couplings do not go to completion, separation of the glycopeptide product 
mixture might be challenging. For N-glycopeptides, endoglycosidases can in one step be 
employed to transfer large oligosaccharide donors to a monoglycosylated GlcNAc-Asn side 
chain of peptides/proteins. In this thesis N-glycopeptides were prepared by the latter 
method, which is described in more detail below. 
1.3.3.1 Endoglycosidase catalyzed oligosaccharide transglycosylation 
For chemoenzymatic N-glycopeptide synthesis, endo-β-N-acetylglucosaminidases (ENGases) 
is an important enzyme class, which targets the chitobiose bond, a β-(1→4)-bond between 
two GlcNAc residues in the N-glycan pentasaccharide core structures.[89-90] Endo-H isolated 
from Streptomyces plicatus or Streptomyces griseus, was specified to cleave this bond,[91] two 
other enzymes; Endo-A from the bacteria Arthrobactor protophormiae[92] and Endo-M from 
the fungi Mucor hiemalis,[93] were able to exchange glycans through the chitobiose bond in a 
17 
 
INTRODUCTION 
 transglycosylation reaction.
[94] Endo-A is specific for high-mannose type N-glycans and 
Endo-M for complex type N-glycans. Using this approach, defined oligosaccharides could in 
one step be coupled[95-96] to a specific site on glycopeptides[97-99] or glycoproteins.[100]  
 
Scheme 18. Enzymatic reaction mechanism for glycopeptide hydrolysis and coupling employing native 
Endo-A or Endo-M. 
 
 
Scheme 19. Transglycosylation mechanism of mutant Endo-M-N175A and Endo-A-E173Q, which hydrolytic 
activity were suppressed. 
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 However, until recently the yields employing this method were limited by hydrolytic activities 
of the native enzymes and further required large excess of complex oligosaccharide donors, 
which usually not are available in large amounts. To solve these problems, the method was 
improved by using endoglycosidase mutants less prone to hydrolyze the formed glycopeptide 
products and by using synthetic oxazoline donors, which function as more reactive transition 
state analogs. 
Several studies were done to identify the endoglycosidase crystal structure[101-102] using thiol 
substituted oxazoline[103] transition state inhibitors. Similar to chitinases[104-106] or 
N-acetyl-β-hexosaminidases,[107-108] the mechanism of the enzymatic coupling was suggested 
to involve a Glu E173 on Endo-A or E177 on Endo-M[109] and an Asn N171 on Endo-A or N175 
on Endo-M, resulting in oxazoline formation and hydrolysis of the β-(1→4) Chitin glycosidic 
bond. Catalyzed by E173/E177 the 4-OH from a GlcNAc glycopeptide acceptor then initiate 
an attack to the oxazoline intermediate, resulting in the formation of a new N-glycopeptide 
glycosidic bond. By using an oxazoline donor the glycan coupling is independent on the 
glycan chitin bond hydrolysis step and by mutation[110] of the Asn into Ala on Endo-M 175 or 
Glu into Gln on Endo-A 173, the hydrolysis properties of the ENGases are dramatically 
reduced, which hinder hydrolysis of the formed glycopeptide product. 
In previous work, different types of oxazoline donors have been evaluated using both the 
endo-A and Endo-M ENGases.[111-113] For Endo-A, the shortest donor tolerated was a 
Manβ-(1→4)GlcNAc oxazoline,[114] additional protecting group modifications or oxazoline 
donors further extended with mannoses generating pentasaccharide core or high-mannose 
structures were also accepted. Extensions of the pentasaccharide core by using glycan 
donors containing terminal Gal or GlcNAc were not accepted by the enzyme. This means that 
complex-type N-glycan oxazoline donors are not accepted by Endo-A. 
The ENGase enzymatic glycosylation could be performed on peptide level as well as on 
protein level, with multiple glycosylation sites modified in one step.[115] The GlcNAc 
monoglycosylated protein must first be obtained, various methods are available,[116-117] 
followed by ENGase glycan extension. In one example from Wang and co-workers,[118] a 
protein was expressed in E. coli,[119-120] a tailored lipid-linked oligosaccharide (LLO) containing 
a GlcNAc at the reducing end was attached to the Asn on the protein by the oligosaccharyl 
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 transferase (OST), undecaprenyl-diphosphooligosaccharide-protein glycotransferase (PgIB), 
and the N-glycan was trimmed by α-N-acetylgalactosaminidase to give a GlcNAc 
monoglycosylated protein. Then a MaN3GlcNAc oxazoline donor was transferred onto the 
protein by the Endo-A enzyme. 
1.4 Analytical methods 
1.4.1 NMR structural analysis of synthetically prepared carbohydrates 
1.4.1.1 NMR chemical shifts of carbohydrate ring protons and common protection groups 
A general overview of chemical shifts of 1H- and 13C NMR signals from common protecting 
groups and carbohydrate ring structures are illustrated below (Figure 2). Chemical shifts of 
the carbohydrate ring protons and carbons are highly influenced by the protecting groups 
employed, glycosidic linkages, configuration and conformation of the stereogenic centers. 
 
 
  
 
Figure 2. Summary of NMR chemical shifts from sugar structures as well as common protection groups. i) 
H1; ii) H2, N-linked(a)/acetyl(b)/glycosylated(c); iii) H3; iv) H4; v) H5; vi) H6; vii) benzylidene acetal CH; viii) 
Troc-CH2; ix) benzyl CH2; x) Fmoc CH2(a)/CH(b); xi) Thr/Ser-CHα(a), Thr-CHβ(b). 
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 Anomeric proton and carbon NMR signals are characterized by the extreme down-field shifts 
at 4.5-5.5 ppm for H-1 and at 90-105 ppm for C-1 (i). Additionally the α/β linkage 
configurations show differences in chemical shifts. Usually the α-anomeric H-1 signal is found 
around 5 ppm and β H-1 signal around 4.5 ppm. The α-anomeric C-1 signal is found 5 ppm 
up-field shifted compared to β C-1 signal. The H-2 signals are found in several areas, 
depending on if the 2-position is linked to a nitrogen (ii-a); to an acetyl or benzoyl (ii-b); or as 
a glycosylation site (ii-c). H-3 and H-4 signals often have similar chemical shifts, around 
3.6-4.5 ppm (iii, iv). H-5 (v) signals are found with proton chemical shifts slightly up-field from 
the H-3 and H-4. The H-6 proton pair is found around 3.5-4.4 ppm and has a characteristic 
carbon shift around 60-65 and if glycosylated in this position around 70 ppm (vi). In general 
the substitution of the hydroxyl groups in the pyranose ring has a great impact on the ring 
proton and carbon chemical shifts. For instance acetylation and other electron withdrawing 
substituents have deshielding effects usually resulting in a down-field shift of the proton 
signal with around 1 ppm. 
CH or CH2 signals from common protecting groups or amino acids found in the carbohydrate 
NMR shift region are also listed: benzylidene acetal CH signal (vii), Troc-CH2 signal (viii), 
benzyl CH2 (ix), Fmoc-CH2 signal (x-a) and CH signal (x-b), Thr/Ser-CHα (xi-a) and Thr-CHβ 
(xi-b). 
1.4.1.2 Coupling constants and 2D-NMR experiments in carbohydrate structure 
elucidation 
The α/β linkage in the anomeric center and other protons in the pyranose ring are 
distinguished by measurements of the 3J coupling constants, which is dependent on the 
dihedral angel of vicinal hydrogen atoms. According to Karplus, trans-diaxial hydrogens with 
a dihedral angel of 180° have a large coupling constant, axial-equatorial and 
equatorial-equatorial orientations with a dihedral angel of 60° have a small coupling constant. 
The measurements of 3J coupling constants are of outmost importance for carbohydrate 
structural elucidation. Besides 1H and 13C spectra, 2-dimentional (2D) NMR experiments give 
additional information about proton and carbon connectivities. 
TOCSY and COSY NMR spectra give information about couplings of adjacent protons, COSY 
links 3J couplings to the nearby protons and TOCSY gives additional information about long 
21 
 
INTRODUCTION 
 distance couplings connecting signals from the same spin system, in this case, from the same 
pyranose ring. 
HSQC and HMBC experiments give information about linkages between carbon and protons. 
In HSQC spectra the direct H-C connectivities are outlined, which is highly useful to get an 
overview of the CH pairs and their corresponding chemical shifts. Additionally, signals with 
overlapping proton shifts in the 1D spectra are here separated from each other by the 
differences in carbon shift. The HSQC spectra are usually measured as phase-sensitive 
experiments, CH/CH3 vs. CH2 with positive/negative signals are labeled in different colors. 
HMBC spectra which measures C,H bond connectivities at 2-3 bond distance, are highly 
useful for structural assignment of the connectivities between different CH pairs in the ring 
and to elucidate for instance connections between glycosidic bonds. 
1.4.1.3 NMR structural elucidation of a tetrasaccharide N-glycan building block 
One tetrasaccharide synthesized in this thesis work, compound 87 (Scheme 20 A) was 
selected as example to illustrate the process of interpreting complex glycan structures. 
To assign each proton and carbon pair and to assign characteristic signals to the specific 
structure, the HSQC spectrum was initially inspected. By empirical knowledge of chemical 
shifts (Figure 2), certain signals could be distinguished (Figure 3), four anomeric CH pairs 
signals were observed (ii), proving the compound to be a tetrasaccharide. Acylated signals 
are found in area (iii) should be H22, H23 and H24 with high proton shifts, while the NPhth 
linked C21 should have a low carbon shift, identified in area (vii). 
 
  
 
Scheme 20. NMR interpretation of tetrasaccharide 87. A) The chemical structure with numbering of the 
rings; B) Analysis of the substitution on each position, Ac = acylated, Bn = benzylated, Bz = benzoylated, N 
= NPhth. 
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Figure 3. Characteristic signals in the HSQC spectrum. 
  
 
Figure 4. TOCSY spectrum identifying each ring system. 
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 COSY and TOCSY spectra give information of couplings between protons, the COSY show 
H,H-couplings at three bond distances and TOCSY additionally provide information about 
long distance couplings and connectivities within the pyranose ring spin systems. Using 
TOCSY the four pyranose rings systems were identified Figure 4. 
By comparing HSQC and TOCSY signals, the GlcNAc ring 1 could be distinguished since the 
H21 has a charcteristic proton shift determined by HSQC. While the other three mannose ring 
X, Y and Z containing Ac or Bz linked H-2 signals were found at down field shifts. 
By employment of HMBC, the three mannose rings were further distinguished since 
differences between benzoyl and acetyl connectivities were observed (Figure 5). The tertiary 
carbon from the acetyl group coupled to the CH3 around 2.0 ppm (Figure 5 v) and the 
benzoyl carbonyl carbons coupled to the protons in the aromatic region (Figure 5 i). The 
different carbonyl signals additionally coupled to the corresponding H-2 signal in the 
different rings and thereby the Z-ring was identified as pyranose ring 2, while ring X and Y 
remained as the two terminal mannose residues. The cross-coupling of the phthalimide 
carbonyl to H21 (Figure 5 iv) was further observed in this area. 
  
 
Figure 5. HMBC couplings of carbonyl carbons to protons at two or three bond distance. 
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 To distinguish the remaining mannose residues extending the H-3 and H-6 position of the 
inner mannose (the assigned ring-2 structure), the anomeric HMBC cross couplings were 
investigated. The coupling signals were identified in pairs diagonally in HMBC (Figure 6) , the 
CH siganals involved in the HMBC cross-couplings are further marked, the marked × 
corresponds to the interacting signal in the HSQC spectrum (Figure 7). The two dashed lined 
rectangles represent the anomeric cross coupling of ring X and Y to the center mannose. The 
anomeric 1y carbon was found to have a coupling to the 62-CH2 (v and vi) and the anomeric 
1x carbon coupled to the 32 proton(vii and viii), ring X was identified as 3-extended mannose 
and ring Y as the 6-extended. 
After solving the key feature of the structure, a detailed interpretation was achieved by 
matching the assignments from the HSQC and TOCSY spectra (Figure 8). 
 
Figure 6. HMBC signals of the anomeric cross couplings  
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Figure 7. The corresponding HQSC signals identified from HMBC couplings. 
  
 
Figure 8. Fully interpreted HSQC spectrum. 
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 1.4.2 MS structural analysis 
NMR enables identification and detailed characterization of glycans and glycopeptides. Mass 
spectrometry is a complement method that further support the identity of the synthesized 
or isolated molecules. For efficient analysis of more complex molecules, mass spectrometry 
have become the most powerful methodolgy since it enables fast analysis with low amounts 
of material. Further, technical and bioinformatic developments have resulted in that mass 
spectrometry have revolutionized the field of proteomics. In glycoproteomic analysis, 
glycoproteins are typically trypsin-digested into (glyco-)peptides before proceeding with MS 
detection. By direct analysis of intact glycopeptides, knowledge about the glycan structure, 
glycosylation site and protein identity may be obtained from the same molecule. Enriched 
fractions of glycopeptides originating from complex samples can be analysed via the use of 
proteomic dedicated protocols such as nano-flow liquid chromatography – electrospray 
ionisation/tandem mass spectrometry (LC-ESI-MS/MS). By the use of collision induced 
dissociation (CID), the identity of saccharide units can be designated based on stepwise 
glycosidic fragmentation patterns. By electron capture/transfer dissociation (ECD/ETD) the 
entire glycan mass can be pinpointed to its attachment site, but further glycan structure 
information is here not provided. By collisional activation, using positive mode higher energy 
dissociation (HCD), information about both the peptide backbone and glycan structure can 
simultaneously be obtained. Matrix-assisted laser desorption/ionization (MALDI) 
spectrometry are commonly used for analysis of intact proteins in ranges of higher molecular 
weights. In this thesis MALDI was employed to characterize glycopeptide-protein conjugates 
(common molecular weights of 50-100 kDa), to determine the loading of glycopeptide 
antigen attached on the protein immune carrier. 
1.4.3 ELISA experiment for antibody evaluation 
The enzyme-linked immunosorbent assay (ELISA) is one of the most common methods used 
to estimate the amount of induced serum antibodies (antibody titers) that recognize the 
antigen structure. The ELISA may further be used to briefly evaluate the binding specificity of 
the induced antibodies. The principle of this experiment is described as follows (Scheme 21). 
The antigen structure alone or conjugated BSA or other protein carriers are immobilized on a 
microtiter plate, the surface is blocked with a blocking solution. Then incubated with a 
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 primary antibody, in our study immunized rabbit serum was applied in dilution series. After 
washing a secondary antibody was applied, here an anti-rabbit antibody labeled with biotin, 
followed by incubation with streptavidin-horseradish peroxidase, which binds to the biotin 
group of the secondary antibody. A mixture of ABTS and H2O2 was then added in each well 
resulting in oxidation of ABTS by H2O2 and horseradish peroxidase catalysis. A green color is 
obtained and the absorption measured at 414 nm.  
ELISA neutralization experiments are further employed to elucidate the specificity of the 
antibody sera. In a neutralization experiment different peptides or antigen related structures, 
competing with the surface-coated antigen BSA conjugate, are added to the wells and 
incubated simultaneously with the primary antibody. If the (glyco-)peptide structures are 
able to interact with the primary antibody sera, a reduction of the detected ELISA signal “a 
neutralization” to the antigen structure will be observed. ELISA neutralization experiments 
consume relatively large amount of precious synthetic glycopeptides, microarray experiment 
were here considered to be a material- and time-saving alternative. 
 
Scheme 21. Basic principle of ELISA experiment to evaluate the binding efficiency of a primary antibody to 
antigen structure. Primary antibody Secondary antibody Streptavidin-horseradish peroxidase 
1.4.4 Microarray experiments for antibody and lectin binding evaluation 
Microarray experiments were here used as an alternative approach for evaluation of binding 
specificity of induced antibody sera as well as to elucidate binding recognition of glycan 
binding proteins, lectins. A library of glycopeptides was spotted in a defined pattern on a 
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 microarray glass slide (Shott
® slide H) coated with N-Hydroxysuccinimide esters on the 
surface. The free amine groups on a N- or C-terminal spacer of the peptides, could react with 
the surface forming a native amide bond and thereby covalently immobilize the peptides 
(Scheme 22). 
 
Scheme 22. The amide linkage from plate to peptides. 
Scheme 23. Microarray printing and antibody recognition. 
Each microarray slide could be divided into different wells, a common 8×2 format was for 
instance selected in order to spot a library of peptides with several spot duplications spread 
evenly over the well (Scheme 23). The spotted slide was kept in a 75% humidity chamber for 
immobilization followed by blocking with ethanolamine in sodium borate buffer to cap 
remaining reactive groups. The antibody incubation steps on the microarray slide are then 
rather similar to the ELISA experiments. A primary antibody, for instance immunized rabbit 
serum or a glycan binding protein are incubated with the immobilized peptide array, then a 
secondary antibody with a fluorophore are reacting to the primary antibody or lectin. The 
fluorescence are quantitatively detected by using a scanner. Sometimes the lectin or primary 
antibody can be directly labeled with biotin or a fluorophore for efficient read out. By 
comparing the relative fluorescence intensities of the different spots, the antibody or lectin 
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 binding recognition to the peptide library are determined. In addition to evaluation of 
binding specificities of glycopeptides and peptides, the microarray technology has a great 
impact in glycomics to study interactions with different glycan binding partners and in DNA 
arrays to evaluate gene transcription.[121-122] 
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2 Project 1: Chemoenzymatic strategies for synthesis and 
application of N-glycopeptides 
2.1 Introduction protein N-glycosylation 
Glycosylation is one of the most complex post-translational modifications in eukaryotes. In 
N-glycoside biosynthesis all N-glycoproteins share a common pentasaccharide core structure, 
Man(α1-3)[Man(α1-6)]Man(β1-4)GlcNAc(β1-4)GlcNAc. Based on different extensions from 
the core, the N-glycosylated oligosaccharides are divided into three types. 
 
Figure 9. Homogeneous native N-glycan structures.[123] 
In the high mannose form, the pentasaccharide core structure is extended with mannose 
residues, linear in the 2-position or 3,6-branched. In complex type N-glycosylation, the 
pentasaccharide core is extended with Gal-GlcNAc units (LacNAc, β1-4 or β1-3) in the core 
mannose 2-position, in a linear fashion or 2,6/2,4-branched. The hybrid form, consists of a 
combination of the high-mannose and complex type glycosylation. These N-glycans have 
been shown to have a wide range of specific biological functions and are essential in intra- 
and intercellular interactions. For instance, N-glycosylation is involved in protein folding 
processes, controlling of resistance to proteases and interactions to cellular receptors.[124-125] 
Project 1: Chemoenzymatic strategies for and 
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Figure 10. Extracellular docking glycoprotein gp120 and transmembrane glycoprotein gp41 on HIV 
virus.[126] 
Availability of homogenous glycoprotein or glycopeptide material is important to generate 
tools to study these processes. Intensive work has been made to synthetically prepare 
homogeneous complex N-glycopeptides[127-128] and glycoproteins.[129-130] One well studied 
example is the glycoprotein gp120[131-133] and gp41[134-136] on HIV, which interacts with host 
cell surface receptors resulting in infection. The gp120 and gp41 glycoproteins are heavily 
N-glycosylated. By analysis of the glycoprotein gp120, it was found to contain 13 complex 
type N-glycans and 11 high-mannose N-glycan structures.[137-138] These glycans shield 
immune recognition and proteolysis by the host immune system and are also involved in the 
HIV infection and transmission processes.[139-140] As a result, the N-glycan is considered as the 
primary target for vaccination[141-142] against HIV infection.[143] Another example is the 
cell-surface N-glycosylation on tumor cells, where N-glycans are involved in many important 
recognition processes such as cell-adhesion, cell-differentiation and tumor metastasis. Here 
the N-glycosylation is dramatically changed, for instance the structural changes involve 
increased core fucosylation, attachment of a fucose connected α-1,6 to the innermost core 
GlcNAc residue. Increased complex type N-glycan branching due to changed expression of 
the β 1-6 GlcNAc transferase GnT-V also occurs. The changed glycosylation on tumor 
glycoproteins are potential targets in the discovery of novel biomarkers for diagnosis. 
Glycomimetics may further be developed to hinder tumor cell-surface adhesion events 
involving tumor associated glycans.[144-145] 
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 2.2 Project aim 
This PhD project aimed at making N-glycopeptides available for glycomic and glycoproteomic 
studies. By using a chemoenzymatic approach, combining synthetic N-glycan oxazoline 
donors with GlcNAc-Asn glycopeptides, an efficient strategy was available to synthesize high 
mannose and complex type N-glycopeptides carrying well-defined oligosaccharide structures. 
In this way glycopeptide libraries were going to be constructed and applied in microarray 
analysis to study binding events between glycopeptides and proteins. Synthetic 
N-glycopeptides were further aimed to be used to study MS-CID/HCD fragmentation, which 
would be helpful in order to predict the identity of N-glycopeptide structures, oxonium ion 
traces may here be useful by searching for glycopeptides employing bioinformatics tools. 
Additionally, availability of N-glycopeptide standards was of interest for evaluation of 
glycopeptide purification/enrichment protocols, and also of interest to spike-in as MS 
standards in glycoproteomic quantification analysis.  
The synthesis of the oxazoline glycan donors and evaluation of the endoglycosidase 
chemoenzymatic coupling were considered to be a major challenge in this project. An 
N-glycopeptide with complex type N-glycosylation are often isolated from egg yolk and 
converted to a unique N-glycan oxazoline donor building block, however in this way only low 
amounts are obtained and it would not enable to make a library of different chemically 
defined N-glycans and N-glycopeptide structures.[146-147] Therefore, total synthesis of complex 
type and high mannose type oligosaccharides was considered as the best approach to 
generate N-glycopeptide structures. Since all N-glycans share a Man3-GlcNAc2 
pentasaccharide core, the oligosaccharides synthesis was planned in a systematic fashion 
using common precursor building blocks responsible for glycan extension. After oxazoline 
donor conversion, the N-glycans were coupled to N-GlcNAc peptides using endoglycosidase. 
2.3 Synthetic strategy 
An optimized synthetic route was designed dividing the large N-glycopeptide structure into 
two parts, which could be connected by a chemoenzymatic approach using Endoglycosidase 
A or M ( Scheme 24 A).[148] The parts consisted of a peptide backbone glycosylated with a 
GlcNAc residue on the Asn amino acid and an oligosaccharide oxazoline donor responsible 
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for glycan extension. By using different oxazoline donors that could be coupled to a large 
number of peptide sequences in parallel employing an endoglycosidase enzyme, 
N-glycopeptides could be efficiently generated. Such an approach would be suitable for 
building up peptide libraries for microarray or MS analysis. 
 Scheme 24. Retrosynthetic analysis for N-glycopeptides synthesis by oxazoline conjugation to peptide. 
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 Different oxazoline donors were synthesized, however since all N-glycans contain the same 
pentasaccharide core structure, a common disaccharide building block could be prepared 
Manβ1-4GlcNAc 26 and extended at the terminal Man 3- and 6-positions using different Man 
trichloroacetimidate donors ( Scheme 24 B). This functional disaccharide unit could be 
derived from the glucose donor 22 and a 4-OH glucosamine acceptor 16 ( Scheme 24 C). The 
neighboring equatorial acetyl group on the glucose donor would here ensure the formation 
of a β-glycosidic-linkage, which after coupling could be converted to an axial benzoyl group 
forming a β-mannoside. Removal of a p-methoxybenzyl and selective benzylidene acetal ring 
opening would generate free hydroxyl groups in the 3,6 positions, which then is available for 
additional glycan elongation. The GlcNAc glycopeptide part could be generated by 
Fmoc-solid-phase peptide synthesis (Fmoc-SPPS) using a N-glycosyl asparagine Fmoc-amino 
acid 6, which according to a recent publication,[149] could be efficiently synthesized in an 
one-step coupling from the N-acetylglucosamine 4 and aspartic anhydride ( Scheme 24 D). 
The traditional synthesis[150-151] would involve a multi-step synthesis with the formation of 
glycosylamines[152-153] and coupling[154-155] to selectively protected aspartic acid.[156] 
2.4 Synthesis of the N-GlcNAc-aspartate Fmoc-amino acid 
Starting from the N-glucosamine hydrochloride (Scheme 25), the free amine was protected 
with an acetyl group, followed by treatment with acetyl chloride to produce the 
peracetylated GlcNAc chloride 2. The axial chloride was then replaced with an equatorial 
azide using TBAHS and NaN3. The azide in the anomeric center was reduced by catalytic 
hydrogenation using Pd(C) to obtain the amine 4.[157] The N-Fmoc-aspartic anhydride was 
prepared in two steps in high yield, and was then employed in the glycan coupling reaction. 
The choice of solvent was here critical for the coupling, in less polar solvents, an 
isoasparagine derivative is formed as main product, while more polar solvents promote the 
desired glycosylation. The reaction therefore performed in DMSO with consumption of the 
amino-glycoside followed by a ninhydrin test, indicating the reaction was finished in 2 h. The 
obtained glycosylated Fmoc-amino acid 6 was then employed in Fmoc-SPPS to generate the 
desired glycopeptides. 
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Scheme 25. a) glucosamine hydrochloride, MeOH, NaOMe, r.t. 2 h; AcOH, Ac2O, r.t. 24 h; b) AcCl, 40 °C 24 
h; c) TBAHS, NaN3, Sat. NaHCO3, r.t. 2 h; d) H2, Pd(C), MeOH, r.t. 2 h; e) Asn, Na2CO3 in H2O, Fmoc-OSu in 
THF, r.t. 20 h; Ac2O, 120 °C, 5 min; f) DMSO, r.t. 2 h. 
2.5 Synthesis of the Manβ1-4GlcNAc core 
The formation of a β-mannose glycosidic bond is difficult, since both the anomeric effect and 
the use of neighboring group participation would favor the formation of an α-mannosyl 
product. To generate the β-mannosyl product in the synthesis of the Manβ1-4GlcNAc 
disaccharide core, a strategy was selected converting a β-glucoside into a mannose.[158-159] By 
neighboring group participation, a β-glucosidic bond would easily be obtained by coupling a 
2-O-acetyl glucose donor to the GlcNAc acceptor. After removing the-+ acetyl group under 
basic condition and conversion to an equatorial triflate, a good leaving group is generated. 
According to a SN2 mechanism, nucleophile attack from axial direction by a benzoate ion, 
would generate an axial 2-benzoyl product and thereby convert a glucose into the desired 
mannose. Therefore, the synthesis route was designed to prepare a glucose donor and 
glucosamine acceptor, to ensure the β-linkage first, and then convert the glucose to 
mannose. 
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Scheme 26. a) glucosamine hydrochloride in MeOH, NaOH in H2O, 0 °C, 30 min; phthalic anhydride in 
acetone, r.t. 24 h; NaOAc, Ac2O, 160 °C, 2 h; b) EtSH, BF3·Et2O, DCM, r.t. 3 h; c) 0.08 M NaOMe in MeOH, r.t. 
4 h; d) α,α-dimethoxytoluene, p-toluenesulfonic acid, DMF, 50 °C 1 h; e) NaH, BnBr, THF, reflux 2 h; f) 
BnOH, NIS, TfOH, molecular sieves, 0 °C 1h; g) sodium cyanoborohydride, 2N HCl in Et2O, THF, 0 °C 30 min; 
h) NaOAc, Ac2O, 160 °C, 1 h; i) EtSH, BF3·Et2O, DCM, 0 °C 1 h; j) 0.05 M NaOMe in MeOH, r.t. 2 h; k) 
α,α-dimethoxytoluene, p-toluenesulfonic acid, DMF, 50 °C 1 h; l) dibutyltin oxide, MeCN, refluxed 24 h; CsF, 
4-methoxybenzyl bromide, r.t. 48 h; m) Py/Ac2O, r.t. 4 h; n) 22, NIS, TfOH, molecular sieves, DCM, 0 °C 1h; 
o) 0.05 M NaOMe in MeOH/DCM 2:1, r.t. 72 h; Py, Tf2O, DCM, 0 °C 15 min; tetrabutylammonium benzoate, 
Tol, 120 °C 2 h; p) CAN, MeCN/H2O 9:1, r.t. 30 min; q) 1 M BH3 in THF, TMSOTf, DCM, 0 °C 30 min, r.t. 16 h. 
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Other alternative routes for the synthesis of β-mannoside products were developed by Gorin 
and Perl,[160] in principle employing Königs-Knorr conditions, using an α-bromo mannosyl 
donor to generate β-products via a SN2 mechanism. However, the reaction yields are usually 
moderate, and the method is not widely applied anymore. Instead of a bromo donor, an 
α-triflate donor intermediate was developed by Crich and coworkers.[161-163] The reaction was 
performed in a similar SN2 style
[164] and a 4,6-benzylidene acetal ring and a relatively large Bn 
or PMB protecting group at O3 here disfavor oxacarbenium cation formation.[165] 
N-glucosamine hydrochloride was selected as starting material for the acceptor part (Scheme 
26 A), the hydrochloride was removed first and the free amine was protected with phthalic 
anhydride,[166] since phthalimide groups are quite stable during the whole synthesis process 
and favor β-linkage formation on the anomeric position by neighboring group participation. 
The glycan was then treated with sodium acetate / acetic anhydride at reflux to obtain the 
β-acetate product 7. The acetyl group in the anomeric position then reacted with ethanethiol 
(or thiophenol) promoted by boron trifluoride diethyl etherate[167-168] to give the β-SEt 
product 8. The acetyl groups on position 3, 4 and 6 were then removed by sodium methoxide 
in methanol to give 10. The benzylidene acetal protection was then performed at pH 3.5 - 4 
in DMF under reduced pressure, 50 mbar, at 50 °C, thereby methanol produced from the 
reaction was continuously removed as the reaction proceed to give 11.[169] Benzylation of the 
remaining hydroxyl in the 3-position was unsuccessful in DMF, by altering the solvent to 
THF[170] and after refluxing for 2 hours, the reaction proceeded in excellent yield to give 13. 
To replace the SEt in the anomeric position with an O-benzyl protecting group, a NIS/triflic 
acid approach was applied and the reaction was performed smoothly to give 15. For 
benzylidene acetal ring opening to give a free hydroxyl group at the 4-position,[171] 
compound 15 was treated with sodium cyanoborohydride and HCl at optimized conditions, 
to give the N-glucosamine acceptor 16. 
The synthesis of the glucose donor 22 started with acetylation of D-glucose by treatment 
with sodium acetate and acetic anhydride under reflux to give the β-acetylated product 17 
(Scheme 26 B). By reacting with ethanethiol and boron trifluoride diethyl etherate, the 
acetate was converted to the thioglycoside donor 18. The remaining acetyl groups were then 
removed using sodium methoxide in methanol followed by benzylidene acetal formation 
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 according to the standard conditions described above. A few procedures
[172-173] were 
available for selective benzylation on the glucose 3-position in the presence of a free 
hydroxyl group in 2-position, the employed dibutyltin oxide promoted benzylation suffered 
from byproduct formation and only moderate yields were achieved to produce 21. The 
remaining free 2-hydroxyl group was acetylated to give the SEt glucose donor 22. 
The NIS/TfOH promoted coupling reaction of donor 22 and acceptor 16 was finished after 1 h 
at 0 °C and the coupling product 23 was obtained in a good yield (Scheme 26 C). A 
deacetylation step followed[174] and treatment with triflic anhydride then generated a triflate 
intermediate, which immediately was reacted with tetrabutylammonium benzoate to give 
the benzoyl group in axial position, converting glucose into mannose obtaining 24. To 
prepare the disaccharide building block for further extension, the p-methoxybenzyl 
protecting group in the mannose 3-position was removed using cerium ammonium nitrate to 
give 25.[175] A free hydroxyl group in the mannose 6-position was obtained by benzylidene 
acetal ring opening using borane, catalyzed by TMSOTf,[29] to give the 3,6-hydroxyl 
Manβ1-4GlcNAc acceptor 26. 
2.6 Design of building block elongations 
In order to prepare more complex oligosaccharide oxazoline donor building blocks for later 
use in couplings to monoglycosylated GlcNAc-Asn N-glycopeptides, the synthetic 
Manβ1-4GlcNAc disaccharide core structure 26 was extended with different 
trichloroacetimidate donors at the 3,6 position on mannose. The extension building blocks 
were divided into two types, resulting in complex type (Scheme 27 A) or a high mannose 
type (Scheme 27 C) N-glycosylation. In the complex type, the mannose was extended with 
GlcNAc monosaccharide or Glaβ1-4GlcNAc disaccharide units (Scheme 27 B) forming a linear 
β1-2 linkage product or β1-2, β1-4 and β1-2, β1-6 branched products. For high mannose 
formation (Scheme 27 C), a building block was repeatingly extending the mannose residue in 
2-position for linear elongation or in 3,6-position for branched elongation(Scheme 27 D). 
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Scheme 27. A) Complex type glycosylation; B) GlcNAc-Man and Gal-GlcNAc-Man linear and 2,4 / 2,6 
branched elongation for generation of complex type building blocks; C) High mannose type glycosylation; 
D) Linear and 3,6 branched elongation for generation of high mannose type building blocks. 
2.7 Synthesis of complex type building block extensions 
A unified synthesis strategy was applied generating the different complex type N-glycan 
building blocks. A Galβ1-4GlcNAc disaccharide or a GlcNAc monosaccharide donor extended 
three kinds of mannose acceptors, a mannose with a free 2-hydroxyl 29 or a mannose with 
two free hydroxyls in 2,6- or 2,4-position compound 31 resp. compound 30 (Scheme 28, 
Scheme 29). An Allyl protecting group was used to protect the anomeric center of the 
mannose acceptors, which after glycan extension could be selectively removed by 
Wilkinson’s or Baudry catalyst, converting the building block into a trichloroacetimidate 
donor.  
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Scheme 28. Retrosynthetic analysis for complex type building blocks with Gal-GlcNAc elongation. 
The GlcNAc monosaccharide donor was available from the previous Manβ1-4GlcNAc 
disaccharide core synthesis. With simple protecting group manipulations, the reactivity of 
the GlcNAc donor could be modulated, and further Galβ1-4GlcNAc disaccharide donors with 
different protecting groups were also prepared to modulate the reactivity in the coupling 
reactions. 
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Scheme 29. Retrosynthetic analysis for complex type building blocks with GlcNAc elongation. 
The synthesis of all mannose acceptor building blocks started with allylation of D-mannose in 
the anomeric center, generating 27 as a common intermediate (Scheme 30 A). 
α,α-Dimethoxytoluene was used for 4,6-benzylidene acetal formation[176] to give 28 and for 
selective benzylation in the mannose 3-position, dibutyltin oxide was used[177] resulting in 
the 2-hydroxyl acceptor 29 in a high yield. A few methods were tested for selective 
benzylidene acetal ring opening[178-180] to generate a 2,4 or 2,6-hydroxyl acceptor, but the 
ring opening conditions were not compatible with the allyl group and therefore none of the 
attempts were successful. Instead, another procedure was adopted using tributyltin oxide 
that selectively benzylated the mannose 3- and 6-position in a moderate yield to give 30 as a 
2,4- hydroxyl acceptor. By forming a 3,4-acetal ring with butanedione[181-182] 31 was formed 
as a 2,6- hydroxyl acceptor. 
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 In order to tune the reactivity during coupling to the mannose acceptors 29 - 31, lactosamine 
(Galβ1-4GlcNAc) disaccharide donors were prepared with different protecting groups and 
leaving groups in the anomeric center e.g. the SEt or SPh group (Scheme 30 B). The 
disaccharide donor synthesis started with acetylation of D-galactose. A catalytical amount of 
perchloric acid was used resulting in the formation of the α-acetate 32. Deacetylation of the 
anomeric center using hydrazine acetate was followed and the free hydroxyl was treated 
with trichloroacetonitrile and DBU to give the galactose trichloroacetimidate donor 34. Two 
GlcNPhth acceptors were prepared starting from intermediates described in the 
Manβ1-4GlcNAc disaccharide core synthesis above, compound 8 and 9 (Scheme 26 A). After 
deacetylation of 8 and 9, protection with a TBS group in the primary hydroxyl 6-position was 
followed to give 35 and 36. Reaction of the acceptors 35 and 36 with the Gal 
trichloroacetimidate 34 selectively gave the 4-coupling products, since the hydroxyl 
4-position is more reactive then the 3 position in glucose. After coupling the remaining free 
hydroxyl was acetylated forming 38 and 39. Two benzylated lactosamine disaccharide donors 
were prepared according to another route. A GlcNPhth acceptor was obtained by performing 
a reductive sodium cyanoborohydride benzylidene acetal ring opening[183] on compound 13 
and 14 to give the 3,6-benzylated 4-hydroxyl acceptor 40 and 41. Coupling of the acceptors 
40 and 41 with the Gal trichloroacetimidate donor 34 generated the disaccharides 42 and 43. 
The lactosamine disaccharide donors 38, 39, 42 and 43 were employed in coupling reactions 
with the 2-OH, 2,4-OH and 2,6-OH mannose acceptors 29-31, the successful reactions are 
shown in Scheme 30 C. Certain differences among the donors were found, the SEt leaving 
group were considered more reactive, but if the reactivity was too high more byproducts 
could be formed compared with using SPh groups. However, the suitable reactivity required 
for a coupling reaction also depends on the acceptor and the mannose acceptors 29-31 
reacted considerably slower to the donors with SPh groups 43 and 39 compared with the SEt 
donors 42 and 38, which resulted lower yields. 
The reactivity of the Galβ1-4GlcNAc disaccharide donors were also affected by the protecting 
groups on the glucosamine, the benzyl and TBS groups were considered to have an electron 
donating effect, increasing the reactivity of the glycan donor, while the acetyl groups are 
electron withdrawing, decreasing the donor reactivity. In practice, the 3,6 benzylated 
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disaccharide donor 42 or 3-acetyl 6-TBS donor 38 containing the same leaving group (SEt), 
did not show much differences, but 38 showed a cleaner reaction on TLC with 10% higher 
yield. Additionally, the synthesis of the disaccharide donor 38 was two steps shorter and 
therefore the donor of choice. 
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Scheme 30. a) D-mannose, allyl alcohol, BF3·Et2O, 120 °C 30 min; b) α,α-dimethoxytoluene, 
p-toluenesulfonic acid, DMF, 50 °C 1 h; c) dibutyltin oxide, Tol, refluxed 24 h; tetra-n-butylammonium 
bromide, CsF, BnBr, r.t. 24 h, 80 °C 24 h, 120 °C 1 h; d) tributyltin oxide, Tol, refluxed 24 h; BnBr, r.t. 72 h; e) 
trimethyl orthoformate, CSA, butanedione, MeOH, 90 °C 24 h; f) D-galactose, Ac2O, HClO4, 25 - 30 °C 30 
min; g) hydrazine acetate, DMF, 50 °C 3 h; h) trichloroacetonitrile, DBU, DCM, 0 °C 3 h; i) 0.08 M NaOMe in 
MeOH, r.t. 4 h; TBSCl, imidazole, DMF, r.t. 2 h; j) 34, TMSOTf, molecular sieves, DCM, -60 °C 1 h; k) Py/Ac2O, 
r.t. 24 h; l) sodium cyanoborohydride, 2N HCl in Et2O, THF, 0 °C 30 min; m) 34, TMSOTf, molecular sieves, 
Et2O, -50 °C 4 h; n) NIS, TfOH, molecular sieves, DCM, -50 °C 1h; o) Wilkinson’s catalyst, Tol/EtOAc/H2O 
20:10:1, reflux 5.5 h; I2, THF/H2O 4:1, r.t. 30 min; p) NIS, TfOH, molecular sieves, DCM, 0 °C 4h; q) NIS, 
TfOH, molecular sieves, DCM, 0 °C 3h; r) NIS, TfOH, molecular sieves, DCM, 0 °C 4h.  
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Deallylation was performed on the simplest coupling product 44 by Wilkinson’s 
catalyst,[184-185] which required heating to reflux in a Tol/EtOAc/H2O 20:10:1 mixture. A single 
product was obtained, verified by NMR the benzylidene acetal group on the mannose 
residue was also removed during the reflux. The results indicated that the glycan allyl groups 
could be efficiently removed by Wilkinson’s catalyst, but additional optimization would be 
required depending on the applied glycan protecting groups. 
The mannose acceptors 29 - 31, were also extended with glucosamine monosaccharide 
donors. The glucosamine donors were prepared with different protecting groups, acetylated 
or benzylated GlcNPhth or p-methoxybenzyl GlcNTroc donors (Scheme 31 A). Glycan donors 
containing NHTroc protection were considered to be slightly more reactive than GlcNPhth 
donors. However, in contrast to the phthalimido group, the Troc group is quite sensitive to 
base and would be removed by treatment with sodium hydride during the benzylation step. 
On the other hand the Troc group could be deprotected under mild conditions by zinc 
reduction, while the deprotection of the phthalimide require rather harsh base treatment by 
heating with hydrazine monohydrate. To synthesize the N-Troc glucosamine glycan donor 
with benzyl or p-methoxybenzyl protection, the glucosamine was first converted to the 
corresponding azide and acetylated to give 50.[186] Treatment with titanium tetrachloride 
generated the α-chloride 51, which reacted with thiophenol to give the SPh-β-thioglycoside 
52. Deacetylation by sodium methoxide and p-methoxybenzylation followed to obtain 53.[187] 
The azide was then reduced and the amine protected with a Troc group forming the GlcNTroc 
donor 54. The benzylated phthalimide donor was synthesized in one step since the 
intermediate 10 was available from the previous synthesis described above (Scheme 26 A). 
Compound 10 was benzylated in high yield to give the GlcNPhth donor 55. The peracetylated 
GlcNPhth donor 8 was available from previous synthesis as well. 
The GlcN donors 8, 54 and 55 were employed in couplings with the mannose acceptors 29 - 
31 (Scheme 31). The GlcNPhth donor 55 was applied in a NIS-triflic acid promoted with the 
mannose acceptor 29 to give the 2-extended coupling product 56 in high yield (Scheme 31 B). 
A deallylation step was followed by using the Baudry catalyst and the deallylated product 
was then converted into a trichloroacetimidate donor 58. 
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 The GlcNPhth donor 55 was also used in the coupling with the 2,4 hydroxyl acceptor 30 
(Scheme 31 C), in this case, both donor and acceptor were completely protected with benzyl 
groups, the reaction was instant and a lot of side-products were formed even by reducing the 
reaction temperature to - 60 °C and gave the desired product 59 only in a low yield. The 
benzylated acceptor-donor pair was probably too reactive and the less active donor 8 with 
acetyl protection was instead used in the coupling, which gave 60 in a significantly increased 
yield. Deallylation and trichloroacetimidate formation performed in high yield to give 62. 
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Scheme 31. a) sodium azide, sulfuryl chloride, MeCN, r.t. 18 h; imidazole, r.t. 4 h; b) glucosamine 
hydrochloride, K2CO3, CuSO4·5H2O, MeOH, r.t. 4 h; Py/Ac2O, r.t. 24 h; c) titanium (IV) chloride, CHCl3, reflux 
4 h; d) thiophenol, KOH, EtOH, CHCl3, r.t. 4 h; 0.25 M NaOMe in MeOH, r.t. 4 h; e) NaH, 4-methoxybenzyl 
chloride, DMF, r.t. 2 h; f) Zn, dioxane/AcOH 10:1, r.t. 24 h; g) NaH, BnBr, DMF, r.t. 24 h; h) NIS, TfOH, 
molecular sieves, DCM, 0 °C 1h; i) Baudry catalyst, THF, r.t. 2 h; I2, NaHCO3, H2O, r.t. 0.5 h; j) 
trichloroacetonitrile, DBU, DCM, 0 °C 3 h; k) NIS, TfOH, molecular sieves, DCM, -18 °C 0.5 h, 0 °C 1h; l) NIS, 
TfOH, molecular sieves, DCM, 0 °C 15 min; m) Baudry catalyst, THF, r.t. 2 h; I2, NaHCO3, H2O, r.t. 0.5 h; n) 
trichloroacetonitrile, DBU, DCM, 0 °C 3 h; o) NIS, TfOH, molecular sieves, DCM, 0 °C 15 min; p) Baudry 
catalyst, THF, r.t. 2 h; I2, NaHCO3, H2O, r.t. 0.5 h; q) trichloroacetonitrile, DBU, DCM, 0 °C 3 h; r) NIS, TfOH, 
molecular sieves, DCM, 0 °C 2 h; s) TFA/TIPS/H2O 15:0.9:0.9, r.t. 2 h; t) NaH, BnBr, DMF, r.t. 24 h; u) Baudry 
catalyst, THF, r.t. 2 h; I2, NaHCO3, H2O, r.t. 0.5 h; v) trichloroacetonitrile, DBU, DCM, 0 °C 3 h. 
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 Both the p-methoxybenzyl GlcNHTroc 54 and the benzyl GlcNPhth 55 donors were used in 
the coupling with 31 to generate 2,6 branched mannose products 63 and 66 (Scheme 31 D). 
Since the dimethoxymethyl 3,4-acetal might influence the reactivity in later coupling steps, 
the 3,4-acetal group was removed by acid treatment on compound 66. In this case the acetal 
was easily removed by TFA and replaced by benzyl groups and then converted to a 
trichloroacetimidate donor. For compound 63 the p-methoxybenzyl groups, which are acid 
sensitive, would not allow cleavage of the acetal in this stage. As a result, 63 was directly 
deallylated and converted to trichloroacetimidate 65. Compared with Wilkinson’s catalyst, 
the reaction conditions are much milder using the Baudry catalyst in the deallylation step. 
The Baudry catalyst is therefore more suitable for deallylation of larger and more complex 
molecules, while Wilkinson’s catalyst usually works perfect for monosaccharide or 
disaccharides. 
2.8 Synthesis of high mannose building block extension units 
High mannose building blocks were prepared by repeated extensions with the 2-acetyl 
3,4,6-benzyl mannose trichloroacetimidate donor 76 in the 2-position of the mannose 
acceptor 29 forming a linear oligosaccharide or in the 3,6-position of acceptor 78 forming a 
branched oligosaccharide (Scheme 32).  
  
 
Scheme 32. Retrosynthetic analysis for high mannose building blocks elongated with a mannose 
monosaccharide donor and employing different acceptors. 
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The 2-acetyl 3,4,6-benzyl mannose trichloroacetimidate donor 76 was prepared within a few 
steps of synthesis (Scheme 33 A). Catalyzed by Iodine, the starting material D-mannose was 
acetylated in acetic anhydride,[188-189] and brominated with 30% HBr in AcOH to give the 
α-bromo-mannoside 71.[190] The bromide was considered to be a good leaving group when 
treated with 2,4,6-collidine to form the 1,2-ortho ester 72.[191] The acetyl groups were 
removed by treatment with K2CO3 in MeOH and replaced with benzyl groups using standard 
conditions to give 73.[192-193] The orthoester was converted into acetates by treatment with 
acetic acid, and gave the desired 1,2-di-acetyl 74 as main product and 10% of the 1-hydroxyl 
2-acetyl product 75,[194] which is the desired product in the next step. Compound 74 was 
converted to 75 by removing the anomeric acetate group using hydrazine acetate and then 
converted to the trichloroacetimidate donor 76. 
The synthesis of the 3,6-hydroxyl acceptor 78 started with selective tributyl tin oxide assisted 
trityl protection in the 3,6-positions of the allyl-mannoside 27.[195] Then the 2,4 positions 
were benzylated and the trityl groups were removed to give the 3,6-hydroxyl mannose 
acceptor 78 (Scheme 33 B). The mannose acceptor 29 responsible for linear glycan extension 
in the 2-position, were the same as described above in the synthesis complex type N-glycan 
donors. 
By stepwise coupling of the mannose donor 76 with the linear acceptor 29 or the branched 
acceptor 78,[196] the high mannose type building blocks 79 and 82 were obtained (Scheme 33 
C). By deacetylation of the coupling product 79 and coupling again with donor 76, the 
mannose elongation product 81 was formed. 
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Scheme 33. a) D-mannose, I2, Ac2O, 90 °C 0.5 h; 30% HBr in AcOH, AcOH, r.t. 24 h; b) 2,4,6-collidine, 
MeOH/CHCl3 1:4, r.t. 24 h; c) K2CO3, MeOH, r.t. 0.5 h; NaH, BnBr, DMF, r.t. 2 h; d) AcOH/H2O 1.54:1, r. t. 24 
h; e) hydrazine acetate, DMF, 50 °C 3 h; f) trichloroacetonitrile, DBU, DCM, 0 °C 3 h; g) tributyltin oxide, Tol, 
refluxed 24 h; trityl chloride, r.t. 24 h; h) NaH, BnBr, DMF, r.t. 2 h; AcOH, r.t. 2 h; i) TMSOTf, molecular 
sieves, DCM, r.t. 0.5 h; j) 0.07 M NaOMe in MeOH/DCM 4:1, r.t. 24 h; k) TMSOTf, molecular sieves, DCM, r.t. 
2 h; l) TMSOTf, molecular sieves, DCM, r.t. 0.5 h; m) 0.08 M NaOMe in MeOH/DCM 4:1, r.t. 24 h. 
2.9 Extension of the Manβ1-4GlcNAc disaccharide core with complex type 
building blocks 
The synthetic Manβ1-4GlcNAc disaccharide core acceptor 26 was used for glycan extension 
at the 3,6-positions of the terminal mannose, employing the above described 
trichloroacetimidate donor building blocks. The simple peracetylated mannose donor 86 was 
first synthesized and used in the coupling of 26, forming a precursor to the N-glycan 
pentasaccharide core (Scheme 34). The peracetylated donor 86 was not fully converting 26 
to product during the coupling reaction, suggesting that the acetylated donor was not active 
enough. The 3,4,6-benzylated donor 76 was instead employed (Scheme 34 B), which was far 
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more reactive and the reaction was finished in 15 min in a good yield. A few protecting group 
manipulation steps followed. The Phthalimido groups and the benzoyl group were removed 
by hydrazine monohydrate. Then all benzyl groups were removed by catalytic Pd(C) 
hydrogenation, followed by global acetylation. The synthesized peracetylated tetrasaccharide 
89 was stored at this stage, since the oxazoline product was considered less stable. Final 
conversion to the oxazoline proceeded short before use in the chemoenzymatic couplings to 
GlcN-Asn-N-glycopeptides. 
 
 
Scheme 34. a) Py/Ac2O, r.t. 24 h; b) hydrazine acetate, DMF, 50 °C 3 h; c) trichloroacetonitrile, DBU, DCM, 
0 °C 3 h; d) TMSOTf, molecular sieves, DCM, 0 °C 15 min; e) hydrazine monohydrate, MeOH, 70 °C 24 h; 
Py/Ac2O, r.t. 24 h; f) H2, Pd(C), MeOH/AcOH 30:2, r.t. 48 h; Py/Ac2O, r.t. 24 h. 
After successfully coupling of the monosaccharide donor 76 symmetrically on 26, more 
complex donors were used, the 2,6 branched trisaccharide 70 and 2,4 branched trisaccharide 
62 were tested according to similar coupling conditions.[197-198] The results showed that a 
mono glycosylated coupling product on the 3- or 6-position of the mannose on the 
Manβ1-4GlcNAc disaccharide acceptor was formed to a large extend. More equivalents of 
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 donor could not increase the product formation. To avoid potential problems with steric 
hindrance, the synthesis strategy was therefore changed and the coupling reactions were 
instead performed stepwise, glycosylating the Man 6- and 3-position with the smaller linear 
GlcNAcβ1-2Man glycan donors that after coupling was branched in the 4 or 6 position of the 
terminal mannose residues. 
By using the slightly smaller GlcNAcβ1-2Man disaccharide donor 58 in the coupling to 
acceptor 26, the reaction gave the double glycosylated product 90 in a good yield, 76% 
(Scheme 35 A). After final coupling, the benzylidene acetal was cleaved off under acidic 
conditions using p-toluenesulfonic acid in MeCN,[199] then the phthalimido groups were 
removed and replaced with acetyl groups. Deprotection of the benzyl groups and acetylation 
again followed forming the peracetylated (GlcNAcβ1-2Manα1)2-3,6-Manβ1-4GlcNAc 
hexasaccharide 96.  
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Scheme 35 a) TMSOTf, molecular sieves, DCM, -50 °C to 0 °C over 6 h; b) p-toluenesulfonic acid, MeCN, r.t. 
30 min; c) hydrazine monohydrate, Tol/EtOH 1:1, 80 °C 72 h; Py/Ac2O, r.t. 24 h; d) H2, Pd(C), MeOH/AcOH 
30:2, r.t. 48 h; Py/Ac2O, r.t. 24 h; e) NaOMe, MeOH/DCM 5:1, r.t. 3 days; f) 55, NIS, TfOH, molecular sieves, 
DCM, 0 °C 30 min; g) hydrazine monohydrate, Tol/EtOH 1:1, 80 °C 5 days; Py/Ac2O, r.t. 2 days; h) H2, Pd(C), 
MeOH/AcOH 30:2, r.t. 16 days; Py/Ac2O, r.t. 3 days; i) 1 M BH3 in THF, TMSOTf, DCM, 0 °C 30 min, r.t. 16 h; j) 
55, NIS, TfOH, molecular sieves, DCM, 0 °C 30 min; k) hydrazine monohydrate, Tol/EtOH 1:1, 80 °C 10 days; 
Py/Ac2O, r.t. 2 days; l) H2, Pd(C), MeOH/AcOH 30:2, r.t. 15 days; Py/Ac2O, r.t. 3 days. 
The 2-extended hexasaccharide 96 was also synthesized by another route (Scheme 35 B). 
From previous synthesis (Scheme 34 B), the tetrasaccharide core unit 87 was deacetylated to 
give 93, which was extended in the terminal mannose 2-OH positions using the benzylated 
GlcNPhth donor 55 forming the hexasaccharide 94. After a few protecting group modification 
steps, the acetylated hexasaccharide 96 was obtained. 
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The coupling product 90, described above, was also used for generating more branched 
saccharides, the benzylidene acetal was selectively ring opened generating a free hydroxyl at 
the 6-position on the two mannose residues, with 1 M BH3 in THF catalyzed by TMSOTf 
(Scheme 35 C). The hexasaccharide was then elongated in the two 6-OH positions using the 
GlcNAc donor 55. After similar protecting group modulations as described above, the 
peracetylated 2,6 branched octasaccharide 100 was obtained. Benzylidene acetal ring 
opening in the 4-position instead to generate a 2,4 branched extended octasaccharide was 
also tested on the intermediate 90 but suffered from formation of break down products. 
To generate the 2,4 branched extended octasaccharide, the mannose residue 30 was in a few 
steps converted to the mannose donor 103 which could potentially extended the 2,4 
positions (Scheme 36 A). The trichloroacetimidate donor 103 was coupled to the 
Manβ1-4GlcNAc acceptor 26 in a high yield (Scheme 36 B). Deacetylation of the coupling 
product 104 performed carefully at pH 9.5 to avoid simultaneous cleavage of the benzoyl 
group. A quadruple coupling was then performed with 6.0 eq of the benzylated GlcNPhth 
donor 55 to the symmetrical 2,4-hydroxyl acceptor 105 to give the coupling product 106 in a 
good yield. The protection groups were modified to give the final 2,4 branched extended 
octasaccharide 108. 
In conclusion, with generation of larger oligosaccharide structures, the difficulty of the 
elongation step increased with the size of the donor building blocks, probably due to sterical 
hindrance. Monosaccharide donors achieved 70-90% yield in a double glycosylation of the 
Manβ1-4GlcNAc acceptor 26 or 50-60% yield in a quadruple couplings of the tetrasaccharide 
acceptor 105. Using disaccharide donors, the double coupling to acceptor 26 performed in 
70-80% coupling yields, while using trisaccharide donors, the yields dropped to only 10-15% 
and in attempts to form double glycosylated products, mono glycosylated coupling products 
were dominating instead. By coupling monosaccharide donors stepwise with functional 
group orthogonally, large building blocks were synthesized efficiently. 
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Scheme 36. a) Py/Ac2O, r.t. 24 h; b) Wilkinson’s catalyst, Tol/EtOAc/H2O 20:10:1, reflux 24 h; I2, THF/H2O 
4:1, r.t. 2 h; c) trichloroacetonitrile, DBU, DCM, 0 °C 3 h; d) TMSOTf, molecular sieves, DCM, 0 °C 2 h; e) 
NaOMe, MeOH/DCM 5:1, r.t. 12 days; f) 55, NIS, TfOH, molecular sieves, DCM, 0 °C 30 min; g) hydrazine 
monohydrate, Tol/EtOH 1:1, 80 °C 4 days; Py/Ac2O, r.t. 2 days; h) H2, Pd(C), MeOH/AcOH 30:2, r.t. 12 days; 
Py/Ac2O, r.t. 3 days. 
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2.10 Producing oxazoline donors for chemoenzymatic coupling with 
N-glycopeptides 
A few examples of converting N-glycans into oxazoline donors have been reported in recent 
years,[200-201] the structures reported vary from monosaccharides to hexasaccharide or 
decasaccharides.[202-203] The following conditions were used, treatment of the glycan acetate 
with BF3 etherate, trimethylsilyl bromide in the presence of a base, 2,4,6-collidine or 
tri-tert-butyl pyrimidine in dichloroethane (DCE) at 40 °C. A proposed reaction mechanism 
involve that the acetyl group leave, promoted by the BF3 etherate, and the trimethylsilyl 
bromide support the formation of a glycosyl bromide to create an intermediate that lower 
the energy barrier of the reaction. Then, the carbonyl oxygen of the neighboring NHAc group 
make a nucleophilic attack to form a five membered ring, which with the help of base 
abstract the hydrogen from the NH group to form the oxazoline (Scheme 37). 
 
Scheme 37. Mechanism of oxazoline formation. 
The oxazoline formation was performed on tetrasaccharide 89 and hexasaccharide 96 
(Scheme 38) in high yields. For smaller molecules, the product showed a distinguished 
change of Rf value on TLC, but for the larger saccharide structures, the difference were not so 
pronounced. Instead the reaction needed to be followed by mass spectrometry or NMR. 
Since the oxazolines were acid sensitive, ammonium buffer was used in the MS 
measurements. During these conditions potential formation of hydrolysis product could be 
discriminated from the oxazoline peak in the high-resolution mass spectrum. 
Characterization by NMR showed a unique CH3 peak from the oxazoline in the 
13C spectrum 
around 13 - 15 ppm and a quaternary carbon from the oxazoline ring at 165 ppm, which gave 
cross coupling signals to H1, H2 and the CH3 group in the HMBC spectrum. Deacetylation 
performed similar to the deacetylation steps during glycopeptide synthesis, keeping the pH 
constant at 9.5-10 for 24 h. 
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Scheme 38. a) Trimethylsilyl bromide, BF3·Et2O, tri-tert-butyl pyrimidine, 40 °C 4 h; b) NaOMe, MeOH, r.t. 
24 h; c) Trimethylsilyl bromide, BF3·Et2O, tri-tert-butyl pyrimidine, 40 °C 4 h; d) NaOMe, MeOH, r.t. 48 h. 
2.11 N-GlcNAc glycopeptides synthesis and in solution chemoenzymatic 
coupling of a tetrasaccharide oxazoline donor 
Two sets of N-glycopeptides were synthesized, with or without a spacer, the glycopeptides 
with a spacer were aimed for spotting on glycopeptide microarrays to study interactions with 
glycan binding proteins. The peptides without spacer aimed to be used as standards to study 
glycopeptide MS-fragmentation and to evaluate glycoproteomic methodology. Initially 
synthetic mono-GlcNAc N-glycopeptides were used to evaluate the enzymatic coupling of the 
oxazoline donor in solution and later also in on-slide glycosylations reacting directly on the 
microarray slide. Mono-GlcNAc N-glycopeptides were synthesized based on peptide 
sequences with N-glycosylation sites previously identified from human platelet proteins 
(Table 2).[204-205] A Fmoc-solid-phase peptide synthesis strategy was applied here, the 
glycosylated Fmoc-GlcNAc-Asn amino acid 6 was added manually, using less excess and 
longer reaction times.[206] After complete peptide assembly the peptides were released from 
resin using a mixture of TFA:TIPS:H2O. A deacetylation step removing the glycan protecting 
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groups was followed, achieving the glycopeptides in good total yields after the final HPLC 
purification step. The synthetic glycopeptides are summarized in Table 1 and Table 2.  
Table 1. Synthesis of tryptic N-glycopeptides, selected from previously identified human platelet proteins. 
Comp 
Nr 
Peptide Nr on 
microarray plate 
Sequence with 
N-terminal spacer 
MS 
Mass 
(mg) 
Yield 
150 1 SpIN*TTADEKDPTNPFR 2125.26 17.5 66% 
151 2 SpAN*HSGAVVLLKR 1670.91 17.8 85% 
152 3 SpVVN*STTGPGEHLR 1772.92 19.0 86% 
153 4 SpWVSN*KTEGR 1482.6 9.43 51% 
154 5 SpLRPDDSKN*FSIQVR 2081.29 10.7 41% 
155 6 SpGEYFVN*VTTR 1591.72 4.7 23% 
156 7 SpAYSWN*ISR 1402.51 10.2 58% 
157 8 SpN*LTALPPDLPK 1584.81 12.7 64% 
158 9 SpLQN*LTLPTNASIK 1819.07 14.7 64% 
158 10 SpSN*YSSPSNISK 1589.66 7.45 37% 
160 11 SpELISN*ASDALDK 1681.8 13.4 64% 
161 12 SpLLDLSGNN*LTHLPK 1941.19 18.3 75% 
162 13 SpLQNLTLPTN*ASIK 1819.07 15.0 66% 
163 14 SpSNYSSPSN*ISK 1589.66 9.6 48% 
Table 2. Second set of N-glycopeptides with a triethyleneglycol spacer, which was used in the microarray 
experiments. 
Comp 
Nr 
Peptides Sequence MS 
Mass 
(mg) 
Yield 
136 ADAM10:  IN*TTADEKDPTNPFR 1922.02 17.5 73% 
137 Integrin alpha-6:  AN*HSGAVVLLKR 1467.67 15.2 83% 
138 Thrombospondin-1:  VVN*STTGPGEHLR 1569.68 16.0 82% 
139 Antithrombin III:  WVSN*KTEGR 1279.36 14.0 88% 
140 Integrin beta-3: LRPDDSKN*FSIQVR 1878.05 20.1 86% 
141 Integrin alpha-2:  GEYFVN*VTTR 1388.48 1.3 7.5% 
142 P-Selectin:  AYSWN*ISR 1199.27 9.6 64% 
143 Platelet glycoprotein 1b alpha:  N*LTALPPDLPK 1381.57 10.7 62% 
144 Multimerin 1:  LQN*LTLPTNASIK 1615.83 11.5 57% 
145 Coagulationfactor V: SN*YSSPSNISK 1386.42 8.8 51% 
146 Endoplasmin:  ELISN*ASDALDK 1478.56 6.6 34% 
146 Platelet glycoprotein V:  LLDLSGNN*LTHLPK 1737.95 13.0 60% 
148 Multimerin 1:  LQNLTLPTN*ASIK 1615.83 12.0 60% 
149 Coagulationfactor V: SNYSSPSN*ISK 1386.42 12.9 74% 
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 After completing the synthesis of the mono-GlcNAc N-glycopeptides and the oxazoline 
donors, the endoglycosidase coupling was tested.[207-208] The following conditions were used, 
6-8 eq of oxazoline donor was mixed with 1.0 eq target peptide using 12.5 mU 
Endo-M-N175Q in 50 mM phosphate buffer pH 7.1. The reaction was kept at 25 °C and 
followed by analytical HPLC. The mono-GlcNAc N-glycopeptide 136 was first tested under 
these conditions, reacting with the tetrasaccharide oxazoline 110 resulting in the formation 
of the pentasaccharide core glycopeptide 164. The progress of the reaction was followed by 
HPLC from 0.5 h to 6 h and compared with the starting material (Figure 11). 
Followed by analytical HPLC, the chromatogram showed the consumption of the two starting 
materials and formation of the enzyme coupling product. The fully deprotected oxazoline 
donor was very hydrophilic coming out with the front around 4.4 min, and peptide substrate 
136 eluted at 23.3 min, while the enzymatically extended N-glycopeptide product 164 eluted 
slightly faster than the starting peptide, at 22.4 min. The enzymatic coupling was already 
finished after 30-40 min and by waiting longer, a clear glycan hydrolysis back to the starting 
peptide was observed after 2-3 hours and after 6 h around 24% of the product was 
hydrolyzed back to the starting peptide. Although the endoglycosidase is a N175Q mutant of 
Endo-M, in which the hydrolysis property should be suppressed, after certain time, the back 
hydrolysis will still take place. 
 
Scheme 39. Enzymatic endoglycosidase coupling of an oxazoline donor to a N-GlcNAc peptide 136, 
sequence: IN*TTADEKDPTNPFR from ADAM10. 
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Figure 11. HPLC chromatogram following the enzymatic coupling, taken from 40 min, 1 h, 2 h, 3.25 h, 4.75 
h up to 6 hours.  
 
Figure 12. MS2 fragmentation of the enzyme coupling product, pentasaccharide core N-glycopeptide 164. 
The coupling product was verified by high resolution mass spectrometry, and a major 3+ ion 
peak was identified and further fragmented by tandem MS/MS. Different MS2 peaks were 
identified showing that the sugar residue on the glycopeptide was cleaved sequentially in 2+ 
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 and 3
+ ions until the peptide backbone was observed as well as the cleaved Man-GlcNAc and 
Man-Man-GlcNAc fragments. 
Based on previous conditions, four more triethyleneglycol spacer peptides (152, 153, 157 
and 162) were coupled with the tetrasaccharide oxazoline 110 under endoglycosidase 
catalysis. All these couplings were finished in 0.5 h with full conversion, confirmed by HPLC 
and MS. The obtained pentasaccharide core peptides were all used in the followed 
microarray studies. 
2.12 Enzymatic on-slide coupling of the tetrasaccharide oxazoline to 
synthetic N-GlcNAc N-glycopeptides combined with microarray studies 
To generate a N-glycopeptide library, by enzymatic coupling of the N-GlcNAc peptides to 
different oxazoline donors one by one in solution is time consuming. Another approach is 
that the N-GlcNAc peptide library first is printed on a microarray slide and then the 
enzymatic coupling with the oxazoline donor take place directly on the slide, on-slide 
glycosylation. In this way, multiple N-glycopeptides can in parallel be extended with the 
oligosaccharide oxazoline donor in one synthetic step. To evaluate this approach, several 
enzymatic couplings were first evaluated in solution, indicating that the coupling conditions 
are optimal and that no hydrolysis took place. Although the in-solution reactions behave 
slightly different from performing the enzymatic coupling on-slide, it could at least be 
indicative for the on-slide reaction progress. By enzymatic coupling in solution, testing the 
coupling conditions, four selected N-GlcNAc peptides 152, 153, 157 and 162 (peptide Nr 3, 4, 
8 and 13 in Table 2) were converted into pentasaccharide glycopeptides (containing a 
triethyleneglycol spacer) 165 - 168 (referring to Nr 3p, 4p, 8p, 13p in Figure 13 A). These 
glycopeptides were printed on the microarray slide as internal standards together with the 
mono glycosylated N-GlcNAc peptide acceptors 150 - 163, which were going to be 
enzymatically extended with the oxazoline donor oligosaccharides (peptide Nr 1 - 14 in Table 
2, referring to Nr 1 - 14 in Figure 13 A). 
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Figure 13. Enzymatic N-glycan extension performed on a microarray slide including a few in-solution 
extended reference peptides. A) Spotting pattern, Nr 1 - 14 corresponds to the N-GlcNAc peptides 150 - 
163 in Table 2, and Nr 3p, 4p, 8p, 13p refer to the reference peptides 165 - 168, already extended with 
pentasaccharide core N-glycosylation; B) Peptides printed at 50 µM, with enzymatic on-slide N-glycan 
extension and recognized by incubation with ConA; C) Peptides printed at 50 µM, directly recognized by 
incubation with ConA without enzymatic on-slide extension; D) Peptides printed at 100 µM, with 
enzymatic N-glycan on-slide extension and recognized by incubation with ConA; E) Peptides printed at 100 
µM, directly recognized by incubation with ConA without enzymatic on-slide extension. 
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Figure 14. A) Direct data comparing well D and B in Figure 13, the peptide substrate was printed in two 
concentrations, 50 µM and 100 µM; B) Comparing the intensity of the 100 µM signals with the double 
intensity of the 50 µM signals; C) Comparing signal intensities of four peptides spotted at 100 µM 
concentration and the double signal intensities spotted at 50 µM concentration. i, internal standard, in 
solution N-glycan extended peptides from well D and B in Figure 13, ii, the same peptides synthesized by 
on-slide enzymatic N-glycan extension from well D and B in Figure 13. 
Two concentrations, 50 µM and 100 µM, were selected for printing the N-glycopeptide 
library and after immobilization the library were treated with the tetrasaccharide oxazoline 
donor 110 and the N175Q Endo-M enzyme for 1 h. The on-slide enzymatically extended 
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glycopeptides (Figure 13 B and D) and the blank control without enzymatic on-slide 
extension (Figure 13 C and E) were incubated with the biotin-labeled glycan binding lectin 
ConA, which recognize α-mannoside residues. After treatment with Cy5 streptavidin, the 
relative fluorescence were detected and the binding data analyzed.  
Shown in Figure 14 A, in solution enzyme extended N-glycopeptides and the on-slide enzyme 
extended N-glycopeptides showed similar average signal intensity, indicating that all of the 
14 N-GlcNAc peptides were converted to the pentasaccharide core N-glycopeptides. Shown 
in Figure 14 B, comparing the signals of the peptides spotted at 100 µM with the double 
signal intensity of the peptides spotted at 50 µM, indicated that the binding affinity observed 
from two experiments are similar. Certain fluctuations were observed between the different 
peptides, which in part can be explained by differences in lectin recognition to the N-glycan 
residue presented on different peptide backbones. In Figure 14 C, four glycopeptides 
pre-synthesized by in-solution enzymatic extension, were used as internal standards. The 
internal standard peptides were directly compared with the on-slide enzymatic reaction and 
showed similar signal intensities. In conclusion, it is feasible to generate an N-glycopeptide 
library with on-slide Endo-M enzymatic extension using an active oxazoline glycan donor and 
multiple N-GlcNAc peptide acceptors immobilized on the slide. Thus the procedure needs to 
be further optimized to reduce background problems and thereby achieving higher 
reproducibility. 
2.13 Coupling of the hexasaccharide oxazoline to N-GlcNAc peptides 
A second oxazoline donor, the hexasaccharide 112, was also evaluated for enzymatic 
glycopeptide extension using the Endo-M mutant. The conditions were in accordance with 
the description above, using 0.07 - 0.1 µmol substrate, 8.0 eq donor and 12.5 µM enzyme. 
The reactions were kept at pH 7.1, 25 °C and followed by analytical HPLC. 
Two different monoglycosylated peptide substrates 136 and 157 were tested in the 
in-solution coupling with hexasaccharide 112, the coupling products were observed on 
analytical HPLC, which were slightly faster than the starting peptides. The conversion rate 
reached up to 20%, and afterwards back hydrolysis to the starting peptides were then 
observed, the same results were shown in both cases. 
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Scheme 40 Enzymatic coupling of hexasaccharide oxazoline donor 112 on N-GlcNAc peptide 136 sequence: 
IN*TTADEKDPTNPFR from ADAM10 and 157 sequence: SpN*LTALPPDLPK from Platelet glycoprotein 1b 
alpha. 
The reason for the slow product formation causing hydrolysis back to the starting peptides 
cannot be completely explained, it might be a substrate limitation by the particular Endo-M 
enzyme mutant, but other Endo-M mutants, have previously shown to catalyze complex type 
oxazoline donors in higher yields. Since the oxazoline donor was not considered to be very 
stable, a desalting step was avoided after deacetylation, however it might be that these salt 
impurities of the donor caused problems in the followed enzymatic coupling reaction. 
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Figure 15. HPLC chromatogram following the hexasaccharide enzymatic coupling. Upper chromatogram 
figure: converting peptide 136 to the coupling product 169; lower chromatogram figure: converting 
peptide 157 to 170. 
Table 3. Peak integration on HPLC chromatogram following the enzymatic coupling. 
The coupling product 169 and 170 were purified and measured by high resolution ESI-MS. 
The major glycopeptide peak of the 3+ ion was detected and further fragmented by MS2 for 
detailed structural analysis. 
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Figure 16. MS2 fragmentation of the heptasaccharide N-glycopeptide 169. 
2.14 Distinctive MS/MS fragmentation pathways of N-glycopeptides for 
saccharide structure identification 
Mass spectrometry (MS)-based proteomics has in the recent years developed into a powerful 
method to qualitatively and quantitatively characterize a substantial number of all the 
proteins expressed in a cell. The use of proteomic methods for the identification of 
post-translational modifications (PTMs) of proteins has also emerged as an important tool to 
investigate protein regulation. In order to increase our knowledge about protein function 
and interactions it is important to continue the development of glycoproteomic methods 
aimed at characterizing glycosylation sites, and the glycan structures occupying such sites. 
MS strategies have frequently been used to determine the structures of released 
glycans,[209-210] the utilization of intact glycopeptides represents a bioconjugate structure 
where the glycosylation site structure and protein identity may be obtained from the same 
molecule. In a collaboration with Dr. Jonas Nilsson, we recently showed that the intensity 
profiles of saccharide oxonium ion spectra generated from collisional activation, using 
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positive mode higher energy dissociation (HCD),[211] of glycopeptides differed depending 
whether the epimeric structure was GalNAc or GlcNAc. A GlcNAc/GalNAc ratio term was 
introduced, where the (138+168)/(126+144) intensity ratio was used to designate 
glycopeptides as GlcNAc- or GalNAc-like showing typical values of 2-50 and 0.2-1, 
respectively. 
To better understand the observed differences of oxonium ion spectra profiles, the 
N-glycopeptides 165 and 166 with synthetically well-defined structures were additionally 
subjected to HCD and multistage CID-MSn experiments. The use of glycopeptides consisting 
of known Hex and HexNAc, linkages, core structures and anomeric configurations, enables 
investigations of the interrelation between small differences in glycan structure and the 
corresponding oxonium ion profiles. Effects of oxonium ion decomposition pathways for 
HexNAc containing glycoconjugates have partly been addressed previously,[212-213] but the 
precise correlation between them, their structure and mechanism of formation have not 
been fully investigated. The unraveling of various oxonium ion decomposition pathways will 
be of help in the design of new and improved methods for qualitative and quantitative 
glycopeptide analysis.  
In addition to the HexNAc oxonium ions, the terminal Man residues on the synthetic 
pentasaccharide core glycopeptides also gave rise to oxonium ions at m/z 163, 145, 127, 97 
and 85, having uneven m/z values and thus lacking nitrogen (Figure 17 A and B). The m/z 163 
→ m/z 145 → m/z 127 → m/z 97 sequence was observed, which is analogous to the m/z 
204 / 366 → m/z 138 decomposition of the HexNAc oxonium ions, and show that this 
pathway is also present for Man-generated Hex oxonium ions. Further, the occurrence of the 
m/z 85 ion is analogous to the m/z 204 → m/z 126 ring-fragmentation pathway for HexNAc 
oxonium ions, indicating that the decomposition of [Hex]+ also is mechanistically similar. 
These Hex-generated oxonium ions are generally not detectable in the HCD spectra of 
glycopeptides carrying terminal HexNAc or HexHexNAc structures, i.e. for complex type 
N-glycopeptides, an example is presented here in (Figure 17 C). Thus, terminal HexNAc is 
substantially more prone to form oxonium ions normally suppressing the simultaneous 
presence of Hex oxonium ions. 
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Scheme 41. Proposed reaction mechanisms for HCD and CID induced saccharide decomposition of A) 
HexNAc and B) mannose; unit loss of H2O, anomerization and ring-cleavage. 
This prevalence may depend on the tendency of the HexNAc N-acetyl group to become 
protonated during the ESI facilitating the formation of charged fragments originating from 
the HexNAc. Similar results, with prominent Man-and GlcNAc-generated oxonium ions, were 
obtained by fragmentation of 166 demonstrating that the peptide part does not influence 
the oxonium ion fragmentation patterns (Section 10). The realisation of these Man-specific 
oxonium ions prompted the investigation whether they also were observable in 
glycoproteomic samples. In a trypsinised and strong anion exchange (SAX) prepared human 
cerebrospinal fluid sample subjected to LC-MS/MS,[214] indeed the presence of 
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Hex-generated oxonium ions was observed in a number of HCD spectra. By analysis of the 
peptide backbone fragmented b- and y-ions one of these was identified to be 
TVLTPATNHMGN*VTFTIPANR from Complement C3 carrying a (Man)5(GlcNAc)2 glycan at the 
underlined Asn (Figure 17 B). These results show that Man-generated oxonium ions indeed 
regularly are formed in the HCD of high-mannose N-glycopeptides and could become 
significant already at the relatively simple (Man)3-substitution level (Figure 17 A and B).  
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Figure 17. HCD of synthetic and native high-mannose N-glycopeptides. A) The HCD spectrum at the NCE 
20% level shown for the m/z 50-220 region a synthetic (Man)3(GlcNAc)2 substituted Antithrombin III 
peptide 166, sequence: NH2-Spacer-WVSN*KTEGR. See also section 10. B) The HCD spectrum, including a 
m/z 100-220 expansion of a native (Man)5(GlcNAc)2 substituted peptide. The sequence is 
TVLTPATNHMGN*VTFTIPANR from complement C3 (UniprotKB id: CO3_HUMAN). C) The HCD spectrum of 
m/z 100-600 expansion of a native (Gal-GlcNAc-Man)2Man(GlcNAc)2 substituted SWPAVGN*CSSALR 
tryptic peptide fragment from hemopexin. 
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3 Project 2: Synthesis of Extended O-Mannose Glycopeptide 
Constructs for Generation of Glycan and Glycopeptide 
Specific Antibodies 
3.1 Introduction to O-Mannose modifications 
Proteins modified with O-mannose glycans on backbone Ser and Thr residues, are involved in 
important functions in brain and muscle glycobiology.[215-216] For example in -Dystroglycan 
(-DSG),[217-219] the O-mannose glycosylation is essential for stabilization of the 
dystrophin-glycoprotein complex acting as a transmembrane linker between the extracellular 
matrix and intracellular cytoskeleton.[220] The O-mannose glycans on -DSG are often 
extended with sialyl-N-acetyllactosamine[221] on the peptide tandem repeats resulting in the 
formation of NeuNAcα2-3Galβ1-4GlcNAcβ1-2Manα tetrasaccharide structures.[222-223] Other 
O-mannose glycan epitopes found on -DSG are extension with fucose-N-acetyllactosamine, 
the HNK-1 epitope and branching on the 6-position of the mannose unit (Scheme 42).[224-225] 
 
Scheme 42. O-Mannose glycans identified on mammalian proteins. A) Gal-GlcNAc-Man trisaccharide; B) 
GlcNAc-Man disaccharide and C) 2,6 di-GlcNAc-Man trisaccharide structures were employed as target for 
vaccine design. 
-DSG were long considered to be the only O-mannosylated protein in mammals, however a 
study on O-glycans from total rabbit brain gave a different picture concluding that about 30% 
of the released O-glycans[226] were identified as O-mannosylated.[227-229] The high abundance 
of protein O-mannosyl glycans in brain was also shown in a study of the mice brain 
Project 2: Synthesi  of e  -m  glycopeptide 
c  for gen ration of glycan and glycopeptide specific 
antibodies 
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proteome.[230] Recently, a handful of additional mammalian glycoproteins were identified 
containing O-mannosyl modifications, the transmembrane protein CD24,[231] a monoclonal 
IgG2 light chain from CHO cells,[232] receptor protein-tyrosine phosphatase, known as 
RPTPβ,[233-234] phosphacan,[235] tenascin-R, neurofascin 186, neurocan,[236-237] brevican and 
versican.[238] These studies altogether raise a conviction that many more not yet identified 
proteins carry O-mannosyl glycans with critical functions in the mammalian brain.  
3.2 Project aim 
In spite of the clear importance of O-mannosyl glycosylation, no tools are to date available 
for specific detection, enrichment and identification of proteins containing these 
modifications. In order to study these processes, a project was initiated to generate glycan 
and glycopeptide specific antibodies, which could be useful tools to detect and enrich 
O-mannosylated proteins. Vaccine-constructs were prepared from glycopeptides containing 
these extended mannose moieties. Since the terminal O-glycans of the O-mannosyl 
modifications show structural similarities with the complex type N-glycans, a few common 
building blocks were used for construction of both O-mannosyl amino acids and N-glycans as 
described in the section above. The prepared Fmoc-O-mannosyl glycosylated amino acids 
were employed in glycopeptide synthesis. The glycopeptides were then incorporated into 
glycopeptide-immune carrier constructs for antibody induction in rabbits. For antibody 
evaluation additional glycopeptides were prepared and employed in ELISA neutralization 
experiments and on glycopeptide microarrays. 
3.3 Synthetic strategy for synthesis of the linear Gal-GlcNAc-Man and 
GlcNAc-Man O-glycoamino acids 
Protein O-mannosylation on mammals typically contain a common Galβ1-4GlcNAcβ1-2Manα 
trisaccharide core structure, which has been found further modified with branching or 
termination with the HNK epitope, sialic acid or fucose residues (Scheme 42 A and B). A few 
chemical and chemoenzymatic synthesis strategies for preparation of simple O-mannosyl 
glycosylated amino acids and glycopeptides were previously reported.[239-243] 
Glycosylated amino acids containing the linear core structures, the Galβ1-4GlcNAcβ1-2Manα 
trisaccharide and the GlcNAcβ1-2Manα disaccharide, were here chemically prepared 
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 (Scheme 43). The disaccharide amino acid containing a terminal GlcNAc residue was 
considered to be more immunogenic, when included in a glycopeptide vaccine construct 
compared with the corresponding trisaccharide with a terminal Gal residue. The chemical 
strategy involved the synthesis of a protected α-mannosylated threonine amino acid building 
block, which could be extended through NIS activation with the Galβ1-4GlcNAc thioglycoside 
donor 115 or the GlcNAc thioglycoside donor 116 to obtain the di- or trisaccharide amino 
acids. The mannosyl threonine could in turn be prepared by coupling of a mannose 
trichloroacetimidate donor 76 with a protected threonine acceptor employing 
trichloroacetimidate chemistry.[244] 
Scheme 43. Retrosynthetic analysis for synthesis of the glycosylated Fmoc amino acid building blocks. 
3.4 Synthesis of the linear Gal-GlcNAc-Man and GlcNAc-Man O-glycoamino 
acids 
The chemical synthesis commenced with the coupling of the mannose trichloroacetimidate 
donor 76, described above in the N-glycan part (Scheme 33 A), with the N-Boc and O-tBu 
protected threonine acceptor[245] resulting in the α-Man-Thr coupling[246-247] product 113 
(Scheme 44 A). The mannose trichloroacetimidate donor 76 contained a single acetyl 
protecting group for selective deprotection and glycan extension in the 2-position, the 
remaining hydroxyls were protected with stable benzyl groups. By neighboring group 
75 
 
Synthesis of extended O-mannose glycopeptides for generation of specific antibodies 
participation, the acetyl group in the mannose 2-position would further promote the 
formation of an α-glycosidic bond during coupling with the threonine acceptor. The 
threonine residue was Boc protected, since the later removal of the glycan benzyl groups by 
catalytic hydrogenation, would be problematic in the presence of Fmoc groups. Amino acid 
Fmoc-protection was necessary to proceed with the later peptide synthesis and the Fmoc 
group was therefore inserted after removal of the benzyl protecting groups.[245] For further 
extension of the α-Man-Thr coupling product 113, the acetyl group in the Man 2-position 
was removed with sodium methoxide in methanol to obtain compound 114. The glycan 
thioglycoside donors employed in α-Man-Thr extension, were converted from N-phthalimido 
protected thioglycoside donors, disaccharide 43 and monosaccharide 55 (Scheme 44 B), to 
the N-Troc protected donors 115 and 116 using hydrazine hydrate followed by treatment 
with acetic anhydride in pyridine. The synthesis of the Phth saccharides 43 and 55 were 
described in the N-glycan section (Scheme 30 B and Scheme 31 A). The N-Troc protecting 
groups on the thioglycoside donors were considered to contribute with increased reactivity 
of the prepared donor building blocks. Additionally, removal of the phthalimido groups in 
later steps under strong base conditions may result in β-elimination and Phth protection was 
therefore not considered to be compatible with O-glycosyl amino acid synthesis.[248-249] The 
deacetylated α-Man-Thr 114 was then elongated with two N-Troc thioglycoside donors 115 
and 116 under NIS, TfOH activation[250-251] to give compound 117 and 121 (Scheme 44 C and 
D). The conversion of the obtained di- and trisaccharide amino acid coupling products into 
stable building blocks compatible with Fmoc solid-phase peptide synthesis (Fmoc-SPPS), was 
achieved by a few protecting group manipulation steps. Initially, the N-Troc groups of 117 
and 121 were removed by zinc reduction followed by acetylation to give 118 and 122. 
Catalytic hydrogenation with 10% Pd(C) and subsequent acetylation resulted in the 
formation of the compounds 119 and 123. Simultaneous removal of the threonine tert-butyl 
ester (tBu) and amine tert-butyloxycarbonyl (NHBoc) using trifluoroacetic acid (TFA) was 
followed by in situ reaction with Fmoc-OSu to give the desired glycosylated amino acid 120 
and 124, which were ready to use in Fmoc-SPPS.[252-253] 
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Scheme 44. a) TMSOTf, molecular sieves, DCM, -40 °C 2 h; b) 0.08 M NaOMe in MeOH, r.t. 2 h; c) 
hydrazine hydrate, MeOH, 70 °C, 2 h, 62%; TrocCl, NaHCO3, dioxane/H2O 2:1, r.t. 2 h; Py/Ac2O, r.t. 24 h; d) 
hydrazine hydrate, Tol/EtOH 2:3, 105 °C 72 h; 1,4-dioxane, NaHCO3 in H2O, TrocCl, r.t. 2 h; e) NIS, TfOH, 
molecular sieves, DCM, -18 °C 2 h; f) Zn, AcOH, 40 °C 48 h; Py/Ac2O, r.t. 24 h; g) H2, Pd(C), MeOH/AcOH 
30:2, r.t. 48 h; Py/Ac2O, r.t. 24 h; h) TFA/DCM/anisole 3:1:0.4, r.t. 24 h; Fmoc-OSu, NaHCO3, dioxane, r.t. 4 h; 
i) NIS, TfOH, DCM, -40 °C, 30 min; j) Zn, AcOH, r.t. 36 h; k) H2, Pd(C), MeOH/AcOH 30:2, r.t. 48 h; Py/Ac2O, 
r.t. 24 h; l) TFA/DCM 3:1, r.t. 3 h; Fmoc-OSu, NaHCO3, dioxane, r.t. 4 h. 
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3.5  Synthetic strategy for synthesis of a branched GlcNAc2-Man-O-Thr 
amino acid building block 
A 2,6 branched O-mannosyl glycosylated amino acid was also prepared for further binding 
specificity analysis of the induced antibodies directed to the linear core O-mannosyl 
structure, which was described above (Scheme 42 C). Additionally it was considered 
interesting to study binding interactions of mannose specific lectins comparing the linear and 
branched O-mannosyl structures. 
Two different synthetic strategies were evaluated for synthesis of the 2,6-branched 
O-mannosyl glycosylated amino acid 135. Similar to the synthesis of the linear 2-elongated 
O-mannosyl glycosylated amino acid described above, a functional mannosyl 
trichloroacetimidate donor 129 was used in the coupling with a protected threonine 126. 
The obtained α-mannosylated threonine amino acid building block was deacetylated on both 
the 2 and 6-positions, which thereafter were extended with the GlcN thioglycoside donor 54 
on both hydroxyls simultaneously (Scheme 45 A and C). In the second approach the 
trisaccharide donor 65, was directly connected to the Fmoc threonine 126 (Scheme 45 B).  
 
 
 
 
 
 
 
 
 
Scheme 45. Retrosynthetic analysis for two synthesis routs of the branched glycosylated Fmoc amino acid 
building blocks. 
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 The trisaccharide donor 65 was in turn obtained by modification of one of the N-glycan 
complex type donor building blocks, which were further described in the N-glycan section. In 
both approaches for synthesis of the 2,6-branched O-mannosyl amino acids, 
p-methoxybenzyl protecting groups were used instead of benzyl groups, since a 
hydrogenation step, which would be problematic in the presence of Fmoc groups was then 
avoided. The p-methoxybenzyl groups were easily removed by CAN treatment. Additional 
steps for later replacement of amino acid Boc groups with Fmoc were thereby unnecessary. 
3.6 Synthesis of a branched GlcNAc2-Man-O-Thr amino acid building block 
The Fmoc protected threonine was directly prepared and employed in 2,6-branched 
O-mannosyl amino acid synthesis (Scheme 46 A). In the first approach, building up a large 
glycan structure stepwise with small monosaccharide donors (Scheme 46 B), the 
2,6-hydroxyl mannose 31, from the above described N-glycan synthesis (Scheme 30 A), was 
converted into the trichloroacetimidate donor 129 in a few steps by acetylation, deallylation 
with Wilkinson’s catalyst and reaction with trichloroacetonitrile in DBU. The coupling of 
trichloroacetimidate donor 129 with acceptor 126 was performed under TMSOTf activation 
to give the α-Man-Thr coupling product 130. The reaction proceeded in Et2O at r.t. to avoid 
orthoester formation, in DCM or at lower temperatures extensive formation of orthoester 
products was observed, confirmed by NMR analysis. Another coupling step then followed to 
elongate the α-Man-Thr 130 with the GlcNTroc thioglycoside donor 54 by NIS/TfOH 
activation to give the coupling product 132 in good yields. In the second synthesis strategy 
approach the trisaccharide donor 65, synthesis described in the N-glycan section (Scheme 31 
D), was by TMSOTf activation connected to the threonine 126 directly and again obtained 
the coupling product 132 in a high yield.  
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Scheme 46. a) NaHCO3, Fmoc-OSu, acetone/H2O 1:1, r.t. 24 h; b) tert-butanol, CuCl, DCC, r.t. 72 h under 
darkness; 125 in DCM added, r.t. 2 h; c) Py/Ac2O, r.t. 24 h; d) Wilkinson’s catalyst, Tol/EtOAc/H2O 20:10:1, 
reflux 24 h; I2, THF/H2O 4:1, r.t. 2 h; e) trichloroacetonitrile, DBU, DCM, 0 °C 3 h; f) 126, TMSOTf, molecular 
sieves, Et2O, r.t. 30 min; g) NaOMe in MeOH, pH 9.5, r.t. 24 h; NaHCO3, 1,4-dioxane/H2O 1:1, Fmoc-OSu, r.t. 
2 h; h) NIS, TfOH, DCM, -50 °C 4 h, 90%; i) TMSOTf, molecular sieves, DCM, r.t. 2 h, 82%; j) CAN, MeCN/H2O 
9:1, r.t. 30 min; Py/Ac2O, r.t. 24 h; k) Zn, AcOH, r.t. 4 days; Py/Ac2O, r.t. 24 h; l) TFA/DCM 3:1, r.t. 24 h. 
The p-methoxybenzyl groups were then removed by CAN followed by acetylation. 
Subsequently the N-Troc groups were converted to NHAc groups by zinc reduction and 
acetylation. The dimethyldimethoxy acetal ring and amino tert-butyl protection groups were 
simultaneously removed[254] in the last step by treatment with TFA to obtain the 
2,6-branched glycoamino acid 135 in a moderate yield, the slow removal of the acetal here 
seemed to be a problem (Scheme 46). 
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 3.7 Synthesis of the Gal-GlcNAc-Man antigen glycopeptides and BSA- and 
KLH-conjugates 
The obtained Galβ1-4GlcNAcβ1-2ManαThr 120 and GlcNAcβ1-2ManαThr 124 were 
employed in the synthesis of the glycopeptides 171 - 173 (Scheme 47).[255-256] Glycine 
residues were here incorporated on each side of the glycosylated amino acids in order to 
generate a vaccine construct inducing antibodies specific to the O-mannosyl glycan amino 
acid structure no matter of the underlying peptide backbone sequence. Starting from 
preloaded Fmoc-Gly Rink amide resin (12.5 μmol),[257-258] coupling of the standard 
Fmoc-amino acids (8 equivalents) was carried out using HBTU/HOBt and the glycosylated 
Fmoc-threonine building block 120 and 124 (2 equivalents) were coupled using HATU/HOAt.  
 
Scheme 47. Synthesis of antigen peptide and similar peptides. a) i: Fmoc-cleavage: Piperidine (20%) in 
DMF, ii: Amino acid-coupling: Fmoc-AA-OH, HBTU, HOBt, DIPEA/DMF; b) Resin-cleavage: TFA/TIPS/H2O 
(15:0.9:0.9), 2 h; c) NaOMe, MeOH, pH 9.5, 20 h. 
The glycosylated amino acids were pre-activated in a smaller volume of solvent and added 
manually to the resin. Furthermore, the reaction time of the glycosylated amino acids were 
extended (to 6h instead of 40 min). After full assembly of the glycopeptides on the resin, the 
peptide was terminated with coupling of a triethylene glycol spacer and subsequent 
detachment from the resin by applying a mixture of trifluoroacetic acid 
(TFA)/triisopropylsilane (TIPS)/H2O (90:5:5). After a desalting step on a C-18 cartridge, the 
O-acetyl groups were removed by treatment with catalytic amounts of NaOMe in methanol 
at pH 9.5.[259] The deprotected glycopeptides 171 - 173 were finally purified by preparative 
HPLC. 
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Scheme 48. Conjugation to BSA/KLH immure carrier. a) EtOH/H2O 1:1, pH 8.0, r.t. 2 h; b) 50 mM Na2HPO4 
buffer, pH 9.3, r.t. 48 h. 
The glycopeptide 171 and non-glycosylated 173 was conjugated to BSA and KLH by an initial 
coupling at the N-terminal amine with diethyl squarate in EtOH/H2O (1:1) at pH 8 to give the 
squaric acid monoamide 174 and 175.[260-261] The coupling to BSA and KLH performed in 
aqueous Na2HPO4 buffer at pH 9.5 to give the glycopeptide BSA and KLH
[262] conjugate 176 - 
179 (Scheme 48). The vaccine construct 178 was used for immunization in Rabbit, while the 
other glycopeptide conjugates were used for ELISA antibody analysis.[263-264] 
To determine the glycopeptide loading on the KLH-conjugate 178, anthranilic acid was used 
to label[265-266] galactose/mannose residues cleaved from the synthesized KLH conjugate with 
10% TFA. The released and labeled monosaccharides was then quantified by HPLC.[267] To 
determine the relationship of UV absorption at 214 nm on the HPLC chromatogram with the 
amount of sugar, a calibration curve was first made. A 1:1 mixture of galactose/mannose, 
was first treated with anthranilic acid labeling solution, then 1 μL of the reaction mixture was 
diluted with 100, 150, 200 and 600 times with 0.1% TFA-H2O. The diluted samples were 
injected into the analytical HPLC, measuring the UV absorbance at 214 nm. The combined 
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 galactose and mannose peak areas were detected and a calibration curve was plotted for the 
corresponding dilutions. 
Dilution Gal-Man mix 
Amount of injected 
monosaccharide (nmol) 
SUM Gal+Man peak 
area at 214 nm 
1:100 1.8 187.43 
1:150 1.2 114.78 
1:200 0.9 93.48 
1:600 0.3 33.86 
 
Figure 18. Calibration curve peak area absorbance at 214 nm versus dilution in nmol of the 1:1 
galactose/mannose mixture.  
The monosaccharides cleaved from KLH conjugate 178 were incubated with anthranilic acid 
labeling solution and the diluted reaction mixture was analyzed by HPLC, measuring the UV 
absorbance at 214 nm with a peak area of 83.549 mAu, which was corresponding to 0.818 
nmol of galactose and mannose respectively. As the molecular weight of KLH (400-3000 kDa, 
given by Sigma-Aldrich), the glycopeptide to KLH ratio was determined to 65 (400 kDa KLH) - 
491 (3000 kDa KLH) mol glycopeptide per mol KLH. 
3.8 Synthesis of the GlcNAc-Man antigen and branched GlcNAc2-Man antigen 
In addition to the synthesis of the KLH vaccine construct 178 containing the 
Galβ1-4GlcNAcβ1-2Manα glycan structure, the GlcNAc-β1-2Manα and the branched 
GlcNAc-β1-2-(GlcNAc-β1-6)Manα glycopeptides were synthesized and conjugated to an 
immune carrier protein (Scheme 49). Starting from Fmoc-Gly trityl resin, the glycosylated 
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Fmoc-threonine building blocks 124 and 135 (2 equivalents) were coupled using HATU/HOAt, 
pre-activated in a smaller volume of solvent and reacting for 8 h. After capping the 
N-terminal with Ac2O, HOBt and DIPEA, the peptides were cleaved form the resin by applying 
a mixture of TFA/TIPS/H2O (90:5:5). A spacer was then connected to the C-terminal for later 
conjugation with an immune carrier or for immobilization on a microarray surface. The 
position of the linker in the C-terminal instead of the N-terminal aimed to avoid having a 
potential immunogenic C-terminal amide or free carboxylic acid close to the glycosylation 
site. After linkage coupling a deacetylation step was followed to obtain peptide 180 - 183. 
The synthesis of the 2,6 branched glycopeptide 181 proceeded in very low yield compared to 
the other glycopeptides and it was believed that steric hindrance with two branched 
glycosylated amino acids next to each other caused a problem. Additionally, a large extend of 
the monoglycosylated peptide byproduct 182 was formed. 
The obtained glycosylated antigen peptides 180 and 181 were extended with a squarate 
linker and conjugated to an immune carrier protein (Scheme 50). The CRM197 immune carrier 
mutant originating from Difteria toxin have successfully been used for immune stimulation of 
different glycoconjugates and was therefore selected for conjugation to our peptides. 
The conjugation proceeded in phosphate buffer at pH 9.3 and after washing using spin filters, 
the glycopeptide loading to the protein carrier was measured be MALDI mass spectrometry. 
For the GlcNAc-Man glycosylated antigen 187, 6.3 equivalents of peptides were loaded on 
each CRM molecule, reacting from 26.4 eq antigen peptide 184, and 13.3 eq of peptides was 
conjugated on the BSA carrier 186 using 17.7 eq of the antigen peptide substrate. The BSA 
conjugates were prepared for ELISA determination of the antibody titers after immunization 
with the desired vaccine constructs. The conjugation of 2,6 branched GlcNAc2-Man 
glycopeptide 185 to BSA/CRM resulted in a loading of around 2-3 eq of peptides, using 28-30 
eq of peptide substrate in the coupling reaction. 
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Scheme 49. Synthesis of antigen peptide and similar peptides with C-terminal spacer. a) i: Fmoc-cleavage: 
Piperidine (20%) in DMF, ii: Amino acid-coupling: Fmoc-AA-OH, HBTU, HOBt, DIPEA/DMF, iii: N-terminal 
capping: Ac2O, HOBt, DIPEA/DMF; b) Resin-cleavage: TFA/TIPS/H2O (15:0.9:0.9), 2.5 h; c) i: 
N-Boc-4,7,10-trioxa-1,13-tridecanediamine  spacer, HATU, HOAt, DIPEA/DMF, 8 h, ii: TFA/TIPS/H2O 
(15:0.9:0.9), 2.5 h; d) NaOMe, MeOH, pH 9.5, 20 h. 
Scheme 50. Glycopeptide conjugations to BSA/CRM immure carriers. a) EtOH/H2O 1:1, pH 8.0, r.t. 2 h; b) 
50 mM Na2HPO4 buffer, pH 9.3, r.t. 72 h. 
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3.9 Synthesis of different linear and branched O-mannosyl glycopeptide 
sequences for antibody and lectin analysis 
The glycopeptides 190 - 195, which contained the three different linear and branched 
O-mannosyl-glycans, were synthesized (Scheme 51). Two glycopeptide sequences were 
selected from α-Dystroglycan (α-DSG), a glycoprotein that is known to be densely modified 
with O-mannosylation. Starting from Fmoc-Gly trityl resin or Fmoc-Arg trityl resin (12.5 μmol) 
and in accordance with the above described glycopeptide synthesis, the linear glycopeptides 
190 - 193 were obtained in good yields, while the more bulky 2,6 branched O-mannosyl 
glycopeptides 194 and 195 were obtained in lower yields. The synthetic O-glycopeptides 
were used in ELISA and microarray studies to investigate the induced O-mannosyl antibodies 
and to evaluated binding interactions with glycan specific lectins. 
 
Scheme 51. Synthesis of α-DSG O-mannosyl glycopeptides. 
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 3.10 Immunization of O-man antigen and evaluation of the antibody serum 
In order to induce antibodies with specific recognition of the Galβ1-4GlcNAcβ1-2Manα 
glycosylated structures on proteins and peptides, two rabbits 21390 and 21391 were 
immunized with the O-mannosyl-glycopeptide KLH conjugate vaccine 178, together with 
Freunds complete adjuvant (CFA). Six booster immunizations were carried out over 8 weeks. 
The induced antibody titers were analyzed on ELISA plates coated with the 
Galβ1-4GlcNAcβ1-2Manα glycopeptide BSA conjugate 176. Analysis of the sera from the 
pre-immune, first bleed and final bleed by ELISA showed that a strong immune response was 
directed against the antigen structure (Figure 19 A). The binding specificity of the obtained 
antibody sera was further evaluated by incubations with glycopeptides 171, 172, 173, 190 
and 191 in a microarray[268] format (Figure 20) or by ELISA neutralization experiments (Figure 
19 B and C).  
Both the ELISA neutralization experiments and the microarray analysis showed that the 
antibody sera were highly specific to the Galβ1-4GlcNAcβ1-2Manα glycopeptide antigen 
structure 171 and with some reactivity to the structurally similar GlcNAcβ1-2Manα 
glycopeptide 172. The antibody sera recognized neither the non-glycosylated antigen peptide 
173 nor the α-DSG peptide 191 glycosylated with the Galβ1-4GlcNAcβ1-2Manα trisaccharide. 
The α-DSG glycopeptide 190 containing the antigen trisaccharide showed a weak neutralizing 
effect by the ELISA neutralization experiments, but no binding interaction was observed on 
the glycopeptide microarray. The obtained results showed that both the glycan residues and 
the peptide backbone were important for the binding recognition of the induced antibodies. 
The induced antibodies were in this case not suitable for applications to generally detect 
O-mannosyl glycosylation on proteins. The results thus prove that antibodies could be 
produced with very high selectivity to chemically defined O-mannosyl glycopeptide 
structures. 
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Figure 19. A) ELISA analysis of pre-immune, first bleed and final bleed of Rabbit 21390 and 21391, 
immunized with Gal-GlcNAc-Man KLH 178. The ELISA plate was coated with Gal-GlcNAc-Man BSA 176; B) 
ELISA neutralization experiments with peptides 171, 172, 173, 190, 191 and Rabbit 21390 final bleed; C) 
ELISA neutralization experiments with peptides 171, 172, 173, 190, 191 and Rabbit 21391 final bleed. 
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Nr 
Compound 
Nr 
Sequence 
Glycan 
structure 
1 172 SpacerGT*G GlcNAc-Man 
2 173 SpacerGTG NON 
3 190 SpacerPVPGKPT*VTIR 
Gal-GlcNAc-Man 4 191 SpacerRGAIIQT*PTLG 
5 171 SpacerGT*G 
 
Figure 20. Microarray results of rabbit serum 23190 and 23191. A) Serum 23190 final bleed 1:5000; B) 
Peptide spotting pattern designed for analysis of serum 23190; C) Serum 23191 final bleed 1:100; D) 
Peptide spotting pattern designed for analysis of serum 23191. 
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Synthesis of extended O-mannose glycopeptides for generation of specific antibodies 
The CRM vaccine construct 187, conjugated with the GlcNAcβ1-2Manα glycopeptide was 
immunized in rabbit 23803 and 23804 with Freunds complete adjuvant (CFA). Six booster 
immunizations were carried out over 8 weeks. Analysis of the antibody sera from the 
pre-immune, first bleed, second bleed and final bleed by ELISA, coated with the 
GlcNAcβ1-2Manα glycopeptide BSA conjugate 186, showed that a strong immune response 
was directed against the antigen structure (Figure 21).  
 
 
 
Figure 21. A) ELISA of pre-immune, first bleed, second bleed and final bleed of Rabbit 23803, immunized 
with GlcNAc-Man CRM 187, ELISA plate coated with GlcNAc-Man BSA 186; B) ELISA of preimmunization, 
first bleed, second bleed and final bleed of Rabbit 23804, immunized with GlcNAc-Man CRM 187, ELISA 
plate coated with GlcNAc-Man BSA 188. 
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Synthesis of extended O-mannose glycopeptides for generation of specific antibodies 
 The binding specificity of the induced antibody sera were analyzed by incubations with 
glycopeptides 171 - 173, 180 - 183 and 190 - 195 in a microarray format (Figure 22). 
Additionally, the O-mannosyl glycopeptide microarray was employed to evaluate the glycan 
binding lectin Concanavalin A (ConA), which is known to recognize α-mannose residues on 
N-glycoproteins. This lectin might as well be useful for detection or enrichment of 
O-mannosyl proteins. 
Nr 
Compound 
Nr 
Peptide sequences 
Glycan 
structure 
Nr Peptides Conc 
1 190 SpacerPVPGKPT*VTIR 
Gal-GlcNAc-Man 
12 
180 
GT*T*GSpacer 
100 µM 
2 191 SpacerRGAIIQT*PTLG 13 50 µM 
3 171 SpacerGT*G 14 10 µM 
4 192 SpacerPVPGKPT*VTIR 
GlcNAc-Man 
15 2 µM 
5 193 SpacerRGAIIQT*PTLG 16 0.5 µM 
6 172 SpacerGT*G 17 
181 
GT*T*GSpacer 
100 µM 
7 194 SpacerPVPGKPT*VTIR 
2,6-GlcNAc2-Man 
18 50 µM 
8 195 SpacerRGAIIQT*PTLG 19 10 µM 
9 182 T*GSpacer 20 2 µM 
10 183 GTTGSpacer 
Non 
21 0.5 µM 
11 173 SpacerGTG (Nr 1-11 applied at 250µM) 
 
Figure 22. Microarray experiment designed for rabbit serum 23803 and 23804. A) Serum 23803 final bleed 
1:25 dilution; B) Serum 23804 final bleed 1:25 dilution; C) ConA 0.1 mg/mL; D) Peptide spotting pattern. 
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The antibody sera 23803 and 23804 recognized the double glycosylated GlcNAc-Man antigen 
peptide 180 exceptionally strong (position 12-16, Figure 22 A and B, Figure 23). Additionally, 
the double-glycosylated peptide 2,6-branched GlcNAc2-Man peptide 181 were also partly 
recognized (position 17-21, Figure 22 A and B, Figure 23). The antigen structure was here 
assembled differently from the previous KLH vaccine construct 178 and, a dimer with higher 
glycan density aimed to increase induction of antibodies directed to the glycosylated amino 
acid structure. As a result, a major binding epitope recognizing the clustered GlcNAc-Man 
structure seems to be dominating in the antibody sera. Additionally the GlcNAc-Man 
monoglycosylated peptides 192, 193 and 172 (position 4-6) and mono-glycosylated 
2,6-branched GlcNAc2-Man peptides 195 and 182 (position 8-9), were recognized to some 
extent. The non-glycosylated backbone sequences were as well partly recognized by the 
immune sera (position 10-11). 
By microarray analysis of the lectin ConA the three mono-glycosylated GlcNAc-Man 
glycopeptides 192, 193 and 172 were in particular well recognized (position 4-6, Figure 22 C 
and Figure 23). The mono-glycosylated linear Gal-GlcNAc-Man glycopeptides 190, 191 and 
171 (position 1-3) and the 2,6-branched GlcNAc2-Man peptides 195 and 182 (position 8-9) 
were only weakly recognized by ConA. The double-glycosylated peptide 180 and 181 were 
not recognized at all (position 12-21). This means that the ConA lectin recognition is both 
influenced by the glycan structure and the presentation in a clustered or monoglycosylated 
form. The observed discriminations, can be very useful for future O-mannosyl structural 
analysis work using the ConA lectin. Further, clustered or elongated O-mannosyl 
glycopeptide or glycoprotein structures will be discriminated by ConA lectin enrichment.   
 
Figure 23. Microarray results of rabbit serum 23803 and 23804 compared with ConA. 
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 In conclusion, efficient methodology was developed for the synthesis of the glycosylated 
amino acid building blocks, Galβ1-4GlcNAcβ1-2ManαThr 120, GlcNAcβ1-2ManαThr 124 and 
GlcNAcβ1-2(GlcNAcβ1-6)ManαThr 135. The glycosylated amino acids were employed in the 
construction of O-mannosyl glycopeptides and the corresponding BSA, KLH and CRM 
glycopeptide conjugates 171 - 195. Immunizations of vaccine 178 in rabbit gave evidence 
that a strong immune response was directed to the glycopeptide antigen structure. 
Evaluation of the antibody sera binding specificity using glycopeptide microarrays and ELISA 
neutralization experiments showed that highly specific antibodies were obtained recognizing 
the O-mannosyl glycopeptide antigen structure. Immunizations of vaccine 187 in rabbit 
showed immune responses directed to the antigen glycan structure presented on different 
peptides evaluated by ELISA and microarrays. In particular a clustered glycan binding epitope 
also present in the glycopeptide antigen structure was highly recognized. Analysis of the 
glycan binding lectin Concanavalin A (ConA), which is known to recognize α-mannose 
residues, showed that unique glycan and glycopeptide structural binding epitopes were 
recognized. The obtained results will have an impact in the structural analysis work of 
O-mannosyl glycoproteins. 
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4 Summary 
This PhD thesis work includes the synthesis of glycans and glycosylated amino acid building 
blocks to generate various glycopeptides to study protein N- and O-glycosylation binding 
events and to provide structural analysis tools. Diverse N-glycan structures and O-mannosyl 
glycosylation, were here of the main focus. These structures include certain structural 
resemblance. Complex type N-glycans and the elongated O-mannosyl glycosylated amino 
acids contain the same terminal structural units and were therefore prepared from common 
building blocks (Figure 24). The high mannose type N-glycosylation further resembles the 
α1-2 O-mannosyl extension commonly found in yeast,[269] while the complex type 
N-glycosylation resembles the elongated O-mannosylation, which extensively have been 
found modifying proteins in eukaryotic brain tissues.  
 
Gal GlcNAc Man  
Figure 24. Synthesized building blocks which were shared in N-oligosaccharide and O-mannosyl glycan 
synthesis. 
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 To prepare the N-glycan oligosaccharides, which contains a common pentasaccharide core 
unit linked to asparagine on proteins and peptides, a Manβ1-4GlcNAc disaccharide core 26 
was initially synthesized. Due to difficulties to perform stereoselective couplings to generate 
the β-Man glycosidic bond, a Glc-GlcNAc disaccharide was initially formed. This disaccharide 
was obtained starting with the coupling of glucose donor 22 to the glucosamine acceptor 16, 
to form a β1-4 linkage (Scheme 26). The disaccharide Glc unit was then converted into a Man 
residue. The symmetrical extensions with trichloroacetimidate donor building blocks on the 
3,6 positions of the disaccharide core mannose structure 26, were tested using the 
monosaccharide donors 76 and 86, disaccharide donor 58, and trisaccharide donors 62 and 
70 (Figure 24). The results indicated that, i) The glycan donor must be active enough for high 
conversion to the desired product, comparing the acetylated donor 86 and benzylated donor 
76, the later donor as expected gave a much higher yield. ii) In case of coupling of 
monosaccharide and disaccharide donors 76 and 58, the core disaccharide acceptor 26 was 
completely consumed in yields of 70-80%  (Scheme 34, Scheme 35 A), however when the 
donor size grow larger, for instance with the trisaccharide 62 and 70, symmetrical couplings 
simultaneously extending the Man 3- and 6-position were problematic. Mixtures of mono- 
and double glycosylated products were obtained. Therefore, glycan donors larger than 
disaccharides were not used in these symmetrical coupling. iii) An alternative approach was 
to building up the large oligosaccharides in a stepwise fashion, employing smaller donor 
units. To obtain the 2,6 branched oligosaccharide 100, the disaccharide donor 58 was first 
coupled to acceptor 26 forming hexasaccharide 96. Then extended with the monosaccharide 
donor 55 to generate the desired octasaccharide (Scheme 35 C). The 2,4 branched 
oligosaccharide 108 was generated in a good yield by quadruple mannose donor 103 
extensions on the 2,4 positions of the two terminal glycan residues of acceptor 104  
(Scheme 36). In summary four complex type N-glycan structures 89, 96, 100 and 108 were 
synthesized and two of them were converted into the oxazoline donors 110 and 112 and 
employed in endoglycosidase enzymatic couplings using a synthetic N-GlcNAc peptide library 
(Figure 25).  
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16 22 
26 
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70 62 
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SUMMARY 
 
 
Figure 25. A) Building block units used in N-glycan synthesis. B) Stepwise synthesis routes to generate 
complex type N-glycans. C) Synthesized complex type N-glycan oligosaccharides. D) Converted oxazolines 
for enzymatic glycopeptide extension. 
The couplings of the tetrasaccharide oxazoline 110 to different N-GlcNAc peptides were 
successful and all in-solution couplings were finished in 0.5 h with full conversion verified by 
HPLC and high resolution ESI-MS. The hexasaccharide oxazoline 112, on the other hand, 
usually only reached 20% conversion to the desired N-glycopeptide products. The couplings 
with this more bulky donor were limited by back-hydrolysis to the starting material, which is 
a general problem by using endoglycosidases combined in N-glycan coupling reactions. 
Endoglycosidase mutants like the employed Endo M 175Q mutant should thus reduce 
back-hydrolysis reactions. 
To efficiently generate a N-glycopeptide library with homogenous complex type glycosylation, 
instead of performing enzymatic couplings one by one in solution, different N-GlcNAc 
peptides were extended by on-slide enzymatic glycosylation. In principle, N-GlcNAc peptides 
were spotted and immobilized on a microarray slide followed by a one step on-slide 
D) 
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enzymatic N-glycan extension using oxazoline donor building blocks. To evaluate the on-slide 
enzymatic glycosylation, four N-GlcNAc reference peptides 165 - 168 were prepared in 
solution using a tetrasaccharide oxazoline, HPLC-purified and spotted on the microarray slide 
together with the N-GlcNAc peptide library 150 - 163. Two experiments performed with 
different concentration of the spotted peptides. By comparing, the on-slide reaction with 
pre-synthesized internal standard peptides it was concluded that the endoglycosidase 
couplings were completed within 1 h. Further the results indicated that the location of the 
N-GlcNAc-Asn residue on the peptide backbone sequence had no dramatic influence on the 
on-slide enzymatic coupling, although the N-GlcNAc peptides were linked to the microarray 
slide through a N-terminal spacer. In summary, the experiments proved that it is possible to 
efficiently generate a library of N-glycopeptides with complex glycosylation directly on the 
microarray slide. The enzymatic extension using larger N-glycan donor building blocks need 
to be further optimized in future studies. The obtained hepta- and pentasaccharide 
N-glycopeptide library was in this work employed in initial microarray studies analyzing 
binding interactions with the lectin Concanavalin A (ConA). Additionally, selected peptides 
were employed in ESI-MS fragmentation studies to improve methodology for N-glycopeptide 
structural analysis. 
Some of the building blocks from the N-glycan synthesis, were also employed in the synthesis 
of O-mannosylated glycosylated amino acids to generate the building blocks 120, 124 and 
135 (Figure 26). Proteins modified with O-mannose glycans on backbone Ser and Thr 
residues, are involved in important functions in brain and muscle glycobiology. In spite of the 
clear importance of O-mannosyl glycosylation, no tools are to date available for specific 
detection, enrichment and identification of proteins containing these modifications. In order 
to study these processes, a project was initiated to generate glycan and glycopeptide specific 
antibodies, which could be useful tools to detect and enrich O-mannosylated proteins. 
Vaccine-constructs were prepared from glycopeptides containing these extended mannose 
moieties, which would be essential for O-mannosylation studies. Different Fmoc-O-mannosyl 
glycosylated amino acids were prepared and employed in glycopeptide synthesis. The 
glycopeptides were then incorporated into glycopeptide-immune carrier constructs for 
antibody induction in rabbits. For antibody evaluation additional glycopeptides were 
prepared and employed in ELISA neutralization experiments and on glycopeptide microarrays. 
98 
 
SUMMARY 
 The obtained O-mannosyl glycopeptide library was further employed to study interactions 
with glycan binding lectins. These lectins were evaluated as potential analytical tools for 
specific O-mannosyl glycoprotein or glycopeptide detection and enrichment. 
 
Figure 26. Synthesized O-mannosyl amino acids and the corresponding antigen peptides included in 
vaccine constructs for antibody induction. 
Procedures were developed to synthesize two linear O-mannosyl amino acids, 
Galβ1-4GlcNAcβ1-2ManαThr 120, GlcNAc-β1-2ManαThr 124 and one branched O-mannosyl 
amino acid, GlcNAc-β1-2-(GlcNAc-β1-6)ManαThr 135. During the synthesis of the 
O-glycosylated amino acids, major considerations about the protecting group strategy were 
135 
120 
124 
171 
180 
181 
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taken. The O-glycosidic bond connected to serine and threonine residues is base labile and, 
protecting group manipulation steps involving strong basic conditions may cause 
β-elimination. Therefore, the N-phthalimide groups, employed in building blocks from the 
N-glycan synthesis, were replaced by NH-Troc groups, which could be removed in mild acidic 
conditions. Glycan donors protected with benzyl groups are usually more reactive than the 
corresponding acetyl group protected donors, which sometimes makes benzyl protection 
more attractive. On the other hand the later debenzylation step is not compatible with the 
desired NHFmoc-protection on the glycosylated amino acid building blocks. During synthesis 
of the linear O-mannosyl amino acid, Galβ1-4GlcNAcβ1-2ManαThr 120, a Boc protected 
amino acid was initially used and converted to a Fmoc protecting group after the benzyl 
groups were removed. To avoid extra steps converting a Boc to a Fmoc group, 
p-methoxybenzyl (PMB) groups were used instead of benzyls in the later synthesis of the 2,6 
branched O-mannosyl Fmoc amino acid GlcNAc-β1-2-(GlcNAc-β1-6)Manα Thr 135. Before 
incorporation of the glycosylated Fmoc-amino acids into peptides, the glycan protection was 
unified and converted to acetyl groups, which could be removed under mild conditions and 
in one step after peptide synthesis. 
To induce hapten-antibodies that generally recognize specific O-mannosyl glycan structures 
on peptides and proteins, short peptides containing glycine residues on each side, were 
synthesized and extended with a spacer to give 171, 180 and 181. The peptides were 
conjugated to KLH and CRM immure carrier proteins through a squarate linker. Accordingly 
BSA conjugates were prepared for ELISA antibody analysis. For further antibody analysis by 
glycopeptide microarrays, a small library of O-mannosyl glycopeptides were prepared. The 
antigen peptide 171 with a Gal-GlcNAc-Man trisaccharide was prepared with monovalent 
glycosylation on the peptide and the N-terminal was extended with a spacer for protein 
conjugation. The Gal-GlcNAc-Man antigen peptide 171 conjugated to the KLH immune carrier 
was administrated into rabbit. The obtained antibody sera was analyzed by normal ELISA, 
ELISA neutralization experiments and glycopeptide microarray analysis. A strong antibody 
titer recognizing the antigen peptide 171 was detected. The microarray analysis showed that 
peptide 172 containing the shorter disaccharide GlcNAc-Man, which was presented on the 
same peptide backbone as the antigen, was recognized to some extend by the antibodies. 
Further, the antibody specificity to the antigen structure was extremely high and when the 
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 O-mannosyl glycans were presented on other peptide sequences like the glycopeptides 190 
and 191, antibody recognition was completly or partly lost.  
To increase the specificity of the induced antibodies to the glycan structure and reducing the 
recognition of the underlying peptide sequence, a second antigen peptide 180 was prepared 
with the GlcNAc-Man disaccharide, di-valent glycosylated on the peptide backbone. The 
N-terminal was capped with an acetyl group and the C-terminal was extended with a spacer 
for protein conjugation. After immunization the obtained antibody sera was again analyzed 
by ELISA and glycopeptide microarray experiments. The immune response directed to the 
antigen glycopeptide was very strong. The raised antibodies additionally recognized other 
glycopeptide sequences containing the same GlcNAc-Man-Thr O-glycosylation like peptide 
192, 193 and 172, and cluster glycan presentation on the peptide backbone dramatically 
favored antibody recognition. The 2,6 branched GlcNAc2-Man-Thr presented with di-valent 
glycosylation on the antigen peptide sequence were also well recognized. Larger O-mannosyl 
glycans with monovalent glycosylation on the peptide backbone like the 2,6 branched 
GlcNAc2-Man-Thr or the linear Gal-GlcNAc-Man-Thr structures were only weakly recognized. 
The non-glycosylated peptide backbone sequence of the GTTG-Spacer was to some extend 
recognized by the induced antibodies. In summary, antibodies were obtained with very high 
specificity to both the O-mannosyl glycan structure and the underlying peptide sequence. 
Presentation with higher glycan density on the peptide backbone, could increase the 
antibody specificity to the glycan structure. 
The O-mannosyl glycopeptide library was also employed to analyze interactions with certain 
lectins. Analysis of the glycan binding lectin Concanavalin A (ConA), which is known to 
recognize α-mannose residues, showed that unique glycan and glycopeptide structural 
binding epitopes were recognized. Here, monoglycosylated peptides containing the simpler 
GlcNAc-Man disaccharide structure was highly recognized, while reactivity to the 2,6 
branched GlcNAc2-Man-Thr or the linear Gal-GlcNAc-Man-Thr structures were rather weak. 
Clustered glycan presentation resulted in no recognition by ConA. These results will have an 
impact in the structural analysis work of O-mannosyl glycoproteins. Additionally, selected 
O-mannosyl peptides were employed in ESI-MS fragmentation studies to improve 
methodology for O-glycopeptide structural analysis work. 
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7 Experimental part 
Reagents and solvents were purchased with high commercial quality and were used without 
further purification unless otherwise stated. Molecular sieves (powdered 4Å) were dried at 
280°C /0.5 torr overnight. Dry dichloromethane and acetonitrile was prepared by distillation 
from CaH2. Solvent concentrations were performed at a reduced pressure (bath temperature 
<50°C). TLC was performed on Silica Gel F254 (Merck, Darmstadt, Germany) with detection 
by UV-light and by staining with 5% sulfuric acid in ethanol. Column chromatography was 
performed on silica gel 60 Å (35-70 m, Acros). NMR spectra were recorded at 303 K with a 
Varian Mercury 400 Oxford NMR spectrometer or Bruker DRX 600 MHz spectrometer using 
CDCl3 (internal CHCl3, δH 7.26 ppm; δC 77.23 at 303 K) or DMSO-d6 (internal DMSO, δH 2.50; 
δC 39.51 ppm at 303 K). Assignments were corroborated by appropriate 2-D experiments. 
The HR-ESI-MS spectra were recorded with a Thermo LTQ-FT ultra mass spectrometer. The 
MALDI-TOF MS were performed with a Bruker autoflex II LRF 50-CID. Specific rotations (*α+D
20) 
were recorded on a Polartronic HH8 from Schmidt and Haensch. HPLC measurements were 
performed using a Dionex ultimate 3000 LC system. The synthesis of compounds 1-195 is 
described herein. 
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 7.1 Synthesis of N-GlcNAc asparagine 
N-acetyl glucosamine (1)[270] 
To a solution of glucosamine hydrochloride (25 g, 116 mmol, 1.0 eq) in 
MeOH (200 mL), sodium methoxide (6.45 g, 119 mmol, 1.03 eq) was added slowly. After 
intensive stirring at for 2 h, acetic acid was added until pH reached 6 - 7, followed by addition 
of acetic anhydride (9.05 g, 8.64 mL, 151 mmol, 1.3 eq). The mixture was mechanically 
stirred for 24 h. The organic layer turned yellow with a white solid that precipitated. The 
volume of MeOH was reduced to 100 mL by rotary evaporation, and the residue was kept in 
a -20 °C freezer for 4 h. After the product was fully precipitated, it was collected by filtration 
together with other inorganic salt from the reaction, NaCl, NaAc for instance. The crude 
product was then dissolved in hot MeOH (100 mL), filtered again the remove the undissolved 
inorganic salt, concentrated to dryness to give the GlcNAc 1 as a white powder, yield 30% 
(7.78 g, 35.2 mmol). Rf = 0.4 (EtOAc/MeOH/AcOH/H2O 12:3:3:2) 
2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-α-D-glucopyranosylchloride (2)[271] 
GlcNAc 1 (7.78 g, 35.2 mmol) was dissolved in acetyl chloride (40 mL) in a 1 L 
round bottom flask with cooling under Ar, kept stirring at 40 °C for 24 h followed by TLC. The 
acetyl chloride was removed and diluted with DCM (100 mL). A solution of 10% of NaHCO3 
was added slowly under ice bath with strong stirring until pH reached 8-9. The aqueous layer 
was extracted with DCM (100 mL×3). The combined organic phase was dried with MgSO4, 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:2) 
gave 2 yield 54% (6.96 g, 19.0 mmol). Rf = 0.6 (
CHex/EtOAc 1:3). 1H-NMR (400 MHz, DMSO-d6, 
gCOSY, gHSQC, gHMBC), δ (ppm): 8.04 (d, J=9.2, 1H, NH), 5.09 (t, J=9.9, 1H, H3), 4.88 (dd, 
J=10.5, 8.8, 1H, H4), 4.86 (d, J=7.3, 1H, H1), 4.16 (dd, J=12.4, 4.9, 1H, H6a), 4.06 (dd, J=12.3, 
2.1, 1H, H6b), 4.00 (ddd, J=10.1, 4.8, 2.2, 1H, H5), 3.80 (dd, J=19.3, 9.8, 1H, H2), 2.01 (s, 3H, 
Ac), 1.96 (s, 3H, Ac), 1.91 (s, 3H, Ac), 1.78 (s, 3H, NHAc). 13C-NMR (100.6 MHz, DMSO-d6, 
gHSQC, gHMBC), δ (ppm): 170.68, 170.27, 170.18, 169.89 (170.3 - 169.9 CO2CH3), 88.16 (C1), 
73.47 (C5), 72.94 (C3), 68.83 (C4), 62.34 (C6), 53.18 (C2), 23.22, 21.15, 21.03, 20.94 (23.2 - 
20.9 CO2CH3). 
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2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosylazide (3)[272] 
To a stirring mixture of 2 (6.96 g, 19.0 mmol, 1.0 eq) and TBAHS (6.51 g, 
19.2 mmol, 1.01 eq) with NaN3 (5.61 g, 86.3 mmol, 4.5 eq) in DCM (70 mL), Sat. NaHCO3 (70 
mL) was added. The two phase mixture was stirred at r.t. for 2 h and followed by TLC. Then 
the reaction was diluted with EtOAc (300 mL) and the organic phase was washed with Sat. 
NaHCO3 (150 mL×2), H2O (150 mL×2), brine (150 mL×1), dried over Na2SO4, the solvent was 
removed and the crude product was purified by column chromatography (cyclohexane-ethyl 
acetate 10:1 to 1:2) and recrystallized from cyclohexane-ethyl acetate to give 3, yield 82% 
(5.83 g, 15.7 mmol). Rf = 0.6 (
CHex/EtOAc 1:2). *α+D
20 = -38° (c = 1.2, CHCl3). ESI-MS (pos), m/z: 
372.73 ([M+H]+, calc. 373.14). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
5.90 (d, J=8.9, 1H, NH), 5.25 (dd, J=10.5, 9.4, 1H, H3), 5.08 (t, J=9.7, 1H, H4), 4.77 (d, J=9.3, 
1H, H1), 4.26 (dd, J=12.4, 4.9, 1H, H6a), 4.16 (dd, J=12.4, 2.3, 1H, H6b), 3.91 (dd, J=19.6, 9.1, 
1H, H2), 3.80 (ddd, J=10.0, 4.9, 2.4, 1H, H5), 2.09 (s, 3H, Ac), 2.03 (s, 3H, Ac), 2.02 (s, 3H, Ac), 
1.97 (s, 3H, NHAc). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.15, 170.88, 
170.70, 169.48 (171.2 - 169.5 CO2CH3), 88.62 (C1), 74.17 (C5), 72.38 (C3), 68.35 (C4), 62.10 
(C6), 54.35 (C2), 23.42 (NHCO2CH3), 20.92 (CO2CH3), 20.83 (CO2CH3), 20.78 (CO2CH3). 
2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosylamine (4)[273-274] 
A dry flask containing Pd(C) (100 mg) was flushed with Ar several times. A 
solution of 3 (500 mg, 1.34 mmol) in MeOH (15 mL) was added via syringe under Ar. The 
reaction was then flushed with H2 and kept under H2 atmosphere for 2 h. After completion of 
the reaction, the flask was flushed again with Ar and the reaction mixture was filtered 
through a layer of Celite, followed by concentration and purification by column 
chromatography (DCM-MeOH 100:1 to 100:5) to give 4, yield 83% (386 mg, 1.11 mmol). Rf = 
0.5 (DCM/MeOH 10:1). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.75 (d, 
J=9.3, 1H, NH), 5.10 - 4.98 (m, 2H, H3, H4), 4.20 (dd, J=12.3, 4.9, 1H, H6a), 4.14 - 4.06 (m, 2H, 
H6b, H1), 4.04 - 3.93 (m, 1H, H2), 3.63 (ddd, J=9.4, 5.0, 2.5, 1H, H5), 2.08 (s, 3H, Ac), 2.02 (s, 
3H, Ac), 2.01 (s, 3H, Ac), 1.96 (s, 3H, NHAc). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 171.76, 170.97, 169.53 (171.8 - 169.6 CO2CH3), 86.64 (C1), 73.66 (C3), 72.99 (C5), 
68.76 (C4), 62.64 (C6), 55.11 (C2), 23.52 (NHCO2CH3), 21.00 (CO2CH3), 20.92 (CO2CH3), 20.83 
(CO2CH3). 
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 N-Fmoc-L-aspartic anhydride (5)[149] 
To a stirring solution of Asn (2.0 g, 15 mmol, 1.0 eq) and Na2CO3 (3.5 g, 33 
mmol, 2.2 eq) in H2O (30 mL), a solution of Fmoc-OSu (5.1 g, 15 mmol, 1.0 eq) 
in THF (30 mL) was added. The reaction was stirred at r.t. and the progression was followed 
by TLC. After 20 h the reaction was completed and the THF was removed under reduced 
pressure. The residue was diluted with H2O (30 mL), washed with Et2O (20 mL×2). The 
aqueous layer was then acidified with conc. HCl to pH = 2, and extracted with EtOAc (30 
mL×2). The organic layer was washed with brine (50 mL×1), dried over MgSO4 and the 
solvent was evaporated to dryness. The crude product was then dissolved in Ac2O (15 mL) 
with rapid heating and shaking at 120 °C for 5 min and then quickly cooled to r.t. The product 
precipitated and was filtered, washed with Et2O (30 mL×2) and dried under high vacuum, 
yield 83% (4.02 g, 11.9 mmol). Rf = 0.9 (EtOAc/MeOH/AcOH/H2O 12:3:3:2). ESI-MS (pos), m/z: 
369.87 ([M+H]+, calc. 684.00), 1366.80 ([2M+H]+, calc. 1367.47), 1384.80 ([2M+NH4]
+, calc. 
1384.50).1H-NMR (400 MHz, DMSO-d6, gCOSY, gHSQC, gHMBC), δ (ppm): 8.16 (d, J=7.7, 1H, 
NH), 7.87 (d, J=7.5, 2H, Fmoc), 7.65 (d, J=7.5, 2H, Fmoc), 7.40 (t, J=7.4, 2H, Fmoc), 7.32 (t, 
J=7.4, 2H, Fmoc), 4.65 (dt, J=9.9, 6.9, 1H, Asp-CHα), 4.48 - 4.32 (m, 2H, FmocCH2), 4.23 (t, 
J=6.4, 1H, FmocCH), 3.22 (dd, J=18.5, 10.0, 1H, Asp-CH2β), 2.84 (dd, J=18.4, 6.2, 1H, 
Asp-CH2β). 
13C-NMR (100.6 MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 172.79, 170.51, 
156.53, 144.30, 144.26, 141.46, 128.36, 127.79, 127.75, 125.76, 125.68, 120.86 (128.4 - 
120.9 Fmoc), 66.75 (FmocCH2), 51.05 (Asp-CH2α), 47.25 (FmocCH), 35.39 (Asp-CH2β). 
2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-N-[N-Fmoc-L-aspart-4-oyl
]-β-D-glucopyranosylamide (6)[149] 
To a stirring solution of 4 (2.62 g, 7.55 mmol, 1.0 eq) in DMSO (4.5 
mL), N-Fmoc-asp anhydride 5 (2.54 g, 7.53 mmol, 1.0 eq) was 
added. The reaction was stirred at r.t. for 2 h, full conversion indicated by TLC and then 
diluted with MeOH (50 mL). The precipitate was filtered and recrystallized from MeOH to 
give 6, yield 63% (3.25 g, 4.75 mmol). Rf = 0.4 (
CHex/EtOAc/MeOH/AcOH/H2O 15:60:3:3:2). 
ESI-MS (pos), m/z: 684.24 ([M+H]+, calc. 684.00), 1366.80 ([2M+H]+, calc. 1367.47), 1384.80 
([2M+NH4]
+, calc. 1384.50).1H-NMR (400 MHz, DMSO-d6, gCOSY, gHSQC, gHMBC), δ (ppm): 
8.56 (d, J=9.2, 1H, GlcNH), 7.87 (d, J=7.8, 3H, Fmoc, NHAc), 7.69 (d, J=7.4, 2H, Fmoc), 7.48 (d, 
J=8.4, 1H, AsnNH), 7.40 (t, J=7.4, 2H, Fmoc), 7.31 (t, J=7.4, 2H, Fmoc), 5.17 (t, J=9.6, 1H, H1), 
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5.09 (t, J=9.9, 1H, H3), 4.81 (t, J=9.8, 1H, H4), 4.37 (dd, J=13.6, 7.3, 1H, Asn-CHα), 4.31 - 4.14 
(m, 4H, FmocCH2, H6a, FmocCH), 3.93 (d, J=11.7, 1H, H6b), 3.87 (dd, J=19.8, 9.9, 1H, H2), 
3.80 (d, J=9.4, 1H, H5), 2.65 (dd, J=16.2, 5.3, 1H, Asn-CH2β), 2.54 - 2.45 (m, 1H, Asn-CH2β), 
1.98 (s, 3H, Ac), 1.95 (s, 3H, Ac), 1.89 (s, 3H, Ac), 1.71 (s, 3H, NHAc). 13C-NMR (100.6 MHz, 
DMSO-d6, gHSQC, gHMBC), δ (ppm): 173.62, 170.70, 170.48, 170.17, 169.98 (170.7 - 170.0 
CO2CH3), 156.51, 144.46, 141.38, 128.31, 127.75, 125.92, 120.78 (128.3 - 120.8 Fmoc), 
113.54, 78.78 (C1), 74.06 (C3), 72.98 (C5), 69.09 (C4), 66.39 (FmocCH2), 62.83, 62.52 (C6), 
52.81 (C2), 50.69 (Asn-CHα), 47.29 (FmocCH), 37.55 (Asn-CH2β), 23.27, 21.20, 21.08, 21.05 
(23.3 - 21.1CO2CH3). 
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 7.2 Synthesis of the 4-OH glucosamine acceptor 
2-deoxy-2-phthalimido-1,3,4,6-tetra-O-acetyl-β-D-glucopyranose (7)[166] 
NaOH (36.2 g, 904 mmol, 1.3 eq) in H2O (600 mL) was added to a stirring 
solution of glucosamine hydrochloride (150 g, 696 mmol, 1.0 eq) in MeOH (300 mL), at 0 °C. 
Then a solution of phthalic anhydride (149.3 g, 1007 mmol, 1.45 eq) in acetone (1200 mL) 
was slowly added over 30 min. The reaction was then kept at r.t. for 2 h and more phthalic 
anhydride (61.8 g, 417 mmol, 0.6 eq) and NaHCO3 (149.6 g, 1781 mmol, 2.56 eq) was added. 
After stirring at r.t. for 24 h, the reaction mixture was brought to pH 1 by adding a small 
portion of conc. HCl. The acetone was removed under reduced pressure and the crude 
product was kept in the fridge for 24 h, filtered, washed with cold water, coevaporated with 
toluene, dried under vacuum to give a white powder, yield 88% (190 g, 614 mmol). Rf = 0.6 
(EtOAc/MeOH/AcOH/H2O 6:3:3:2) 
The intermediate product (87 g, 281 mmol, 1.0 eq) was added in portions into a refluxing 
mixture of NaOAc (25.4 g, 309 mmol, 1.1 eq) in acetic anhydride (265 mL, 2.81 mol, 10 eq) 
and kept refluxing at 160 °C for 2 h, then concentrated followed by dilution with EtOAc (800 
mL), washed with H2O (500 mL×3), Sat. NaHCO3 (500 mL×3), brine (500 mL×1), dried over 
MgSO4. The organic solvent was removed under reduced pressure, the crude product was 
purified by column chromatography (cyclohexane-ethyl acetate 1:1) and was then 
recrystallized from cyclohexane-ethyl acetate to give 7, yield 72% (97 g, 203 mmol). Rf = 0.4 
(CHex/EtOAc 2:1). *α+D
20 = +76° (c = 1.1, CHCl3). ESI-MS (pos), m/z: 494.87 ([M+NH4]
+, calc. 
495.16), 500.00 ([M+Na]+, calc. 500.12). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.86 - 7.81 (m, 2H, Phth), 7.75 - 7.70 (m, 2H, Phth), 6.49 (d, J=8.9, 1H, H1), 5.87 (dd, 
J=10.6, 9.1, 1H, H3), 5.19 (dd, J=10.1, 9.2, 1H, H4), 4.45 (dd, J=10.6, 8.9, 1H, H2), 4.35 (dd, 
J=12.4, 4.4, 1H, H6a), 4.12 (ddd, J=12.2, 5.0, 2.1, 1H, H6b), 4.01 (ddd, J=10.2, 4.4, 2.1, 1H, H5), 
2.09 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.97 (s, 3H, Ac), 1.84 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 170.87, 170.22, 169.68, 168.83 (170.9 - 169.8 CO2CH3), 134.69 
(Phth), 134.67 (Phth), 124.00 (Phth), 89.99 (C1), 72.85 (C5), 70.73 (C3), 68.54 (C4), 61.76 (C6), 
53.72 (C2), 20.96, 20.93, 20.84, 20.80, 20.59 (21.0 - 20.6 CO2CH3). 
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Ethyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (8)[166] 
Under cooling with an ice bath and under Ar atmosphere, BF3 etherate 
(2.7 mL, 21.9 mmol, 1.3 eq) was added via syringe to a stirring solution of 
7 (8.0 g, 16.8 mmol, 1.0 eq) and EtSH (1.58 mL, 21.9 mmol, 1.3 eq) in dry DCM (100 mL). The 
reaction mixture was stirred at r.t. for 3 h, and was then neutralized by addition of Et3N (1 
mL), concentrated to dryness to remove most of the EtSH, dissolved again in DCM (100 mL) 
washed with Sat. NaHCO3 (50 mL×3), H2O (50 mL×3), brine (50 mL×1), dried over MgSO4, and 
the organic solvent was removed under reduced pressure. The crude product was purified by 
column chromatography (cyclohexane-ethyl acetate 4:1 to 1:1), and recrystallized from 
cyclohexane-ethyl acetate to give 8, yield 65% (5.2 g, 10.8 mmol). Rf = 0.7 (
CHex/EtOAc 1:1). 
*α+D
20 = +44° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 496.93 ([M+NH4]
+, calc. 497.16), 502.07 
([M+Na]+, calc. 502.11). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.83 (dd, 
J=5.3, 3.1, 2H, Phth), 7.72 (dd, J=5.5, 2.9, 2H, Phth), 5.80 (dd, J=10.2, 9.2, 1H, H3), 5.46 (d, 
J=10.6, 1H, H1), 5.15 (t, J=9.7, 1H, H4), 4.37 (t, J=10.4, 1H, H2), 4.28 (dd, J=12.3, 4.9, 1H, H6a), 
4.15 (dd, J=12.3, 2.2, 1H, H6b), 3.87 (ddd, J=10.2, 4.9, 2.3, 1H, H5), 2.75 - 2.55 (m, 2H, 
SCH2CH3), 2.07 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.83 (s, 3H, Ac), 1.19 (t, J=7.4, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.85, 170.26, 169.65 (170.9 - 169.7 
CO2CH3), 167.95 (Phth C=O), 167.34 (Phth C=O), 134.64, 134.50, 131.80, 131.38, 123.90 
(134.6 - 123.9 Phth), 81.39 (C1), 76.13 (C5), 71.76 (C3), 69.11 (C4), 62.51 (C6), 53.89 (C2), 
24.55 (SCH2CH3), 20.96, 20.82, 20.64 (21.0 - 20.7 CO2CH3), 15.10 (SCH2CH3). 
Phenyl 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (9)[275] 
Under cooling with an ice bath and under Ar atmosphere, BF3 etherate 
(12.8 mL, 100.8 mmol, 1.5 eq) was added via syringe to a stirring solution 
of 7 (32.1 g, 67.2 mmol, 1.0 eq) and EtSPh (13.7 mL, 134.4 mmol, 2.0 eq) in dry DCM (150 
mL). The reaction mixture was stirred at r.t. for 3 h, and was then neutralized by addition of 
Et3N (7.5 mL), concentrated to dryness to remove most of the EtSPh, dissolved again in DCM 
(200 mL) washed with Sat. NaHCO3 (100 mL×3), H2O (100 mL×3), brine (100 mL×1), dried 
over MgSO4, and the organic solvent was removed under reduced pressure. The crude 
product was purified by column chromatography (cyclohexane-ethyl acetate 4:1 to 1:1), and 
recrystallized from cyclohexane-ethyl acetate to give 9, yield 58% (20.4 g, 38.7 mmol). Rf = 
0.6 (CHex/EtOAc 1:1). *α+D
20 = +55° (c = 0.8, CHCl3). ESI-MS (pos), m/z: 544.93 ([M+NH4]
+, calc. 
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 545.16), 550.00 ([M+Na]
+, calc. 550.11). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.86 (dd, J=5.5, 3.1, 2H, Phth), 7.74 (dd, J=5.4, 3.1, 2H, Phth), 7.42 - 7.37 (m, 2H, SPh), 
7.31 - 7.22 (m, 3H, SPh), 5.79 (dd, J=10.2, 9.2, 1H, H3), 5.71 (d, J=10.6, 1H, H1), 5.13 (t, J=9.7, 
1H, H4), 4.34 (t, J=10.4, 1H, H6a), 4.28 (dd, J=12.3, 5.1, 1H, H6b), 4.20 (dd, J=12.2, 2.3, 1H, 
H2), 3.89 (ddd, J=10.2, 5.1, 2.4, 1H, H5), 2.09 (s, 3H, Ac), 2.01 (s, 3H, Ac), 1.82 (s, 3H, Ac). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.79 (CO2CH3), 170.28 (CO2CH3), 
169.64 (CO2CH3), 168.01 (Phth C=O), 167.13 (Phth C=O), 134.67 (Phth), 134.55 (Phth), 133.49, 
131.20, 129.11, 128.63 (133.5 - 128.6 SPh), 123.92 (Phth), 83.27 (C1), 76.13 (C5), 71.85 (C3), 
68.96 (C4), 62.45 (C6), 53.81 (C2), 20.97 (CO2CH3), 20.82 (CO2CH3), 20.61 (CO2CH3). 
Ethyl 2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (10)[166] 
Compound 8 (10.2 g, 21.2 mmol) was dissolved in 0.08 M NaOMe in MeOH 
(100 mL), stirred at r.t. for 4 h. The deacetylated product was then neutralized with Dowex 
50WX8 ion-exchanger (1 g, prewashed with MeOH), concentrated and coevaporated with 
toluene (50 mL), dried under high vacuum to give 10, yield 99% (7.4 g, 20.9 mmol). Rf = 0.4 
(DCM/MeOH 9:1). *α+D
20 = +6° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 370.80 ([M+NH4]
+, calc. 
371.13), 375.93 ([M+Na]+, calc. 376.08). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.78 (dd, J=5.1, 3.3, 2H, Phth), 7.67 (dd, J=5.4, 3.0, 2H, Phth), 5.28 (d, J=10.4, 1H, H1), 
4.33 - 4.24 (m, 1H, H3), 4.09 (t, J=10.3, 1H, H2), 3.81 (d, J=2.7, 2H, H6a, H6b), 3.62 (t, J=9.2, 
1H, H4), 3.41 (d, J=9.3, 1H, H5), 2.71 - 2.51 (m, 2H, SCH2CH3), 1.12 (t, J=7.4, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 168.50, 134.33 (Phth), 131.94, 131.80, 
123.97 (Phth), 123.51 (Phth), 81.44 (C1), 79.95 (C5), 72.66 (C3), 71.26 (C6), 62.00 (C4), 56.12 
(C2), 24.49 (SCH2CH3), 15.11 (SCH2CH3). 
Ethyl 2-deoxy-2-phthalimido-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (11)[166] 
Compound 10 (7.4 g, 20.9 mmol, 1.0 eq) and α,α-dimethoxytoluene 
(6.37 g, 41.8 mmol, 2.0 eq) were dissolved in DMF (100 mL). 
p-toluenesulfonic acid was added to the reaction mixture to reach pH 4 and was then kept at 
50 mbar, 50 °C for 1 h. The reaction was neutralized with Et3N to pH 7 and DMF was removed 
under reduced pressure. The crude product was purified by column chromatography 
(cyclohexane-ethyl acetate 8:1 to 2:1), and recrystallized from cyclohexane-ethyl acetate to 
give 11, yield 86% (7.95 g, 18.0 mmol). Rf = 0.4 (
CHex/EtOAc 2:1). *α+D
20 = +1° (c = 0.9, CHCl3). 
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ESI-MS (pos), m/z: 899.60 ([2M+NH4]
+, calc. 900.28), 1340.33 ([3M+NH4]
+, calc. 1341.41). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.90 - 7.85 (m, 2H, Phth), 7.74 - 
7.70 (m, 2H, Phth), 7.52 - 7.46 (m, 2H, Ph), 7.39 - 7.31 (m, 3H, Ph), 5.57 (s, 1H, CHPH), 5.40 (d, 
J=10.6, 1H, H1), 4.66 (dd, J=10.0, 8.9, 1H, H3), 4.39 (dd, J=10.3, 4.7, 1H, H6a), 4.32 (t, J=10.3, 
1H, H2), 3.80 (t, J=10.1, 1H, H6b), 3.70 (td, J=9.7, 4.7, 1H, H5), 3.61 (t, J=9.1, 1H, H4), 2.75 - 
2.59 (m, 2H, SCH2CH3), 1.19 (t, J=7.4, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 137.18, 134.42 (Phth), 134.38 (Phth), 129.97, 129.57, 129.21, 128.59 
(benzylidene acetal), 126.54 (benzylidene acetal), 124.07 (Phth), 123.55 (Phth), 102.16 
(CHPH), 82.35 (C4), 82.11 (C1), 70.61 (C5), 69.77 (C3), 68.86 (C6), 55.76 (C2), 24.42 (SCH2CH3), 
15.10 (SCH2CH3). 
Phenyl 2-deoxy-2-phthalimido-4,6-O-benzylidene-1-thio-β-D-glucopyranoside (12)[276] 
Compound 9 (20.4 g, 38.7 mmol) was dissolved in a solution of 
MeOH/DCM 3:1 (266 mL), NaOMe (1.61 g, 29.8 mmol, 0.11 M) was 
added. The reaction mixture was stirred at r.t. for 4 h, and was then neutralized with Dowex 
50WX8 ion-exchanger (1.5 g, prewashed with MeOH), concentrated and coevaporated with 
toluene (50 mL), dried under high vacuum to give the deacetylated product. The residue and 
α,α-dimethoxytoluene (8.81 g, 57.8 mmol, 1.5 eq) were dissolved in DMF (200 mL). 
p-toluenesulfonic acid was added to the reaction mixture to reach pH 4 and was then kept at 
50 mbar, 50 °C for 1 h. The reaction was neutralized with Et3N to pH 7 and DMF was removed 
under reduced pressure. The crude product was purified by column chromatography 
(cyclohexane-ethyl acetate 8:1 to 2:1), and recrystallized from cyclohexane-ethyl acetate to 
give 12, yield 82% (15.4 g, 31.5 mmol). Rf = 0.4 (
CHex/EtOAc 2:1). *α]D
20 = +41° (c = 1.1, CHCl3). 
ESI-MS (pos), m/z: 995.73 ([2M+NH4]
+, calc. 996.28), 1484.40 ([3M+NH4]
+, calc. 1485.41). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.81 - 7.76 (m, 1H, Phth), 7.73 (s, 
1H, Phth), 7.67 - 7.61 (m, 2H, Phth), 7.41 - 7.36 (m, 2H, Ph), 7.33 - 7.28 (m, 2H, SPh), 7.28 - 
7.23 (m, 3H, Ph), 7.19 - 7.15 (m, 3H, SPh), 5.60 (d, J=10.6, 1H, H1), 5.47 (s, 1H, CHPH), 4.54 (t, 
J=9.5, 1H, H3), 4.30 (dd, J=10.4, 4.8, 1H, H6a), 4.23 (t, J=10.3, 1H, H2), 3.73 (t, J=10.2, 1H, 
H6b), 3.59 (td, J=9.7, 4.8, 1H, H5), 3.50 (t, J=9.1, 1H, H4). 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 134.47 (Phth), 134.42 (Phth), 132.84, 132.41, 132.03, 129.58, 129.19, 
128.59, 128.32, 126.56 (132.8 - 126.6 aromatic), 124.08 (Phth), 123.61 (Phth), 102.17 (CHPH), 
84.52 (C1), 82.09 (C4), 70.56 (C5), 69.92 (C3), 68.80 (C6), 55.86 (C2). 
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 Ethyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio-β- 
D-glucopyranoside (13)[170] 
Compound 11 (82.13 g, 186 mmol, 1.0 eq) was dissolved in dry THF (400 mL) under Ar and 
under cooling at 0 °C, NaH (60% suspension, 11.17 g, 279 mmol, 1.5 eq) was added in 
portions. The reaction was kept at 0 °C for 40 min before BnBr (33.18 mL, 279 mmol, 1.5 eq) 
was added dropwise via syringe. The mixture was heated to reflux for 2 h before the solvent 
was removed under reduced pressure. The residue was dissolved in EtOAc (800 mL), filtered 
through a layer of Celite, washed with H2O (500 mL×2), brine (500 mL×1), dried over MgSO4, 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
to give 13, yield 96% (94.56 g, 178 mmol). Rf = 0.7 (Tol/EtOAc 3:1). *α+D
20 = +65° (c = 1.0, 
CHCl3). ESI-MS (pos), m/z: 548.67 ([M+NH4]
+, calc. 549.21), 1079.53 ([2M+NH4]
+, calc. 
1080.38). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.85 (d, J=7.1, 1H, 
Phth), 7.70 (d, J=4.9, 2H, Phth), 7.65 (d, J=6.6, 1H, Phth), 7.53 (dd, J=7.7, 1.8, 2H, CHPh), 7.46 
- 7.34 (m, 3H, CHPh), 7.04 - 6.96 (m, 2H, CH2Ph), 6.96 - 6.81 (m, 3H, CH2Ph), 5.63 (s, 1H, 
CHPh), 5.35 (d, J=10.6, 1H, H1), 4.80 (d, J=12.3, 1H, CH2Ph), 4.51 (d, J=12.3, 1H, CH2Ph), 4.46 
(dd, J=9.8, 9.1, 1H, H3), 4.42 (dd, J=4.5, 10.9, 1H, H6a), 4.30 (t, J=10.3, 1H, H2), 3.87 - 3.79 (m, 
2H, H6b, H4), 3.71 (td, J=9.8, 4.9, H5), 2.78 - 2.54 (m, 2H, SCH2CH3), 1.17 (t, J=7.4, 3H, 
SCH2CH3).
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.04 (C=O), 137.54 (C=O), 
134.15 (Phth), 134.04 (Phth), 129.24, 128.51, 128.31, 128.26, 127.63, 126.27 (129.2-126.3, 
CH2Ph, CHPh), 123.77 (Phth), 123.53 (Phth), 101.55 (CHPh), 83.28 (C4), 82.03 (C1), 75.67 (C3), 
74.43 (CH2Ph), 70.69 (C5), 68.97 (C6), 54.91 (C2), 24.30 (SCH2CH3), 15.08 (SCH2CH3). 
Phenyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-1-thio- 
β-D-glucopyranoside (14)[276] 
Compound 12 (11.95 g, 24.4 mmol, 1.0 eq) was dissolved in dry THF (120 mL) under Ar and 
under cooling at 0 °C, NaH (60% suspension, 1.95 g, 48.8 mmol, 2.0 eq) was added in 
portions. The reaction was kept at 0 °C for 40 min before BnBr (5.26 mL, 44.2 mmol, 1.8 eq) 
was added dropwise via syringe. The mixture was heated to reflux for 2 h before the solvent 
was removed under reduced pressure. The residue was dissolved in EtOAc (100 mL), filtered 
through a layer of Celite, washed with H2O (100 mL×2), brine (100 mL×1), dried over MgSO4, 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
to give 14, yield 96% (94.56 g, 178 mmol). Rf = 0.7 (Tol/EtOAc 3:1).  *α+D
20 = +98° (c = 0.8, 
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CHCl3). ESI-MS (pos), m/z: 579.67 ([M+H]
+, calc. 580.18), 596.80 ([M+NH4]
+, calc. 597.21), 
1175.60 ([2M+NH4]
+, calc. 1176.38). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.87 (d, J=7.0, 1H, Phth), 7.77 - 7.68 (m, 2H, Phth), 7.65 (d, J=6.3, 1H, Phth), 7.53 (dd, 
J=7.7, 1.7, 2H, CHPh), 7.44 - 7.32 (m, 5H, CHPh, SPh), 7.29 - 7.22 (m, 3H, SPh), 7.02 - 6.96 (m, 
2H, CH2Ph), 6.94 - 6.84 (m, 3H, CH2Ph), 5.64 (d, J=10.5, 1H, H1), 5.63 (s, 1H, CHPh), 4.79 (d, 
J=12.3, 1H, CH2Ph), 4.51 (d, J=12.3, 1H, CH2Ph), 4.48 - 4.40 (m, 2H, H3, H6a), 4.32 (t, J=10.2, 
1H, H2), 3.86 (t, J=8.5, 1H, H6b), 3.84 - 3.79 (m, 1H, H4), 3.74 (dd, J=9.7, 4.7, 1H, H5). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 168.00 (Phth C=O), 167.42 (Phth C=O), 
137.94, 137.53, 134.23 (Phth), 134.09 (Phth), 132.99 (SPh), 131.88, 131.82, 129.27, 129.14, 
128.53, 128.38, 128.32, 128.28, 127.67 (131.9 - 127.7 aromatic), 126.30 (CHPh), 123.77 
(Phth), 123.60 (Phth), 101.57 (CHPh), 84.35 (C1), 83.06 (C4), 75.73 (C3), 74.46 (CH2Ph), 70.64 
(C5), 68.91 (C6), 55.00 (C2). 
Benzyl 3-O-benzyl-4,6-O-benzylidene-2-deoxy-2-phthalimido-β-D-glucopyranoside (15)[277] 
Compound 13 (24.23 g, 45.6 mmol, 1.0 eq), benzylalcohol (9.44 mL, 
78.8 mmol, 1.73 eq), N-iodosuccinimide (15.35 g, 68.3 mmol, 1.5 eq) 
and 4 Å molecular sieves (48 g) in dry dichloromethane (240 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the suspension was cooled to 0 °C 
followed by slow addition of trifluoromethanesulfonic acid (606 μL, 6.8 mmol, 0.15 eq). After 
stirring for 1 h at 0 °C, the reaction was quenched by diluting the reaction mixture with more 
DCM (100 mL). The molecular sieves were removed by filtration and the filtrate was washed 
with 1 M Na2S2O3 (75 mL×3), brine (100 mL×1), dried over MgSO4, concentrated and purified 
by column chromatography (toluene-ethyl acetate 100:1 to 10:1) to give 15. Yield: 90% 
(23.76 g, 41.1 mmol). Rf = 0.5 (Tol/EtOAc 6:1). *α+D
20 = +6° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 
577.80 ([M+H]+, calc. 578.22), 594.73 ([M+NH4]
+, calc. 595.24), 1171.73 ([2M+NH4]
+, calc. 
1172.45). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.69 (s, 2H, Phth), 7.52 
(dd, J=7.6, 1.8, 2H, Phth), 7.41 - 7.34 (m, 5H, CHPh), 7.05 - 6.95 (m, 6H, CHPh), 6.91 - 6.83 (m, 
4H, CHPh), 5.63 (s, 1H, CHPh), 5.20 (d, J=8.5, 1H, H1), 4.80 (d, J=12.0, 1H, 1-CH2Ph), 4.77 (d, 
J=11.8, 1H, 3-CH2Ph), 4.48 (d, J=12.3, 2H, 3-CH2Ph, 1-CH2Ph), 4.45 - 4.37 (m, 2H, H6a, H3), 
4.26 (dd, J=10.4, 8.5, 1H, H2), 3.88 (t, J=10.3, 1H, H6b), 3.82 (t, J=9.1, 1H, H4), 3.63 (td, J=9.8, 
5.0, 1H, H5).13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.14, 137.58, 137.07, 
133.90, 131.80, 129.23, 128.92, 128.76, 128.50, 128.39, 128.25, 128.22, 127.88, 127.85, 
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 127.56, 127.19 (129.2 - 126.3, CH2Ph), 126.29, 123.46, 101.56 (CHPh), 98.13 (C1), 83.24 (C4), 
74.68 (C3), 74.26 (3-CH2Ph), 71.39 (1-CH2Ph), 69.03 (C6), 66.28 (C5), 56.06 (C2). 
Benzyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D- glucopyranoside (16)[278] 
Compound 15 (19.49 g, 33.7 mmol, 1.0 eq) and sodium cyanoborohydride 
(8.48 g, 135 mmol, 4.0 eq) was dissolved in anhydrous THF (117 mL). 
Under Ar atmosphere, at 0 °C 2N HCl in Et2O (59.0 mL, 118 mmol, 3.5 eq) was added 
dropwise via syringe. The reaction was followed by TLC. After 30 min stirring at 0 °C, the 
reaction was neutralized by Et3N (10 mL) and the solvent was removed by evaporation under 
reduced pressure and without heating. The residue was purified by column chromatography 
(toluene-ethyl acetate 10:1 to 5:1) to give 16. Yield: 87% (17.07 g, 29.4 mmol). Rf = 0.3 
(Tol/EtOAc 6:1). *α+D
20 = +1° (c = 1.2, CHCl3). ESI-MS (pos), m/z: 597.00 ([M+NH4]
+, calc. 
597.26), 1175.73 ([2M+NH4]
+, calc. 1176.49). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.68 (d, J=2.4, 2H, Phth), 7.37 (m, 6H, Phth, CH2Ph), 7.04 (m, 8H, CH2Ph), 
6.97 - 6.92 (m, 3H, CH2Ph), 5.16 (d, J=8.2, 1H, H1), 4.79 (d, J=12.3, 1H, 1-CH2Ph), 4.72 (d, 
J=12.2, 1H, 3-CH2Ph), 4.67 (d, J=11.9, 1H, 6-CH2Ph), 4.60 (d, J=11.9, 1H, 6-CH2Ph), 4.52 (d, 
J=12.2, 1H, 3-CH2Ph), 4.48 (d, J=12.3, 1H, 1-CH2Ph), 4.26 - 4.21 (m, 2H, H2, H3), 3.84 (m, 3H, 
H6ab, H4), 3.64 (dt, J=9.8, 4.9, 1H, H5). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 138.41, 137.87, 137.35, 133.90, 128.75, 128.36, 128.35, 128.14, 128.08, 128.04, 
127.82, 127.78, 127.63 (128.8 - 127.6, CH2Ph), 97.65 (C1), 78.80 (C3), 74.55 (C4), 74.48 
(3-CH2Ph), 74.04 (6-CH2Ph), 73.79 (C5), 71.06 (1-CH2Ph), 70.93 (C6), 55.64 (C2). 
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7.3 Synthesis of the glucose donor building block 
1,2,3,4,6-penta-O-acetyl-β-D-glucopyranose (17) 
A mixture of sodium acetate (25 g, 305 mmol, 1.1 eq) in acetic anhydride 
(170 mL, 1.80 mol, 6.5 eq) was heated to reflux in a three necked round bottom flask, the 
heating was removed. D-glucose (50 g, 278 mmol, 1.0 eq) was added in portions and the 
reaction started to boil intensively. When the boiling stopped, heating was applied again, and 
the reaction was refluxed for another 1 h. The reaction mixture was concentrated followed 
by dilution with EtOAc (500 mL), washed with H2O (300 mL×3), Sat. NaHCO3 (300 mL×3), 
brine (500 mL×1), dried over MgSO4. The organic solvent was removed under reduced 
pressure, the crude product was purified by column chromatography (cyclohexane-ethyl 
acetate 1:1) and was then recrystallized from cyclohexane-ethyl acetate to give 17, yield 95% 
(107.3 g, 264 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = +22° (c = 1.2, CHCl3). ESI-MS (pos), 
m/z: 407.80 ([M+NH4]
+, calc. 408.15), 412.93 ([M+Na]+, calc. 413.11). 1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.70 (d, J=8.3, 1H, H1), 5.24 (t, J=9.4, 1H, H3), 5.15 - 
5.08 (m, 2H, H2, H4), 4.28 (dd, J=12.5, 4.5, 1H, H6a), 4.10 (dd, J=12.5, 2.2, 1H, H6b), 3.83 
(ddd, J=10.0, 4.5, 2.2, 1H, H5), 2.10 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.02 (s, 6H, Ac×2), 2.00 (s, 3H, 
Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.77, 170.26, 169.56, 169.41, 
169.12 (170.8 - 169.1, CO2CH3), 91.91 (C1), 73.00 (C3), 72.94 (C5), 70.45 (C2), 67.97 (C4), 
61.66 (C6), 20.76 (Ac). 
Ethyl 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranoside (18)[279] 
Under cooling with an ice bath and under Ar atmosphere, BF3 etherate 
(60 mL, 471 mmol, 1.2 eq) was added via syringe to a stirring solution of 17 (150 g, 384 mmol, 
1.0 eq) and EtSH (87 mL, 1.15 mol, 3.0 eq) in dry DCM (500 mL). The reaction was stirred at 
r.t. and after 2h TLC indicated full conversion to product. The reaction mixture was then 
neutralized by addition of Et3N (80 mL) under cooling with an ice bath. Then concentrated to 
dryness to remove most of the EtSH. The residue was dissolved again in DCM washed with 
Sat. NaHCO3 (500 mL×3), H2O (500 mL×3), brine (500 mL×1), dried over MgSO4, and the 
organic solvent was removed under reduced pressure. The crude product was purified by 
column chromatography (cyclohexane-ethyl acetate 4:1 to 1:1), and recrystallized from 
cyclohexane-ethyl acetate to give 18, yield 70% (106 g, 270 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). 
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 *α+D
20 = -26° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 409.87 ([M+NH4]
+, calc. 410.15), 415.00 
([M+Na]+, calc. 415.10). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.21 (t, 
J=9.4, 1H,H3), 5.12 - 4.98 (m, 2H, H4, H2), 4.49 (d, J=10.0, 1H, H1), 4.23 (dd, J=12.4, 5.0, 1H, 
H6a), 4.13 (dd, J=12.3, 2.4, 1H, H6b), 3.70 (ddd, J=10.0, 5.0, 2.4, 1H, H5), 2.79 - 2.60 (m, 2H, 
SCH2CH3), 2.07 (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.01 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.26 (t, J=7.5, 3H, 
SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.82, 170.38, 169.60, 
169.58 (170.8 - 169.6, CO2CH3), 83.73 (C1), 76.10 (C5), 74.14 (C3), 70.07 (C2), 68.58 (C4), 
62.39 (C6), 24.38 (SCH2CH3), 20.93, 20.82, 20.79 (20.9 - 20.8, CO2CH3), 15.04 (SCH2CH3). 
Ethyl 1-thio-β-D-glucopyranoside (19)[280] 
Compound 18 (12.1 g, 30.9 mmol) was dissolved in 0.05 M NaOMe in 
MeOH (40 mL), stirred at r.t. for 2 h. Then neutralized with Dowex 50 ion exchange beads (1 g, 
prewashed with MeOH), concentrated and coevaporated with toluene (50 mL), dried under 
high vacuum to give 19, yield 99% (6.92 g, 30.9 mmol), continued to the next step synthesis 
without further purification. 
Ethyl 4,6-O-benzylidene-1-thio-β-D-glucopyranoside (20)[280] 
Compound 19 (7.16 g, 31.9 mmol, 1.0 eq) and α,α-dimethoxytoluene 
(9.72 g, 63.8 mmol, 2.0 eq) were dissolved in DMF (50 mL). p-toluenesulfonic acid was added 
to the reaction mixture to reach pH 4 and was then kept at 50 mbar, 50 °C for 1 h. The 
reaction was neutralized with Et3N to pH 7 and DMF was removed under reduced pressure. 
The crude product was purified by column chromatography (cyclohexane-ethyl acetate 10:1 
to 2:1), and recrystallized from cyclohexane-ethyl acetate to give 20, yield 72% (7.22 g, 23.1 
mmol). Rf = 0.4 (
CHex/EtOAc 1:1). *α+D
20 = +75° (c = 0.8, CHCl3). ESI-MS (pos), m/z: 312.80 
([M+H]+, calc. 313.11). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.52 - 
7.46 (m, 2H, benzylidene acetal), 7.40 - 7.33 (m, 3H, benzylidene acetal), 5.53 (s, 1H, CHPh), 
4.44 (d, J=9.8, 1H, H1), 4.34 (dd, J=10.5, 4.8, 1H, H6a), 3.84 - 3.78 (m, 1H, H4), 3.78 - 3.72 (m, 
1H, H6b), 3.55 (t, J=9.2, 1H, H3), 3.51 - 3.44 (m, 2H, H2, H5), 2.80 - 2.69 (m, 2H, SCH2CH3), 
1.32 (t, J=7.4, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 137.13, 
129.53, 128.57, 126.52 (129.5 - 126.5 benzylidene acetal aromatic), 102.14 (CHPh), 86.80 
(C1), 80.60 (C3), 74.78 (C4), 73.45 (C2), 70.77 (C5), 68.82 (C6), 27.14, 24.97 (SCH2CH3), 15.51 
(SCH2CH3). 
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Ethyl 4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio-β-D-glucopyranoside (21) 
Compound 20 (17.5 g, 56 mmol, 1.0 eq) and dibutyltin oxide (16.7 g, 67 
mmol, 1.2 eq) was dissolved in MeCN (500 mL) and refluxed for 24 h. 
The reaction mixture was then cooled and diluted with more MeCN (1000 mL), cesium 
fluoride (9.37 g, 62 mmol, 1.1 eq) and 4-methoxybenzyl bromide (13.6 g, 67 mmol, 1.2 eq) 
were added. The reaction mixture was stirred at r.t. for 48 h. The mixture was filtered 
through a layer of Celite, and MeCN was removed under reduced pressure, without heating. 
The residue was diluted with DCM (400 mL), washed with 1 M potassium fluoride (150 mL×3), 
H2O (200 mL×3), brine (300 mL×1), dried over MgSO4, and the organic solvent was removed 
under reduced pressure. The crude product was purified by column chromatography 
(cyclohexane-ethyl acetate 6:1 to 1:1), and recrystallized from cyclohexane-ethyl acetate to 
give 21, yield 42% (10.1 g, 23.4 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = -31° (c = 0.8, CHCl3). 
ESI-MS (pos), m/z: 432.80 ([M+H]+, calc. 433.17), 449.87 ([M+NH4]
+, calc. 450.20), 881.60 
([2M+NH4]
+, calc. 882.36), 886.67 ([2M+Na]+, calc. 887.31). 1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 7.42 (dd, J=7.2, 2.0, 2H, benzylidene acetal), 7.35 - 7.27 (m, 3H, 
benzylidene acetal), 7.22 (d, J=8.4, 2H, PMB), 6.78 (d, J=8.5, 2H, PMB), 5.49 (s, 1H, CHPh), 
4.82 (d, J=11.3, 1H, PMBCH2), 4.66 (d, J=11.3, 1H, PMBCH2), 4.37 (d, J=9.7, 1H, H1), 4.27 (dd, 
J=10.5, 4.9, 1H, H6a), 3.73 - 3.65 (m, 4H, H6b, OCH3), 3.65 - 3.53 (m, 2H, H3, H4), 3.47 (t, 
J=8.9, 1H, H2), 3.40 (td, J=9.3, 4.9, 1H, H5), 2.74 - 2.60 (m, 2H, SCH2CH3), 1.23 (t, J=7.4, 3H, 
SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 159.60 (PMB COCH3), 
137.49 (benzylidene acetal aromatic), 130.61 (PMB), 129.97 (PMB), 129.22, 128.47, 126.25 
(129.2 - 126.3 benzylidene acetal aromatic), 114.12 (PMB), 101.49 (CHPh), 86.78 (C1), 81.48 
(C3), 81.41 (C4), 74.60 (PMBCH2), 73.20 (C2), 71.02 (C5), 68.89 (C6), 55.49 (OCH3), 24.76 
(SCH2CH3), 15.47 (SCH2CH3). 
Ethyl 2-O-acetyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-1-thio-β-D-glucopyranoside (22) 
Compound 21 (10.1 g, 23.4 mmol) was dissolved pyridine / acetic 
anhydride 2:1 (90 mL) and stirred at r.t. for 4 h. The solvent was 
removed and coevaporated with toluene (100 mL×3) and the residue was purified by column 
chromatography (cyclohexane-ethyl acetate 6:1 to 1:1). Then recrystallized from 
cyclohexane-ethyl acetate to give 22, yield 98% (10.9 g, 23.0 mmol). Rf = 0.6 (
CHex/EtOAc 2:1). 
*α+D
20 = -24° (c = 1.2, CHCl3). ESI-MS (pos), m/z: 491.80 ([M+NH4]
+, calc. 492.21), 497.07 
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 ([M+Na]
+, calc. 497.16), 965.73 ([2M+NH4]
+, calc. 966.38), 970.80 ([2M+Na]+, calc. 971.33). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.47 - 7.39 (m, 2H, benzylidene 
acetal), 7.35 - 7.26 (m, 3H, benzylidene acetal), 7.13 (d, J=8.5, 2H, PMB), 6.77 (d, J=8.7, 2H, 
PMB), 5.50 (s, 1H, CHPh), 5.01 - 4.92 (m, 1H, H2), 4.72 (d, J=11.6, 1H, PMBCH2), 4.55 (d, 
J=11.6, 1H, PMBCH2), 4.38 (d, J=10.1, 1H, H1), 4.30 (dd, J=10.5, 5.0, 1H, H6a), 3.74 - 3.69 (m, 
4H, H6b, OCH3), 3.69 - 3.63 (m, 2H, H3, H4), 3.46 - 3.36 (m, 1H, H5), 2.69 - 2.55 (m, 2H, 
SCH2CH3), 1.96 (s, 3H, Ac), 1.17 (t, J=7.5, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 169.63 (CO2CH3), 159.48 (PMB COCH3), 137.41 (benzylidene acetal 
aromatic), 130.47 (PMB), 129.76 (PMB), 129.24, 128.49, 126.22 (129.2 - 126.2 benzylidene 
acetal aromatic), 113.94 (PMB), 101.45 (CHPh), 84.44 (C1), 81.76 (C4), 79.40 (C3), 74.15 
(PMBCH2), 71.52 (C2), 70.92 (C5), 68.84 (C6), 55.49 (OCH3), 24.12 (SCH2CH3), 21.17 (CO2CH3), 
15.03 (SCH2CH3). 
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7.4 Synthesis of the Man-GlcNAc disaccharide core 
Benzyl 2-O-acetyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-β-D-glucopyranosyl-(1→4)-3,6- 
di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (23)[148]  
Compounds 22 (2.09 g, 4.40 mmol, 1.2 eq), 16 (2.13 g, 3.67 
mmol, 1.0 eq), N-iodosuccinimide (1.63 g, 7.25 mmol, 2.0 
eq) and 4 Å molecular sieves (5 g) were suspended in dry dichloromethane (50 mL) and were 
stirred at room temperature for 30 min under argon atmosphere. Then the suspension was 
cooled to 0 °C followed by slow addition of trifluoromethanesulfonic acid (48.9 μL, 0.55 
mmol, 0.15 eq). After stirring for 1 h at 0 °C, the reaction was quenched by dilution with 
more DCM (100 mL). The molecular sieves were removed by filtration and the filtrate was 
washed with 1 M Na2S2O3 (75 mL×3), brine (100 mL×1), dried over MgSO4, concentrated and 
purified by column chromatography (toluene-ethyl acetate 100:1 to 10:1) to give 23. Yield: 
70% (2.55 g, 2.57 mmol). Rf = 0.6 (Tol/EtOAc 6:1). *α+D
20 = +1° (c = 1.3, CHCl3). ESI-MS (pos), 
m/z: 1009.00 ([M+NH4]
+, calc. 1009.41). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.65 (s, 2H, Phth×2), 7.51 - 7.45 (m, 2H, benzylidene acetal aromatic×2), 7.44 - 7.29 
(m, 10H, Phth×2, benzylidene acetal aromatic×3, benzyl aromatic×5), 7.23 - 7.17 (m, 2H, PMB 
aromatic×2), 7.12 - 7.03 (m, 5H, benzyl aromatic×5), 7.01 (dd, J=7.6, 1.7, 2H, benzyl 
aromatic×2), 6.93 - 6.82 (m, 5H, PMB aromatic×2, benzyl aromatic×3), 5.48 (s, 1H, CHPh), 
5.11 (d, J=8.3, 1H, H1), 5.02 - 4.93 (m, 1H, H2’), 4.83 - 4.77 (m, 3H, 1-BnCH2, 6-BnCH2, 
PMBCH2), 4.75 (d, J=12.3, 1H, 3-BnCH2), 4.62 (d, J=5.1, 1H, H1’), 4.59 (d, J=8.7, 1H, PMBCH2), 
4.51 (d, J=9.5, 1H, 6-BnCH2), 4.48 (d, J=9.8, 1H, 1-BnCH2), 4.42 (d, J=12.3, 1H, 3-BnCH2), 4.26 
(dd, J=10.6, 5.0, 1H, H6a’), 4.24 - 4.20 (m, 2H, H2, H3), 4.12 - 4.05 (m, 1H, H4), 3.81 (s, 3H, 
OCH3), 3.80 - 3.75 (m, 2H, H6a, H6b), 3.65 (t, J=9.2, 1H, H4’), 3.56 (t, J=9.1, 1H, H3’), 3.53 - 
3.48 (m, 1H, H5), 3.48 (t, J=10.3, 1H, H6b’), 3.22 (td, J=9.7, 4.9, 1H, H5’), 2.01 (s, 3H, Ac). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 169.32, 167.91 (Phth C=O), 159.49, 
138.74, 138.22, 137.54, 137.43 (138.7 - 137.4 aromatic CCH2O), 133.82 (Phth), 132.56, 
131.87, 130.63, 129.63, 129.60, 129.28, 129.25, 128.78, 128.50, 128.47, 128.37, 128.27, 
128.18, 128.14, 128.04, 127.81, 127.79, 127.29 (131.9 - 127.3 aromatic), 126.28 (benzylidene 
acetal aromatic), 125.55, 123.42, 113.97 (PMB aromatic), 101.42 (CHPh), 101.01 (C1’), 97.64 
(C1), 81.95 (C4’), 78.32 (C3’), 78.24 (C4), 76.86 (C3), 75.14 (C5), 74.76 (3-BnCH2), 73.92 
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 (6-BnCH2), 73.64 (C2’), 71.03 (1-BnCH2), 68.86 (C6’), 67.88 (C6), 66.21 (C5’), 55.94 (C2), 55.53 
(OCH3), 21.18 (Ac). 
Benzyl 2-O-benzoyl-4,6-O-benzylidene-3-O-p-methoxybenzyl-β-D-glucopyranosyl-(1→4)- 
3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (24) [148] 
Compound 23 (15.6 g, 15.7 mmol) was dissolved in 0.05 M 
NaOMe (1.22 g, 22.5 mmol) in MeOH/DCM 2:1 (450 mL) 
and stirred at r.t. for 72 h. Then neutralized with Dowex 50WX8 ion-exchanger (2 g, 
prewashed with MeOH), concentrated and coevaporated with toluene (100 mL×3), dried 
under high vacuum to give the deacetylated intermediate with an equatorial hydroxyl group 
in the glucose 2-position, Rf = 0.6 (Tol/EtOAc 4:1). The residue was dissolved in anhydrous 
DCM (300 mL), treated with pyridine (27.2 mL, 337.6 mmol, 20 eq) at 0 °C before triflic 
anhydride (19.0 mL, 112.9 mmol, 7.2 eq) was added dropwise using a syringe. The reaction 
was finished in 15 min as a product with Rf = 0.8 (Tol/EtOAc 4:1) was formed, concentrated, 
dissolved again with DCM (300 mL) followed by washing with 0.1 M HCl (150 mL×2), Sat. 
NaHCO3 (150 mL×2), H2O (150 mL×2), brine (150 mL×1), dried over MgSO4. The solvent was 
removed and the crude product was dried under high vacuum. The residue was dissolved in 
anhydrous toluene (300 mL) with tetrabutylammonium benzoate (12.3 g, 33.8 mmol 2.2 eq), 
refluxed for 2 h at 120 °C to form the axial 2-O-benzoyl β-mannose product with Rf = 0.7 
(Tol/EtOAc 4:1). The reaction mixture was cooled to r.t. and then diluted with DCM (300 mL), 
washed with Sat. NaHCO3 (200 mL×2), H2O (200 mL×2), brine (300 mL×1), dried over MgSO4. 
The solvent was removed under reduced pressure and the crude product was purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 24, yield 84% (13.9 g, 
13.1 mmol). Rf = 0.7 (Tol/EtOAc 4:1). [α]D
20 = -28° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 1071.07 
([M+NH4]
+, calc. 1071.43). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.10 
(d, J=7.2, 2H, benzoyl aromatic×2), 7.62 (s, 2H, Phth×2), 7.53 - 7.45 (m, 4H, benzoyl 
aromatic×2, benzylidene acetal aromatic×2, benzyl aromatic×5), 7.44 - 7.31 (m, 11H, Phth×2, 
benzylidene acetal aromatic×3), 7.29 - 7.23 (m, 3H, PMB aromatic×2, benzoyl aromatic), 7.10 
- 6.98 (m, 5H, benzyl aromatic×5), 6.85 - 6.80 (m, 2H, PMB aromatic×2), 6.79 - 6.70 (m, 5H, 
benzyl aromatic×5), 5.69 (d, J=3.4, 1H, H2’), 5.57 (s, 1H, CHPh), 5.04 (d, J=8.5, 1H, H1), 4.83 - 
4.70 (m, 4H, H1’, 1-BnCH2, 3-BnCH2, 6-BnCH2), 4.65 (d, J=11.9, 1H, PMBCH2), 4.55 - 4.42 (m, 
3H, 1-BnCH2, 6-BnCH2, PMBCH2), 4.33 (dd, J=10.5, 4.8, 1H, H6a’), 4.28 (d, J=12.6, 1H, 
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3-BnCH2), 4.20 - 4.13 (m, 2H, H2, H4), 4.06 (dd, J=10.6, 8.5, 1H, H3), 3.98 (t, J=9.6, 1H, H4’), 
3.88 (dd, J=11.2, 2.9, 1H, H6a), 3.80 (dd, J=4.1, 3.0, 1H, H6b), 3.77 (s, 3H, OCH3), 3.74 - 3.69 
(m, 1H, H6b’), 3.57 (dd, J=9.8, 3.4, 1H, H3’), 3.53 (d, J=9.6, 1H, H5), 3.23 (td, J=9.7, 4.8, 1H, 
H5’). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 167.77 (Phth C=O), 165.98 
(benzoyl PhCO2), 159.46 (PMB COCH3), 138.60 , 138.09, 137.70, 137.36 (138.6 - 137.4 
aromatic CCH2O), 133.68 (Phth), 133.34 (benzoyl), 131.82, 130.18, 130.12, 130.04, 129.41, 
129.15, 128.84, 128.75, 128.62, 128.39, 128.32, 128.27, 128.25, 128.05, 127.88, 127.83, 
127.74, 127.12 (131.8 - 127.1 aromatic), 126.36 (benzylidene acetal aromatic), 123.30, 
114.00 (PMB aromatic), 101.77 (CHPh), 99.66 (C1’), 97.56 (C1), 79.30 (C4), 78.55 (C4’), 76.60 
(C3), 75.76 (C3’), 74.70 (3-BnCH2), 74.55 (C5), 73.87 (6-BnCH2), 71.46 (3’-PMBCH2), 70.99 
(1-BnCH2), 69.87 (C2’), 68.93 (C6’), 68.68 (C6), 67.27 (C5’), 55.89 (C2), 55.47 (OCH3). 
Benzyl 2-O-benzoyl-4,6-O-benzylidene-β-D-glucopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy- 
2-phthalimido-β-D-glucopyranoside (25)[148] 
To a stirring solution of compound 24 (10.87 g, 10.3 mmol, 
1.0 eq) in MeCN/H2O 9:1 (200 mL), ceric ammonium nitrate (28.4 g, 51.8 mmol, 5.0 eq) was 
added. The reaction was stirred at r.t. for 30 min and then quenched with Sat. NaHCO3 until 
the orange color was removed. The mixture was filtered through a layer of Celite, washed 
with EtOAc (40 mL ×2), H2O (40 mL ×2) then MeOH (40 mL ×2) and DCM (40 mL ×2). The 
filtrate was combined and concentrated to remove most of the organic solvent, and the 
residue was extracted with DCM (20 mL ×3). The organic layer was then washed with brine 
(30 mL), concentrated to dryness. The crude product was acetylated with pyridine/acetic 
anhydride 2:1 (100 mL) for 24 h, concentrated and coevaporated with toluene (150 mL ×3), 
and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 25. 
Yield 77% (7.38 g, 7.90 mmol). Rf = 0.5 (Tol/EtOAc 4:1). [α]D
20 = -14° (c = 1.0, CHCl3). ESI-MS 
(pos), m/z: 933.80 ([M+H]+, calc. 934.34), 950.87 ([M+NH4]
+, calc. 951.37), 1884.73 
([2M+NH4]
+, calc. 1885.71). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.10 
(d, J=8.4, 2H, benzoyl aromatic×2), 7.62 (s, 2H, Phth×2), 7.55 - 7.34 (m, 15H, Phth×2, 
benzylidene acetal aromatic×5, benzyl aromatic×5, benzoyl aromatic×3), 7.10 - 6.96 (m, 5H, 
benzyl aromatic×5), 6.80 - 6.67 (m, 5H, benzyl aromatic×5), 5.54 (s, 2H, H2’, CHPh), 5.05 (d, 
J=8.5, 1H, H1), 4.89 - 4.80 (m, 2H, H1’ , 6-BnCH2), 4.76 (dd, J=14.5, 12.5, 2H, 1-BnCH2, 
3-BnCH2), 4.53 (d, J=12.0, 1H, 6-BnCH2), 4.46 (d, J=12.3, 1H, 1-BnCH2), 4.33 (dd, J=10.5, 4.9, 
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 1H, H6a’), 4.28 (d, J=12.5, 1H, 3-BnCH2), 4.23 - 4.12 (m, 2H, H2, H4), 4.06 (dd, J=10.6, 8.6, 1H, 
H3), 3.91 (dd, J=11.3, 2.9, 1H, H6a), 3.89 - 3.83 (m, 1H, H4’), 3.83 - 3.74 (m, 2H, H6b, H3’), 
3.70 (t, J=10.3, 1H, H6b’), 3.52 (d, J=9.8, 1H, H5), 3.26 (td, J=9.5, 5.0, 1H, H5’). 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 167.78 (Phth C=O), 166.21 (benzoyl PhCO2), 
138.61, 138.13, 137.35, 137.32 (138.6 - 137.3 aromatic CCH2O), 133.70 (Phth), 133.49 
(benzoyl), 131.81, 130.16, 129.90, 129.51, 129.26, 128.89, 128.70, 128.57, 128.45, 128.37, 
128.33, 128.30, 128.23, 128.04, 127.93, 127.85, 127.81, 127.76, 127.17 (131.8 - 127.2 
aromatic), 126.51 (benzylidene acetal aromatic), 123.33, 102.37 (CHPh), 99.67 (C1’), 97.56 
(C1), 79.61 (C4), 79.25 (C4’), 76.60 (C3), 74.72 (3-BnCH2), 74.59 (C5), 73.93 (6-BnCH2), 72.01 
(C2’), 71.00 (1-BnCH2), 70.19 (C3’), 68.88 (C6’), 68.59 (C6), 66.95 (C5’), 55.90 (C2). 
Benzyl 2-O-benzoyl-4-O-benzyl-β-D-glucopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phtha 
limido-β-D-glucopyranoside (26)[148] 
To a stirring solution of 25 (3.48 g, 3.72 mmol, 1.0 eq) in 
anhydrous DCM (37 mL, 10 mL/mmol) at 0 °C, a 1 M solution of BH3 in THF (18 mL, 5 
mL/mmol) was added slowly over 30 min, followed by addition of TMSOTf (101 μL, 0.56 
mmol, 0.15 eq). The mixture was stirred at r.t. for 16 h and neutralized with Et3N (0.2 mL), 
then MeOH (5 mL) was added until no more hydrogen gas was eluted. The organic solvent 
was evaporated under reduced pressure without heating, and the residue was dissolved in 
DCM (100 mL), washed with NaHCO3 (50 mL ×2), brine (50 mL ×2), dried over MgSO4, 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
to give 26. Yield: 66% (2.31 g, 2.46 mmol). Rf = 0.6 (Tol/EtOAc 2:1). *α+D
20 = -4° (c = 0.9, CHCl3). 
ESI-MS (pos), m/z: 953.07 ([M+NH4]
+, calc. 953.39), 1871.53 ([2M+H]+, calc. 1872.71), 
1888.73 ([2M+NH4]
+, calc. 1889.74). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 8.10 - 8.03 (m, 2H, benzoyl aromatic×2), 7.60 (d, J=19.5, 2H, Phth×2), 7.54 - 7.25 (m, 
15H, Phth×2, benzyl aromatic×10, benzoyl aromatic×3), 7.11 - 6.98 (m, 5H, benzyl 
aromatic×5), 6.85 - 6.67 (m, 5H, benzyl aromatic×5), 5.45 (d, J=2.3, 1H, H2’), 5.05 (d, J=8.4, 
1H, H1), 4.84 - 4.72 (m, 5H, H1, 4’-BnCH2, 3-BnCH2, 6-BnCH2, 1-BnCH2), 4.66 (d, J=11.3, 1H, 
4’-BnCH2), 4.53 (d, J=12.1, 1H, 6-BnCH2), 4.46 (d, J=12.3, 1H, 1-BnCH2), 4.28 (d, J=12.5, 1H, 
3-BnCH2), 4.23 - 4.04 (m, 3H, H2, H4, H3), 3.88 - 3.82 (m, 2H, H6a, H6a’), 3.80 - 3.74 (m, 1H, 
H6b), 3.75 - 3.57 (m, 3H, H3’, H4’, H6b’), 3.54 (d, J=9.0, 1H, H5), 3.30 - 3.21 (m, 1H, H5’). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 167.82 (Phth C=O), 166.37 (benzoyl 
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PhCO2), 138.41, 138.27, 138.04, 137.37 (138.4 - 137.4 aromatic CCH2O), 133.77 (Phth), 
133.49 (benzoyl), 131.79, 130.13, 129.94, 128.86, 128.76, 128.71, 128.56, 128.34, 128.20, 
128.09, 127.84, 127.76, 127.59, 127.28 (131.8 - 127.3 aromatic), 123.35, 98.73 (C1’), 97.55 
(C1), 78.93 (C4), 76.63 (C3), 75.78 (C4’, C5’), 75.07 (4’-BnCH2), 74.63 (C5), 74.51 (3-BnCH2), 
73.92 (6-BnCH2), 73.36 (C3’), 72.39 (C2’), 70.98 (1-BnCH2), 68.51 (C6), 62.26 (C6’), 55.86 (C2). 
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 7.5 Synthesis of a mannosyl acceptor building block 
Allyl α-D-mannopyranoside (27)[176, 281] 
D-mannose (45.0 g, 250 mmol, 1.0 eq) was dissolved in allyl alcohol (300 mL) 
and BF3 etherate (4.6 mL, 50 mmol, 0.2 eq) was then added. The mixture was refluxed at 
120 °C. After 10 min the mannose was dissolved and the reaction was kept refluxing for 
another 30 min to full conversion, cooled and quenched by addition of Et3N (10 mL). The 
solvent was removed and the residue was purified by column chromatography (DCM-MeOH 
100:1 to 4:1) to give 27, yield 96% (53.1 g, 241 mmol). Rf = 0.6 (EtOAc/MeOH/AcOH/H2O 
20:3:3:2). [α]D
20 = +83° (c = 2.0, H2O). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 5.87 (dtd, J=15.9, 10.7, 5.6, 1H, CH2CH=CH2), 5.27 (dd, J=17.2, 1.5, 1H, CH2CH=CH2), 
5.18 (dd, J=10.5, 1.2, 1H, CH2CH=CH2), 4.86 (s, 1H, H1), 4.19 - 4.07 (m, 1H, CH2CH=CH2), 4.03 - 
3.88 (m, 4H, CH2CH=CH2, H6a, H2, H4), 3.85 (dd, J=9.7, 2.9, 1H, H3), 3.77 (d, J=11.3, 1H, H6b), 
3.53 (d, J=9.0, 1H, H5). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 133.86 
(CH2CH=CH2), 117.75 (CH2CH=CH2), 99.51 (C1), 72.58 (C5), 71.78 (C3), 71.17 (C2), 68.34 
(CH2CH=CH2), 66.47 (C4), 61.19 (C6). 
Allyl 4,6-O-benzylidene-α-D-mannopyranoside (28)[176, 281] 
The compound 27 (31.6 g, 143 mmol, 1.0 eq) and α,α-dimethoxytoluene 
(24.0 g, 158 mmol, 1.1 eq) were dissolved in DMF (150 mL). Then p-toluenesulfonic acid was 
added to the reaction mixture to reach pH 4 and was kept at 50 mbar, 50 °C for 1 h. The 
reaction was neutralized with Et3N to pH 7 and DMF was removed under reduced pressure. 
The crude product was purified by column chromatography (toluene-ethyl acetate 6:1 to 2:1) 
to give 28, yield 65% (28.7 g, 93 mmol). Rf = 0.3 (Tol/EtOAc 2:1). [α]D
20 = +53° (c = 1.0, CHCl3). 
ESI-MS (pos), m/z: 308.87 ([M+H]+, calc. 309.13), 638.93 ([2M+Na]+, calc. 639.24). 1H-NMR 
(400 MHz, DMSO-d6, gCOSY, gHSQC, gHMBC), δ (ppm): 7.54 - 7.46 (m, 2H, aromatic), 7.40 - 
7.29 (m, 3H, aromatic), 6.05 - 5.89 (m, 1H, CH2CH=CH2), 5.59 (s, 1H, CHPh), 5.32 (dddd, 
J=17.2, 8.9, 3.4, 1.7, 1H, CH2CH=CH2), 5.24 - 5.15 (m, 1H, CH2CH=CH2), 4.82 (s, 1H, H1), 4.25 - 
4.13 (m, 2H, CH2CH=CH2, H6a), 4.05 - 3.98 (m, 1H, CH2CH=CH2), 3.95 - 3.91 (m, 2H, H3, H4), 
3.90 (s, 1H, H2), 3.87 - 3.71 (m, 2H, H5, H6b). 13C-NMR (100.6 MHz, DMSO-d6, gHSQC, 
gHMBC), δ (ppm): 138.12, 134 (CH2CH=CH2).15, 128.69, 127.84, 126.33 (128.7 - 126.3 
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aromatic), 116.37 (CH2CH=CH2), 102.19 (CHPh), 100.61 (C1), 79.01 (C4), 71.48 (C2), 68.64 
(C3), 68.41 (C6), 67.98 (CH2CH=CH2), 64.16 (C5). 
Allyl 3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (29)[176, 282] 
Compound 28 (11.6 g, 37.6 mmol, 1.0 eq) and dibutyltin oxide (9.37 g, 
37.6 mmol, 1.0 eq) were dissolved in toluene (200 mL) and refluxed for 24 h using a 
Dean-Stark apparatus. The reaction mixture was then cooled to r.t. followed by addition of 
tetra-n-butylammonium bromide (13.3 g, 41.4 mmol, 1.1 eq), cesium fluoride (5.86 g, 38.5 
mmol, 1.025 eq) and benzyl bromide (4.72 mL, 39.5 mmol, 1.05 eq). The mixture was stirred 
at r.t. for 24 h, then heated to 80 °C for 24 h and refluxed at 120 °C for 1 h. The mixture was 
filtered through a layer of Celite and diluted with EtOAc (400 mL), washed with 1 M 
potassium fluoride (200 mL×3), H2O (200 mL×3), brine (300 mL×1), dried over MgSO4 and 
concentrated. Then purified by column chromatography (cyclohexane-ethyl acetate 8:1 to 
1:1) to give 29, yield 90% (13.5 g, 33.8 mmol). Rf = 0.6 (Tol/EtOAc 2:1). [α]D
20 = +46° (c = 0.8, 
CHCl3). ESI-MS (pos), m/z: 398.87 ([M+H]
+, calc. 399.18), 415.93 ([M+NH4]
+, calc. 416.21), 
421.13 ([M+Na]+, calc. 421.16). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.46 - 7.39 (m, 2H, benzylidene acetal aromatic), 7.35 - 7.19 (m, 7H, aromatic), 5.82 (dddd, 
J=17.2, 10.4, 6.2, 5.3, 1H, CH2CH=CH2), 5.54 (s, 1H, CHPh), 5.21 (dq, J=17.2, 1.6, 1H, 
CH2CH=CH2), 5.14 (ddd, J=10.4, 2.8, 1.2, 1H, CH2CH=CH2), 4.84 (d, J=1.4, 1H, H1), 4.79 (d, 
J=11.9, 1H, BnCH2), 4.64 (d, J=11.9, 1H, BnCH2), 4.22 - 4.18 (m, 1H, H6a), 4.11 (ddt, J=12.9, 
5.2, 1.5, 1H, CH2CH=CH2), 4.07 - 4.01 (m, 1H, H4), 4.00 (dd, J=3.5, 1.5, 1H, H2), 3.95 - 3.89 (m, 
1H, CH2CH=CH2), 3.87 (dd, J=9.6, 3.5, 1H, H3), 3.80 - 3.76 (m, 2H, H5, H6b). 
13C-NMR (100.6 
MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.26, 133.72 (CH2CH=CH2), 129.13, 128.69, 128.43, 
128.12, 128.03, 126.27 (129.1 - 126.3 aromatic), 118.06 (CH2CH=CH2), 101.81 (CHPh), 99.40 
(C1), 79.14 (C4), 75.93 (C3), 73.31 (BnCH2), 70.26 (C2), 69.09 (C6), 68.41 (CH2CH=CH2), 63.62 
(C5). 
Allyl 3,6-di-O-benzyl-α-D-mannopyranoside (30)[283] 
The compound 27 (16.1 g, 73.1 mmol, 1.0 eq) and tributyltin oxide (61.0 g, 
102.3 mmol, 1.4 eq) was dissolved in toluene (250 mL) and refluxed for 24 h with a 
Dean-Stark apparatus. The reaction mixture was then cooled to r.t., benzyl bromide (19.1 mL, 
160.8 mmol, 2.2 eq) was added and the mixture was stirred at r.t. for 72 h. Then the mixture 
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 was shaken with 1 M potassium fluoride solution (120 mL) intensively, the precipitated salt 
was filtered off and the filtrate was separated. The organic layer was washed with H2O (100 
mL×3), brine (150 mL×1), dried over MgSO4, concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 30, yield 55% (16.1 g, 40.2 
mmol). Rf = 0.3 (Tol/EtOAc 2:1). [α]D
20 = +31° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 418.00 
([M+NH4]
+, calc. 418.22), 800.67 ([2M+H]+, calc. 801.39), 817.73 ([2M+NH4]
+, calc. 818.41), 
822.80 ([2M+Na]+, calc. 823.37). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.44 - 7.24 (m, 10H, aromatic), 5.90 (ddd, J=22.3, 10.8, 5.6, 1H, CH2CH=CH2), 5.28 (dd, J=17.2, 
1.6, 1H, CH2CH=CH2), 5.20 (dd, J=10.4, 1.5, 1H, CH2CH=CH2), 4.92 (s, 1H, H1), 4.74 - 4.64 (m, 
2H, BnCH2), 4.63 - 4.55 (m, 2H, BnCH2), 4.23 - 4.16 (m, 1H, CH2CH=CH2), 4.04 - 4.01 (m, 1H, 
H2), 4.01 - 3.95 (m, 1H, CH2CH=CH2), 3.92 (d, J=9.1, 1H, H4), 3.82 - 3.78 (m, 1H, H5), 3.76 (s, 
2H, H6a, H6b), 3.72 (dd, J=9.2, 3.3, 1H, H3). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 138.28, 138.17, 133.96 (CH2CH=CH2), 128.83, 128.61, 128.26, 128.15, 127.89 (128.8 - 
127.9 aromatic), 117.72 (CH2CH=CH2), 98.87 (C1), 79.81 (C3), 73.83 (BnCH2), 72.19 (BnCH2), 
70.92 (C5), 70.57 (C6), 68.24 (CH2CH=CH2), 68.13 (C2), 68.11 (C4). 
Allyl 3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D- mannopyranoside (31)[182] 
To a stirring solution of 27 (14.21 g, 64.5 mmol), trimethyl orthoformate 
(25.8 mL, 0.4 mL/mmol) and camphorsulfonic acid (1.10 g, 17 mg/mmol) in 
MeOH (250 mL) was added. Followed by addition of butanedione (6.45 mL, 
0.1 mL/mmol). The mixture was refluxed for 24 h at 90 °C, then the reaction was cooled to r.t. 
and neutralized by addition of Et3N (1.3 mL). Then concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 2:1 to 1:4) to give 31, yield 65% (14.0 g, 41.9 
mmol). Rf = 0.4 (Tol/EtOAc 1:3). [α]D
20 = +219° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 351.93 
([M+NH4]
+, calc. 352.20), 357.13 ([M+Na]+, calc. 357.15), 685.80 ([2M+NH4]
+, calc. 686.36), 
690.93 ([2M+Na]+, calc. 691.32). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
5.97 - 5.78 (m, 1H, CH2CH=CH2), 5.24 (dq, J=17.2, 1.5, 1H, CH2CH=CH2), 5.16 (dd, J=10.4, 1.3, 
1H, CH2CH=CH2), 4.86 (d, J=1.3, 1H, H1), 4.18 - 4.05 (m, 2H, CH2CH=CH2), 4.01 (dd, J=10.3, 3.0, 
1H, H4), 3.95 (ddd, J=12.9, 6.2, 1.2, 1H, CH2CH=CH2), 3.92 (dd, J=2.9, 1.5, 1H, H2), 3.76 (dd, 
J=9.0, 3.5, 3H, H3, H6a, H6b), 3.24 (s, 3H, OCH3), 3.23 (s, 3H, OCH3), 1.28 (s, 3H, CH3), 1.26 (s, 
3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 133.89 (CH2CH=CH2), 
117.81 (CH2CH=CH2), 100.51 (COCH3(CH3)), 100.01 (COCH3(CH3)), 99.52 (C1), 70.97 (C3), 
141 
 
EXPERIMENTAL PART 
69.87 (C2), 68.36 (C4), 68.33 (CH2CH=CH2), 63.15 (C5), 61.40 (C6), 48.26 (OCH3), 48.05 (OCH3), 
17.97 (CH3), 17.87 (CH3).  
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 7.6 Synthesis of Gal-GlcNAc donors 
1,2,3,4,6-penta-O-acetyl-α-D-glactopyranose (32)[284]  
Acetic anhydride (330 mL, 3.5 mol, 7.0 eq) with HClO4 (2.5 mL, 4.2 mmol, 0.08 
eq) was stirred at r.t. in a three-necked round bottom flask with a thermometer inside the 
solution. D-galactose (90 g, 0.5 mol, 1.0 eq) was then added in portions, since the reaction 
temperature raised during addition, an ice bath was applied to keep the reaction at 25 - 30 °C. 
The reaction was instant, and was stirred for another 15 min after addition of the final 
portion of galactose. Then the mixture was concentrated and the residue diluted with EtOAc 
(1 L), washed with Sat. NaHCO3 (300 mL×3), H2O (300 mL×3), brine (500 mL×1) and dried 
over MgSO4. The organic solvent was removed under reduced pressure, the crude product 
was recrystallized from Et2O to give 32, yield 80% (157 g, 402 mmol). Rf = 0.5 (
CHex/EtOAc 
2:1). *α+D
20 = +101° (c = 1.1, CHCl3). ESI-MS (pos), m/z: 407.87 ([M+NH4]
+, calc. 408.15), 
413.00 ([M+Na]+, calc. 413.11). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
6.34 (d, J=1.9, 1H, H1), 5.49 - 5.45 (m, 1H, H4), 5.32 - 5.29 (m, 2H, H3, H2), 4.31 (t, J=6.7, 1H, 
H5), 4.12 - 4.01 (m, 2H, H6a, H6b), 2.13 (s, 3H), 2.12 (s, 3H), 2.01 (s, 3H), 1.99 (s, 3H), 1.97 (s, 
3H, 2.13 - 1.97 Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.50, 170.29, 
170.26, 170.02, 169.07 (170.5 - 169.1 CO2CH3), 89.90 (C1), 68.95 (C5), 67.62 (C4), 67.55 (C3), 
66.64 (C2), 61.42 (C6), 21.05, 20.82, 20.80, 20.77, 20.70 (21.0 - 20.7 CO2CH3). 
2,3,4,6-tetra-O-acetyl-α/β-D-glactopyranose (33)[285]  
Compound 32 (43.97 g, 113 mmol, 1.0 eq) was dissolved in dry DMF (100 
mL) and hydrazine acetate (10.70 g, 116 mmol, 1.03 eq) was added. The reaction was 
finished after heating at 50 °C for 3 h, concentrated and taken up in EtOAc (500 mL), washed 
with Sat. NaHCO3 (300 mL×1), H2O (200 mL×3), brine (300 mL×1) and dried over MgSO4. The 
organic solvent was removed under reduced pressure to give 33, as a 2:1 α:β mixture, yield 
88% (33.57 g, 96 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = +77° (c = 1.1, CHCl3). ESI-MS (pos), 
m/z: 365.87 ([M+NH4]
+, calc. 366.14), 371.00 ([M+Na]+, calc. 371.10), 715.13 ([2M+NH4]
+, 
calc. 714.25). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.50 (d, J=3.3, 1H, 
H1α), 5.46 (d, J=3.3, 1H, H2α), 5.41 (d, J=3.4, 1H, H3β), 5.39 (d, J=3.3, 1H, H3α), 5.14 (dd, 
J=10.8, 3.6, 1H, H4), 5.08 - 5.06 (m, 1H, H4β), 5.06 (d, J=1.1, 1H, H2β), 4.69 (d, J=5.7, 1H, 
H1β), 4.46 (t, J=6.6, 1H, H5α), 4.14 (d, J=6.6, 2H, H6β), 4.12 - 4.03 (m, 2H, H6α), 3.95 (t, J=6.7, 
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1H, H5β), 2.17 - 1.94 (Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.36, 
170.78, 170.74, 170.61, 170.46, 170.39, 170.29, 170.24 (171.4 - 170.2 CO2CH3), 96.20 (C1β), 
90.88 (C1α), 71.26 (C5β), 71.23 (C2β), 70.58 (C4β), 68.55 (C4α), 68.42 (C2α), 67.46 (C3α), 
67.36 (C3β), 66.44 (C5α), 62.02 (C6α), 61.68 (C6β), 21.02, 20.92, 20.90, 20.86, 20.84, 20.81, 
20.76 (21.0 - 20.8 CO2CH3). 
2,3,4,6-tetra-O-acetyl-α-D-glactopyranosyl trichloroacetimidate (34)[286] 
DBU (2.90 mL, 19.4 mmol, 0.2 eq) was added to a solution of 33 (33.57 g, 
96 mmol, 1.0 eq) and trichloroacetonitrile (29.16 mL, 292 mmol, 3.0 eq) 
in anhydrous DCM (380 mL) and under Ar atmosphere. After stirring at 0 °C for 3 h, the 
reaction mixture was concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 5:1 to 1:1) and recrystallized from cyclohexane-ethyl acetate to 
give 34, yield 72% (34.5 g, 70 mmol). Rf = 0.6 (
CHex/EtOAc 2:1). *α+D
20 = +115° (c = 0.9, CHCl3). 
ESI-MS (pos), m/z: 513.80 ([M+Na]+, calc. 514.01). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 8.66 (s, 1H, NH), 6.60 (d, J=3.3, 1H, H1), 5.58 - 5.52 (m, 1H, H4), 5.42 (dd, 
J=10.8, 3.0, 1H, H3), 5.36 (dd, J=10.8, 3.5, 1H, H2), 4.43 (t, J=6.6, 1H, H5), 4.16 (dd, J=11.3, 
6.6, 1H, H6a), 4.08 (dd, J=11.3, 6.6, 1H, H6b), 2.16 (s, 3H, Ac), 2.03 - 2.00 (m, 9H, Ac). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.47, 170.28, 170.26, 170.15 (170.5 
- 170.2 CO2CH3), 161.16 (C=NH), 93.77 (C1), 69.22 (C5), 67.73 (C3), 67.60 (C4), 67.13 (C2), 
61.47 (C6), 20.86, 20.83, 20.81, 20.75 (20.9 - 20.8 CO2CH3). 
Ethyl 6-O-tert-butyldimethylsilyl-2-deoxy-2-phthalimido-1-thio-β-D- 
glucopyranoside (35)[287] 
Compound 8 (16.8 g, 35.0 mmol, 1.0 eq) was dissolved in 0.08 M NaOMe in MeOH (150 mL), 
stirred at r.t. for 4 h and neutralized with Dowex 50WX8 ion-exchanger (1 g, prewashed with 
MeOH). Then concentrated and coevaporated with toluene (50 mL×3) under reduced 
pressure to give 10. The crude product was dissolved in dry DMF (170 mL) and TBSCl (5.8 g, 
38.5 mmol, 1.1 eq) and imidazole (5.48 g, 80.5 mmol, 2.3 eq) was added. The reaction 
mixture was stirred at r.t. for 2 h. The solvent was removed and the residue was purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 35. Yield: 86% (14.4 g, 
30.1 mmol). Rf = 0.5 (Tol/EtOAc 2:1). *α+D
20 = -15° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 484.87 
([M+NH4]
+, calc. 485.21), 951.67 ([2M+NH4]
+, calc. 952.39). 1H-NMR (400 MHz, CDCl3, gCOSY, 
144 
 
EXPERIMENTAL PART 
 gHSQC, gHMBC), δ (ppm): 7.83 (s, 2H, Phth), 7.74 - 7.67 (m, 2H, Phth), 5.31 (d, J=10.4, 1H, 
H1), 4.39 (dd, J=10.3, 8.5, 1H, H3), 4.19 (t, J=10.4, 1H, H2), 3.99 (dd, J=10.4, 4.7, 1H, H6a), 
3.85 (dd, J=10.4, 6.3, 1H, H6b), 3.62 (t, J=8.9, 1H, H4), 3.58 - 3.52 (m, 1H, H5), 2.74 - 2.53 (m, 
2H, SCH2CH3), 1.17 (t, J=7.4, 3H, SCH2CH3), 0.90 (s, 9H, tBu), 0.11 (s, 3H, SiCH3), 0.10 (s, 3H, 
SiCH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 134.23 (Phth), 123.67 (Phth), 
81.10 (C1), 77.75 (C5), 75.20 (C4), 72.60 (C3), 65.20 (C6), 55.25 (C2), 25.95 (C(CH3)3), 23.98 
(SCH2CH3), 18.32, 15.04 (SCH2CH3), -5.36 (SiCH3). 
Phenyl 6-O-tert-butyldimethylsilyl-2-deoxy-2-phthalimido-1-thio-β-D- 
glucopyranoside (36)[288] 
Compound 9 (5.0 g, 9.48 mmol, 1.0 eq) was dissolved in 0.08 M NaOMe in MeOH (50 mL) 
and was stirred at r.t. for 4 h. Then neutralized with Dowex 50WX8 ion-exchanger (0.5 g, 
prewashed with MeOH), concentrated and coevaporated with toluene (50 mL×3) to give a 
deacetylated intermediate. The crude product was dissolved in dry DMF (170 mL) and TBSCl 
(1.57 g, 10.4 mmol, 1.1 eq) and imidazole (1.48 g, 21.8 mmol, 2.3 eq) was added. The 
reaction mixture was stirred at r.t. for 2 h. The solvent was removed and the residue purified 
by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 36. Yield: 82% 
(4.02 g, 7.80 mmol). Rf = 0.4 (Tol/EtOAc 1:1). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.72 (s, 2H, Phth), 7.65 - 7.58 (m, 2H, Phth), 7.30 - 7.23 (m, 2H, SPh), 7.16 - 
7.09 (m, 3H, SPh), 5.50 (d, J=10.4, 1H, H1), 4.26 (dd, J=10.4, 8.2, 1H, H3), 4.08 (t, J=10.4, 1H, 
H2), 3.87 (dd, J=10.5, 4.7, 1H, H6a), 3.78 (dd, J=10.5, 5.4, 1H, H6b), 3.56 - 3.40 (m, 2H, H4, 
H5), 0.81 (s, 9H, tBu), 0.02 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 134.28 (Phth), 132.65 (Ph), 132.37 (Ph), 131.85 (Ph), 128.99 (Ph), 
127.87 (Ph), 123.84 (Phth), 83.78 (C1), 78.65 (C5), 74.10 (C4), 72.87 (C3), 64.62 (C6), 55.48 
(C2), 26.04 (C(CH3)3), 18.41, -5.25 (SiCH3). 
Ethyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-6-O-tert-butyldimethylsilyl-2-deoxy- 
2-phthalimido-1-thio-β-D-glucopyranoside (37)[289] 
The trichloroacetimidate donor 34 (7.34 g, 14.9 mmol, 1.1 eq) 
and acceptor 35 (6.34 g, 13.6 mmol, 1.0 eq) was dissolved in 
dry DCM (60 mL) and 4 Å molecular sieves (12 g) was added. The suspension was stirred 
under argon at r.t. for 30 min and cooled to -70 °C, then trimethylsilyl 
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-trifluoromethanesulfonate (TMSOTf) (369 μL, 2.02 mmol, 0.15 eq) was added. The reaction 
was kept stirring at -70 to -60 °C for 1 h, then quenched with triethylamine (0.7 mL). The 
molecular sieves were removed by filtering over a layer of Celite. The filtrate was 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
to give 37. Yield 70% (7.60 g, 9.52 mmol). Rf = 0.7 (
CHex/EtOAc 1:1). *α+D
20 = +18° (c = 0.9, 
CHCl3). ESI-MS (pos), m/z: 814.87 ([M+NH4]
+, calc. 815.31), 1594.40 ([2M+H]+, calc. 1595.56), 
1611.67 ([2M+NH4]
+, calc. 1612.58). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.87 - 7.79 (m, 2H, Phth), 7.70 (dd, J=5.4, 3.1, 2H, Phth), 5.35 (d, J=3.4, 1H, H4’), 5.29 
(d, J=10.5, 1H, H1), 5.22 (dd, J=10.4, 8.1, 1H, H2’), 4.96 (dd, J=10.4, 3.4, 1H, H3’), 4.61 (d, 
J=8.0, 1H, H1’), 4.43 (dd, J=10.0, 8.6, 1H, H3), 4.16 (t, J=10.4, 1H, H2), 4.06 (d, J=6.6, 2H, H6a’, 
H6b’), 3.96 (t, J=6.6, 1H, H5’), 3.87 (d, J=11.4, 1H, H6a), 3.75 (dd, J=11.5, 3.5, 1H, H6b), 3.66 
(t, J=9.0, 1H, H4), 3.51 (dd, J=9.6, 1.9, 1H, H5), 2.73 - 2.54 (m, 2H, SCH2CH3), 2.11 (s, 3H, Ac), 
2.07 (s, 3H, Ac), 1.96 (s, 3H, Ac), 1.89 (s, 3H, Ac), 1.17 (t, J=7.4, 3H, SCH2CH3), 0.92 (s, 9H, tBu), 
0.12 (s, 3H, Si(CH3)2), 0.09 (s, 3H, Si(CH3)2). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 170.49, 170.17, 170.08, 169.28, 168.20, 167.82, 134.14, 131.97, 131.81, 123.70, 
123.33 (134.1 - 123.3 Phth), 101.80 (C1’), 81.82 (C4), 80.51 (C1), 78.84 (C5), 71.30 (C5’), 
71.03 (C3’), 70.69 (C3), 68.86 (C2’), 66.90 (C4’), 61.79 (C6), 61.53 (C6’), 55.31 (C2), 26.00 
(C(CH3)3), 23.44 (SCH2CH3), 20.81 (Ac), 20.67 (Ac), 20.61 (Ac), 20.40 (Ac), 18.40, 15.02 
(SCH2CH3), -4.80 (Si(CH3)2), -5.05 (Si(CH3)2). 
Ethyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsil 
yl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (38)[289] 
The compound 37 (3.73 g, 4.67 mmol) was dissolved in 
pyridine / acetic anhydride 2:1 (36 mL) and stirred at r.t. for 24 
h. Then the reaction mixture was concentrated and coevaporated with toluene (50 ml×3). 
The residue was purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
and gave 38 in 97% yield (3.36 g, 4.00 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = +18° (c = 0.8, 
CHCl3). ESI-MS (pos), m/z: 839.47 ([M+H]
+, calc. 840.29), 856.87 ([M+NH4]
+, calc. 857.32), 
1695.47 ([2M+NH4]
+, calc. 1696.61). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.86 - 7.80 (m, 2H, Phth), 7.73 - 7.68 (m, 2H, Phth), 5.72 (t, J=9.7, 1H, H3), 5.40 (d, 
J=10.5, 1H, H1), 5.32 (d, J=3.5, 1H, H4’), 5.07 (dd, J=10.4, 8.0, 1H, H2’), 4.92 (dd, J=10.4, 3.5, 
1H, H3’), 4.71 (d, J=8.0, 1H, H1’), 4.23 (t, J=10.4, 1H, H2’), 4.07 (dd, J=6.8, 3.1, 2H, H6a’, H6b’), 
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 4.00 - 3.90 (m, 2H, H4, H6a), 3.86 (dd, J=11.6, 2.8, 1H, H6b), 3.81 (t, J=6.7, 1H, H5’), 3.52 (d, 
J=9.8, 1H, H5), 2.72 - 2.52 (m, 2H, SCH2CH3), 2.10 (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.03 (s, 3H, Ac), 
1.94 (s, 3H, Ac), 1.87 (s, 3H, Ac), 1.18 (t, J=7.4, 3H, SCH2CH3), 0.93 (s, 9H, tBu), 0.13 (s, 3H, 
Si(CH3)2), 0.11 (s, 3H, Si(CH3)2). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.42, 
170.29, 170.21, 170.11, 168.93, 167.80, 167.58, 134.42, 134.18, 131.84, 131.37, 123.77, 
123.66 (134.2 - 123.7 Phth), 100.43 (C1’), 80.39 (C1), 79.58 (C5), 74.97 (C4), 71.84 (C3), 71.30 
(C3’), 70.71 (C5’), 69.34 (C2’), 66.99 (C4’), 61.26 (C6), 61.13 (C6’), 54.12 (C2), 26.00 (C(CH3)3), 
23.65 (SCH2CH3), 20.84 (Ac), 20.73 (Ac), 20.71 (Ac), 20.65 (Ac), 18.39, 15.10 (SCH2CH3), -4.85 
(Si(CH3)2), -5.11 (Si(CH3)2). 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethyl 
silyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (39) 
The trichloroacetimidate donor 34 (2.26 g, 4.74 mmol, 1.1 eq) 
and acceptor 36 (2.23 g, 4.32 mmol, 1.0 eq) was dissolved in 
dry DCM (22 mL) and 4 Å molecular sieves (2.2 g) was added. The suspension was stirred 
under argon at r.t. for 30 min and cooled to -50 °C and then trimethylsilyl 
trifluoromethanesulfonate (TMSOTf) (157 μL, 0.86 mmol, 0.2 eq) was added. The reaction 
was kept stirring at -45 to -50 °C for 2 h, then quenched with triethylamine (0.3 mL). The 
molecular sieves were removed by filtering over a layer of Celite. The filtrate was 
concentrated and the residue purified by column chromatography (cyclohexane-ethyl acetate 
10:1 to 2:1) to give the disaccharide product, Yield 71% (2.59 g, 3.06 mmol). Rf = 0.3 
(CHex/EtOAc 2:1). The disaccharide (3.89 g, 4.60 mmol) was then dissolved in pyridine / 
acetic anhydride 2:1 (24 mL) and stirred at r.t. for 24 h. The reaction mixture was then 
concentrated, coevaporated with toluene (50 ml×3), followed by purification by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 39 in 93% yield (3.78 g, 4.26 
mmol). Rf = 0.5 (
CHex/EtOAc 2:1). [α]D
20 = +23° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 887.27 
([M+H]+, calc. 887.29), 904.93 ([M+NH4]
+, calc. 905.32), 1791.47 ([2M+NH4]
+, calc. 1792.61). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.71 (tt, J=7.9, 4.0, 2H, Phth), 
7.64 - 7.56 (m, 2H, Phth), 7.29 - 7.24 (m, 2H, SPh), 7.16 - 7.07 (m, 3H, SPh), 5.60 - 5.53 (m, 2H, 
H3, H1), 5.20 (dd, J=3.4, 0.8, 1H, H4’), 4.95 (dd, J=10.4, 8.0, 1H, H2’), 4.79 (dd, J=10.4, 3.5, 1H, 
H3’), 4.58 (d, J=8.0, 1H, H1’), 4.07 (t, J=10.4, 1H, H2), 3.95 (dd, J=6.8, 2.3, 2H, H6a’, H6b’), 
3.87 - 3.78 (m, 2H, H4, H6a), 3.74 (dd, J=11.7, 2.9, 1H, H6b), 3.68 (td, J=6.7, 0.7, 1H, H5’), 
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3.40 (d, J=9.9, 1H, H5), 1.98 (s, 3H, Ac), 1.92 (s, 3H, Ac), 1.90 (s, 3H, Ac), 1.82 (s, 3H, Ac), 1.73 
(s, 3H, Ac), 0.83 (s, 9H, C(CH3)3), 0.04 (s, 3H, SiCH3), 0.00 (s, 3H, SiCH3). 
13C-NMR (100.6 MHz, 
CDCl3, gHSQC, gHMBC), δ (ppm): 170.43, 170.31, 170.22, 170.17, 168.91 (170.4-168.9 
COCH3), 167.91, 167.31, 134.46 (Phth), 134.24 (Phth), 133.43, 131.84, 131.49, 131.39, 
129.14, 128.95, 128.33, 128.30 (131.8 - 128.3 aromatic), 125.41, 123.83 (Phth), 123.65 (Phth), 
100.42 (C1’), 83.07 (C1), 79.68 (C5), 74.78 (C4), 71.95 (C3), 71.31 (C3’), 70.72 (C5’), 69.33 
(C2’), 66.98 (C4’), 61.20 (C6), 61.10 (C6’), 54.12 (C2), 26.06 (C(CH3)3), 20.84, 20.75, 20.68, 
20.67 (20.8-20.7 COCH3), 18.43, -4.82 (SiCH3), -5.11 (SiCH3). 
Phenyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (40)[290] 
Compound 13 (23.65 g, 44.5 mmol, 1.0 eq) was dissolved in anhydrous THF 
(71 mL) and stirred at 0 °C under Ar atmosphere. Sodium cyanoborohydride 
(11.19 g, 178 mmol, 4.0 eq) was added followed by dropwise addition of 2N HCl in Et2O (77.9 
mL, 156 mL, 3.5 eq). After stirring for 30 min at 0 °C, the reaction was neutralized by addition 
of Et3N (10 mL) and the solvent was removed under reduced pressure without heating. The 
residue was purified by column chromatography (toluene-ethyl acetate 10:1 to 5:1) to give 
40. Yield: 85% (20.18 g, 37.8 mmol). Rf = 0.2 (Tol/EtOAc 4:1). *α+D
20 = +48° (c = 0.9, CHCl3). 
ESI-MS (pos), m/z: 550.93 ([M+NH4]
+, calc. 551.22), 1083.67 ([2M+NH4]
+, calc. 1084.41). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.82 (d, J=5.6, 1H, Phth), 7.72 - 
7.66 (m, 3H, Phth), 7.40 - 7.29 (m, 5H, CH2Ph), 7.08 - 7.02 (m, 2H, CH2Ph), 6.98 - 6.92 (m, 3H, 
CH2Ph), 5.28 (d, J=10.0, 1H, H1), 4.75 (d, J=12.2, 1H, 3-CH2Ph), 4.67 - 4.57 (m, 2H, 6-CH2Ph), 
4.54 (d, J=12.1, 1H, 3-CH2Ph), 4.32 - 4.19 (m, 2H, H3, H2), 3.88 - 3.74 (m, 3H, H6ab, H4), 3.69 
(dd, J=9.7, 4.9, 1H, H5), 2.72 - 2.54 (m, 2H, SCH2CH3), 1.16 (t, J=7.4, 3H, SCH2CH3). 
13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.34, 137.79, 134.12 (Phth), 134.02 (Phth), 
131.88, 128.73, 128.37, 128.13, 128.11, 128.02, 127.65 (128.7 - 127.7, CH2Ph), 123.74 (Phth), 
123.48 (Phth), 81.40 (C1), 79.81 (C3), 77.77 (C5), 74.80 (C4), 74.68 (3-CH2Ph), 74.02 
(6-CH2Ph), 71.16 (C6), 54.62 (C2), 24.19 (SCH2CH3), 15.13 (SCH2CH3). 
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 Phenyl 3,6-di-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (41)[291] 
Compound 14 (49.95 g, 86.2 mmol, 1.0 eq) was dissolved in anhydrous THF 
(290 mL) and stirred at 0 °C under Ar atmosphere. Sodium 
cyanoborohydride (21.66 g, 345 mmol, 4.0 eq) was added followed by dropwise addition of 
2N HCl in Et2O (150.5 mL, 302 mL, 3.5 eq). After stirring for 30 min at 0 °C, the reaction was 
neutralized by Et3N (15 mL) and the solvent was removed under reduced pressure without 
heating. The residue was purified by column chromatography (toluene-ethyl acetate 10:1 to 
5:1) to give 41. Yield: 87% (43.66 g, 75.1 mmol). Rf = 0.3 (Tol/EtOAc 4:1). *α+D
20 = +56° (c = 0.8, 
CHCl3). ESI-MS (pos), m/z: 598.93 ([M+NH4]
+, calc. 599.22), 1179.73 ([2M+NH4]
+, calc. 
1180.41). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.84 (d, J=6.6, 1H, 1H, 
Phth), 7.70 (dd, J=7.9, 4.4, 3H, Phth), 7.43 - 7.13 (m, 10H, CH2Ph, SPh), 7.04 (dd, J=6.3, 2.6, 
2H, CH2Ph), 6.99 - 6.88 (m, 3H, CH2Ph), 5.59 - 5.55 (m, 1H, H1), 4.74 (d, J=12.2, 1H, CH2Ph), 
4.63 (d, J=11.9, 1H, CH2Ph), 4.58 (d, J=11.8, 1H, CH2Ph), 4.54 (d, J=12.2, 1H, CH2Ph), 4.29 - 
4.25 (m, 2H, H3, H2), 3.88 - 3.78 (m, 3H, H6ab, H4), 3.70 (dt, J=9.6, 4.8, 1H, H5). 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.23, 137.93, 134.20 (Phth), 134.09 (Phth), 
132.67, 129.05, 128.72, 128.40, 128.17, 128.09, 128.03, 128.01, 127.70 (129.1 - 127.7, 
aromatic), 123.76 (Phth), 123.56 (Phth), 83.89 (C1), 79.94 (C3), 78.12 (C5), 74.77 (CH2Ph), 
74.27 (C4), 74.00 (CH2Ph), 70.90 (C6), 54.68 (C2), 27.16. 
Ethyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthali 
mido-1-thio-β-D-glucopyranoside (42)[292] 
The trichloroacetimidate donor 34 (572 mg, 1.2 mmol, 1.2 eq) 
and acceptor 40 (534 g, 1.0 mmol, 1.0 eq) was dissolved in dry 
DCM (8 mL) and 4 Å molecular sieves (427 mg) was added. The suspension was stirred under 
argon at r.t. for 30 min and cooled to -50 °C, trimethylsilyl -trifluoromethanesulfonate 
(TMSOTf) (469 μL, 2.58 mmol, 0.3 eq) was added. The reaction was kept stirring at -45 to 
-50 °C for 4 h, then quenched with triethylamine (0.5 mL). The molecular sieves were 
removed by filtering over a layer of Celite. The filtrate was concentrated and purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) to give 42. Yield 75% (650 
mg, 0.75 mmol). Rf = 0.3 (Tol/EtOAc 5:1). *α+D
20 = 30° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 
881.00 ([M+NH4]
+, calc. 881.32), 1743.40 ([2M+NH4]
+, calc. 1744.60). 1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.71 (d, J=5.9, 1H, Phth), 7.65 - 7.52 (m, 3H, Phth), 
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7.36 - 7.13 (m, 5H, aromatic), 6.99 - 6.92 (m, 2H, aromatic), 6.86 - 6.77 (m, 3H, aromatic), 
5.20 (d, J=3.5, 1H, H4’), 5.14 (d, J=10.0, 1H, H1), 5.08 (dd, J=10.4, 8.0, 1H, H2’), 4.79 (dd, 
J=10.4, 3.5, 1H, H3’), 4.74 (d, J=3.6, 1H, 3-BnCH2), 4.71 (d, J=3.4, 1H, 6-BnCH2), 4.55 (d, J=8.0, 
1H, H1’), 4.43 (d, J=12.0, 1H, 6-BnCH2), 4.37 (d, J=12.2, 1H, 3-BnCH2), 4.25 - 4.12 (m, 2H, H3, 
H2), 4.02 (dd, J=9.7, 8.3, 1H, H4), 3.95 - 3.83 (m, 2H, H6a’, H6b’), 3.72 (d, J=2.3, 2H, H6a, H6b), 
3.57 (t, J=6.9, 1H, H5’), 3.48 (dt, J=10.3, 2.5, 1H, H5), 2.66 - 2.46 (m, 2H, SCH2CH3), 1.99 (s, 3H, 
Ac), 1.95 (s, 6H, Ac), 1.90 (s, 3H, Ac), 1.10 (t, J=7.5, 3H, SCH2CH3). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 170.48, 170.39, 170.22, 169.38 (170.5 - 169.4 CO2CH3), 138.71, 
138.11, 134.02 (Phth), 133.89 (Phth), 131.84, 128.80, 128.22, 128.10, 128.06, 127.30 (128.8 - 
127.3 aromatic), 123.65 (Phth), 123.46 (Phth), 100.52 (C1’), 81.33 (C1), 79.32 (C5), 78.06 (C4), 
77.86 (C3), 74.76 (3-BnCH2), 73.82 (6-BnCH2), 71.23 (C3’), 70.68 (C5’), 69.75 (C2’), 67.98 (C6), 
67.14 (C4’), 60.92 (C6’), 54.92 (C2), 27.13, 24.08 (SCH2CH3), 21.02, 20.88, 20.81, 20.77 
(CO2CH3), 15.12 (SCH2CH3). 
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthali 
mido-1-thio-β-D-glucopyranoside (43)[293] 
The trichloroacetimidate donor 34 (5.32 g, 11.2 mmol, 1.3 eq) 
and acceptor 41 (5.00 g, 8.60 mmol, 1.0 eq) was dissolved in 
dry Et2O (50 mL) and 4 Å molecular sieves (6.5 g) was added. The suspension was stirred 
under argon at r.t. for 30 min and cooled to -50 °C, trimethylsilyl -trifluoromethanesulfonate 
(TMSOTf) (469 μL, 2.58 mmol, 0.3 eq) was added. The reaction was kept stirring at -45 to 
-50 °C for 4 h, then quenched with triethylamine (0.5 mL). The molecular sieves were 
removed by filtering over a layer of Celite. The filtrate was concentrated and purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) to give 43. Yield 54% (4.23 g, 
4.64 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = 48° (c = 1.5, CHCl3). ESI-MS (pos), m/z: 929.00 
([M+NH4]
+, calc. 929.32), 1839.87 ([2M+NH4]
+, calc. 1840.40). 
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 7.7 Synthesis of complex type building blocks with Gal-GlcNAc extension 
Allyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthali 
mido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (44) 
Compounds 42 (1.05 g, 1.22 mmol, 1.0 eq), 29 (578 mg, 1.45 
mmol, 1.2 eq), N-iodosuccinimide (652 mg, 2.90 mmol, 2.4 eq) 
and 4 Å molecular sieves (1.0 g) was suspended in dry 
dichloromethane (10 mL). The mixture was cooled to -50 °C, 
stirred for 30 min under argon atmosphere, followed by slow addition of 
trifluoromethanesulfonic acid (30.7 μL, 0.35 mmol, 0.28 eq). After stirring for 2 h at -40 to - 
50 °C, the reaction was quenched by diluting with more DCM (40 mL). The molecular sieves 
were removed by filtration and the filtrate was washed with 1 M Na2S2O3 (15 mL×3), brine 
(30 mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:1) to give 44. Yield: 65% (952 mg, 0.79 mmol). Rf = 0.3 
(CHex/EtOAc 2:1). *α+D
20 = +14° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1217.4732 ([M+NH4]
+, calc. 1217.4706), 1222.4290 ([M+Na]+, calc. 
1222.4260). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.67 (s, 2H, Phth), 
7.47 - 7.15 (m, 17H, aromatic), 7.10 - 6.98 (m, 2H, aromatic), 6.95 - 6.85 (m, 3H, aromatic), 
5.72 (ddd, J=22.3, 11.1, 5.8, 1H, CH2CH=CH2), 5.42 (s, 1H, CHPh), 5.28 (dd, J=7.9, 3.8, 1H, 
H4’’), 5.21 - 5.06 (m, 4H, H2’’, H1, CH2CH=CH2), 4.90 (dd, J=10.3, 3.6, 1H, H3’’), 4.81 (d, J=12.3, 
1H, BnCH2), 4.76 - 4.71 (m, 2H, BnCH2), 4.69 - 4.62 (m, 2H, H1’’, BnCH2), 4.51 - 4.43 (m, 3H, 
BnCH2, H1’), 4.33 - 4.25 (m, 2H, H3’, H2’), 4.10 - 4.05 (m, 2H, H4’, H2), 4.03 - 3.97 (m, 2H, 
H6a’’, H6b’’), 3.96 - 3.83 (m, 3H, H4, H3, CH2CH=CH2), 3.83 - 3.76 (m, 2H, H6a’, H6b’), 3.73 - 
3.64 (m, 3H, CH2CH=CH2, H5’’, H6a), 3.56 (d, J=10.0, 1H, H5’), 3.52 - 3.45 (m, 1H, H5), 3.08 (t, 
J=10.2, 1H, H6b), 2.07 (s, 3H, Ac), 2.02 (s, 6H, Ac), 1.98 (s, 3H, Ac). 13C-NMR (100.6 MHz, 
CDCl3, gHSQC, gHMBC), δ (ppm): 170.52, 170.40, 170.22, 169.44 (170.5 - 169.4 CO2CH3), 
138.85, 138.82, 138.16, 137.81, 134.66, 133.84 (Phth), 133.30 (CH2CH=CH2), 132.05, 129.95, 
129.22, 128.95, 128.92, 128.84, 128.76, 128.62, 128.50, 128.46, 128.42, 128.34, 128.31, 
128.28, 128.14, 128.12, 128.09, 127.93, 127.80, 127.61, 127.48, 127.41, 127.38, 127.32 
(129.2 - 127.3 aromatic), 126.24, 123.21 (Phth), 118.06 (CH2CH=CH2), 101.61 (CHPh), 100.68 
(C1’’), 97.15 (C1, C1’), 78.39 (C4’, C4), 76.79 (C3’), 75.48 (C5’), 75.31 (C2), 74.52 (BnCH2), 
74.03 (BnCH2), 74.00 (C3), 71.58 (BnCH2), 71.26 (C3’’), 70.81 (C5’’), 69.84 (C2’’), 68.58 (C6), 
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68.32 (C6’, CH2CH=CH2), 67.21 (C4’’), 64.07 (C5), 61.08 (C6’’), 55.86 (C2’), 29.91, 21.01, 20.89, 
20.82, 20.79 (21.0 - 20.8 CO2CH3). 
2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-
D-glucopyranosyl-(1→2)-3-O-benzyl-α-D-mannopyranose (45) 
Compound 44 (60 mg, 0.05 mmol, 1.0 eq) was dissolved in 
Tol/EtOAc/H2O 20:10:1 (930 μL) and Wilkinson’s catalyst (6.9 mg, 
7.5 μmol, 0.15 eq) was added. After refluxing for 5.5 h, the 
reaction mixture was cooled to r.t., filtered through a layer of Celite and concentrated. The 
residue was dissolved in THF/H2O 4:1 (3 mL) followed by addition of I2 (50.7 mg, 0.20 mmol, 
4.0 eq). The reaction was kept stirring at r.t. for 30 min and neutralized with 1 M Na2S2O3. 
The suspension was concentrated to remove most of the THF and was then diluted with DCM 
(10 mL), washed with 1 M Na2S2O3 (5 mL×2), H2O (5 mL×2), brine (5 mL×1) and dried over 
MgSO4. The solvent was removed and the residue was purified by column chromatography 
(toluene-ethyl acetate 1:1 to 1:3) to give 45, yield 72% (42 mg, 0.036 mmol). Rf = 0.2 
(Tol/EtOAc 1:3). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.58 (dd, J=11.5, 
7.7, 2H, Phth), 7.47 (t, J=7.3, 2H, Phth), 7.42 - 7.08 (m, 10H, aromatic), 6.97 (d, J=6.6, 2H, 
aromatic), 6.86 - 6.75 (m, 3H, aromatic), 5.22 - 5.18 (m, 1H, H4’’), 5.13 - 5.06 (m, 2H, H1’, 
H2’’), 4.82 (s, 1H, H1), 4.78 (dd, J=11.6, 2.9, 1H, H3’’), 4.75 - 4.70 (m, 2H, BnCH2), 4.61 (d, 
J=13.0, 1H, BnCH2), 4.56 (d, J=8.9, 1H, H1’’), 4.39 (d, J=12.4, 1H, BnCH2), 4.30 (dd, J=11.5, 4.2, 
2H, BnCH2), 4.25 (dd, J=10.9, 2.0, 1H, H3’), 4.16 (d, J=8.4, 1H, H2’), 4.06 (s, 1H, H2), 4.02 - 
3.96 (m, 1H, H4’), 3.94 - 3.85 (m, 2H, H6a’’, H6b’’), 3.73 - 3.64 (m, 2H, H6a’, H6b’), 3.62 - 3.56 
(m, 2H, H3, H4), 3.51 (d, J=9.6, 1H, H5’’), 3.47 (d, J=7.3, 2H, H5’, H5), 3.26 (dd, J=11.0, 1.5, 1H, 
H6a), 2.85 (dd, J=11.1, 5.2, 1H, H6b), 2.00 (s, 3H, Ac), 1.94 (s, 3H, Ac), 1.93 (s, 3H, Ac), 1.90 (s, 
3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.52, 170.39, 170.23, 
169.44 (170.5 - 169.4 CO2CH3), 138.78, 138.17, 138.01, 132.37 (Phth), 132.27 (Phth), 132.22, 
128.81, 128.78, 128.69, 128.61, 128.47, 128.14, 128.03, 128.01 (128.8 - 128.0 aromatic), 
123.35 (Phth), 100.71 (C1’’), 96.65 (C1’), 91.76 (C1), 78.47 (C4’), 76.83 (C3’), 76.69 (C4), 75.26 
(C5’’), 74.54 (BnCH2), 73.99 (BnCH2), 72.57 (C2), 71.77 (C5’), 71.25 (C3’’), 70.78 (C3), 70.22 
(BnCH2), 69.84 (C2’’), 68.46 (C6’), 67.38 (C5), 67.17 (C4’’), 63.27 (C6), 61.03 (C6’’), 55.82 (C2’), 
21.00, 20.88, 20.82, 20.78 (21.0 - 20.8 CO2CH3). 
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 Allyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsil 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene-α-D-ma
nnopyranoside (46) 
Compounds 38 (1.09 g, 1.30 mmol, 1.08 eq), 29 (479 mg, 1.20 
mmol, 1.0 eq), N-iodosuccinimide (675 mg, 3.00 mmol, 2.5 eq) 
and 4 Å molecular sieves (1 g) in dry dichloromethane (10 mL) 
were stirred at room temperature for 30 min under argon atmosphere. Then the suspension 
was cooled to 0 °C followed by slow addition of trifluoromethanesulfonic acid (21 μL, 0.24 
mmol, 0.2 eq). After stirring for 4 h at 0 °C, the reaction was quenched by diluting with more 
DCM (50 mL). The molecular sieves were removed by filtration and the filtrate was washed 
with 1 M Na2S2O3 (30 mL×3), brine (30 mL×1) and dried over MgSO4. Then concentrated and 
purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 46. Yield: 
75% (1.05 g, 0.90 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = +8° (c = 1.0, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1176.4486 ([M+H]+, calc. 
1176.4472), 1193.4742 ([M+NH4]
+, calc. 1193.4737), 1198.4321 ([M+Na]+, calc. 1198.4291), 
1214.4051 ([M+K]+, calc. 1214.4031). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.83 - 7.72 (m, 2H, Phth), 7.68 - 7.61 (m, 2H, Phth), 7.38 - 7.07 (m, 11H, aromatic), 
5.73 - 5.59 (m, 2H, H3’ , CH2CH=CH2), 5.35 - 5.23 (m, 3H, H1’, CHPh, H4’’), 5.09 - 4.98 (m, 3H, 
H2’’, CH2CH=CH2), 4.85 (dd, J=10.4, 3.5, 1H, H3’’), 4.66 (d, J=7.9, 1H, H1’’), 4.64 (d, J=10.7, 1H, 
BnCH2), 4.57 (d, J=12.5, 1H, BnCH2), 4.54 (d, J=1.2, 1H, H1), 4.19 (dd, J=10.8, 8.5, 1H, H2’), 
4.06 - 3.97 (m, 3H, H2, H6a’’, H6b’’), 3.94 - 3.85 (m, 2H, H4’ , CH2CH=CH2), 3.83 - 3.65 (m, 6H, 
H4, H3, H5’’, H6a’, H6b’, CH2CH=CH2), 3.56 (dd, J=10.2, 4.7, 1H, H6a), 3.40 (d, J=9.8, 2H, H5, 
H5’), 2.86 (t, J=10.2, 1H, H6b), 2.05 (s, 3H, Ac), 1.99 (s, 3H, Ac), 1.97 (s, 3H, Ac), 1.88 (s, 3H, 
Ac), 1.84 (s, 3H, Ac), 0.84 (s, 9H, tBu), 0.02 (s, 3H, Si(CH3)2), -0.00 (s, 3H, Si(CH3)2). 
13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.47, 170.31, 170.19, 168.94 (170.5 - 168.9 
CO2CH3), 138.68, 137.65, 134.08 (Phth), 133.18 (CH2CH=CH2), 128.86, 128.23, 128.20, 127.73, 
127.39, 126.09 (128.9 - 126.1 aromatic), 123.74 (Phth), 123.55 (Phth), 123.32 (Phth), 117.95 
(CH2CH=CH2), 101.47 (CHPh), 100.39 (C1’’), 96.65 (C1), 96.22 (C1’), 78.58 (C4), 75.84 (C5’), 
75.13 (C2), 75.06 (C4’), 73.67 (C3), 71.89 (BnCH2), 71.33 (C3’’), 70.78 (C3’, C5’’), 69.40 (C2’’), 
68.44 (C6), 68.30 (CH2CH=CH2), 67.07 (C4’’), 63.94 (C5), 61.25 (C6’’), 61.14 (C6’), 55.16 (C2’), 
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27.04, 26.07 (C(CH3)3), 20.87, 20.81, 20.76, 20.67 (20.9 - 20.7 CO2CH3), 18.40, -4.69 (Si(CH3)2), 
-5.22 (Si(CH3)2). 
Allyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsil 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[2,3,4,6-tetra-O-acetyl-β-D-glactopyra
nosyl)-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsilyl-2-deoxy-2-phthalimido-β-D-glucopyran
osyl]-(1→6)-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyranoside (47) 
Compounds 38 (1.48 g, 1.76 mmol, 2.2 eq), 31 (267 mg, 0.80 
mmol, 1.0 eq), N-iodosuccinimide (538 mg, 2.39 mmol, 3.0 eq) 
and 4 Å molecular sieves (0.8 g) in dry dichloromethane (8 mL) 
were stirred at room temperature for 30 min under argon 
atmosphere. Then the suspension was cooled to 0 °C 
followed by slow addition of trifluoromethanesulfonic acid (14 μL, 0.16 mmol, 0.2 eq). After 
stirring for 3 h at 0 °C, the reaction was quenched by diluting with more DCM (50 mL). The 
molecular sieves were removed by filtration and the filtrate was washed with 1 M Na2S2O3 
(30 mL×3), brine (30 mL×1) and dried over MgSO4. Then concentrated and purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 47. Yield: 58% (877 
mg, 0.46 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = +24° (c = 1.0, CHCl3). HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1890.6982 ([M+H]+, calc. 1889.7034), 
1906.7319 ([M+NH4]
+, calc. 1906.7300). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.90 - 7.59 (m, 8H, Phth), 5.64 - 5.55 (m, 2H, H32, H33), 5.47 - 5.34 (m, 1H, 
CH2CH=CH2), 5.28 (dd, J=14.6, 3.3, 2H, H4
4, H45), 5.23 (d, J=8.4, 1H, H12), 5.02 (ddd, J=12.9, 
10.4, 7.9, 2H, H24, H25), 4.94 - 4.80 (m, 4H, CH2CH=CH2, H3
4, H35), 4.74 (d, J=8.3, 1H, H13), 
4.61 (d, J=8.1, 2H, H14, H15), 4.25 (s, 1H, H11), 4.12 (dd, J=10.9, 8.4, 1H, H22), 4.00 (d, J=6.7, 
4H, H6a4, H6b4, H6a5, H6b5), 3.92 (dd, J=9.4, 6.9, 1H, H23), 3.89 - 3.66 (m, 11H, H42, H43, H6a2, 
H6b2, H6a3, H6b3, H6a1, H54, H55, H41, H21), 3.46 - 3.37 (m, 2H, H51, CH2CH=CH2), 3.31 (t, 
J=9.9, 2H, H52, H53), 3.24 - 3.17 (m, 1H, H31), 3.04 (s, 3H, OCH3), 3.03 - 2.98 (m, 1H, 
CH2CH=CH2), 2.94 (s, 3H, OCH3), 2.30 - 2.24 (m, 1H, H6b
1), 2.06 (s, 3H), 2.05 (s, 4H), 2.01 (s, 
3H), 1.99 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.90 (s, 3H), 1.88 (s, 3H), 1.82 (s, 3H), 1.80 (s, 3H, 
2.06 - 1.80 Ac), 1.04 (s, 3H, CH3), 0.98 (s, 3H, CH3), 0.85 (s, 9H, tBu), 0.85 (s, 9H, tBu), 0.05 (s, 
3H, Si(CH3)2), 0.02 (s, 3H, Si(CH3)2), 0.01 (s, 3H, Si(CH3)2), 0.00 (s, 3H, Si(CH3)2). 
13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.46, 170.42, 170.29, 170.21, 170.06, 169.09, 
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 168.97 (170.5 - 168.9 CO2CH3), 167.67, 167.36, 134.37, 133.98 (134.4 - 133.9 Phth), 133.10 
(CH2CH=CH2), 131.72, 123.67 (Phth), 123.48 (Phth), 117.91 (CH2CH=CH2), 100.67 (C1
4), 
100.51 (C15), 99.83 (COCH3(CH3)), 99.35 (COCH3(CH3)), 97.76 (C1
3), 95.72 (C11), 95.25 (C12), 
75.62 (C43), 75.57 (C52), 75.21 (C53), 75.11 (C42), 73.19 (C34, C35), 71.27 (C32), 70.83 (C33), 
70.74 (C54), 70.70 (C55), 70.25 (C51), 69.42 (C24), 69.31 (C25), 68.41 (C61), 67.19 (CH2CH=CH2), 
67.04 (C44), 66.94 (C45), 66.58 (C41), 63.42 (C31), 61.24 (C64, C65), 61.09 (C62, C63), 55.85, 
55.17 (C23), 54.50 (C22), 47.77 (OCH3), 47.40 (OCH3), 29.72, 27.01, 26.09 (C(CH3)3), 26.01 
(C(CH3)3), 20.88, 20.81, 20.74, 20.71, 20.65 (20.9 - 20.7 CO2CH3), 18.41, 17.69 (CH3), 17.56 
(CH3), -4.54, -4.86, -5.14, -5.18 (-4.5 - -5.2 Si(CH3)2). 
Allyl 2,3,4,6-tetra-O-acetyl-β-D-glactopyranosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsil 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[2,3,4,6-tetra-O-acetyl-β-D-glactopyra
nosyl-(1→4)-3-O-acetyl-6-O-tert-butyldimethylsilyl-2-deoxy-2-phthalimido-β-D-glucopyrano
syl]-(1→4)-3,6-di-O-benzyl-α-D-mannopyranoside (48) 
Compounds 38 (2.55 g, 3.04 mmol, 2.2 eq), 30 (553 mg, 1.38 
mmol, 1.0 eq), N-iodosuccinimide (1.19 g, 5.30 mmol, 3.8 eq) 
and 4 Å molecular sieves (1 g) in dry dichloromethane (10 mL) 
were stirred at room temperature for 30 min under argon atmosphere. Then the suspension 
was cooled to 0 °C followed by slow addition of trifluoromethanesulfonic acid (49 μL, 0.55 
mmol, 0.4 eq). After stirring for 4 h at 0 °C, the reaction was quenched by diluting with more 
DCM (50 mL). The molecular sieves were removed by filtration and the filtrate was washed 
with 1 M Na2S2O3 (30 mL×3), brine (30 mL×1), dried over MgSO4. Then concentrated and 
purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 48. Yield: 
57% (1.55 g, 0.79 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = -2° (c = 1.1, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1956.7187 ([M+H]+, calc. 
1956.7326), 1973.7480 ([M+NH4]
+, calc. 1973.7591), 995.8998 ([M+2NH4]
2+, calc. 995.8968), 
997.8476 ([M+Na+NH4]
2+, calc. 997.8728). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), 
δ (ppm): 7.88 - 7.61 (m, 8H, Phth), 7.36 - 7.11 (m, 10H, aromatic), 5.72 (ddd, J=9.9, 8.0, 4.4, 
1H, CH2CH=CH2), 5.67 - 5.62 (m, 1H, H3
2), 5.56 (dd, J=10.7, 9.2, 1H, H33), 5.43 (d, J=8.4, 1H, 
H12), 5.38 (d, J=8.5, 1H, H13), 5.31 (dd, J=8.8, 3.5, 2H, H44, H45), 5.10 - 4.98 (m, 4H, 
CH2CH=CH2, H2
4, H25), 4.91 (dd, J=10.4, 3.5, 1H, H34), 4.86 (dd, J=10.4, 3.5, 1H, H35), 4.74 (d, 
J=8.1, 1H, H14), 4.71 (d, J=3.2, 1H, BnCH2), 4.67 (d, J=8.0, 1H, H1
5), 4.58 (d, J=3.4, 1H, H11), 
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4.43 (d, J=12.5, 1H, BnCH2), 4.18 (dd, J=10.8, 8.5, 1H, H2
2), 4.13 - 3.99 (m, 6H, H21, H6a4, 
H6b4, H6a5, H6b5, H23), 3.96 - 3.84 (m, 6H, H42, H6a3, CH2CH=CH2, BnCH2, H4
3), 3.84 - 3.75 (m, 
5H, H54, H6b3, H41, H55, CH2CH=CH2), 3.71 (dd, J=12.8, 6.2, 1H, H3
1), 3.53 - 3.39 (m, 3H, H6a2, 
H51, H52), 3.35 (d, J=11.5, 1H, H6b2), 3.14 (dd, J=10.9, 2.2, 1H, H6a1), 3.00 (d, J=9.5, 1H, H53), 
2.93 (dd, J=10.8, 5.9, 1H, H6b1), 2.10 (s, 3H), 2.09 (s, 3H), 2.06 (s, 3H), 2.03 (s, 6H), 1.99 (s, 
3H), 1.95 (s, 3H), 1.94 (s, 3H), 1.87 (s, 3H), 1.83 (s, 3H, 2.10 - 1.83 Ac), 0.90 (s, 9H, tBu), 0.89 
(s, 9H, tBu), 0.07 (s, 3H, Si(CH3)2), 0.06 (s, 3H, Si(CH3)2), 0.03 (s, 3H, Si(CH3)2), 0.01 (s, 3H, 
Si(CH3)2). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.45, 170.42, 170.32, 
170.20, 170.16, 169.23, 168.93, 168.78 (170.5 - 168.8 CO2CH3), 167.95, 167.68, 139.04, 
138.48, 134.38 (Phth), 133.91 (CH2CH=CH2), 131.73, 131.56, 128.21, 128.12, 127.23, 127.03, 
126.89 (128.2 - 126.9 aromatic), 123.68 (Phth), 123.38 (Phth), 117.30 (CH2CH=CH2), 100.31 
(C15), 100.16 (C14), 97.73 (C13), 96.78 (C11), 96.06 (C12), 77.36 (C13), 75.64 (C52), 75.11 (C42), 
75.04 (C53), 74.72 (C41), 74.50 (C43), 73.08 (C12), 72.44 (BnCH2), 71.36 (C3
4), 71.30 (C35), 
71.10 (C31, C33), 70.95 (C51), 70.83 (BnCH2), 70.71 (C5
4), 70.63 (C55), 69.38 (C24), 69.31 (C61), 
69.29 (C25), 68.32 (CH2CH=CH2), 67.02 (C4
4), 66.98 (C45), 61.19 (C64, C65), 61.04 (C63), 60.48 
(C62), 55.58 (C23), 55.13 (C22), 29.79, 29.71, 26.09 (C(CH3)3), 26.01 (C(CH3)3), 20.84, 20.74, 
20.66 (20.8 - 20.7 CO2CH3), 18.38, 18.30, -4.63, -4.85, -5.28, -5.33(-4.6 - -5.3 Si(CH3)2). 
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 7.8 Synthesis of GlcNAc donor for building blocks extension 
Imidazole-1-sulfonyl azide hydrochloride (49)[186]  
To a suspension of sodium azide (35.2 g, 541 mmol, 1.0 eq) in MeCN (650 mL) 
at 0 °C, sulfuryl chloride (72.6 g, 537 mmol, 1.0 eq) was added dropwise. After 
stirring at r.t. for 18 h, imidazole (69.6 g, 1.02 mol, 1.9 eq) was added in portions and the 
reaction mixture was kept stirring for 4 h, diluted with 1.2 L EtOAc followed by washing with 
H2O (400 mL×2) and Sat. NaHCO3 (400 mL×2) and dried over MgSO4. The organic solvent was 
concentrated and then the residue was cooled with an ice-bath. The mixture was acidified 
with HCl in MeOH solution (65 mL AcCl dropped into 225 mL ice-cooled anhydrous MeOH), 
stored at -20 °C freezer for 24 h. The precipitate was filtered off and washed with EtOAc to 
give 49, yield 80% (89.5 g, 427 mmol). 
1,3,4,6-tetra-O-acetyl-2-azido-2-deoxy-α/β-D-glucopyranose (50)[186] 
To a suspension of K2CO3 (80.7 g, 583 mmol, 2.07 eq) and CuSO4·5H2O 
(694 mg, 2.8 mmol 0.01 eq) in MeOH (800 mL), glucosamine hydrochloride (60.9 g, 282 
mmol, 1.0 eq) and compound 49 (64.2 g, 306 mmol, 1.09 eq) were added sequentially. After 
mechanical stirring at r.t. for 4 h, the solvent was removed by rotary evaporation and 
coevaporated with toluene (200 ml×3). The residue was then acetylated with pyridine / 
acetic anhydride 2:1 (900 mL) at r.t. for 24 h, concentrated and coevaporated with toluene 
(200 ml×3). The residue was then acetylated with pyridine / acetic anhydride 2:1 (900 mL) at 
r.t. for 24 h and concentrated, coevaporated with toluene (200 ml×3). The residue was 
diluted with EtOAc (800 mL), washed with H2O (300 mL×2), Sat. NaHCO3 (300 mL×2), brine 
(500 mL×1), dried over MgSO4, the solvent was removed and crude product was purification 
by column chromatography (cyclohexane-ethyl acetate 8:1 to 2:1) gave 50 in 95% yield (99.6 
g, 227 mmol). Rf = 0.4 (
CHex/EtOAc 2:1). *α+D
20 = +35° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 
390.87 ([M+NH4]
+, calc. 391.15). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
5.54 (d, J=8.6, 1H, H1), 5.13 - 4.97 (m, 2H, H3, H4), 4.27 (dd, J=12.5, 4.5, 1H, H6a), 4.06 (dd, 
J=12.5, 2.0, 1H, H6b), 3.79 (ddd, J=9.7, 4.4, 2.1, 1H, H5), 3.64 (t, J=8.9, 1H, H2), 2.16 (s, 3H, 
Ac), 2.07 (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.00 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.72, 169.96, 169.80, 168.73 (170.7 - 168.7 CO2CH3), 92.75 (C1), 72.91 
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(C3), 72.89 (C5), 68.01 (C4), 62.78 (C2), 61.61 (C6), 21.04, 20.85, 20.79, 20.72 (21.0 - 20.7 
CO2CH3). 
3,4,6-tri-O-acetyl-2-azido-2-deoxy-α-D-glucopyranosylchloride (51)[294] 
To a stirring solution of 50 (99.3 g, 266 mmol, 1.0 eq) in anhydrous CHCl3 (600 
mL) at 0 °C, titanium (IV) chloride (58.3 mL, 532 mL, 2.0 eq) was added dropwise. The 
temperature was raised to r.t. and the mixture heated to reflux for 4 h. The reaction mixture 
was diluted with DCM (600 mL), washed with H2O (500 mL×2), Sat. NaHCO3 (500 mL×2), 
brine (800 mL×1), dried over MgSO4 and the solvent was removed under reduced pressure. 
The residue was purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) 
to give 51 in 60% yield (56.3 g, 161 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). [α]D
20 = +140° (c = 1.0, 
CHCl3). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 6.10 (d, J=3.8, 1H, H1), 
5.51 - 5.42 (m, 1H, H3), 5.08 (t, J=9.6, 1H, H4), 4.35 - 4.27 (m, 2H, H5, H6a), 4.09 (dt, J=4.6, 
3.2, 1H, H6b), 3.84 (dd, J=10.3, 3.8, 1H, H2), 2.07 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.02 (s, 3H, Ac). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.59, 169.88, 169.79 (170.6 - 169.8 
CO2CH3), 91.83 (C1), 70.92 (C5), 70.86 (C3), 67.79 (C4), 62.43 (C2), 61.31 (C6), 20.82, 20.79, 
20.71 (20.8 - 20.7 CO2CH3). 
Phenyl 2-azido-2-deoxy-1-thio-β-D-glucopyranoside (52)[295] 
To a stirring solution of thiophenol (18.0 mL, 176 mmol, 1.1 eq) and KOH 
(9.89 g, 176 mmol, 1.1 eq) in EtOH (300 mL), a solution of 51 (56.0 g, 160 mmol, 1.0 eq) in 
CHCl3 (300 mL) was added dropwise. After stirring at r.t. for 3 h. The reaction was diluted 
with DCM (600 mL), washed with H2O (500 mL×2), Sat. NaHCO3 (500 mL×2), brine (800 
mL×1), dried over Na2SO4. The solvent was removed and the crude product was dissolved in 
0.25 M NaOMe in MeOH (400 mL) solution. Then stirred at r.t. for 2 h, neutralized with 
Dowex 50WX8 ion-exchanger (3 g, prewashed with MeOH), concentrated and coevaporated 
with toluene (250 mL×3). The residue was purified by column chromatography 
(cyclohexane-ethyl acetate 5:1 to 1:2) gave 52 in 64% yield (30.2 g, 102 mmol). Rf = 0.3 
(EtOAc). *α+D
20 = -13° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 298.13 ([M+H]
+, calc. 298.09). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.50 (dd, J=8.3, 1.3, 2H, SPh), 
7.37 - 7.30 (m, 2H, SPh), 7.30 - 7.25 (m, 1H, SPh), 4.69 (d, J=10.2, 1H, H1), 3.69 (dd, J=11.9, 
1.7, 1H, H6a), 3.46 (dd, J=11.9, 5.7, 1H, H6b), 3.35 (t, J=9.0, 1H, H3), 3.27 (ddd, J=9.8, 5.6, 1.7, 
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 1H, H5), 3.19 - 3.10 (m, 2H, H2, h4). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 
133.54, 131.62, 129.70, 127.98 (133.5 - 128.0 SPh), 84.96 (C1), 81.66 (C5), 77.22 (C3), 70.31 
(C4), 66.03 (C2), 61.44 (C6). 
Phenyl 2-azido-2-deoxy-3,4,6-tri-O-p-methoxybenzyl-1-thio-β-D-glucopyranoside (53) 
Compound 52 (20.82 g, 73.5 mmol, 1.0 eq) was dissolved in dry DMF 
(200 mL) under Ar and NaH (60% suspension, 10.29 g, 257 mmol, 3.5 eq) 
was added in portions under cooling with an ice-bath. The reaction was kept at 0 °C for 40 
min before 4-methoxybenzyl chloride (31.0 mL, 237 mmol, 3.23 eq) was added dropwise 
using a syringe. After 2 h stirring at r.t., the organic solvent was removed under reduced 
pressure and the residue was dissolved in EtOAc (300 mL), washed with H2O (150 mL×2), 
brine (150 mL×1), dried over MgSO4. The solvent was removed, the residue purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) and then recrystallized from 
cyclohexane-ethyl acetate to give 53, yield 63% (30.60 g, 46.5 mmol). Rf = 0.5 (
CHex/EtOAc 
3:1). *α+D
20 = -67° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 675.00 ([M+NH4]
+, calc. 675.29), 1331.27 
([2M+NH4]
+, calc. 1332.54). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.66 
- 7.57 (m, 2H, PMB), 7.34 - 7.23 (m, 7H, PMB, SPh), 7.16 - 7.11 (m, 2H, PMB), 6.91 - 6.80 (m, 
6H, PMB), 4.80 (s, 2H, PMBCH2), 4.73 (d, J=10.5, 1H, PMBCH2), 4.57 (d, J=11.6, 1H, PMBCH2), 
4.51 (d, J=8.0, 1H, PMBCH2), 4.49 (d, J=9.6, 1H, PMBCH2), 4.41 (d, J=10.1, 1H, H1), 3.83 - 3.79 
(m, 9H, PMBCH3), 3.75 (d, J=10.9, 1H, H6a), 3.70 (dd, J=10.9, 4.2, 1H, H6b), 3.56 (t, J=9.3, 1H, 
H3), 3.52 - 3.46 (m, 1H, H4), 3.46 - 3.40 (m, 1H, H5), 3.34 (t, J=9.6, 1H, H2). 13C-NMR (100.6 
MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 159.69 (PMB), 159.60 (PMB), 159.44 (PMB), 133.79, 
131.55, 130.54, 130.30, 130.10, 129.74, 129.51, 129.20, 128.52 (133.8 - 128.5 aromatic), 
114.17 (PMB), 114.10 (PMB), 114.01 (PMB), 86.17 (C1), 84.99 (C4), 79.66 (C5), 77.61 (C3), 
75.72 (PMBCH2), 74.89 (PMBCH2), 73.33 (PMBCH2), 68.64 (C6), 65.33 (C2), 55.51 (PMBCH3). 
Phenyl 2-deoxy-3,4,6-tri-O-p-methoxybenzyl-1-thio-2-N-(2,2,2-trichloroethoxycarbonylami 
no)-β-D-glucopyranoside (54) 
To a stirring solution of 53 (32.14 g, 48.9 mmol, 1.0 eq) in dioxane/AcOH 
10:1  (330 mL) at 0 °C, zinc powder (15.88 g, 244.3 mmol, 5.0 eq) was added. After stirring 
at r.t. for 24 h, the zinc was removed by filtering through a layer of Celite, the filtrate was 
concentrated, diluted with EtOAc (500 mL) and washed with H2O (250 mL×3), Sat. NaHCO3 
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(250 mL×2), brine (300 mL×1) and dried over MgSO4. The organic solvent was removed under 
reduced pressure. The crude product was dissolved in dioxane/H2O 2:1 (600 mL) and NaHCO3 
(9.46 g, 112.6 mmol, 2.3 eq) was then added. The mixture was stirred at room temperature 
for 15 min then cooled to 0 °C followed by slow addition of TrocCl (8.07 ml, 58.6 mmol, 1.2 
eq). The reaction was kept stirring at r.t. for 24 h and concentrated under reduced pressure 
to remove most of the dioxane. The residue was extracted with EtOAc (200 mL×3), the 
organic layers were combined and washed with brine (300 mL×1), dried over MgSO4, 
concentrated and purified by column chromatography (toluene-ethyl acetate 20:1 to 4:1). 
Then recrystallized from cyclohexane-ethyl acetate to give 54, yield 94% (37.04 g, 45.9 mmol). 
Rf = 0.4 (
CHex/EtOAc 3:1). *α+D
20 = +12° (c = 1.0 CHCl3). ESI-MS (pos), m/z: 822.80 ([M+NH4]
+, 
calc. 823.20), 1629.20 ([2M+NH4]
+, calc. 1630.36). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.56 - 7.47 (m, 2H, PMB), 7.30 - 7.19 (m, 7H, PMB, SPh), 7.14 (d, J=8.5, 2H, 
PMB), 6.92 - 6.80 (m, 6H, PMB), 5.09 (d, J=8.4, 1H, NH), 4.90 (d, J=10.2, 1H, H1), 4.80 - 4.69 
(m, 4H, PMBCH2, TrocCH2), 4.64 (d, J=10.8, 1H, PMBCH2), 4.56 (d, J=11.6, 1H, PMBCH2), 4.52 
(d, J=10.7, 1H, PMBCH2), 4.48 (d, J=11.7, 1H, PMBCH2), 3.83 - 3.77 (m, 10H, PMBCH3, H3), 
3.77 - 3.72 (m, 1H, H6a), 3.69 (dd, J=10.9, 4.6, 1H, H6b), 3.60 (t, J=9.1, 1H, H4), 3.52 (dd, 
J=12.1, 1.8, 1H, H5), 3.48 - 3.42 (m, 1H, H2). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 159.60 (PMB), 159.57 (PMB), 159.41 (PMB), 154.04 (TrocC=O), 132.52, 130.36, 129.99, 
129.81, 129.60, 129.13, 127.92 (132.5 - 127.9 aromatic), 114.12 (PMB), 114.08 (PMB), 
114.00 (PMB), 95.77 (CCl3), 86.18 (C1), 82.01 (C3), 79.59 (C5), 78.46 (C4), 74.97 (PMBCH2), 
74.73 (PMBCH2, TrocCH2), 73.33 (PMBCH2), 68.84 (C6), 56.85 (C2), 55.51 (PMBCH3). 
Phenyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-1-thio-β-D-glucopyranoside (55)[296] 
Compound 9 (50.1 g, 95.0 mmol, 1.0 eq) was dissolved in 0.08 M NaOMe 
in MeOH (500 mL) and was stirred at r.t. for 4 h. Then neutralized with 
Dowex 50WX8 ion-exchanger (0.5 g, prewashed with MeOH), concentrated and 
coevaporated with toluene (50 mL×3) to give a crude product, yield 99% (37.6 g, 94.0 mmol). 
The deacetylated intermediate (34.8 g, 86.8 mmol, 1.0 eq) was dissolved in dry DMF (150 mL) 
under Ar, NaH (60% suspension, 9.89 g, 247 mmol, 2.8 eq) was added in portion and the 
reaction was kept at 0 °C for 40 min before BnBr (41.3 mL, 347 mmol, 4.0 eq) was added 
dropwise via syringe. The solvent was removed by high vacuum after 24 h stirring at r.t. and 
the residue was dissolved in EtOAc (800 mL), filtered through a layer of Celite, washed with 
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 H2O (500 mL×2), brine (500 mL×1), dried over MgSO4, concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 55, yield 80% (46.4 g, 69.1 
mmol). Rf = 0.7 (Tol/EtOAc 6:1). [α]D
20 = +64° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 688.93 
([M+NH4]
+, calc. 689.27), 1359.73 ([2M+NH4]
+, calc. 1360.50). 1H-NMR (400 MHz, CDCl3, 
gCOSY, gHSQC, gHMBC), δ (ppm): 7.82 (d, J=6.8, 1H, Phth), 7.73 - 7.60 (m, 3H, Phth), 7.46 - 
7.14 (m, 15H, CH2Ph, SPh), 7.00 (d, J=7.7, 2H, CH2Ph), 6.93 - 6.82 (m, 3H, CH2Ph), 5.57 (d, 
J=10.4, 1H, H1), 4.86 (d, J=11.0, 1H, CH2Ph), 4.80 (d, J=12.0, 1H, CH2Ph), 4.69 (d, J=8.3, 1H, 
CH2Ph), 4.66 (d, J=9.4, 1H, CH2Ph), 4.59 (d, J=12.0, 1H, CH2Ph), 4.46 (d, J=12.0, 1H, CH2Ph), 
4.41 (dd, J=10.3, 8.5, 1H, H3), 4.29 (t, J=10.3, 1H, H2), 3.88 - 3.81 (m, 2H, H6a, H6b), 3.79 (d, 
J=8.3, 1H, H4), 3.76 - 3.70 (m, 1H, H5). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 
168.25 (Phth C=O), 167.53 (Phth C=O), 138.52, 138.23, 138.06, 134.09 (Phth), 133.98 (Phth), 
132.82, 132.40, 129.02, 128.70, 128.60, 128.30, 128.18, 128.17, 128.08, 128.01, 127.92, 
127.80, 127.61 (129.0 - 127.6, aromatic), 123.67 (Phth), 123.55 (Phth), 83.53 (C1), 80.59 (C3), 
79.70 (C4), 79.65 (C5), 75.24 (CH2Ph), 75.21 (CH2Ph), 73.70 (CH2Ph), 69.13 (C6), 55.21 (C2). 
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7.9 Synthesis of complex type building blocks with GlcNAc extension 
Allyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6- 
O-benzylidene-α-D-mannopyranoside (56) 
Compounds 55 (6.02 g, 8.96 mmol, 1.2 eq), 29 (2.96 g, 7.43 mmol, 1.0 
eq), N-iodosuccinimide (2.08 g, 9.25 mmol, 1.25 eq) and 4 Å molecular 
sieves (3 g) in dry dichloromethane (30 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the suspension was cooled to -18 °C 
followed by slow addition of trifluoromethanesulfonic acid (98.6 μL, 1.12 mmol, 0.15 eq). 
After stirring for 0.5 h at -18 °C, the temperature was raised to 0 °C continued for another 1h, 
then the reaction was quenched by diluting with more DCM (100 mL). The molecular sieves 
were removed by filtration and the filtrate was washed with 1 M Na2S2O3 (75 mL×3), brine 
(100 mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 8:1) to give 56. Yield: 85% (6.03 g, 6.28 mmol). Rf = 0.5 
(Tol/EtOAc 4:1). *α+D
20 = +25° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 977.4254 ([M+NH4]
+, calc. 977.4225), 982.3814 ([M+Na]+, calc. 
982.3778). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.69 (s, 2H, Phth), 
7.48 - 7.42 (m, 2H, Phth), 7.43 - 7.19 (m, 20H, benzyl aromatic), 7.08 (d, J=6.9, 2H, 
benzylidene acetal aromatic), 6.99 - 6.85 (m, 3H, benzylidene acetal aromatic), 5.77 (ddd, 
J=22.2, 10.9, 5.7, 1H, CH2CH=CH2), 5.47 (s, 1H, CHPh), 5.25 (d, J=8.4, 1H, H1’), 5.16 (d, J=5.2, 
1H, CH2CH=CH2), 5.12 (dd, J=13.3, 1.6, 1H, CH2CH=CH2), 4.91 (d, J=10.9, 1H, 4’-BnCH2), 4.86 
(d, J=12.1, 1H, 3’-BnCH2), 4.79 (d, J=12.4, 1H, 3-BnCH2), 4.71 (d, J=11.0, 1H, 4’-BnCH2), 4.67 (d, 
J=12.4, 1H, 3-BnCH2), 4.62 (q, J=12.0, 2H, 6’-BnCH2), 4.55 - 4.45 (m, 3H, 3’-BnCH2, H1, H3’), 
4.38 (dd, J=10.8, 8.4, 1H, H2’), 4.18 - 4.14 (m, 1H, H2), 3.97 - 3.90 (m, 2H, CH2CH=CH2, H4), 
3.87 (dd, J=10.0, 2.8, 1H, H3), 3.85 - 3.80 (m, 2H, H6a’, H6b’), 3.79 - 3.72 (m, 3H, CH2CH=CH2, 
H5’, H4’), 3.70 (dd, J=10.0, 4.5, 1H, H6a), 3.52 (td, J=9.7, 4.6, 1H, H5), 3.11 (t, J=10.2, 1H, H6b). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.68, 138.24, 138.14, 137.97, 
137.70, 133.65 (Phth), 133.21 (CH2CH=CH2), 131.93, 128.76, 128.54, 128.42, 128.17, 128.14, 
128.12, 127.97, 127.82, 127.77, 127.67, 127.63, 127.39, 127.27, 126.09 (128.8 - 126.1 
aromatic), 123.01, 117.77 (CH2CH=CH2), 101.44 (CHPh), 97.12 (C1), 96.84 (C1’), 79.81 (C4’), 
79.17 (C3’), 78.20 (C4), 75.52 (C5’), 75.16 (4’-BnCH2), 74.85 (C2), 74.78 (3’-BnCH2), 73.72 
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 (6’-BnCH2), 73.67 (C3), 71.20 (3-BnCH2), 69.38 (C6’), 68.44 (C6), 68.21 (CH2CH=CH2), 63.89 
(C5), 55.97 (C2’). 
3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6-O-benz
ylidene-α-D-mannopyranose (57) 
A suspension of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine) 
iridium(I) hexafluorophosphate (228 mg, 0.27 mmol, 0.05 eq) in 
anhydrous THF (12 mL) was stirred under Ar atmosphere and H2 gas 
was added until the orange color disappeared. The activated catalyst suspension was then 
added into a solution of 56 (5.17 g, 5.39 mmol, 1.0 eq) in anhydrous THF (60 mL), after 2 h 
stirring at r.t. a faster main product on TLC was observed, Rf = 0.6 (Tol/EtOAc 4:1). NaHCO3 
(1.72 g, 20.5 mmol, 3.8 eq) and H2O (18 mL) was added to the previous reaction mixture 
followed with I2 (3.45 g, 13.5 mmol, 2.5 eq), continued stirring at r.t. for 0.5 h as the 
deallylated product was formed. 1 M Na2S2O3 was added until the purple color disappeared, 
and THF was then removed under reduced pressure. The residue was diluted with DCM (200 
mL), washed with 1 M Na2S2O3 (100 mL×2), H2O (100 mL×2), brine (150 mL×1), dried over 
MgSO4, the solvent was removed and crude product was purified by column chromatography 
(cyclohexane-ethyl acetate 8:1 to 1:1) to give 57, yield 72% (3.57 g, 3.88 mmol). Rf = 0.1 
(Tol/EtOAc 4:1). *α+D
20 = -10° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 920.3353 ([M+H]+, calc. 920.3646), 937.3927 ([M+NH4]
+, calc. 937.3912), 
942.3475 ([M+Na]+, calc. 942.3465). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.67 (s, 2H, Phth), 7.46 - 7.12 (m, 22H, Phth, benzyl aromatic), 7.10 (d, J=7.5, 2H, 
benzylidene acetal aromatic), 6.90 (t, J=7.5, 3H, benzylidene acetal aromatic), 5.45 (s, 1H, 
CHPh), 5.40 (d, J=8.5, 1H, H1’), 5.01 - 4.84 (m, 4H, H1, 4’-BnCH2, 3’-BnCH2, H3), 4.75 (d, 
J=14.1, 1H, 3-BnCH2), 4.63 - 4.50 (m, 4H, 4’-BnCH2, 3’-BnCH2, 3-BnCH2, 6’-BnCH2), 4.43 - 4.30 
(m, 3H, H2’, 6’-BnCH2, H2), 3.96 (t, J=8.7, 1H, H5’), 3.89 - 3.80 (m, 3H, H4, H3, H6a’), 3.68 - 
3.51 (m, 4H, H5, H6b’, H4’, H6a), 3.05 (t, J=10.0, 1H, H6b). 13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 138.85, 138.29, 138.05, 137.25, 133.81 (Phth), 133.63, 132.12, 
128.93, 128.83, 128.78, 128.76, 128.71, 128.42, 128.34, 128.19, 128.12, 128.05, 127.69, 
127.46, 126.34 (128.9 - 126.3 aromatic), 101.65 (CHPh), 97.10 (C1’), 92.86 (C1), 80.83 (C4’), 
79.55 (C3’), 78.47 (C4), 75.83 (4’-BnCH2), 75.68 (C2), 75.17 (3’-BnCH2), 75.06 (C5’), 73.46 
(3-BnCH2), 73.15 (C3), 70.89 (6’-BnCH2), 69.83 (C6’), 68.88 (C6), 63.68 (C5), 56.28 (C2’). 
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3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6-O-benz
ylidene-α-D-mannopyranosyl trichloroacetimidate (58) 
To a solution of 57 (3.47 g, 3.77 mmol, 1.0 eq) and 
trichloroacetonitrile (1.13 mL, 11.2 mmol, 3.0 eq) in anhydrous 
DCM (80 mL) under Ar at 0 °C, DBU (0.11 mL, 0.75 mmol, 0.2 eq) 
was added. After stirring at 0 °C for 3 h, the reaction mixture was 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 5:1 to 1:1) 
to give 58, yield 90% (3.63 g, 3.41 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = +49° (c = 1.0, 
CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1080.3018 
([M+NH4]
+, calc. 1080.3008), 1085.2570 ([M+Na]+, calc. 1085.2562), 1101.2311 ([M+K]+, calc. 
1101.2301). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.49 (s, 1H, NH), 
7.68 (d, J=2.3, 2H, Phth), 7.47 - 7.39 (m, 2H, Phth), 7.39 - 7.24 (m, 17H, benzyl aromatic), 7.24 
- 7.16 (m, 3H, benzyl aromatic), 7.05 (d, J=6.7, 2H, benzylidene acetal aromatic), 6.95 - 6.81 
(m, 3H, benzylidene acetal aromatic), 5.93 (d, J=1.5, 1H, H1), 5.46 (s, 1H, CHPh), 5.37 (d, 
J=8.3, 1H, H1’), 4.89 (d, J=10.9, 1H, 4’-BnCH2) , 4.83 (d, J=12.1, 1H, 3’-BnCH2), 4.79 - 4.66 (m, 
3H, 4’-BnCH2, 3-BnCH2), 4.60 (q, J=12.0, 2H, 6’-BnCH2), 4.51 - 4.41 (m, 2H, 3’-BnCH2, H3’), 
4.36 (dd, J=10.8, 8.3, 1H, H2’), 4.20 (dd, J=2.9, 2.1, 1H, H2), 3.99 (t, J=9.8, 1H, H3), 3.89 - 3.74 
(m, 5H, H4, H6a’, H6a, H6b’, H4’), 3.73 - 3.63 (m, 1H, H5), 3.08 (t, J=10.1, 1H, H6b). 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 160.06, 138.39, 138.22, 138.15, 137.55, 133.98 
(Phth), 131.97, 129.09, 128.74, 128.64, 128.49, 128.40, 128.34, 128.30, 128.24, 128.16, 
127.99, 127.87, 127.76, 127.64, 126.24 (129.1 - 126.2 aromatic), 123.42, 101.69 (CHPh), 
97.14 (C1’), 95.72 (C1), 90.77, 79.96 (C4’), 79.37 (C3’), 77.82 (C3), 75.82 (C5’), 75.35 
(4’-BnCH2), 75.07 (3’-BnCH2), 73.89 (6’-BnCH2), 73.45 (C2), 72.66 (C4), 71.75 (3-BnCH2), 69.50 
(C6’), 68.32 (C6), 66.70 (C5), 56.00 (C2’). 
Allyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-benz 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)+-3,6-di-O-ben
zyl-α-D-mannopyranoside (59) 
Compounds 55 (819 mg, 1.22 mmol, 2.2 eq), 30 (222 mg, 0.55 mmol, 
1.0 eq), N-iodosuccinimide (312 mg, 1.39 mmol, 2.5 eq) and 4 Å 
molecular sieves (0.45 g) in dry dichloromethane (4.5 mL) were stirred at room temperature 
for 30 min under argon atmosphere. Then the suspension was cooled to -18 °C followed by 
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 slow addition of trifluoromethanesulfonic acid (19.6 μL, 0.22 mmol, 0.4 eq). After stirring for 
0.5 h at -18 °C, the temperature was raised to 0 °C continued for another 1h, then the 
reaction was quenched by diluting with more DCM (20 mL). The molecular sieves were 
removed by filtration and the filtrate was washed with 1 M Na2S2O3 (15 mL×3), brine (20 
mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:1) to give 59. Yield: 35% (293 mg, 0.19 mmol). Rf = 0.6 
(CHex/EtOAc 2:1). *α+D
20 = +25° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1524.6299 ([M+H]+, calc. 1524.6300), 1541.6448 ([M+NH4]
+, calc. 
1541.6566), 1546.6130 ([M+Na]+, calc. 1546.6120), 1562.5881 ([M+K]+, calc. 1562.5859). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.78 - 7.42 (m, 8H, Phth), 7.38 - 
7.13 (m, 30H, aromatic), 6.98 (dd, J=11.6, 7.6, 4H, aromatic), 6.92 - 6.82 (m, 6H, aromatic), 
5.71 (dq, J=10.4, 5.6, 1H, CH2CH=CH2), 5.28 (d, J=8.3, 1H, H1’), 5.25 (d, J=8.4, 1H, H1’’), 5.08 - 
4.98 (m, 2H, CH2CH=CH2), 4.85 - 4.68 (m, 5H, BnCH2), 4.62 (dd, J=10.7, 3.8, 2H, BnCH2), 4.56 - 
4.36 (m, 7H, BnCH2), 4.35 - 4.29 (m, 1H, H3’), 4.29 - 4.21 (m, 2H, H2’, H3’’), 4.12 (t, J=9.6, 1H, 
H2’’), 4.07 (t, J=2.8, 1H, H2), 3.94 (dd, J=5.3, 2.4, 1H, H3), 3.86 (dd, J=12.8, 5.4, 1H, 
CH2CH=CH2), 3.81 - 3.57 (m, 9H, H4’ , BnCH2, CH2CH=CH2, H4’’, H4, H6a’, H6b’, H5’’), 3.54 (dd, 
J=11.2, 3.4, 1H, H6a’’), 3.51 - 3.46 (m, 1H, H5), 3.40 (d, J=10.8, 1H, H6b’’), 3.30 (d, J=9.8, 1H, 
H5’), 3.10 (d, J=10.9, 1H, H6a), 2.94 (dd, J=10.9, 6.3, 1H, H6b). 13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 139.31, 138.66, 138.56, 138.50, 138.43, 138.32, 138.30, 138.25, 
134.14 (CH2CH=CH2), 133.68 (Phth), 133.61 (Phth), 131.82, 128.66, 128.61, 128.57, 128.49, 
128.25, 128.22, 128.17, 128.13, 128.08, 128.06, 128.04, 128.02, 127.93, 127.73, 127.63, 
127.47, 127.44, 127.40, 127.23, 127.10 (128.7 - 127.1 aromatic), 123.42 (Phth), 117.29 
(CH2CH=CH2), 98.89 (C1’’), 97.82 (C1), 96.99 (C1’), 79.93 (C4’’), 79.61 (C4’), 79.50 (C3’), 79.29 
(C3’’), 77.10 (C3), 76.21 (C4), 75.38 (C5’’), 75.19 (BnCH2), 75.04 (C5’), 74.99 (BnCH2), 74.92 
(BnCH2), 74.88 (BnCH2), 74.21 (C2), 73.75 (BnCH2), 73.56 (BnCH2), 72.52 (BnCH2), 71.41 
(BnCH2), 70.88 (C5), 69.68 (C6), 69.23 (C6’), 68.36 (CH2CH=CH2), 68.26 (C6’’), 56.62 (C2’’), 
56.14 (C2’). 
  
165 
 
EXPERIMENTAL PART 
Allyl 3,4,6-tri-O-acetyl-β-D-glucopyranosyl-2-deoxy-2-phthalimido-(1→2)-[3,4,6-tri-O-acetyl 
-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)+-3,6-di-O-benzy
l-α-D-mannopyranoside (60)[297] 
Compounds 8 (1269 mg, 2.65 mmol, 2.2 eq), 30 (482 mg, 1.20 
mmol, 1.0 eq), N-iodosuccinimide (676 mg, 3.01 mmol, 2.5 eq) and 
4 Å molecular sieves (1.0 g) in dry dichloromethane (10 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the suspension was cooled to -0 °C 
followed by slow addition of trifluoromethanesulfonic acid (37 μL, 0.42 mmol, 0.35 eq). After 
stirring for 15 min at 0 °C, the reaction was quenched by diluting with more DCM (40 mL). 
The molecular sieves were removed by filtration and the filtrate was washed with 1 M 
Na2S2O3 (30 mL×3), brine (50 mL×1), dried over MgSO4, concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 60. Yield: 60% (970 mg, 0.72 
mmol). Rf = 0.4 (
CHex/EtOAc 1:1). *α+D
20 = +13° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1235.4087 ([M+H]+, calc. 1235.4084), 1252.4363 
([M+NH4]
+, calc. 1252.4349), 1257.3928 ([M+Na]+, calc. 1257.3903). 1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.72 (dd, J=4.6, 3.7, 2H, Phth), 7.60 (dd, J=5.4, 2.9, 
2H, Phth), 7.49 (s, 2H, Phth), 7.38 (d, J=7.5, 2H, Phth), 7.32 (t, J=7.4, 3H, aromatic), 7.28 - 
7.15 (m, 5H, aromatic), 6.86 - 6.77 (m, 2H, aromatic), 5.76 - 5.59 (m, 3H, H3’, CH2CH=CH2, 
H3’’), 5.50 (d, J=8.4, 1H, H1’’), 5.45 (d, J=8.5, 1H, H1’), 5.19 - 4.98 (m, 4H, H4’, CH2CH=CH2, 
H4’’), 4.77 (d, J=11.7, 1H, BnCH2), 4.51 (d, J=2.8, 1H, H1), 4.51 (d, J=11.8, 1H, BnCH2), 4.38 (dd, 
J=10.7, 8.5, 1H, H2’), 4.17 (dd, J=10.7, 8.5, 1H, H2’’), 4.13 - 3.99 (m, 4H, H6a’, H6b’, H2, H6a’’), 
3.89 (dd, J=7.3, 3.2, 1H, H3), 3.87 - 3.64 (m, 8H, H3, CH2CH=CH2, H4, H5’, BnCH2, H6b’’), 3.51 - 
3.42 (m, 1H, H5), 3.37 (d, J=10.0, 1H, H5’’), 3.08 (dd, J=11.5, 1.4, 1H, H6a), 3.00 (dd, J=11.4, 
5.2, 1H, H6b), 2.02 (s, 3H), 1.99 (s, 3H), 1.99 (s, 3H), 1.95 (s, 3H), 1.82 (s, 3H), 1.78 (s, 3H, 2.02 
- 1.78, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 177.90, 170.93, 170.85, 
170.41, 170.31, 169.67 (170.9 - 169.7 CO2CH3), 138.79, 138.34, 134.18 (Phth), 133.70 
(CH2CH=CH2), 128.42, 128.18, 127.55, 127.51, 127.33, 127.29 (128.4 - 127.3 aromatic), 
123.53 (Phth), 117.73 (CH2CH=CH2), 98.44 (C1’’), 97.29 (C1’), 97.02 (C1), 76.69 (C3), 75.60 
(C4), 74.57 (C2), 72.49 (BnCH2), 72.12 (C5’), 71.69 (C5’’), 71.04 (C5), 70.97 (C3’, C3’’, BnCH2), 
69.16 (C4’), 68.68 (C4’’), 68.62 (C6), 68.35 (CH2CH=CH2), 62.28 (C6’), 61.65 (C6’’), 60.62, 
55.28 (C2’’), 54.71 (C2’), 29.79, 21.25, 20.93, 20.81, 20.65, 20.60 (21.3 - 20.6 CO2CH3), 14.39. 
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 3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-acetyl-2-de
oxy-2-phthalimido-β-D-glucopyranosyl-(1→4)+-3,6-di-O-benzyl-α-D-mannopyranose (61) 
A suspension of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine) 
iridium(I) hexafluorophosphate (140 mg, 0.17mmol, 0.25 eq) in fresh 
dry THF (7 mL) was stirred under Ar atmosphere and H2 gas was 
added until the orange color disappeared. The activated catalyst 
suspension was then added into a solution of 60 (793 mg, 0.64 mmol, 1.0 eq) in anhydrous 
THF (8 mL) via syringe, after 2 h stirring at r.t. a faster main product was observed on TLC, Rf = 
0.5 (CHex/EtOAc 1:1). NaHCO3 (178 mg, 2.12 mmol, 3.3 eq) and H2O (10 mL) was added to 
the previous reaction mixture followed with I2 (356 mg, 1.39 mmol, 2.2 eq), continued 
stirring at r.t. for 0.5 h as the deallylated product was formed. 1 M Na2S2O3 was added until 
the purple color disappeared, and THF was then removed under reduced pressure. The 
residue was diluted with DCM (20 mL), washed with 1 M Na2S2O3 (10 mL×2), H2O (10 mL×2), 
brine (15 mL×1), dried over MgSO4, the solvent was removed and the residue was purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 61, yield 91% (693 
mg, 0.58 mmol). Rf = 0.2 (
CHex/EtOAc 1:1). *α+D
20 = +1° (c = 0.8, CHCl3). HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1195.3774 ([M+H]+, calc. 1195.3771), 
1212.4049 ([M+NH4]
+, calc. 1212.4036), 1217.3595 ([M+Na]+, calc. 1217.3590). 1H-NMR (400 
MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.74 (dd, J=5.3, 3.2, 2H, Phth), 7.64 (dd, J=5.5, 
3.1, 2H, Phth), 7.49 (s, 2H, Phth), 7.40 (d, J=7.2, 2H, Phth), 7.36 - 7.30 (m, 3H, aromatic), 7.29 
- 7.16 (m, 5H, aromatic), 6.88 - 6.80 (m, 2H, aromatic), 5.77 (dd, J=10.8, 9.1, 1H, H3’), 5.67 
(dd, J=10.7, 9.1, 1H, H3’’), 5.59 (d, J=8.5, 1H, H1’), 5.45 (d, J=8.4, 1H, H1’’), 5.18 - 5.12 (m, 1H, 
H4’), 5.10 - 5.03 (m, 1H, H4’’), 4.90 (s, 1H, H1), 4.73 (d, J=11.9, 1H, BnCH2), 4.55 (d, J=11.9, 1H, 
BnCH2), 4.39 (dd, J=10.8, 8.5, 1H, H2’), 4.17 (dd, J=10.7, 8.4, 1H, H2’’), 4.14 - 4.09 (m, 2H, 
H6a’, H6b’), 4.08 - 4.01 (m, 2H, H2, H6a’’), 3.93 - 3.78 (m, 3H, H5’, H6b’’, H3), 3.74 - 3.59 (m, 
4H, BnCH2, H4, H5), 3.41 (ddd, J=10.2, 3.6, 2.5, 1H, H5’’), 3.13 - 3.03 (m, 1H, H6a), 2.65 (dd, 
J=10.4, 6.0, 1H, H6b), 1.99 (s, 3H), 1.98 (s, 3H), 1.97 (s, 3H), 1.95 (s, 3H), 1.83 (s, 4H), 1.79 (s, 
3H, 1.99 - 1.79, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.91, 170.86, 
170.28, 170.25, 169.67, 169.62 (170.9 - 169.6 CO2CH3), 138.74, 137.97, 134.20 (Phth), 131.56, 
128.60, 128.41, 128.36, 128.29, 127.70, 127.63, 127.57, 127.52, 127.26 (128.6 - 127.3 
aromatic), 123.58 (Phth), 97.82 (C1’’), 96.49 (C1’), 91.61 (C1), 75.43 (C4), 75.12 (C3), 74.13 
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(C2), 72.73 (BnCH2), 72.09 (C5’), 71.69 (C5’’), 70.97 (C3’’), 70.85 (C3’, BnCH2), 70.58 (C5), 
69.38 (C6), 69.22 (C4’), 68.79 (C4’’), 62.23 (C6’), 61.70 (C6’’), 55.31 (C2’’), 54.72 (C2’), 20.93, 
20.82, 20.67, 20.61 (20.9 - 20.6 CO2CH3). 
3,4,6-tri-O-acetyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[ 3,4,6-tri-O-acetyl-2-d
eoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)+-3,6-di-O-benzyl
-α-D-mannopyranosyl trichloroacetimidate (62) 
To a solution of 61 (645 mg, 0.54 mmol, 1.0 eq) and 
trichloroacetonitrile (161 μL, 1.61 mmol, 3.0 eq) in anhydrous 
DCM (6.5 mL) under Ar at 0 °C, DBU (16 μL, 0.11 mmol, 0.2 eq) 
was added. After stirring at 0 °C for 3 h, the reaction mixture was concentrated and purified 
by column chromatography (cyclohexane-ethyl acetate 5:1 to 1:1) to give 62, yield 87% (630 
mg, 0.47 mmol). Rf = 0.4 (
CHex/EtOAc 1:1). *α+D
20 = +29° (c = 1.0, CHCl3). HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1355.3133 ([M+NH4]
+, calc. 1355.3133), 
1360.2717 ([M+Na]+, calc. 1380.2687). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 8.42 (s, 1H, NH), 7.68 (s, 2H, Phth), 7.59 (s, 2H, Phth), 7.47 (s, 2H, Phth), 7.40 (d, J=7.8, 
2H, Phth), 7.33 (t, J=7.6, 3H, aromatic), 7.30 - 7.16 (m, 5H, aromatic), 6.77 (d, J=3.4, 2H, 
aromatic), 5.99 (d, J=2.0, 1H, H1), 5.69 (dt, J=19.4, 9.9, 2H, H3’, H3’’), 5.58 (d, J=8.4, 1H, H1’), 
5.53 (d, J=8.4, 1H, H1’’), 5.16 (t, J=9.6, 1H, H4’), 5.08 (t, J=9.6, 1H, H4’’), 4.80 (d, J=11.9, 1H, 
BnCH2), 4.59 (d, J=11.9, 1H, BnCH2), 4.43 (dd, J=10.5, 8.7, 1H, H2’), 4.25 - 4.14 (m, 3H, H2’’, 
H2, H6a’), 4.14 - 4.06 (m, 2H, H6’, H6a’’), 4.04 - 3.97 (m, 1H, H3), 3.90 (dd, J=7.3, 2.6, 1H, H4), 
3.83 (d, J=10.1, 1H, H5’), 3.77 - 3.69 (m, 3H, H6b’’, BnCH2), 3.68 - 3.63 (m, 1H, H5), 3.41 (d, 
J=10.1, 1H, H5’’), 3.09 (s, 2H, H6a, H6b), 2.03 (s, 3H), 2.00 (s, 3H), 1.98 (s, 3H), 1.96 (s, 3H), 
1.82 (s, 3H), 1.78 (s, 3H, 2.03 - 1.78, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 170.84, 170.75, 170.32, 170.23, 169.63, 169.60 (170.8 - 169.6 CO2CH3), 160.34 
(C=NH), 138.36, 138.12, 134.17 (Phth), 131.40, 128.53, 128.20, 127.71, 127.63, 127.61, 
127.38 (128.5 - 127.4 aromatic), 123.63 (Phth), 98.62 (C1’’), 97.33 (C1’), 96.16 (C1), 90.92 
(CCl3), 75.86 (C4), 74.78 (C3), 73.96 (C5), 72.92 (C2), 72.55 (BnCH2), 72.30 (C5’), 71.81 (C5’’), 
71.18 (BnCH2), 71.01 (C3’), 70.98 (C3’’), 69.05 (C4’), 68.64 (C4’’), 68.01 (C6), 62.15 (C6’), 
61.59 (C6’’), 55.33 (C2’’), 54.66 (C2’), 31.87, 21.25, 20.93, 20.82, 20.62, 20.59, 19.47 (21.3 - 
19.5 CO2CH3), 14.41, 14.11. 
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 Allyl 2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycarbonylamino)-β-D- 
glucopyranosyl-(1→2)-[2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycar
bonylamino)-β-D-glucopyranosyl-(1→6)]-3,4-O-(2’,3’-dimethoxyb
utane-2’,3’-diyl)-α-D-mannopyranoside (63) 
Compounds 54 (5.00 g, 6.19 mmol, 2.2 eq), 31 (941 mg, 2.81 
mmol, 1.0 eq), N-iodosuccinimide (1.57 g, 7.04 mmol, 2.5 eq) and 
4 Å molecular sieves (2.0 g) in dry dichloromethane (20 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the suspension was cooled to -0 °C 
followed by slow addition of trifluoromethanesulfonic acid (49.8 μL, 0.65 mmol, 0.2 eq). 
After stirring for 15 min at 0 °C, the reaction was quenched by diluting with more DCM (100 
mL). The molecular sieves were removed by filtration and the filtrate was washed with 1 M 
Na2S2O3 (50 mL×3), brine (50 mL×1), dried over MgSO4, concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 63. Yield: 55% (2.69 g, 1.56 
mmol). Rf = 0.3 (Tol/EtOAc 3:1). *α+D
20 = +39° (c = 0.8, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1744.4860 ([M+NH4]
+, calc. 1744.4853), 1749.4977 
([M+Na]+, calc. 1749.4407), 881.2613 ([M+2NH4]
2+, calc. 881.2599), 883.7098 ([M+Na+NH4]
2+, 
calc. 883.7376). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.32 - 7.17 (m, 
8H, aromatic), 7.11 (dd, J=10.2, 8.7, 4H, aromatic), 6.90 - 6.76 (m, 12H, aromatic), 6.35 (s, 1H, 
NH’), 5.84 (ddd, J=22.3, 10.8, 5.6, 1H, CH2CH=CH2), 5.24 (dd, J=17.2, 1.6, 1H, CH2CH=CH2), 
5.15 (dd, J=10.4, 1.3, 1H, CH2CH=CH2), 5.03 (s, 1H, NH’’), 5.02 (d, J=8.4, 1H, H1’), 4.93 (d, 
J=12.2, 1H, PMBCH2), 4.83 (s, 1H, H1), 4.80 - 4.63 (m, 8H, TrocCH2, PMBCH2), 4.60 (d, J=9.4, 
1H, H1’’), 4.58 - 4.42 (m, 9H, H3’ , H3’’, TrocCH2, PMBCH2), 4.18 - 4.13 (m, 1H, CH2CH=CH2), 
4.13 - 4.08 (m, 1H, H2), 4.08 - 4.04 (m, 1H, H3), 3.97 - 3.85 (m, 3H, H4, CH2CH=CH2, H5), 3.80 
- 3.77 (m, 18H, PMBOCH3), 3.74 - 3.64 (m, 6H, H6a, H6b, H6a’, H6b’, H6a’’, H6b’’), 3.64 - 3.57 
(m, 1H, H4’’), 3.57 - 3.49 (m, 3H, H2’’. H5’’, H4’), 3.48 - 3.44 (m, 1H, H5’), 3.26 (s, 3H, OCH3), 
3.21 (s, 3H, OCH3), 1.36 (s, 3H, CH3), 1.26 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 159.54, 159.50, 159.45, 159.41, 159.39 (159.5 - 159.4 PMB), 154.49 (Troc), 
154.27 (Troc), 134.02 (CH2CH=CH2), 131.10, 130.77, 130.60, 130.46, 130.38, 129.83, 129.79, 
129.72, 129.69, 129.61, 129.55 (131.1 - 129.6 aromatic), 117.66 (CH2CH=CH2), 114.05 (PMB), 
113.99 (PMB), 100.95 (C1’’), 100.40 (C(CH3)OCH3), 99.76 (C(CH3)OCH3), 99.00 (C1), 97.37 
(C1’), 96.17 (Troc), 95.76 (Troc), 80.66 (C3’’), 79.18 (C3’), 78.64 (C4’), 78.35 (C4’’), 75.71 (C5’’), 
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75.27 (C5’), 74.71, 74.65, 74.56, 74.52, 74.36, 73.39, 73.31 (74.7 - 73.3 TrocCH2, PMBCH2), 
70.91 (C2, C5), 68.68 (C6’, C6’’), 68.09 (CH2CH=CH2), 67.78 (C6), 67.43 (C3), 64.00 (C4), 57.74 
(C2’), 57.62 (C2’’), 55.49 (PMBOCH3), 55.47 (PMBOCH3), 48.51 (OCH3), 48.23 (OCH3), 17.98 
(CH3), 17.92 (CH3). 
2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucop
yranosyl-(1→2)-[ 2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycarbonyla
mino)-β-D-glucopyranosyl-(1→6)]-3,4-O-(2’,3’-dimethoxybutane-
2’,3’-diyl)-α-D-mannopyranose (64) 
A suspension of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine) 
iridium(I) hexafluorophosphate (258 mg, 0.31mmol, 0.15 eq) in 
anhydrous THF (12.5 mL) was stirred under Ar atmosphere and H2 gas was added until the 
orange color disappeared. The activated catalyst suspension was then added into a solution 
of 63 (3.51 g, 2.03 mmol, 1.0 eq) in anhydrous THF (25 mL) via syringe, after 24 h stirring at 
r.t. a faster main product was observed. NaHCO3 (0.64 g, 7.62 mmol, 3.8 eq) and H2O (10 mL) 
was added to the reaction mixture followed with I2 (1.29 g, 5.04 mmol, 2.5 eq) and continued 
stirring at r.t. for 0.5 h as the deallylated product was formed. 1 M Na2S2O3 was added until 
the purple color disappeared, and THF was then removed under reduced pressure. The 
residue was diluted with DCM (100 mL), washed with 1 M Na2S2O3 (50 mL×2), H2O (50 mL×2), 
brine (75 mL×1), dried over MgSO4, the solvent was removed and the residue was purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 64, yield 93% (3.20 g, 
1.90 mmol). Rf = 0.3 (Tol/EtOAc 2:1). *α+D
20 = +42° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1687.4352 ([M+H]+, calc. 1687.4275), 1704.4615 
([M+NH4]
+, calc. 1704.4540), 861.2448 ([M+2NH4]
2+, calc. 861.2442), 863.6932 
([M+Na+NH4]
2+, calc. 863.7219). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.34 - 7.22 (m, 8H, aromatic), 7.20 - 7.03 (m, 4H, aromatic), 6.91 - 6.78 (m, 12H, aromatic), 
6.29 (s, 1H, NH’), 5.22 (d, J=38.6, 1H, H1), 5.06 (d, J=4.2, 1H, H1’), 4.98 (d, J=11.7, 1H, 
PMBCH2), 4.81 - 4.67 (m, 9H, H1’’, PMBCH2, TrocCH2), 4.63 - 4.40 (m, 9H, H3’, H3’’, PMBCH2), 
4.25 - 4.14 (m, 3H, H2, H3, H5), 3.87 - 3.76 (m, 19H, H4, PMBOCH3), 3.75 - 3.47 (m, 11H, H2’’, 
H5’, H5’’, H4’’, H4’, H6a, H6b, H6a’, H6b’, H6a’’, H6b’’), 3.34 - 3.21 (m, 7H, H2’, OCH3), 1.41 (s, 
3H, CH3), 1.30 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 159.29, 
159.25, 159.18 (159.3 - 159.2 PMB), 154.52 (Troc), 154.21 (Troc), 130.51, 130.31, 130.12, 
170 
 
EXPERIMENTAL PART 
 129.76, 129.68, 129.57, 129.53, 129.45, 129.38 (130.5 - 129.4 aromatic), 113.87 (PMB), 
113.80 (PMB), 113.78 (PMB), 100.16 (C(CH3)OCH3), 99.54 (C(CH3)OCH3), 97.30 (C1’), 95.21 
(C1), 93.84 (C1’’), 78.87 (C3’), 78.72 (C3’’), 78.42 (C4’), 78.13 (C4’’), 75.39 (C5’), 74.94 (C5’’), 
74.65, 74.46, 74.40, 74.28, 74.12, 73.19, 73.07, 72.99 (74.7 - 73.0 TrocCH2, PMBCH2), 72.06 
(C5), 71.47 (C2), 68.42 (C6), 68.31 (C6’), 68.18 (C6’’), 66.84 (C3), 64.72 (C4), 57.69 (C2’’), 
57.43 (C2’), 55.28 (PMBOCH3), 55.24 (PMBOCH3), 48.45 (OCH3), 48.11 (OCH3), 17.74 (CH3), 
17.69 (CH3). 
2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucop
yranosyl-(1→2)-[ 2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichloroethoxycarbonyla
mino)-β-D-glucopyranosyl-(1→6)]-3,4-O-(2’,3’-dimethoxybut
ane-2’,3’-diyl)-α-D-mannopyranosyl trichloroacetimidate (65) 
To a solution of 64 (3.09 g, 1.83 mmol, 1.0 eq) and 
trichloroacetonitrile (542 μL, 5.42 mmol, 3.0 eq) in anhydrous 
DCM (30 mL) under Ar at 0 °C, DBU (54.3 μL, 0.37 mmol, 0.2 
eq) was added. After stirring at 0 °C for 3 h, the reaction mixture was concentrated and 
purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 65, yield 
85% (2.87 g, 1.56 mmol). Rf = 0.6 (Tol/EtOAc 2:1). *α+D
20 = +42° (c = 1.4, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1849.3727 ([M+NH4]
+, calc. 
1849.3607), 1854.3125 ([M+Na]+, calc. 1854.3161), 925.6590 ([M+H+NH4]
2+, calc. 925.6860), 
927.6561 ([M+Na+H]2+, calc. 927.6620), 933.6576 ([M+2NH4]
2+, calc. 933.6467), 936.1464 
([M+Na+NH4]
2+, calc. 936.1753), 938.6557 ([M+2Na]2+, calc. 938.6530). 1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.54 (s, 1H, C=NH), 7.32 - 7.17 (m, 8H, aromatic), 
7.10 (dd, J=20.2, 8.6, 4H, aromatic), 6.94 - 6.74 (m, 2H, aromatic), 6.35 (s, 1H, NH’), 6.18 (s, 
1H, H1), 5.07 (d, J=7.9, 2H, H1’, NH’’), 4.96 (d, J=11.9, 1H, PMBCH2), 4.76 - 4.63 (m, 8H, 
PMBCH2), 4.60 (d, J=5.7, 1H, H1’’), 4.58 - 4.40 (m, 9H, H3’, H3’’, PMBCH2), 4.23 (s, 1H, H2), 
4.12 (s, 1H, H6a), 4.09 (s, 1H, H3), 4.06 - 3.98 (m, 2H, H4, H5), 3.81 - 3.76 (m, 18H, PMBOCH3), 
3.75 - 3.44 (m, 10H, H6b, H2’’, H6a’, H6b’, H6a’’, H6b’’, H4’’, H4’, H5’, H5’’), 3.25 - 3.20 (m, 7H, 
H2’, OCH3), 1.35 (s, 3H, CH3), 1.26 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), 
δ (ppm): 159.44 (PMB), 159.40 (PMB), 131.02, 130.77, 130.41, 129.82, 129.74, 129.52 (131.0 
- 129.5 aromatic), 113.98 (PMB), 100.82 (C1’’), 100.42 (C(CH3)OCH3), 99.82 (C(CH3)OCH3), 
97.54 (C1’), 97.46 (C1), 79.22 (C3’), 79.15 (C3’’), 78.53 (C4’’), 78.30 (C4’), 75.84 (C5’), 75.21 
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(C5’’), 74.66, 74.57, 74.49, 74.43, 74.32 (C5), 73.44, 73.27 (74.7 - 73.3 TrocCH2, PMBCH2), 
69.93 (C2), 68.68 (C6’), 68.59 (C6’’), 67.02 (C3), 66.89 (C6), 63.13 (C4), 57.79 (C2), 57.43 
(C2’’), 55.49 (PMBOCH3), 55.46 (PMBOCH3), 48.28 (OCH3), 17.97 (CH3), 17.86 (CH3). 
Allyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→2)-[3,4,6-tri-O-benz 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-O-(2’,3’-
dimethoxybutane-2’,3’-diyl)-α-D-mannopyranoside (66) 
Compounds 55 (871 mg, 1.30 mmol, 2.2 eq), 31 (222 mg, 0.59 
mmol, 1.0 eq), N-iodosuccinimide (331 mg, 1.48 mmol, 2.5 eq) and 
4 Å molecular sieves (0.4 g) in dry dichloromethane (4.0 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the suspension was cooled to -0 °C 
followed by slow addition of trifluoromethanesulfonic acid (20.8 μL, 0.24 mmol, 0.4 eq). 
After stirring for 2 h at 0 °C, the reaction was quenched by diluting with more DCM (20 mL). 
The molecular sieves were removed by filtration and the filtrate was washed with 1 M 
Na2S2O3 (15 mL×3), brine (20 mL×1), dried over MgSO4, concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 66. Yield: 73% (629 mg, 0.43 
mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = +77° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1474.6299 ([M+H]+, calc. 1474.6274), 1479.5822 
([M+NH4]
+, calc. 1479.5828), 1491.6283 ([M+NH4+NH3]
+, calc. 1491.6540), 748.7799 
([M+Na+NH4]
2+, calc. 748.8086). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.64 (s, 8H, Phth), 7.40 - 7.21 (m, 20H, aromatic), 6.99 (d, J=7.6, 4H, aromatic), 6.93 - 6.84 (m, 
6H, aromatic), 5.46 (qd, J=11.2, 5.7, 1H, CH2CH=CH2), 5.21 (d, J=8.3, 1H, H1’), 4.95 - 4.88 (m, 
2H, CH2CH=CH2), 4.85 - 4.73 (m, 5H, H1’’, BnCH2), 4.68 - 4.61 (m, 4H, BnCH2), 4.57 (dd, J=12.1, 
5.9, 2H, BnCH2), 4.42 (dd, J=12.1, 3.2, 2H, BnCH2), 4.36 (s, 1H, H1), 4.36 (t, J=10.0, 1H, H3’’), 
4.32 - 4.25 (m, 1H, H3’), 4.27 - 4.20 (m, 1H, H2’), 4.08 (dd, J=10.9, 8.5, 1H, H2’’), 3.85 - 3.68 
(m, 9H, H3, H6a, H6a’, H6b’, H6a’’, H6b’’, H2, H4’, H4’’), 3.60 - 3.45 (m, 5H, CH2CH=CH2, H5, 
H5’, H5’’), 3.36 (t, J=10.5, 1H, H4), 3.15 (ddd, J=13.1, 6.1, 1.0, 1H, CH2CH=CH2), 3.10 (s, 3H, 
OCH3), 2.96 (s, 3H, OCH3), 2.61 (dd, J=10.3, 8.7, 1H, H6b), 1.10 (s, 3H, CH3), 0.97 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.51, 138.48, 138.36, 138.33, 
138.25, 133.89 (Phth), 133.81 (Phth), 133.45 (CH2CH=CH2), 132.05, 128.68, 128.61, 128.58, 
128.57, 128.21, 128.16, 128.13, 128.07, 127.96, 127.94, 127.88, 127.81, 127.79, 127.46 
(128.7 - 127.5 aromatic), 123.35 (Phth), 117.50 (CH2CH=CH2), 99.93 (C(CH3)OCH3), 99.44 
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 (C(CH3)OCH3), 98.71 (C1’’), 96.35 (C1), 96.30 (C1’), 79.91 (C4’’), 79.61 (C4’), 79.58 (C3’’), 
79.50 (C3’), 75.84 (C5’), 75.33 (C5’’), 75.20 (BnCH2), 75.08 (BnCH2), 74.99 (BnCH2), 74.78 
(BnCH2), 73.74 (BnCH2), 73.62 (C2), 70.54 (C5), 68.93 (C6’), 68.84 (C6), 68.55 (C6’’), 67.24 
(CH2CH=CH2), 67.02 (C3), 63.83 (C4), 56.23 (C2’’), 55.18 (C2’), 47.97 (OCH3), 47.57 (OCH3), 
27.15, 17.86 (CH3), 17.59 (CH3). 
Allyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl)-(1→2)-[3,4,6-tri-O-benz 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-α-D-mannopyranoside (67) 
Compound 66 (663 mg, 0.45 mmol) was dissolved in TFA/TIPS/H2O 
15:0.9:0.9 (3.36 mL) and stirred at r.t. for 2 h. The solution was then 
concentrated and coevaporated three times with toluene, followed 
by purification by column chromatography (cyclohexane-ethyl 
acetate 5:1 to 1:2) to give 67. Yield: 51% (310 mg, 0.23 mmol). Rf = 0.2 (
CHex/EtOAc 1:1). 
MALDI-TOF-MS (Bruker autoflex II MALDI spectrometer): 1367.494 ([M+Na]+, calc. 1366.518), 
1383.531 ([M+K]+, calc. 1382. 492). 
Allyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-benz 
yl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-di-O-benz
yl-α-D-mannopyranoside (68) 
Compound 67 (310 mg, 0.23 mmol, 1.0 eq) was dissolved in dry DMF 
(2 mL) under Ar and NaH (60% suspension, 27.7 mg, 0.69 mmol, 3.0 
eq) was added in portions. The reaction mixture was kept at 0 °C for 40 min before BnBr 
(82.3 μL, 0.69 mmol, 3.0 eq) was added dropwise via syringe. After 24 h stirring at r.t., the 
solvent was removed by evaporation under reduced pressure and the residue was dissolved 
in EtOAc (10 mL), filtered through a layer of Celite, washed with H2O (10 mL×2), brine (10 
mL×1), dried over MgSO4. Then concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:1) to give 68, yield 83% (291 mg, 0.19 mmol). Rf = 0.7 
(CHex/EtOAc 1:1). *α+D
20 = +12 (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1524.6307 ([M+H]+, calc. 1524.6300), 1541.6596 ([M+NH4]
+, calc. 
1541.6566), 1545.6062 ([M+Na]+, calc. 1545.6068). 
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3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-benzyl-2-d
eoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-di-O-benzyl-α-D-mannopyranose (69) 
A suspension of (1,5-Cyclooctadiene)bis(methyldiphenylphosphine) 
iridium(I) hexafluorophosphate (24 mg, 0.028 mmol, 0.15 eq) in 
anhydrous THF (1.2 mL) was stirred under Ar atmosphere and H2 gas 
was added until the orange color disappeared. The activated catalyst 
suspension was then added into a solution of 68 (290 mg, 0.19 mmol, 1.0 eq) in anhydrous 
THF (1.2 mL) via syringe. After stirring for 24 h at r.t., a faster major product was observed on 
TLC. NaHCO3 (60 mg, 0.71 mmol, 3.8 eq) and H2O (0.6 mL) was added to the reaction mixture 
followed with I2 (120 mg, 0.47 mmol, 2.5 eq), continued stirring at r.t. for 0.5 h as the 
deallylated product was formed. 1 M Na2S2O3 was added until the purple color disappeared, 
and THF was then removed by evaporation under reduced pressure. The residue was diluted 
with DCM (10 mL), washed with 1 M Na2S2O3 (5 mL×2), H2O (5 mL×2), brine (7.5 mL×1), dried 
over MgSO4. The solvent was removed and the residue was purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 69, yield 60% (170 mg, 0.11 
mmol). Rf = 0.3 (
CHex/EtOAc 1:1). MALDI-TOF-MS (Bruker autoflex II MALDI spectrometer): 
1507.161 ([M+Na]+, calc. 1506.581), 1523.207 ([M+K]+, calc. 1522.555). 
3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-benzyl-2-d
eoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-di-O-benzyl
-α-D-mannopyranosyl trichloroacetimidate (70) 
To a stirred solution of 69 (170 mg, 0.11 mmol, 1.0 eq) and 
trichloroacetonitrile (34.4 μL, 0.34 mmol, 3.0 eq) in anhydrous 
DCM (2 mL) under Ar at 0 °C, DBU (3.4 μL, 0.023 mmol, 0.2 eq) 
was added. After stirring at 0 °C for 3 h, the reaction mixture was concentrated and purified 
by column chromatography (cyclohexane-ethyl acetate 5:1 to 1:1) and recrystallized from 
cyclohexane-ethyl acetate to give 70, yield 81% (145 mg, 0.089 mmol). Rf = 0.4 (
CHex/EtOAc 
1:1). *α+D
20 = +12 (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), 
m/z: 824.5727 ([M+H+Na]+, calc. 824.7474), 831.4875 ([M+2NH4]
2+, calc. 931.2847). 1H-NMR 
(400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.98 (s, 1H, NH), 7.71 (s, 4H, Phth), 7.59 (s, 
4H, Phth), 7.40 - 7.12 (m, 30H, aromatic), 7.04 (d, J=6.5, 2H, aromatic), 7.01 - 6.96 (m, 2H, 
aromatic), 6.95 - 6.85 (m, 6H, aromatic), 5.78 (d, J=1.8, 1H, H1), 5.33 (d, J=8.2, 1H, H1’), 4.91 - 
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 4.73 (m, 4H, BnCH2), 4.71 - 4.58 (m, , 5H, H1’’, BnCH2), 4.57 - 4.51 (m, 2H, BnCH2), 4.47 (dd, 
J=11.9, 4.2, 2H, BnCH2), 4.43 - 4.28 (m, 3H, H3’, H2’, BnCH2), 4.26 - 4.19 (m, 2H, H3’’, BnCH2), 
4.14 - 4.10 (m, 1H, H2), 3.97 (dd, J=10.7, 8.5, 1H, H2’’), 3.81 - 3.64 (m, 9H, H4’, H4, H4’’, H3, 
H6a, H6a’, H6b’, H6a’’, H6b’’), 3.63 - 3.57 (m, 1H, H5), 3.40 (dt, J=10.1, 3.0, 1H, H5’), 3.29 (t, 
J=9.4, 1H, H5’’), 2.66 (dd, J=10.7, 7.1, 1H, H6b). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), 
δ (ppm): 159.72 (C=NH), 138.28, 138.19, 138.17, 138.13, 138.11, 138.09, 138.07, 137.95, 
133.81 (Phth), 133.53, 131.73, 128.57, 128.56, 128.51, 128.47, 128.40, 128.34, 128.31, 
128.28, 128.17, 128.11, 128.09, 128.04, 127.95, 127.88, 127.80, 127.76, 127.74, 127.70, 
127.61, 127.46, 127.38 (128.6 - 127.4 aromatic),, 123.37 (Phth), 98.89 (C1’’), 96.62 (C1’), 
94.99 (C1), 90.69 (CCl3), 79.78 (C4’), 79.65 (C4’’), 79.52 (C3’), 79.41 (C3’’), 76.69 (C3), 75.36 
(C4), 75.09 (C5’), 75.01 (BnCH2), 74.91 (BnCH2), 74.83 (BnCH2), 74.77 (BnCH2), 74.31 (C5’’), 
73.79 (C5), 73.65 (BnCH2), 73.60 (BnCH2), 71.38 (C2), 70.86 (BnCH2), 69.73 (C6), 69.41 (C6’), 
68.78 (C6’’), 55.74 (C2’’), 55.72 (C2’). 
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7.10 Synthesis of 2-OAc-3,4,6-OBn mannosyl donor 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosylbromide (71)[193] 
Acetic anhydride (330 mL, 3.5 mol, 7.0 eq) at was heated to 90 °C and I2 (4.8 g, 
19 mmol, 0.038 eq) was then added. After the heating was removed, mannose 
(90 g, 0.5 mol, 1.0 eq) was added in portions to the reaction mixture. After 30 min of stirring 
the reaction was completed. Sat. Na2S2O3 (45 mL) was added to neutralize the remaining I2 
and the mixture was concentrated under reduced pressure. The residue was diluted with 
DCM (1 L), washed with Sat. NaHCO3 (300 mL×3), H2O (300 mL×3), brine (500 mL×1), dried 
over MgSO4 and the solvent was removed to give penta-acetylated mannose. Rf = 0.3 
(CHex/EtOAc 2:1). The acetylated product was dissolved in glacial AcOH (270 mL) and the 
stirred solution was cooled with an ice bath. 30% HBr in AcOH (112 mL, 0.65 mol, 1.3 eq) was 
added. After stirring at r.t. for 24 h, the reaction mixture was concentrated under reduced 
pressure to remove most of the AcOH and HBr at 10 – 15 °C. The residue was washed with 
H2O (200 mL×3), and the aqueous layer was re-extracted with DCM (300 mL×3), the 
combined organic layers were washed with Sat. NaHCO3 (300 mL×3), brine (500 mL×1), dried 
over MgSO4. The solvent was removed at low temperature and to give 71, yield 70% (144.7g, 
352 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). ). *α+D
20 = +125° (c = 1.0, CHCl3). 
1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.39 (dd, J=10.1, 3.4, 1H, H2), 5.28 (dd, J=6.7, 3.2, 1H, 
H4), 5.26 - 5.22 (m, 1H, H3), 5.21 (s, 1H, H1), 4.26 - 4.18 (m, 2H, H5, H6a), 4.15 - 4.08 (m, 1H, 
H6b), 2.13 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.02 (s, 3H, Ac), 1.97 (s, 3H, Ac). 13C-NMR (100.6 MHz, 
CDCl3, gHSQC, gHMBC), δ (ppm): 171.15, 170.49, 170.33, 170.08 (171.2 - 170.1 CO2CH3), 
92.33 (C1), 70.33 (C3), 69.04 (C2), 68.61 (C5), 66.43 (C4), 62.82 (C6), 21.10, 20.95, 20.90, 
20.89 (21.1 - 20.9 CO2CH3). 
3,4,6-tri-O-acetyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (72)[193] 
Compound 71 (150.6 g, 365 mmol) and 2,4,6-collidine (88.5 g, 97.2 mL, 730 
mmol, 2.0 eq) was dissolved in a methanol/chloroform 1:4 mixture (500 mL), stirred at r.t. for 
24 h. The reaction was diluted with DCM (400mL), washed with H2O (300 mL×3), brine (500 
mL×1), dried over MgSO4, the solvent was removed and the crude product was dried at 
reduced pressure to remove the remaining collidine. Then the residue was recrystallized 
from cyclohexane-ethyl acetate to give 72, yield 81% (103.3 g, 285 mmol). Rf = 0.4 (Tol/EtOAc 
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 2:1). *α+D
20 = -20° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 379.67 ([M+NH4]
+, calc. 380.16), 385.00 
([M+Na]+, calc. 385.11). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.48 (d, 
J=2.6, 1H, H1), 5.28 (t, J=9.7, 1H, H4), 5.13 (dd, J=9.9, 4.0, 1H, H3), 4.60 (dd, J=3.9, 2.6, 1H, 
H2), 4.22 (dd, J=12.1, 4.9, 1H, H6a), 4.13 (dd, J=12.1, 2.7, 1H, H6b), 3.67 (ddd, J=9.5, 4.9, 2.7, 
1H, H5), 3.26 (s, 3H, OCH3), 2.10 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.04 (s, 3H, Ac), 1.72 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.82, 170.55, 169.61 (170.8 - 169.6 
CO2CH3), 124.69 (COCH3(CH3)), 97.59 (C1), 76.78 (C2), 71.55 (C5), 70.82 (C3), 65.73 (C4), 
62.53 (C6), 50.11 (OCH3), 24.55 (CH3), 20.94, 20.90, 20.86 (20.9 - 20.8 CO2CH3). 
3,4,6-tri-O-benzyl-1,2-O-(1-methoxyethylidene)-β-D-mannopyranose (73)[193] 
To a stirring mixture of 72 (18.9 g, 52.2 mmol, 1.0 eq) in MeOH (80 mL), 
anhydrous K2CO3 (629 mg, 4.6 mmol, 0.087 eq) was added. The reaction 
mixture was stirred at r.t. for 30 min, then concentrated and coevaporated with toluene (80 
mL×3) and dried under reduced pressure. The residue was dissolved in dry DMF (150 mL), 
stirred under Ar and NaH (60% suspension, 8.33 g, 208 mmol, 4.0 eq) was then added in 
portions. The reaction was kept at 0 °C for 40 min, before BnBr (30.9 mL, 260 mmol, 5.0 eq) 
was added dropwise. After stirring at r.t. for 2 h, the organic solvent was removed under 
reduced pressure and the residue was dissolved in EtOAc (400 mL), filtered through a layer of 
Celite, washed with H2O (150 mL×2), brine (150 mL×1), dried over MgSO4. Then concentrated 
and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 73, 
yield 88% (23.7 g, 46.2 mmol). Rf = 0.7 (Tol/EtOAc 2:1). *α+D
20 = +33° (c = 1.0, CHCl3). ESI-MS 
(pos), m/z: 528.73 ([M+Na]+, calc. 529.22). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), 
δ (ppm): 7.44 - 7.23 (m, 15H, aromatic), 5.35 (d, J=2.5, 1H, H1), 4.90 (d, J=10.8, 1H, BnCH2), 
4.79 (s, 2H, BnCH2), 4.64 - 4.53 (m, 3H, BnCH2), 4.41 (dd, J=3.9, 2.6, 1H, H2), 3.93 (t, J=9.3, 1H, 
H4), 3.79 - 3.68 (m, 3H, H3, H6a, H6b), 3.46 - 3.40 (m, 1H, H5), 3.29 (s, 3H, OCH3), 1.75 (s, 3H, 
CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.47, 138.08, 128.78, 128.75, 
128.71, 128.62, 128.53, 128.26, 128.22, 127.99, 127.86, 127.75, 127.73, 127.57, 127.19 
(128.8 - 127.2 aromatic), 124.22, 97.80 (C1), 79.27 (C3), 77.36 (C2), 75.46 (BnCH2), 74.46 (C4), 
74.42 (C5), 73.61 (BnCH2), 72.60 (BnCH2), 69.27 (C6), 49.99 (OCH3), 24.62 (CH3). 
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1,2-di-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranose (74)[194] 
Compound 73 (74 g, 146 mmol) was dissolved in AcOH/H2O 1.54:1 (740 mL : 
480 mL) and stirred at r. t. for 24 h. The reaction was concentrated and diluted with DCM 
(500 mL), washed with Sat. NaHCO3 (200 mL×3), H2O (250 mL×2), brine (300 mL×1), dried 
over MgSO4. The solvent was removed and crude product was identified as a mixture of 74 
and 75, which were separated by column chromatography (cyclohexane-ethyl acetate 10:1 to 
2:1). to give 75, yield 11% (7.8 g, 15.8 mmol). Rf = 0.3 (
CHex/EtOAc 2:1) and a major product 
of 74, yield 77% (60.2 g, 113 mmol), Rf = 0.6 (
CHex/EtOAc 2:1). ESI-MS (pos), m/z: 557.22 
([M+Na]+, calc. 557.22). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.40 - 
7.15 (m, 15H, aromatic), 6.13 (d, J=2.0, 1H, H1), 5.37 (t, J=2.4, 1H, H2), 4.87 (d, J=10.6, 1H, 
BnCH2), 4.74 (d, J=11.2, 1H, BnCH2), 4.69 (d, J=12.1, 1H, BnCH2), 4.60 - 4.49 (m, 3H, BnCH2), 
4.01 - 3.94 (m, 2H, H4, H3), 3.89 - 3.79 (m, 2H, H5, H6a), 3.70 (dd, J=10.9, 1.6, 1H, H6b), 2.17 
(s, 3H, Ac), 2.08 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.31 
(CO2CH3), 168.57 (CO2CH3), 138.38, 137.89, 128.67, 128.60, 128.56, 128.33, 128.18, 128.11, 
128.04, 127.98, 127.85 (128.7 - 127.9 aromatic), 91.53 (C1), 77.92 (C3), 75.59 (BnCH2), 74.09 
(C5), 73.96 (C4), 73.78 (BnCH2), 72.19 (BnCH2), 68.74 (C6), 67.78 (C2), 27.15, 21.21 (CO2CH3), 
21.13 (CO2CH3).  
2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranose (75)[194] 
Compound 74 (60.2 g, 113 mmol, 1.0 eq) was dissolved in dry DMF (120 mL) 
and hydrazine acetate (11.4 g, 124 mmol, 1.1 eq) was added. The reaction was heated at 
50 °C for 3 h, then concentrated and coevaporated with toluene (200 mL×3) and dried under 
reduced pressure to give 75, yield 98% (54.8 g, 111 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = 
+28° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 509.93 ([M+NH4]
+, calc. 510.25), 515.13 ([M+Na]+, 
calc. 515.20). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.40 - 7.16 (m, 15H, 
aromatic), 5.38 (dd, J=3.2, 1.9, 1H, H2), 5.21 (s, 1H, H1), 4.89 (d, J=10.9, 1H, BnCH2), 4.72 (d, 
J=11.2, 1H, BnCH2), 4.62 (d, J=12.1, 1H, BnCH2), 4.58 - 4.47 (m, 3H, BnCH2), 4.13 - 4.02 (m, 2H, 
H4, H3), 3.79 - 3.68 (m, 3H, H5, H6a, H6b), 2.16 (s, 3H, CO2CH3). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 170.77 (CO2CH3), 138.55, 138.20, 138.05, 128.70, 128.64, 128.62, 
128.56, 128.34, 128.30, 128.12, 127.98, 127.88 (128.7 - 127.9 aromatic), 92.64 (C1), 77.94 
(C3), 75.31 (BnCH2), 74.90 (C5), 73.63 (BnCH2), 72.02 (BnCH2), 71.24 (C4), 69.57 (C2), 69.47 
(C6), 27.18, 21.39 (CO2CH3). 
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 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (76)[194] 
To a stirred solution of 75 (62.6 g, 127 mmol, 1.0 eq) and 
trichloroacetonitrile (25.5 mL, 254 mmol, 2.0 eq) in anhydrous DCM 
(380 mL) under Ar at 0 °C, DBU (3.8 mL, 25.4 mmol, 0.2 eq) was added. 
After stirring at 0 °C for 3 h, the reaction mixture was concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 4:1) to give 76, yield 72% (58.1 g, 91 
mmol). Rf = 0.6 (Tol/EtOAc 6:1). ESI-MS (pos), m/z: 635.87 ([M+H]
+, calc. 636.13). 1H-NMR 
(400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.70 (s, 1H, NH), 7.41 - 7.18 (m, 15H, 
aromatic), 6.32 (d, J=1.8, 1H, H1), 5.52 (t, J=2.1, 1H, H2), 4.89 (d, J=10.6, 1H, 4-BnCH2), 4.76 
(d, J=11.3, 1H, 3-BnCH2), 4.70 (d, J=12.0, 1H, 6-BnCH2), 4.60 (d, J=11.2, 1H, 3-BnCH2), 4.58 - 
4.50 (m, 2H, 4-BnCH2, 6-BnCH2), 4.10 - 3.97 (m, 3H, H4, H3, H5), 3.86 (dd, J=11.2, 3.6, 1H, 
H6a), 3.74 (dd, J=11.1, 1.5, 1H, H6b), 2.20 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.32, 160.19, 138.40, 138.35, 137.74, 128.76, 128.69, 128.61, 128.56, 
128.53, 128.31, 128.22, 128.16, 128.02, 127.94, 127.85 (128.8 - 127.9 aromatic), 95.61 (C1), 
77.57 (C3), 75.68 (4-BnCH2), 74.63 (C5), 73.93 (C4), 73.68 (6-BnCH2), 72.32 (2-BnCH2), 68.64 
(C6), 67.59 (C2), 27.16, 21.25 (CO2CH3). 
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7.11 Synthesis of 3,6-OH mannosyl acceptor 
Allyl 3,6-di-O-triphrnylmethyl-α-D-mannopyranoside (77)[195] 
Compound 27 (26.9 g, 122 mmol, 1.0 eq) and tributyltin oxide (87.2 mL, 171 
mmol, 1.4 eq) was dissolved in toluene (400 mL) and was refluxed for 24 h 
using a Dean-Stark apparatus. The reaction mixture was then cooled to 50 – 60 °C and trityl 
chloride (88.0 g, 316 mmol, 2.6 eq) was added. The reaction mixture was stirred at r.t. for 24 
h, was then concentrated and the residue was diluted with EtOAc (1200 mL) followed by 
intensive extraction with 1 M potassium fluoride solution (200 mL). The precipitated salt was 
filtered off and the filtrate was separated. The EtOAc layer was reduced to 900 mL under 
reduced pressure, washed with H2O (400 mL×3), brine (500 mL×1) and dried over MgSO4. 
The concentrated residue was dissolved in cyclohexane (400 mL), the excess of trityl chloride 
was precipitated and removed by filtration. The crude product was concentrated and purified 
by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 77, yield 59% 
(50.7 g, 72 mmol). Rf = 0.6 (Tol/EtOAc 2:1). *α+D
20 = +34 (c = 0.8, CHCl3). 
1H-NMR (400 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.63 - 7.18 (m, 30H, aromatic), 5.80 (ddt, J=17.2, 
10.3, 5.1, 1H, CH2CH=CH2), 5.19 - 5.10 (m, 2H, CH2CH=CH2), 4.63 (d, J=1.8, 1H, H1), 4.11 (ddt, 
J=13.5, 4.7, 1.6, 1H, CH2CH=CH2), 3.95 (td, J=9.3, 2.9, 1H, H4), 3.90 - 3.82 (m, 2H, H3, 
CH2CH=CH2), 3.62 (dt, J=9.5, 4.7, 1H, H5), 3.40 - 3.30 (m, 2H, H6a, H6b), 2.80 (dd, J=5.2, 3.4, 
1H, H2). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 144.69, 144.14, 134.08 
(CH2CH=CH2), 129.23, 128.96, 128.21, 128.03, 127.67, 127.22 (129.2 - 127.2 aromatic), 
116.53 (CH2CH=CH2), 98.65 (C1), 87.63 (CPh3), 87.12 (CPh3), 75.06 (C3), 71.67 (C5), 69.41 (C2), 
68.32 (C4), 67.64 (CH2CH=CH2), 64.90 (C6). 
Allyl 2,4-di-O-benzyl-α-D-mannopyranoside (78)[298] 
Compound 77 (47.2 g, 67.0 mmol, 1.0 eq) was dissolved in dry DMF (200 mL) 
and was stirred under Ar atmosphere. The solution was cooled to 0°C and NaH (60% 
suspension, 8.03 g, 201 mmol, 3.0 eq) was added in portions. The reaction was kept at 0 °C 
for 20 min and BnBr (31.8 mL, 268 mmol, 4.0 eq) was then added dropwise. After stirring for 
2 h at r.t., the solvent was removed under reduced pressure and the residue was dissolved in 
EtOAc (400 mL), filtered through a layer of Celite, washed with H2O (150 mL×2), brine (150 
mL×1), dried over MgSO4. Then concentrated, dried and the residue (Rf = 0.5 (Tol/EtOAc 
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 10:1)) was dissolved in AcOH (400 mL) followed by addition of H2O (100 mL). After stirring at 
r.t. for 2 h, the mixture was concentrated and diluted with EtOAc (400 mL), washed with H2O 
(150 mL×3), Sat. NaHCO3 (150 mL×2), brine (300 mL×1) and dried over MgSO4. The 
concentrated residue was dissolved in cyclohexane (400 mL) and the precipitate was 
removed by filtration. The crude product was concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 78, yield 65% (17.4 g, 43 
mmol). Rf = 0.5 (Tol/EtOAc 3:1). *α+D
20 = +31° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 418.2230 ([M+NH4]
+, calc. 418.2230), 423.1780 
([M+Na]+, calc. 423.1784). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.57 - 
7.13 (m, 10H, aromatic), 5.91 - 5.79 (m, 1H, CH2CH=CH2), 5.25 (dq, J=17.2, 1.6, 1H, 
CH2CH=CH2), 5.18 (ddd, J=10.4, 2.8, 1.3, 1H, CH2CH=CH2), 4.91 (dd, J=6.2, 4.9, 2H, H1, BnCH2), 
4.76 - 4.58 (m, 3H, BnCH2), 4.18 - 4.11 (m, 1H, CH2CH=CH2), 4.07 - 4.01 (m, 1H, H3), 3.94 (ddt, 
J=13.0, 6.0, 1.3, 1H, CH2CH=CH2), 3.89 - 3.78 (m, 2H, H6a, H6b), 3.77 - 3.60 (m, 3H, H2, H4, 
H5). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.56, 137.89, 133.75 
(CH2CH=CH2), 128.94, 128.83, 128.70, 128.30, 128.26, 128.10, 128.07, 128.05 (128.9 - 128.0 
aromatic), 117.68 (CH2CH=CH2), 96.53 (C1), 78.70 (C2), 76.72 (C4), 75.18 (BnCH2), 73.37 
(BnCH2), 71.97 (C3), 71.66 (C5), 68.19 (CH2CH=CH2), 62.51 (C6). 
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7.12 Synthesis of high mannose building blocks 
Allyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylide 
ne-α-D-mannopyranoside (79) 
The trichloroacetimidate donor 76 (11.90 g, 18.7 mmol, 1.2 eq) and 29 
(6.21 g, 15.6 mmol, 1.0 eq) was dissolved in dry DCM (90 ml) and 4 Å 
molecular sieves (9 g) was added. The suspension was stirred under argon 
at room temperature for 30 min and then cooled to 0°C followed by dropwise addition of a 
solution of trimethylsilyl-trifluoromethanesulfonate (TMSOTf) (0.14 mL, 0.77 mmol, 0.05 eq) 
in DCM (7 mL). The reaction was almost instant and kept stirring at r.t. for 30 min, then 
quenched with triethylamine (2.8 mL). The molecular sieves were removed by filtering over a 
layer of Celite. The filtrate was concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 3:1) to give 79. Yield 84% (11.45 g, 13.1 mmol). Rf = 0.7 
(Tol/EtOAc 6:1). *α+D
20 = +22° (c = 1.0, CHCl3). ESI-MS (pos), m/z: 890.07 ([M+NH4]
+, calc. 
890.41). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.65 - 7.10 (m, 25H, 
aromatic), 5.83 (ddd, J=15.8, 10.8, 5.5, 1H, CH2CH=CH2), 5.66 (s, 1H, CHPh), 5.64 - 5.59 (m, 
1H, H2’), 5.28 - 5.17 (m, 2H, CH2CH=CH2), 5.15 (s, 1H, H1’), 4.92 (s, 1H, H1), 4.88 (dd, J=11.4, 
5.2, 2H, 3-BnCH2, 4’-BnCH2), 4.80 (d, J=11.0, 1H, 3’-BnCH2), 4.72 - 4.66 (m, 2H, 3-BnCH2, 
6’-BnCH2), 4.62 - 4.47 (m, 3H, 3’-BnCH2, 6’-BnCH2, 4’-BnCH2), 4.27 - 4.22 (m, 1H, H6a), 4.12 - 
4.03 (m, 4H, CH2CH=CH2, H2, H3’, H4), 4.01 (dd, J=9.8, 2.9, 1H, H3), 3.96 - 3.90 (m, 1H, H5’), 
3.90 - 3.69 (m, 5H, H6, H4’, CH2CH=CH2, H6b, H6a’, H6b’), 2.16 (s, 3H, Ac). 
13C-NMR (100.6 
MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.23 (CO2CH3), 138.77, 138.47, 138.39, 138.24, 
137.84, 133.76 (CH2CH=CH2), 129.08, 128.74, 128.62, 128.56, 128.54, 128.51, 128.47, 128.42, 
128.41, 128.34, 128.28, 128.07, 127.99, 127.95, 127.88, 127.78, 127.70, 126.33 (129.1 - 
126.3 aromatic), 117.68 (CH2CH=CH2), 101.72 (CHPh), 100.40 (C1’), 99.19 (C1), 79.30 (C4), 
78.26 (C3’), 77.01 (C2), 75.92 (C3), 75.58 (4’-BnCH2), 74.68 (C4’), 73.71 (6’-BnCH2), 73.22 
(3-BnCH2), 72.18 (C5’), 72.10 (3’-BnCH2), 69.28 (C6’), 69.06 (C6), 68.74 (C2’ ), 68.29 
(CH2CH=CH2), 64.20 (C5), 21.33 (CO2CH3). 
  
182 
 
EXPERIMENTAL PART 
 Allyl 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene-α-D- 
mannopyranoside (80) 
Compound 79 (5.90 g, 6.76 mmol) was dissolved in MeOH/DCM 4:1 (75 
mL) and NaOMe (280 mg, 0.07 M) was added. The reaction mixture was 
stirred for 24 h at r.t. and then neutralized by a small amount of Dowex 
50WX8 ion-exchanger (1.4 g, prewashed with MeOH), filtered and concentrated. The residue 
was purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) to give 80. 
Yield: 99% (5.61 g, 6.76 mmol). Rf = 0.4 (Tol/EtOAc 6:1). *α+D
20 = +32° (c = 1.0, CHCl3). ESI-MS 
(pos), m/z: 848.00 ([M+NH4]
+, calc. 848.40). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.58 - 7.17 (m, 25H, aromatic), 5.83 (ddd, J=21.8, 10.6, 5.4, 1H, 
CH2CH=CH2), 5.64 (s, 1H, CHPh), 5.25 - 5.11 (m, 3H, H1’ , CH2CH=CH2), 4.96 (s, 1H, H1), 4.89 - 
4.81 (m, 2H, 3-BnCH2, 4’-BnCH2), 4.77 - 4.68 (m, 3H, 3’-BnCH2, 3-BnCH2), 4.67 - 4.62 (m, 1H, 
6’-BnCH2), 4.60 - 4.51 (m, 2H, 6’-BnCH2, 4’-BnCH2), 4.27 - 4.22 (m, 2H, H6a, H2’), 4.12 - 4.00 
(m, 4H, CH2CH=CH2, H2, H3, H4), 3.98 - 3.90 (m, 2H, H5’, H3’), 3.88 - 3.78 (m, 3H, 
CH2CH=CH2,H5, H6b, H4’), 3.76 - 3.70 (m, 2H, H6a’, H6b’). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 138.65, 138.44, 138.38, 138.18, 137.86, 133.84 (CH2CH=CH2), 
129.10, 128.77, 128.67, 128.64, 128.61, 128.58, 128.53, 128.52, 128.41, 128.31, 128.16, 
128.13, 128.11, 128.05, 127.87, 127.86, 127.80, 127.77, 126.32 (129.1 - 126.3 aromatic), 
117.60 (CH2CH=CH2), 102.10 (C1’), 101.72 (CHPh), 99.34 (C1), 80.09 (C3’), 79.22 (C4), 77.38 
(C2), 76.00 (C3), 75.51 (4’-BnCH2), 74.75 (C4’), 73.72 (6’-BnCH2), 73.25 (3-BnCH2), 72.28 
(3’-BnCH2), 71.91 (C5’), 69.41 (C6’), 69.10 (C6), 68.54 (C2’), 68.34 (CH2CH=CH2), 64.20 (C5). 
Allyl 3,4,6-tri-O-benzyl-2-O-acetyl-α-D-mannopyranosyl-(1→2)-3,4,6-tri-O-benzyl-α-D-man 
nopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranoside (81) 
The trichloroacetimidate donor 76 (322 mg, 0.51 mmol, 1.2 eq) and the 
disaccharide 80 (350 g, 0.42 mmol, 1.0 eq) was dissolved in dry DCM (5 
ml) and 4 Å molecular sieves (500 mg) was added. The suspension was 
stirred under argon at room temperature for 30 min and then cooled to 
0°C followed by addition of trimethylsilyl-trifluoromethanesulfonate (TMSOTf) (3.8 μL, 0.021 
mmol, 0.05 eq). The suspension was kept stirring at r.t. for 2 h and more donor 76 was added, 
after another 2 h, the reaction was quenched with triethylamine (76 μL). The molecular 
sieves were removed by filtering over a layer of Celite. The filtrate was concentrated and 
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purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) to give 81. Yield 
46% (250 mg, 0.19 mmol). Rf = 0.8 (Tol/EtOAc 3:1). *α+D
20 = +21° (c = 1.0, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1305.5743 ([M+H]+, calc. 
1305.5787), 1322.6072 ([M+NH4]
+, calc. 1322.6052), 1327.5422 ([M+Na]+, calc. 1327.5606). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.49 - 7.00 (m, 40H, aromatic), 
5.71 (ddd, J=22.3, 10.7, 5.6, 1H, CH2CH=CH2), 5.52 (s, 1H, CHPh), 5.44 (s, 1H, H2’’), 5.13 (d, 
J=5.5, 1H, H1’), 5.13 - 5.02 (m, 2H, CH2CH=CH2), 5.01 (s, 1H, H1’’), 4.83 (s, 1H, H1), 4.75 (dt, 
J=22.6, 11.3, 2H, BnCH2), 4.65 - 4.50 (m, 6H, BnCH2), 4.49 - 4.41 (m, 3H, BnCH2), 4.37 (t, 
J=10.7, 2H, BnCH2), 4.26 (d, J=12.0, 1H, BnCH2), 4.15 - 4.08 (m, 2H, H6a, H2’), 3.99 - 3.92 (m, 
2H, H2, CH2CH=CH2), 3.92 - 3.85 (m, 2H, H3’’, H4), 3.85 - 3.77 (m, 5H, H3, H4’, H4’’, H5’, H5’’), 
3.77 - 3.66 (m, 3H, H3’, CH2CH=CH2, H5), 3.66 - 3.57 (m, 4H, H6a’, H6b’, H6a’’, H6b’’), 3.48 (d, 
J=11.1, 1H, H6b), 2.05 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 
170.26 (CO2CH3), 138.67, 138.48, 138.41, 138.35, 138.29, 138.15, 137.76, 133.71 
(CH2CH=CH2), 128.94, 128.50, 128.43, 128.38, 128.34, 128.32, 128.26, 128.19, 128.03, 
127.92, 127.88, 127.84, 127.79, 127.75, 127.72, 127.68, 127.60, 127.53, 127.45, 126.19 
(128.9 - 126.2 aromatic), 117.45 (CH2CH=CH2), 101.50 (CHPh), 101.36 (C1’), 99.39 (C1’’), 
99.21 (C1), 79.17 (C4), 78.18 (C3’), 77.16 (C2), 75.64 (C3), 75.34 (BnCH2), 75.20 (BnCH2), 
74.93 (C3’), 74.73 (C2’), 74.39 (C4’, C4’’), 73.43 (BnCH2), 72.72 (BnCH2), 72.41 (C5’), 72.07 
(C5’’), 71.99 (BnCH2), 69.57 (C6’), 68.94 (C6’’, C2’’), 68.89 (C6), 68.21 (CH2CH=CH2), 64.01 (C5), 
21.27 (CO2CH3). 
Allyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[2-O-acetyl-3,4,6-tri-O-benz 
yl-α-D-mannopyranosyl-(1→6)]-2,4-di-O-benzyl-α-D-mannopyranoside (82) 
The trichloroacetimidate donor 76 (14.01 g, 22.0 mmol, 2.2 eq) and 78 
(4.00 g, 10.0 mmol, 1.0 eq) was dissolved in dry DCM (100 ml) and 4 Å 
molecular sieves (10 g) was added. The suspension was stirred under 
argon at room temperature for 30 min and then cooled to 0°C followed 
by dropwise addition of a solution of trimethylsilyl-trifluoromethanesulfonate (TMSOTf) 
(0.15 mL, 0.8 mmol, 0.08 eq) in DCM (5 mL). The reaction was instant and kept stirring at r.t. 
for 30 min, then quenched with triethylamine (3.0 mL). The molecular sieves were removed 
by filtering over a layer of Celite. The filtrate was concentrated and recrystallized from 
cyclohexane-ethyl acetate to remove solid impurities. The mother liquid was then 
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 concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) 
to give 82. Yield 88% (11.87 g, 8.80 mmol). Rf = 0.5 (Tol/EtOAc 6:1). *α+D
20 = +39° (c = 0.8, 
CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1349.6056 ([M+H]
+, 
calc. 1349.6049), 1366.6333 ([M+NH4]
+, calc. 1366.6314), 1371.5882 ([M+Na]+, calc. 
1371.5868). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.43 - 7.12 (m, 40H, 
aromatic), 5.80 (ddd, J=15.6, 10.7, 5.6, 1H, CH2CH=CH2), 5.56 - 5.52 (m, 1H, H2’’), 5.51 - 5.47 
(m, 1H, H2’), 5.25 - 5.17 (m, 2H, H1’’, CH2CH=CH2), 5.13 (dd, J=10.5, 1.2, 1H, CH2CH=CH2), 
4.99 (d, J=1.3, 1H, H1’), 4.92 - 4.82 (m, 3H, H1, BnCH2), 4.78 (d, J=11.1, 1H, BnCH2), 4.72 - 
4.60 (m, 6H, BnCH2), 4.54 - 4.43 (m, 7H, BnCH2), 4.20 (dd, J=9.4, 3.0, 1H, H3), 4.14 - 4.03 (m, 
2H, CH2CH=CH2, H3’’), 4.01 - 3.85 (m, 7H, CH2CH=CH2, H3’, H4’, H4’’, H2, H4, H6a), 3.84 - 3.80 
(m, 1H, H5’), 3.78 - 3.58 (m, 6H, H5’’, H6b, H6a’, H6a’’, H6b’’, H6b’), 2.17 (s, 3H, Ac), 2.11 (s, 
3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.49 (CO2CH3), 170.32 
(CO2CH3), 138.89, 138.79, 138.50, 138.41, 138.16, 138.11, 138.08, 133.91 (CH2CH=CH2), 
128.85, 128.65, 128.63, 128.62, 128.58, 128.55, 128.51, 128.49, 128.46, 128.45, 128.38, 
128.35, 128.30, 128.23, 128.18, 128.02, 127.97, 127.94, 127.89, 127.87, 127.86, 127.82, 
127.76, 127.74, 127.69 (128.9 - 127.7 aromatic), 117.53 (CH2CH=CH2), 99.95 (C1’’), 98.27 
(C1’), 96.38 (C1), 78.97 (C3), 78.36 (C3’’), 77.88 (C3’), 77.86 (C2), 75.31 (BnCH2), 75.26 
(BnCH2), 75.14 (BnCH2), 74.65 (C4’’), 74.44 (C4’), 73.71 (BnCH2), 73.58 (BnCH2), 72.48 (BnCH2), 
72.07 (BnCH2), 71.73 (BnCH2, C5’), 71.60 (C5’’), 71.47 (C5’), 69.40 (C6’’), 69.06 (C6’), 68.99 
(C2’’), 68.69 (C2’), 68.13 (CH2CH=CH2), 66.69 (C6), 21.38 (CO2CH3), 21.24 (CO2CH3). 
Allyl 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[ 3,4,6-tri-O-benzyl-α-D-mannopyranos 
yl-(1→6)]-2,4-di-O-benzyl-α-D-mannopyranoside (83) 
Compound 82 (8.90 g, 6.82 mmol) was dissolved in a solution of 
NaOMe (540 mg, 0.08 M) in MeOH/DCM 4:1 (125 mL). The reaction 
mixture was stirred for 24 h at r.t. and then neutralized by a small 
amount of Dowex 50WX8 ion-exchanger (2.7 g, prewashed with MeOH), filtered and 
concentrated. The residue was purified by column chromatography (cyclohexane-ethyl 
acetate 10:1 to 2:1) to give 83. Yield: 62% (5.75 g, 4.26 mmol). Rf = 0.5 (Tol/EtOAc 3:1). *α+D
20 
= +53° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 
1265.5870 ([M+H]+, calc. 1265.5838), 1282.6148 ([M+NH4]
+, calc. 1282.6103), 1288.5751 
([M+Na]+, calc. 1288.5691), 1303.5456 ([M+K]+, calc. 1303.5396). 1H-NMR (400 MHz, CDCl3, 
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gCOSY, gHSQC, gHMBC), δ (ppm): 7.43 - 7.16 (m, 40H, aromatic), 5.88 - 5.77 (m, 1H, 
CH2CH=CH2), 5.28 - 5.21 (m, 2H, H1’ , CH2CH=CH2), 5.16 (dd, J=10.4, 1.6, 1H, CH2CH=CH2), 
5.12 (d, J=1.4, 1H, H1’’), 4.91 - 4.84 (m, 3H, BnCH2, H1), 4.73 (d, J=11.2, 1H, BnCH2), 4.69 (d, 
J=8.0, 1H, BnCH2), 4.68 - 4.59 (m, 7H, BnCH2), 4.58 - 4.49 (m, 5H, BnCH2), 4.21 (dd, J=9.4, 3.0, 
1H, H3), 4.16 - 4.13 (m, 1H, H2’’), 4.13 - 4.08 (m, 1H, CH2CH=CH2), 4.07 (dd, J=3.1, 1.8, 1H, 
H2’), 4.04 - 4.00 (m, 1H, H5’), 3.98 - 3.86 (m, 8H, H3’, H4, H3’’, H2, H4’’, H4’ , CH2CH=CH2, 
H6a), 3.85 - 3.80 (m, 1H, H5’’), 3.78 - 3.69 (m, 5H, H5, H6a’, H6b’, H6b, H6a’’), 3.68 - 3.64 (m, 
1H, H6b’’). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 138.81, 138.73, 138.57, 
138.56, 138.53, 138.34, 138.15, 138.14, 133.97 (CH2CH=CH2), 128.84, 128.73, 128.63, 128.55, 
128.53, 128.51, 128.34, 128.21, 128.14, 128.13, 128.07, 128.02, 128.00, 127.97, 127.94, 
127.83, 127.78, 127.75  (128.8 - 127.8 aromatic), 117.66 (CH2CH=CH2), 101.74 (C1’), 99.94 
(C1’’), 96.45 (C1), 80.36 (C3’), 79.91 (C3’’), 79.44 (C3), 78.14 (C4), 75.31 (BnCH2), 75.20 
(BnCH2), 75.12 (C2), 74.73 (C4’), 74.53 (C4’’), 73.79 (BnCH2), 73.64 (BnCH2), 72.52 (BnCH2), 
72.27 (BnCH2), 72.24 (C5’), 71.95 (C5), 71.77 (C5’’), 71.41 (BnCH2), 69.55 (C6’), 69.11 (C6’’), 
68.98 (C2’), 68.31 (C2’’), 68.24 (CH2CH=CH2), 66.32 (C6). 
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 7.13 Synthesis of a tetra acetylated mannosyl donor building block 
1,2,3,4,6-penta-O-acetyl-β-D-mannopyranose (84)[299] 
A mixture of sodium acetate (25.9 g, 315 mmol, 1.05 eq) in acetic 
anhydride (198 mL, 2.10 mol, 7.0 eq) was heated to reflux at 140 - 160 °C. The heating was 
removed and D-mannose (54 g, 300 mmol, 1.0 eq) was added in portions. The reaction 
started to boil intensively, when the boiling stopped, heating was applied again, and the 
reaction refluxed for another 4 h. The reaction mixture was concentrated followed by 
dilution with EtOAc (500 mL), washed with H2O (300 mL×3), Sat. NaHCO3 (300 mL×3), brine 
(500 mL×1) and dried over MgSO4. The organic solvent was removed under reduced pressure, 
the crude product was purified by column chromatography (cyclohexane-ethyl acetate 1:1) 
to give 84, yield 97% (114 g, 292 mmol). Rf = 0.6 (
CHex/EtOAc 1:1). [α]D
20 = +36° (c = 0.9, 
CHCl3). ESI-MS (pos), m/z: 407.87 ([M+NH4]
+, calc. 408.15), 412.93 ([M+Na]+, calc. 413.11). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 6.06 (d, J=1.6, 1H, H1), 5.32 (dt, 
J=3.1, 1.9, 2H, H3, H4), 5.24 - 5.21 (m, 1H, H2), 4.28 - 4.21 (m, 1H, H6a), 4.11 - 4.05 (m, 1H, 
H6b), 4.05 - 3.99 (m, 1H, H5), 2.15 (s, 3H, Ac), 2.14 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.03 (s, 3H, 
Ac), 1.98 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.77, 170.13, 
169.88, 169.68, 168.21 (170.8 - 168.2 CO2CH3), 90.80 (C1), 70.81 (C5), 68.93 (C3), 68.53 (C2), 
65.75 (C4), 62.30 (C6), 21.03, 20.94, 20.88, 20.83, 20.81 (21.0 - 20.8 CO2CH3). 
2,3,4,6-tetra-O-acetyl-β-D-mannopyranose (85)[299] 
Compound 84 (21.4 g, 55.0 mmol, 1.0 eq) was dissolved in dry DMF (50 mL) 
and hydrazine acetate (5.57 g, 59.7 mmol, 1.1 eq) was added. The reaction was  heated at 
50 °C for 3 h, then concentrated and coevaporated with toluene (100 mL×3) and dried under 
reduced pressure to give 85, yield 73% (14.0 g, 40.4 mmol). Rf = 0.4 (
CHex/EtOAc 1:1). [α]D
20 = 
+20° (c = 0.8, CHCl3). ESI-MS (pos), m/z: 365.87 ([M+NH4]
+, calc. 366.14), 370.93 ([M+Na]+, 
calc. 371.10). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.40 (dd, J=10.1, 
3.4, 1H, H3), 5.32 - 5.26 (m, 1H, H4), 5.26 - 5.23 (m, 1H, H2), 5.21 (d, J=1.6, 1H, H1), 4.27 - 
4.19 (m, 2H, H5, H6a), 4.15 - 4.07 (m, 1H, H6b), 2.14 (s, 3H, Ac), 2.08 (s, 3H, Ac), 2.03 (s, 3H, 
Ac), 1.98 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.08, 170.44, 
170.26, 170.04 (171.1 - 170.0 CO2CH3), 92.35 (C1), 70.36 (C2), 69.04 (C3), 68.59 (C5), 66.44 
(C4), 62.81 (C6), 21.10, 20.96, 20.91, 20.89 (21.1 - 20.9 CO2CH3). 
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2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl trichloroacetimidate (86)[299] 
 Compound 85 (18.2 g, 52.6 mmol, 1.0 eq) and trichloroacetonitrile 
(10.6 mL, 105.1 mmol, 2.0 eq) was dissolved in anhydrous DCM (300 mL) 
and stirred under Ar at 0 °C, DBU (1.58 mL, 10.5 mmol, 0.2 eq) was 
added and the reaction mixture was stirred at 0 °C for 3 h, then concentrated and purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 4:1) to give 86, yield 70% (18.1g, 
36.8 mmol). Rf = 0.6 (Tol/EtOAc 6:1). [α]D
20 = +53° (c = 0.9, CHCl3). ESI-MS (pos), m/z: 513.80 
([M+Na]+, calc. 514.01). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.78 (s, 
1H, NH), 6.26 (d, J=1.8, 1H, H1), 5.45 (dd, J=3.0, 2.0, 1H, H2), 5.40 - 5.36 (m, 2H, H3, H4), 4.26 
(dd, J=11.9, 4.7, 1H, H6a), 4.21 - 4.11 (m, 2H, H5, H6b), 2.18 (s, 3H, Ac), 2.07 (s, 3H, Ac), 2.05 
(s, 3H, Ac), 1.99 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.66, 
169.89, 169.81, 169.71 (170.7 - 169.7 CO2CH3), 159.86 (C=NH), 94.63 (C1), 90.62 (CCl3), 71.32 
(C5), 68.91 (C3), 67.98 (C2), 65.52 (C4), 62.16 (C6), 20.87, 20.79, 20.71 (20.9 - 20.7 CO2CH3). 
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 7.14 Synthesis of tetrasaccharide for oxazoline conversion 
Benzyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[2-O-acetyl-3,4,6-tri-O- 
benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,
6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (87)  
The trichloroacetimidate donor 76 (1539 mg, 2.42 mmol, 3.0 eq) 
and acceptor 26 (754 mg, 0.81 mmol, 1.0 eq) was dissolved in 
dry DCM (15 mL) and 4 Å molecular sieves (1.5 g) was added. 
The suspension was stirred under argon at r.t. for 30 min and cooled to 0 °C, trimethylsilyl 
-trifluoromethanesulfonate (TMSOTf) (29.3 μL, 0.16 mmol, 0.2 eq) was added. The reaction 
was kept stirring at 0 °C for 15 min, then quenched with triethylamine (0.1 mL). The 
molecular sieves were removed by filtering over a layer of Celite. The filtrate was 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) 
to give 87. Yield 76% (1151 mg, 0.61 mmol). Rf = 0.4 (Tol/EtOAc 4:1). [α]D
20 = +9° (c = 0.9, 
CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 960.4149 
([M+2NH4]
2+, calc. 960.4162), 962.3620 ([M+Na+NH4]
2+, calc. 962.3922). 1H-NMR (600 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.97 (dd, J=6.5, 3.0, 2H, benzoyl), 7.42 (s, 2H, Phth), 
7.30 - 6.78 (m, 50H, aromatic), 6.43 - 6.35 (m, 3H, aromatic), 6.29 (t, J=7.4, 2H, aromatic), 
5.48 (d, J=3.1, 1H, H22), 5.28 - 5.25 (m, 1H, H24), 5.23 - 5.20 (m, 1H, H23), 4.98 (d, J=0.9, 1H, 
H13), 4.82 (d, J=8.5, 1H, H11), 4.81 (s, 1H, H14), 4.69 - 4.43 (m, 9H, H12, BnCH2), 4.38 - 4.23 (m, 
9H, BnCH2), 4.19 (d, J=13.1, 1H, BnCH2), 4.13 (d, J=11.0, 1H, BnCH2), 4.09 (d, J=11.0, 1H, 
BnCH2), 3.99 - 3.88 (m, 3H, H2
1, H53, H41), 3.82 (dd, J=10.5, 8.5, 1H, H31), 3.79 - 3.72 (m, 4H, 
H6a2, H44, H42, H34), 3.71 - 3.66 (m, 3H, H6b2, H43, H33), 3.65 - 3.59 (m, 3H, H6a4, H6a3, H32), 
3.58 - 3.52 (m, 4H, H6b4, h6b3, H6a1, H54), 3.42 (d, J=9.3, 1H, H6b1), 3.28 (d, J=9.8, 1H, H51), 
3.02 (d, J=9.6, 1H, H52), 1.93 (s, 3H, Ac), 1.69 (s, 3H, Ac). 13C-NMR (150.9 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.35 (CO2CH3), 170.07 (CO2CH3), 167.60, 165.83 (benzoyl), 138.98, 
138.74, 138.60, 138.56, 138.43, 138.31, 138.08, 137.97, 137.42 (139.0 - 137.4 benzyl), 
133.49 (Phth), 131.87, 130.18 (benzoyl), 130.15 (benzoyl), 128.98, 128.87, 128.62, 128.59, 
128.55, 128.49, 128.46, 128.44, 128.42, 128.32, 128.30, 128.18, 128.13, 128.09, 128.03, 
128.00, 127.88, 127.83, 127.80, 127.79, 127.70, 127.58, 126.99 (129.0 - 127.0 aromatic), 
123.23, 99.93 (C13), 99.34 (C12), 98.76 (C14), 97.47 (C11), 79.49 (C41), 78.88 (C32), 78.16 (C34), 
78.05 (C33), 76.14 (C31), 75.36 (BnCH2), 75.22 (BnCH2), 75.03 (C4
2), 74.71 (C52, C51), 74.60 
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(BnCH2), 74.53 (BnCH2), 74.35 (C4
3), 74.18 (C44), 73.69 (BnCH2), 73.66 (BnCH2), 72.58 (C5
3), 
72.39 (C54), 72.22 (BnCH2), 71.96 (C2
2), 71.59 (BnCH2), 70.88 (BnCH2), 69.25 (C2
3), 69.13 
(C63), 68.95 (C61), 68.59 (C64), 68.32 (C24), 66.28 (C62), 55.87 (C21), 21.25 (CO2CH3), 20.94 
(CO2CH3). 
Benzyl 2-O-acetyl-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[2-O-acetyl-3,4,6-tri-O- 
benzyl-α-D-mannopyranosyl-(1→6)]-2-O-acetyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-2-N
-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside (88) 
To a heated solution of 87 (1.83 g, 0.97 mmol) in MeOH (60 mL) 
at 70 °C, hydrazine monohydrate (12 mL) was added. The 
reaction was kept at 70 °C for 24 h, the solvent was removed 
and coevaporated with toluene (50 mL×3). The residue was taken up in pyridine / acetic 
anhydride 2:1 (30 mL) and stirred at room temperature overnight. Evaporation and 
co-evaporation three times with toluene was followed. Purification by column 
chromatography (cyclohexane-ethyl acetate 5:1 to 1:2) gave 88. Yield: 83% (1.40 g, 0.81 
mmol). Rf = 0.5 (Tol/EtOAc 1:1). [α]D
20 = +14° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1735.7661 ([M+H]+, calc. 1735.7608), 1752.7704 
([M+NH4]
+, calc. 1752.7873), 887.3584 ([M+Na+NH4]
2+, calc. 887.3869). 1H-NMR (600 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.44 - 7.12 (m, 50H, aromatic), 5.50 (dd, J=2.9, 1.8, 
1H, H23), 5.47 - 5.44 (m, 1H, H24), 5.43 (d, J=2.7, 1H, H22), 5.19 (d, J=1.6, 1H, H13), 5.14 (d, 
J=7.5, 1H, NH), 4.96 (d, J=1.5, 1H, H14), 4.95 - 4.77 (m, 6H, H11, BnCH2), 4.75 - 4.65 (m, 4H, 
H12, BnCH2), 4.62 (d, J=12.1, 1H, BnCH2), 4.59 - 4.41 (m, 10H, BnCH2), 4.37 (d, J=12.1, 1H, 
BnCH2), 4.11 (t, J=8.1, 1H, H4
1), 4.03 (t, J=8.3, 1H, H31), 4.00 - 3.90 (m, 5H, H53, H43, H44, H34, 
H33), 3.86 - 3.80 (m, 3H, H6a1, H54, H32), 3.77 - 3.73 (m, 5H, H42, H6a2, H6b1, H6a3, H6b3), 
3.72 - 3.69 (m, 1H, H6b2), 3.62 - 3.54 (m, 2H, H6a4, H51), 3.39 (dd, J=16.0, 7.8, 1H, H21), 3.33 - 
3.27 (m, 1H, H52), 3.23 (dd, J=10.8, 1.2, 1H, H6b4), 2.14 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.05 (s, 
3H, Ac), 1.63 (s, 3H, NHAc). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.56, 
170.42, 170.26 (CO2CH3), 139.36, 138.96, 138.85, 138.69, 138.56, 138.35, 138.26, 138.17, 
138.13, 137.81, 128.83, 128.75, 128.64, 128.61, 128.51, 128.48, 128.44, 128.38, 128.19, 
128.07, 128.01, 127.99, 127.96, 127.91, 127.88, 127.85, 127.82, 127.80, 127.74, 127.72 
(128.8 - 127.7 aromatic), 100.19 (C13), 99.63 (C11), 98.10 (C14), 97.68 (C12), 78.91 (C32), 
78.59 (C34), 77.95 (C31), 77.91 (C33), 76.23 (C41), 75.67 (BnCH2), 75.50 (C4
2), 75.31 (BnCH2), 
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 74.94 (C5
2, BnCH2), 74.66 (C4
4), 74.39 (C51), 74.27 (C43), 74.17 (BnCH2), 73.70 (BnCH2), 73.68 
(BnCH2), 73.59 (BnCH2), 72.64 (C5
3), 72.13 (BnCH2), 72.11 (BnCH2), 71.81 (C5
4), 71.42 (C22), 
71.21 (BnCH2), 69.17 (C2
4, C23), 69.12 (C63), 69.06 (C64), 68.81 (C61), 66.08 (C62), 56.42 (C21), 
23.56 (NHCO2CH3), 21.27 (CO2CH3), 21.25 (CO2CH3), 21.19 (CO2CH3). 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-[2,3,4,6-tetra-O-acetyl-α-D-mannopyran
osyl-(1→6)+-2,4-di-O-acetyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-1,3,6-di-O-acetyl-2-
deoxy-β-D-glucopyranose (89)[148] 
Compound 88 (1.33 g, 0.77 mmol) was dissolved in MeOH / 
acetic acid 30:2 (31 mL). The solution was added to a 
suspension of 10% Pd(C) (950 mg) in MeOH (30 mL), stirred 
under argon. The reaction mixture was then stirred under hydrogen atmosphere for 48 h. 
After flushing the mixture with argon, the suspension was filtered through Celite and the 
filtrate concentrated and co-concentrated three times with toluene. The residue was 
dissolved in pyridine / acetic anhydride 2:1 (30 mL) and stirred at room temperature 
overnight. The solvent was removed and co-evaporation three times with toluene was 
followed by column chromatography (cyclohexane-ethyl acetate 1:1 to 1:5) to give 89. Yield: 
91% (0.88 g, 0.70 mmol). Rf = 0.2 (
CHex/EtOAc 1:3). [α]D
20 = +32° (c = 1.0, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1254.3946 ([M+H]+, calc. 
1254.3936), 1271.4204 ([M+NH4]
+, calc. 1271.4201), 1278.3788 ([M+Na]+, calc. 1276.3755), 
647.1755 ([M+Na+NH4]
2+, calc. 647.2050). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), 
δ (ppm): 6.05 (d, J=3.5, 1H, H11), 5.90 (s, 1H, NH), 5.36 - 5.23 (m, 6H, H43, H44, H23, H22, H33, 
H31), 5.09 (dd, J=10.2, 3.3, 1H, H34), 5.05 (t, J=7.5, 1H, H42), 4.98 (dd, J=3.2, 1.8, 1H, H24), 
4.97 (d, J=1.6, 1H, H13), 4.82 (d, J=1.4, 1H, H12), 4.77 (s, 1H, H14), 4.37 - 4.30 (m, 2H, H21, 
H6a1), 4.29 - 4.24 (m, 3H, H6b1, H6a4, H6b4), 4.23 - 4.18 (m, 1H, H6a3), 4.13 - 4.06 (m, 2H, 
H6b3, H54), 4.00 - 3.88 (m, 5H, H53, H6a2, H51, H41, H32), 3.67 (dd, J=10.4, 4.0, 1H, H6b2), 3.64 
- 3.58 (m, 1H, H52), 2.17 (s, 3H), 2.13 (s, 6H), 2.11 (s, 3H), 2.10 (s, 3H), 2.08 (s, 9H), 2.07 (s, 
3H), 2.04 (s, 3H), 2.03 (s, 3H), 1.97 (s, 3H), 1.95 (s, 3H), 1.90 (s, 3H) (2.17 - 1.90 Ac). 13C-NMR 
(150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.35, 170.83, 170.75, 170.67, 170.42, 170.13, 
170.12, 170.10, 170.07, 169.94, 169.89, 169.80, 169.21 (171.4 - 169.2 CO2CH3), 98.04 (C1
3), 
97.56 (C14), 97.17 (C12), 90.78 (C11), 74.54 (C32), 72.74 (C52), 71.15 (C31), 70.28 (C41, C51), 
69.44 (C24), 69.39 (C22, C54), 69.14 (C23), 68.91 (C33), 68.73 (C53), 68.49 (C34), 68.38 (C42), 
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66.96 (C62), 66.01 (C43), 65.52 (C44), 62.24 (C63, C64), 61.94 (C61), 50.79 (C21), 22.97, 21.10, 
20.96, 20.91, 20.88, 20.87, 20.83, 20.79, 20.72, 20.66 (23.0 - 20.7 CO2CH3). 
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 7.15 Synthesis of complex type hexasaccharide for oxazoline conversion 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-4,6- 
O-benzylidene-α-D-mannopyranosyl-(1→3)-[3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-
glucopyranosyl-(1→2)-3-O-benzyl-4,6-O-benzylidene-α-D-mannopyranosyl-(1→6)]-2-O-ben
zoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-be
nzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (90)  
The trichloroacetimidate donor 58 (2.37 mg, 2.23 mmol, 
2.4 eq) and acceptor 26 (866 mg, 0.93 mmol, 1.0 eq) was 
dissolved in dry DCM (30 mL) and 4 Å molecular sieves (3 
g) was added. The suspension was stirred under argon at 
r.t. for 30 min and cooled to -50 °C, trimethylsilyl 
-trifluoromethanesulfonate (TMSOTf) (25.4 μL, 0.14 mmol, 0.15 eq) was added. The reaction 
was kept stirring at -50 °C for 1 h, -45 °C for 1 h, -40 °C for 1 h, -30 °C for 1 h and 0 °C for 2 h, 
then quenched with triethylamine (0.1 mL). The molecular sieves were removed by filtering 
over a layer of Celite. The filtrate was concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:1) to give 90. Yield 76% (1.92 g, 0.71 mmol). Rf = 0.4 
(CHex /EtOAc 2:1). *α+D
20 = -20° (c = 1.2, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1387.5600 ([M+2NH4]
2+, calc. 1387.5581), 1390.5403 ([M+Na+NH4]
2+, 
calc. 1390.5375). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.32 (d, J=7.5, 
2H, benzoyl), 7.74 - 6.57 (m, 85H, aromatic), 5.65 (s, 1H, PhCH3), 5.59 (s, 1H, PhCH
4), 5.48 (d, 
J=8.5, 1H, H15), 5.37 (d, J=3.5, 1H, H22), 5.22 (d, J=13.3, 1H, BnCH2), 5.07 (d, J=8.3, 1H, H1
1), 
5.04 (s, 1H, BnCH2), 5.02 (d, J=5.2, 1H, H1
6), 4.93 (d, J=13.5, 1H, BnCH2), 4.91 - 4.86 (m, 3H, 
H35, BnCH2), 4.85 - 4.78 (m, 3H, BnCH2), 4.77 - 4.70 (m, 5H, H1
2, BnCH2), 4.67 (d, J=9.3, 1H, 
BnCH2), 4.65 (d, J=11.5, 1H, BnCH2), 4.61 (d, J=11.7, 1H, BnCH2), 4.55 - 4.44 (m, 6H, BnCH2), 
4.42 (d, J=10.3, 2H, H25, BnCH2), 4.38 (d, J=2.6, 1H, H2
3), 4.35 (s, 1H, H13), 4.32 (d, J=2.4, 1H, 
H24), 4.25 - 4.19 (m, 4H, H26, BnCH2), 4.17 - 4.12 (m, 2H, H2
1, H31), 4.11 - 4.05 (m, 4H, H41, 
H6a1, H45, H6a3), 3.98 - 3.87 (m, 6H, H6b1, H55, H43, H44, H46, H6b3), 3.79 - 3.77 (m, 2H, H6a5, 
H6b5), 3.75 - 3.70 (m, 2H, H32, H14), 3.62 - 3.57 (m, 4H, H6a2, H54, H51, H53), 3.55 - 3.51 (m, 
2H, H6a4, H6a2), 3.45 - 3.38 (m, 2H, H53, H6b4), 3.37 - 3.32 (m, 3H, H52, H6a6, H6b6), 3.06 (t, 
J=9.9, 1H, H6b2), 2.92 (td, J=9.6, 4.9, 1H, H54), 2.14 (d, J=9.6, 1H, H56). 13C-NMR (150.9 MHz, 
CDCl3, gHSQC, gHMBC), δ (ppm): 167.88 (Phth C=O), 167.08 (Phth C=O), 166.28 (benzoyl 
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C=O), 139.63, 139.20, 139.16, 138.82, 138.78, 138.73, 138.58, 138.49, 138.12, 138.02, 
138.01, 137.94, 137.61, 137.17 (139.6 - 137.2 benzyl), 133.85 (Phth), 133.49 (Phth), 131.64, 
130.51, 129.74, 129.51, 128.90, 128.78, 128.75, 128.72, 128.65, 128.49, 128.44, 128.36, 
128.33, 128.27, 128.26, 128.23, 128.17, 128.09, 128.04, 127.98, 127.96, 127.95, 127.88, 
127.86, 127.82, 127.79, 127.73, 127.71, 127.67, 127.63, 127.61, 127.60, 127.54, 127.53, 
127.43, 127.40, 127.34, 127.31, 127.25, 127.05, 127.00, 126.86, 126.26, 126.22, 126.16 
(129.7 - 126.2 aromatic), 123.37, 123.13, 102.38 (C14), 101.27 (PhC3H), 101.24 (PhC4H), 
100.80 (C13), 99.11 (C15), 97.83 (C16), 97.25 (C11), 96.99 (C12), 82.06 (C32), 79.34 (C45), 79.10 
(C53), 78.71 (C35), 78.23 (C46), 77.92 (C41), 77.12 (C43), 76.81 (C44), 76.30 (C31), 76.10 (C53), 
75.72 (C51), 74.91 (C55), 74.48 (BnCH2), 74.34 (BnCH2), 74.28 (BnCH2), 74.24 (C5
2), 73.92 
(BnCH2), 73.89 (BnCH2), 73.82 (C5
4), 73.62 (BnCH2), 73.47 (BnCH2), 73.38 (C5
6), 73.33 (BnCH2), 
73.27 (BnCH2), 72.57 (C2
4), 71.72 (C23), 71.01 (C62), 70.60 (BnCH2), 69.70 (BnCH2), 69.61 
(C61), 69.58 (BnCH2), 69.48 (C2
2), 68.81 (C66), 68.42 (C63), 68.01 (C64), 67.01 (C54), 56.54 
(C25), 56.22 (C26), 55.93 (C21). 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3-O-benzyl-α-D- 
mannopyranosyl-(1→3)-[3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→
2)-3-O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1
→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (91) 
To a stirring solution of 90 (540 mg, 0.197 mmol) in MeCN 
(4 mL), a solution of p-toluenesulfonic acid (100 mg) in 
MeCN (4 mL) was added. Et3N (75 μL) was used to 
neutralize the reaction after stirring at r.t. for 30 min. The 
reaction was concentrated and coevaporated with 
toluene and the crude product was purified by column 
chromatography (cyclohexane-ethyl acetate 5:1 to 1:2) to give 91. Yield 76% (384 mg, 0.150 
mmol). Rf = 0.2 (Tol/EtOAc 1:1). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), 
m/z: 1291.0153 ([M+H+NH4]
2+, calc. 1291.0136), 1299.5268 ([M+2NH4]
2+, calc. 1299.5273), 
1301.9730 ([M+Na+NH4]
2+, calc. 1302.0045). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 8.24 (d, J=5.3, 2H, benzoyl), 7.89 - 6.44 (m, 75H, aromatic), 5.49 (d, J=7.7, 
1H, H15), 5.39 (s, 1H, H22), 5.21 (d, J=10.6, 1H, BnCH2), 5.07 (d, J=7.5, 1H, H1
1), 5.06 (d, J=7.0, 
1H, H16), 5.01 - 4.94 (m, 2H, BnCH2), 4.93 - 4.82 (m, 3H, H3
5, BnCH2), 4.79 - 4.71 (m, 2H, 
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 BnCH2), 4.70 - 4.59 (m, 4H, H1
2, BnCH2), 4.54 (dd, J=29.1, 11.3, 3H, BnCH2), 4.49 - 4.22 (m, 
14H, H25, H24, H23, H13, H14, BnCH2), 4.14 (d, J=13.8, 3H, H2
6, H22, BnCH2), 4.09 - 3.99 (m, 3H, 
H41, H31, H6a1), 3.99 - 3.86 (m, 5H, H45, H36, H55, BnCH2, H6b
1), 3.83 - 3.75 (m, 3H, H6a5, 
H6b5, H43), 3.72 (d, J=11.3, 2H, H6a3, H6a4), 3.68 - 3.56 (m, 6H, H32, H46, H52, H51, H6a2, H44), 
3.55 - 3.49 (m, 1H, H6b3), 3.42 (d, J=8.8, 1H, H33), 3.39 - 3.32 (m, 2H, H42, H6b4), 3.28 (d, 
J=10.7, 3H, H6a6, H54, H34), 3.24 (s, 1H, H6b6), 3.14 (t, J=9.5, 1H, H6b2), 3.04 (s, 1H, H53), 2.12 
(d, J=9.1, 1H, H56). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 168.61, 168.33, 
167.62 (Phth C=O), 167.50 (Phth C=O), 166.19 (benzoyl C=O), 138.85, 138.81, 138.75, 138.51, 
138.28, 138.06, 138.00, 137.95, 137.76, 137.05 (138.9 - 137.1 benzyl), 133.89 (Phth), 133.83 
(Phth), 133.62, 133.29, 132.99, 132.29, 132.24, 131.54, 131.43, 130.37 (benzoyl), 129.60, 
129.23, 128.87, 128.78, 128.69, 128.49, 128.46, 128.39, 128.34, 128.31, 128.28, 128.27, 
128.21, 128.18, 128.09, 128.05, 127.98, 127.87, 127.82, 127.79, 127.73, 127.69, 127.66, 
127.64, 127.60, 127.56, 127.49, 127.46, 127.38, 127.34, 127.31, 127.19, 127.09, 126.99 
(129.6 - 127.0 aromatic), 123.38 (Phth), 123.12 (Phth), 122.71, 122.66, 101.34 (C16), 100.46 
(C13), 99.20 (C15), 97.49 (C14), 97.12 (C11), 96.80 (C12), 81.42 (C32), 79.69 (C33), 79.44 (C45), 
79.26 (C34), 79.14 (C46), 78.75 (C35), 78.27 (C36), 77.55 (C14), 76.11 (C31, C54), 75.33 (C53), 
74.84 (C55), 74.70 (C52), 74.55 (BnCH2), 74.43 (BnCH2), 74.33 (C4
2), 74.04 (BnCH2), 73.96 
(C51), 73.86 (BnCH2), 73.82 (BnCH2), 73.60 (BnCH2), 73.41 (C5
6), 73.34 (BnCH2), 73.24 (BnCH2), 
72.63 (C23), 70.65 (BnCH2), 69.91 (BnCH2), 69.66 (BnCH2), 69.57 (C6
1), 69.50 (C24), 69.44 
(C22), 69.40 (C62), 68.63 (C66), 67.84 (C65), 67.29 (C43), 66.88 (C44), 63.45 (C63), 63.22 (C64), 
56.57 (C25), 56.20 (C26), 55.97 (C21). 
Benzyl 2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→2)-4,6-di-O-acet 
yl-3-O-benzyl-α-D-mannopyranosyl-(1→3)-[2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-g
lucopyranosyl-(1→2)-4,6-di-O-acetyl-3-O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-acetyl-4-
O-benzyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-3,
6-di-O-benzyl-2-deoxy-β-D-glucopyranoside (92)  
To a heated solution of 91 (284 mg, 0.111 mmol) in Tol / 
EtOH 1:1 (10 mL) at 80 °C, hydrazine monohydrate (2 mL) 
was added. The reaction was kept at 80 °C for 72 h, the 
solvent was removed and coevaporated with toluene (20 
mL×3). The residue was taken up in pyridine / acetic anhydride 2:1 (10 mL) and stirred at r.t. 
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for 24 h. Evaporation and co-evaporation three times with toluene was followed. Purification 
by column chromatography (cyclohexane-ethyl acetate 5:1 to 1:3) gave 92. Yield: 97% (260 
mg, 0.108 mmol). Rf = 0.2 (EtOAc). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), 
m/z: 1203.5214 ([M+2H]2+, calc. 1203.5212), 1212.0370 ([M+H+NH4]
2+, calc. 1212.0345), 
1220.5514([M+2NH4]
2+, calc. 1220.5478), 1222.9987 ([M+Na+NH4]
2+, calc. 1223.0255). 
1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.48 - 7.05 (m, 60H, aromatic), 
6.01 (s, 1H, NH5), 5.93 (d, J=5.6, 1H, NH1), 5.81 (s, 1H, NH6), 5.25 - 5.10 (m, 5H, H22, H11, H43, 
H44, BnCH2), 5.00 (dd, J=14.2, 8.0, 2H, H1
5, BnCH2), 4.92 - 4.59 (m, 11H, H1
6, BnCH2), 4.59 - 
4.50 (m, 5H, H12, BnCH2), 4.49 - 4.38 (m, 6H, H1
3, BnCH2), 4.37 - 4.24 (m, 4H, H2
3, H31, 
BnCH2), 4.21 - 4.07 (m, 4H, H2
4, H6a3, H6b3, BnCH2), 4.07 - 4.00 (m, 3H, H6a
4, H35, H14), 3.97 
- 3.91 (m, 2H, H6b4, H41), 3.90 - 3.75 (m, 6H, H25, H26, H6a1, H42, H32, H36), 3.76 - 3.63 (m, 
9H, H6a5, H6b5, H6a4, H6b4, H6b1, H6a2, H55, H56, H45), 3.63 - 3.53 (m, 3H, H6b2, H55, H46), 
3.52 - 3.44 (m, 3H, H51, H33, H52), 3.40 (d, J=10.1, 1H, H34), 3.08 (d, J=8.1, 1H, H21), 2.60 (d, 
J=8.3, 1H, H54), 2.10 (s, 3H, OAc), 2.09 (s, 3H, OAc), 2.06 (s, 6H, OAc), 1.97 (s, 3H, OAc), 1.85 
(s, 2H, NHAc), 1.60 (s, 3H, NHAc), 1.58 (s, 3H, NHAc). 13C-NMR (150.9 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 174.48, 171.27, 171.24, 170.89, 170.78, 170.60, 169.65, 169.45 (171.3 - 
169.5 CO2CH3 ), 138.99, 138.72, 138.66, 138.61, 138.46, 138.40, 138.34, 138.23, 137.97, 
137.89, 137.85, 137.70 (138.9 - 137.9 benzyl), 129.37, 128.82, 128.70, 128.59, 128.52, 
128.48, 128.42, 128.40, 128.32, 128.28, 128.23, 128.20, 128.05, 128.00, 127.98, 127.93, 
127.87, 127.86, 127.78, 127.75, 127.66, 127.61, 127.54, 127.46, 127.44, 127.38, 127.35, 
127.32 (129.4 - 127.3 aromatic), 102.48 (C14), 101.94 (C16), 100.07 (C15), 99.30 (C11), 98.73 
(C13), 97.69 (C12), 82.71 (C36), 79.49 (C32), 79.05 (C35), 77.95 (C41), 77.88 (C31), 77.72 (C42), 
77.37 (C45) 77.24 (C52), 76.14 (C34), 75.25 (C24), 74.92 (C52), 74.80 (C34), 74.06 (C55), 74.02 
(C56), 73.82 (C51), 73.77 (BnCH2), 73.64 (BnCH2), 73.50 (BnCH2), 73.36, (BnCH2) 73.31 (BnCH2), 
73.21 (BnCH2), 73.05 (C5
5), 72.17 (C23), 72.05 (C54), 71.64 (BnCH2), 70.58 (C6
2), 70.26 
(BnCH2), 70.22 (BnCH2), 70.05 (BnCH2), 69.39 (C6
6), 68.87 (C61), 68.38 (C65), 68.21 (C22), 
67.40 (C43), 66.10 (C44), 63.68 (C63), 62.39 (C64), 58.27 (C21), 56.12 (C25, C26), 21.11, 21.08, 
21.00, 20.97, 20.94, 20.89, 20.83 (21.1 - 20.8 CO2CH3).  
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 Benzyl 3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→3)-[3,4,6-tri-O-benzyl-α-D-mannopyrano 
syl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranoside (93) 
To a solution of 87 (1115 mg, 0.592 mmol) in MeOH / DCM 5:1 
(60 mL), NaOMe (65 mg) was added to reach pH 9.5. The 
reaction was kept at r.t. for 3 days and neutralized with Dowex 
50WX8 ion-exchanger (1 g, prewashed with MeOH), concentrated and coevaporated with 
toluene (50 mL×3). Then purified by column chromatography (cyclohexane-ethyl acetate 10:1 
to 1:2) and recrystallized from cyclohexane-ethyl acetate to give 93, yield 89% (947 mg, 0.526 
mmol). Rf = 0.6 (Tol/EtOAc 1:1). *α+D
20 = +7° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1818.7658 ([M+NH4]
+, calc. 1818.7768), 918.4052 
([M+ NH4+NH4]
2+, calc. 918.4056), 920.8824 ([M+ Na+NH4]
2+, calc. 920.8833). 1H-NMR (600 
MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.13 (d, J=7.3, 2H, benzoyl), 7.65 (s, 1H, Phth), 
7.62 - 7.57 (m, 1H, Phth), 7.46 - 7.14 (m, 47H, aromatic), 7.12 - 7.01 (m, 4H, aromatic), 6.67 - 
6.47 (m, 4H, aromatic), 5.66 (d, J=2.9, 1H, H22), 5.20 (s, 1H, H13), 5.13 (s, 1H, H14), 5.02 (d, 
J=8.5, 1H, H11), 4.83 - 4.80 (m, 2H, BnCH2), 4.80 - 4.76 (m, 4H, H1
2, BnCH2), 4.75 (d, J=12.4, 
1H, BnCH2), 4.64 (d, J=11.1, 1H, BnCH2), 4.61 (d, J=12.3, 1H, BnCH2), 4.59 - 4.56 (m, 2H, 
BnCH2), 4.56 - 4.52 (m, 3H, BnCH2), 4.52 - 4.49 (m, 2H, BnCH2), 4.48 - 4.43 (m, 3H, BnCH2), 
4.42 (d, J=11.4, 1H, BnCH2), 4.33 (d, J=13.2, 1H, BnCH2), 4.18 - 4.13 (m, 2H, H2
1, H41), 4.08 - 
4.06 (m, 1H, H24), 4.06 - 4.03 (m, 1H, H53), 3.99 (dd, J=10.5, 8.7, 1H, H31), 3.97 - 3.92 (m, 2H, 
H6a2, H44), 3.90 (t, J=9.7, 4H, H6b2, H23, H43, H42), 3.86 (dd, J=9.2, 3.1, 1H, H34), 3.83 - 3.78 
(m, 4H, H6a3, H6a4, H6b4, H54), 3.78 - 3.72 (m, 3H, H6b3, H33, H32), 3.70 (dd, J=10.9, 4.2, 1H, 
H6a1), 3.60 (d, J=9.6, 1H, H6b1), 3.48 (d, J=9.8, 1H, H51), 3.26 (d, J=9.5, 1H, H52). 13C-NMR 
(150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 165.40 (benzoyl), 138.61, 138.39, 138.38, 
138.36, 138.22, 138.02, 137.87, 137.83, 137.18 (138.6 - 137.2 benzyl), 133.17 (Phth), 130.06, 
(benzoyl) 129.99, 128.71, 128.57, 128.43, 128.36, 128.32, 128.31, 128.29, 128.16, 128.13, 
128.11, 127.98, 127.95, 127.94, 127.88, 127.85, 127.80, 127.73, 127.72, 127.66, 127.62, 
127.55, 127.53, 127.50 (128.7 - 127.5 aromatic), 126.84, 101.70 (C13), 99.80 (C14), 98.97 
(C12), 97.17 (C11), 80.10 (C34), 79.66 (C32), 79.37 (C33), 79.03 (C41), 75.92 (C31), 75.24 
(BnCH2), 75.05 (BnCH2), 74.83 (C4
2), 74.49 (BnCH2), 74.44 (C5
1), 74.38 (C52), 74.30 (BnCH2), 
74.18 (C43), 73.89 (C44), 73.46 (BnCH2), 73.44 (BnCH2), 72.21 (BnCH2), 72.02 (C2
2), 71.86 
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(C53), 71.68 (C54), 71.56 (BnCH2), 70.65 (BnCH2), 68.91 (C2
3), 68.89 (C63), 68.67 (C61), 68.27 
(C64), 68.18 (C24), 66.13 (C62), 55.61 (C12). 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3,4,6-tri-O-ben 
zyl-α-D-mannopyranosyl-(1→3)-[3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyrano
syl-(1→2)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-man
nopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (94)  
Compounds 55 (1291 mg, 1.92 mmol, 4.0 eq), 93 (865 mg, 
0.48 mmol, 1.0 eq), N-iodosuccinimide (432 mg, 1.92 
mmol, 4.0 eq) and 4 Å molecular sieves (1 g) in dry 
dichloromethane (20 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then 
the suspension was cooled to 0 °C followed by slow 
addition of trifluoromethanesulfonic acid (16.4 μL, 0.12 mmol, 0.25 eq). After stirring for 0.5 
h at 0 °C, the reaction was quenched by diluting with more DCM (20 mL). The molecular 
sieves were removed by filtration and the filtrate was washed with 1 M Na2S2O3 (15 mL×3), 
brine (30 mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 8:1) to give 94. Yield: 63% (883 mg, 0.30 mmol). Rf = 0.4 
(CHex/EtOAc 2:1). *α+D
20 = -5° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1471.1086 ([M+H+NH4]
2+, calc. 1471.1075), 1479.6320 ([M+NH4+NH4]
2+, 
calc. 1479.6207), 1482.0734 ([M+ Na+NH4]
2+, calc. 1482.0984). 1H-NMR (600 MHz, CDCl3, 
gCOSY, gHSQC, gHMBC), δ (ppm): 8.15 (d, J=7.5, 2H, benzoyl), 7.71 (s, 2H, Phth), 7.64 - 7.56 
(m, 4H, Phth), 7.54 - 6.86 (m, 67H, aromatic), 6.71 (d, J=7.3, 2H, aromatic), 6.49 (d, J=6.9, 3H, 
aromatic), 5.39 (d, J=2.2, 1H, H22), 5.01 (s, 1H, H13), 4.99 (d, J=8.6, 1H, H11), 4.95 - 4.91 (m, 
2H, H15, H16), 4.89 (d, J=10.9, 1H, BnCH2), 4.87 - 4.64 (m, 10H, BnCH2), 4.64 - 4.59 (m, 2H, 
H14, BnCH2), 4.59 - 4.44 (m, 7H, BnCH2), 4.44 - 4.38 (m, 5H, H1
2, BnCH2), 4.38 - 4.31 (m, 2H, 
BnCH2), 4.29 - 4.20 (m, 4H, H2
6, H25, BnCH2), 4.16 - 4.08 (m, 6H, H2
1, H24, H35, BnCH2), 4.08 - 
4.00 (m, 3H, H41, H36, H33), 3.99 - 3.94 (m, 1H, H31), 3.88 - 3.81 (m, 4H, H23, H34, BnCH2), 
3.74 - 3.64 (m, 5H, H6a1, H42, H43, H45, H46), 3.61 - 3.52 (m, 4H, H6a3, H6b3, H44, H32), 3.52 - 
3.44 (m, 4H, H6b1, H6a6, H6a5, H53), 3.43 - 3.34 (m, 4H, H6b6, H6a2, H51, H54), 3.28 (d, J=10.5, 
1H, H6b5), 3.23 (d, J=10.4, 1H, H6a4), 2.91 (dd, J=11.0, 5.9, 1H, H6b4), 2.78 (d, J=9.6, 1H, H52), 
2.74 (dd, J=10.6, 6.6, 1H, H6b2), 2.52 (d, J=9.2, 1H, H56), 2.20 (d, J=8.7, 1H, H55). 13C-NMR 
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 (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 167.55 (Phth C=O), 165.06 (benzoyl C=O), 
139.07, 138.85, 138.72, 138.66, 138.51, 138.38, 138.32, 138.28, 138.26, 138.19, 138.09, 
138.01, 137.21 (138.9 - 137.2 benzyl), 133.49 (Phth), 133.08 (Phth), 131.97, 131.82, 130.36, 
130.02, 129.13, 128.97, 128.53, 128.47, 128.44, 128.41, 128.36, 128.34, 128.30, 128.26, 
128.20, 128.15, 128.12, 128.08, 128.04, 128.00, 127.95, 127.90, 127.80, 127.75, 127.72, 
127.66, 127.56, 127.51, 127.47, 127.39, 127.34, 127.30, 127.26, 127.13 (129.6 - 127.1 
aromatic), 125.98, 123.09 (Phth), 98.89 (C12), 98.35 (C13), 97.63 (C14), 97.17 (C11), 97.12 
(C16), 95.69 (C15), 79.38 (C45), 79.30 (C46), 79.20 (C33), 78.94 (C36), 78.88 (C35), 77.68 (C32), 
77.44 (C34), 77.21 (C43), 75.38 (C31), 75.29 (BnCH2), 74.67 (BnCH2), 74.62 (C5
6), 74.57 
(BnCH2), 74.34 (C4
4, C51, C55), 74.14 (BnCH2), 74.07 (C4
2), 73.97 (BnCH2), 73.81 (BnCH2), 
73.71 (C53), 73.46 (BnCH2), 73.43 (BnCH2), 73.15 (C5
2), 73.10 (BnCH2), 72.80 (C2
3), 72.68 
(BnCH2), 72.57 (C2
4), 72.19 (C22), 72.10 (C54), 72.06 (C41), 71.20 (BnCH2), 70.78 (BnCH2), 
70.67 (C62), 69.75 (C64), 69.60 (BnCH2), 68.79 (C6
6), 68.76 (C65), 68.22 (C63), 66.67 (C61), 
55.73 (C21), 55.67 (C25), 55.65 (C26). 
Benzyl 2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→2)-3,4,6-tri-O-ben 
zyl-α-D-mannopyranosyl-(1→3)-[2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyran
osyl-(1→2)-3,4,6-tri-O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-ma
nnopyranosyl-(1→4)-2-N-acetamido-3,6-di-O-benzyl-2-deoxy-β-D-glucopyranoside (95) 
To a heated solution of 94 (750 mg, 256 μmol) in Tol / 
EtOH 1:1 (20 mL) at 80 °C, hydrazine monohydrate (4 mL) 
was added. The reaction was kept at 80 °C for 5 days, the 
solvent was removed and coevaporated with toluene (20 
mL×3). The residue was taken up in pyridine / acetic 
anhydride 2:1 (20 mL) and stirred at r.t. for 48 h. 
Evaporation and co-evaporation three times with toluene was followed. Purification by 
column chromatography (cyclohexane-ethyl acetate 5:1 to 1:3) gave 95. Yield: 88% (590 mg, 
227 μmol). Rf = 0.8 (Tol/EtOAc 1:2). *α+D
20 = +19° (c = 1.2, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 1299.5947 ([M+2H]2+, calc. 1299.5940), 1308.1093 
([M+H+NH4]
2+, calc. 1308.1073), 1319.0694 ([M+ Na+NH4]
2+, calc. 1319.0982). 1H-NMR (600 
MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.47 - 7.06 (m, 80H, aromatic), 5.92 - 5.82 (m, 
2H, NH6, NH1), 5.42 (d, J=2.9, 2H, H22, NH5), 5.05 (s, 1H, H13), 5.03 (d, J=8.1, 1H, H16), 4.97 (d, 
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J=11.3, 1H, BnCH2), 4.92 (d, J=10.8, 1H, BnCH2), 4.88 - 4.85 (m, 2H, H1
1, BnCH2), 4.84 - 4.74 
(m, 9H, H14, H12, H15, BnCH2), 4.73 - 4.70 (m, 2H, BnCH2), 4.69 - 4.58 (m, 7H, BnCH2), 4.58 - 
4.53 (m, 5H, H36, BnCH2), 4.53 - 4.40 (m, 9H, BnCH2), 4.32 (d, J=11.7, 1H, BnCH2), 4.25 (s, 1H, 
H24), 4.18 (t, J=9.5, 1H, H35), 4.13 (t, J=8.3, 1H, H31), 4.11 - 4.05 (m, 4H, H23, H43, H41, H44), 
3.92 (dd, J=9.4, 2.7, 1H, H34), 3.85 - 3.78 (m, 3H, H42, H32, H33), 3.78 - 3.71 (m, 3H, H6a4, 
H6b4, H6a3), 3.70 - 3.63 (m, 2H, H6a1, H6b3), 3.63 - 3.55 (m, 7H, H6a5, H6b5, H51, H53, H54, 
H21, H46), 3.55 - 3.46 (m, 4H, H6b1, H6a2, H56, H45), 3.19 (d, J=10.5, 1H, H6b2), 3.18 - 3.12 (m, 
2H, H25, H52), 3.08 (d, J=4.9, 1H, H26), 3.03 (dd, J=9.6, 2.9, 1H, H55), 1.95 (s, 3H, Ac), 1.73 (s, 
3H, Ac), 1.69 (s, 3H, Ac), 1.65 (s, 3H, Ac). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ 
(ppm): 171.98, 171.67, 170.31, 169.87 (171.9 - 169.8 C=O), 139.17, 139.02, 138.97, 138.85, 
138.77, 138.52, 138.45, 138.31, 138.29, 138.25, 138.19, 138.01, 128.74, 128.67, 128.65, 
128.60, 128.56, 128.53, 128.51, 128.45, 128.42, 128.41, 128.37, 128.36, 128.30, 128.15, 
128.10, 128.07, 127.96, 127.93, 127.90, 127.87, 127.82, 127.78, 127.75, 127.73, 127.69, 
127.66, 127.64, 127.63, 127.60, 127.58, 127.51, 127.49, 126.72 (139.2 - 126.7 aromatics), 
99.99 (C11), 99.71 (C13), 98.01 (C14), 97.97 (C12), 97.57 (C15), 97.50 (C16), 80.04 (C35), 79.94 
(C36), 79.55 (C33), 78.89 (C31, C46), 78.82 (C45), 78.02 (C34), 77.58 (C32), 76.39 (C44), 75.43 
(BnCH2), 74.89 (BnCH2), 74.80 (C5
6, BnCH2), 74.70 (BnCH2), 74.60 (C5
5), 74.56 (BnCH2), 74.52 
()C53, 74.43, (C54) 74.34, (C43) 74.19, (C52) 74.12 (BnCH2), 73.91 (C4
1), 73.58 (BnCH2), 73.48 
(BnCH2), 73.43 (BnCH2), 73.39 (BnCH2), 73.21 (BnCH2), 73.18 (BnCH2), 72.84 (C2
4), 72.42 (C42), 
71.62 (C51), 71.47 (C22), 71.05 (BnCH2), 70.81 (BnCH2), 69.36 (C6
6), 69.30 (C65), 69.21 (C63), 
68.99 (C64), 68.94 (C62), 66.24 (C61), 58.67 (C26), 58.16 (C25), 56.05 (C21), 23.47 (Ac), 23.44 
(Ac), 23.33 (Ac), 21.08 (Ac). 
2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-3,4,6-tri-O-acetyl-α-D-
mannopyranosyl-(1→3)-[2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→
2)-3,4,6-tri-O-acetyl-α-D-mannopyranosyl-(1→6)]-2,4-di-
O-acetyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-1,3,
6-di-O-acetyl-2-deoxy-β-D-glucopyranose (96) 
Compound 92 (200 mg, 83 μmol) and 10% Pd(C) (111 mg) 
was suspended in MeOH / acetic acid 30:2 (6.82 mL). The 
suspension was stirred under argon and then flushed with 
H2 gas. The reaction was stirred under hydrogen 
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 atmosphere for 5 days and after completion flushed with argon again. The suspension was 
filtered through Celite and the filtrate concentrated and co-concentrated three times with 
toluene. The residue was dissolved in pyridine / acetic anhydride 2:1 (10 mL) and stirred at 
room temperature overnight. The solvent was removed and co-evaporated three times with 
toluene, purified by column chromatography (cyclohexane-ethyl acetate 1:1 to MeOH-ethyl 
acetate 5%) to give 96. Yield: 74% (112 mg, 61 μmol). Rf = 0.2 (MeOH/EtOAc 5%). 
Compound 95 (518 mg, 199 μmol) and 10% Pd(C) (300 mg) was suspended in MeOH / acetic 
acid 30:2 (16 mL). The suspension was stirred under argon and flushed with H2 gas. The 
reaction was stirred under hydrogen atmosphere for 16 days and after completion flushed 
with argon again. The suspension was filtered through Celite and the filtrate concentrated 
and co-concentrated three times with toluene. The residue was dissolved in pyridine / acetic 
anhydride 2:1 (15 mL) and stirred at room temperature for 3 days. The solvent was removed 
and co-evaporated three times with toluene, purified by column chromatography 
(cyclohexane-ethyl acetate 1:1 to MeOH-ethyl acetate 5%) to give 96. Yield: 85% (310 mg, 
170 μmol). Rf = 0.4 (EtOAc/MeOH/AcOH/H2O 60:3:3:2). 
*α+D
20 = -37° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 
1828.6148 ([M+H]+, calc. 1828.5946), 1845.6204 ([M+NH4]
+, calc. 1845.6211), 1850.5700 
([M+Na]+, calc. 1850.5765), 914.8005 ([M+2H]2+, calc. 914.8012), 923.2163 ([M+H+NH4]
2+, 
calc. 923.3145), 934.2767 ([M+Na+NH4]
2+, calc. 934.3055).1H-NMR (600 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 6.33 (d, J=9.1, 1H, NH5), 6.10 (d, J=3.6, 1H, H11), 5.97 (s, 1H, NH6), 
5.83 (d, J=9.1, 1H, NH1), 5.51 - 5.42 (m, 2H, H22, H36), 5.31 - 5.12 (m, 3H, H34, H33, H31), 5.11 
- 5.06 (m, 1H, H35), 5.06 - 5.00 (m, 1H, H46), 4.99 - 4.93 (m, 1H, H45), 4.93 - 4.86 (m, 2H, H16, 
H42), 4.80 - 4.74 (m, 2H, H12, H43), 4.72 (dd, J=10.1, 3.0, 1H, H44), 4.61 - 4.55 (m, 2H, H14, 
H13), 4.52 (d, J=8.3, 1H, H15), 4.43 - 4.38 (m, 3H, H21, H24, H6a1), 4.33 - 4.10 (m, 7H, H25, 
H6a4, H6a6, H6b1, H6a3, H23, H6a5), 4.07 - 3.92 (m, 4H, H6b6, H6b4, H6b3, H6b5), 3.92 - 3.74 
(m, 5H, H26, H6a2, H41, H51, H32), 3.72 - 3.64 (m, 3H, H6b2, H52, H56), 3.59 - 3.53 (m, 3H, H54, 
H53, H55), 2.18 (s, 3H), 2.17 (s, 3H), 2.14 (s, 6H), 2.12 (s, 3H), 2.10 (s, 3H), 2.09 (s, 3H), 2.07 (s, 
3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 - 1.99 (m, 15H), 1.99 (s, 3H), 1.98 (s, 3H), 1.94 
(s, 3H), 1.89 (s, 3H). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.20, 171.16, 
171.08, 171.04, 170.94, 170.91, 170.83, 170.78, 170.43, 170.36, 170.28, 170.10, 169.66, 
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169.57, 169.49, 169.26, 168.88 (171.2 - 168.9 CO2CH3 ), 100.66 (C1
6), 100.18 (C14), 99.89 
(C15), 99.23 (C13), 98.53 (C12), 90.47 (C11), 78.58 (C32), 75.63 (C14), 73.83 (C35), 73.37 (C56), 
73.28 (C24), 72.89 (C53), 72.80 (C54), 72.23 (C44), 72.06 (C36), 71.95 (C31), 71.76 (C55), 71.66 
(C52), 71.47 (C43), 71.05 (C23), 70.61 (C51), 69.11 (C45), 68.90 (C46), 68.67 (C22), 68.23 (C62), 
66.84 (C42), 65.63 (C34), 65.31 (C33), 62.44, 62.38, 62.02 (62.4 - 62.0 C61, C63, C64, C65), 55.23 
(C26), 53.95 (C25), 50.85 (C21), 23.45, 23.29, 23.05 (23.3 - 23.1 NHAc), 21.29, 21.19, 21.14, 
21.08, 21.01, 20.98, 20.89, 20.84, 20.82, 20.80, 20.79, 20.74, 20.10 (21.3 - 20.1 OAc). 
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 7.16 Synthesis of complex type 2,6 branched octasaccharide 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-3,4-di-O-benzyl 
-α-D-mannopyranosyl-(1→3)-[3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl
-(1→2)-3,4-di-O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopy
ranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside (97)  
To a stirring solution of 90 (868 mg, 0.32 mmol) in 
anhydrous DCM (6.4 mL, 20 mL/mmol) and at 0 °C, a 
solution of 1 M BH3 in THF (3.17 mL, 10 mL/mmol) was 
slowly added over 30 min. Addition of TMSOTf (17.1 μL, 0. 
96 mmol, 0.3 eq) followed and the mixture was stirred at 
r.t. for 16 h. Neutralization with first Et3N (0.1 mL) was 
followed and then MeOH was added until no more hydrogen gas was formed. The organic 
solvent was evaporated under reduced pressure without heating, and the residue was 
dissolved in DCM (20 mL), washed with NaHCO3 (20 mL ×2), brine (20 mL ×2) and dried over 
MgSO4. Then concentrated and purified by column chromatography (cyclohexane-ethyl 
acetate 10:1 to 1:1) to give 97. Yield: 68% (595 g, 0.22 mmol). Rf = 0.2 (
CHex/EtOAc 2:1). 
*α+D
20 = -10° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 
1381.0651 ([M+H+NH4]
2+, calc. 1381.0605), 1389.5671 ([M+2NH4]
2+, calc. 1389.5738), 
1392.0249 ([M+Na+NH4]
2+, calc. 1392.0515). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 8.18 - 8.08 (m, 2H, benzoyl), 7.57 - 6.41 (m, 85H, aromatic), 5.34 (d, J=8.5, 
1H, H15), 5.24 (d, J=3.3, 1H, H22), 5.13 (d, J=12.0, 1H, BnCH2), 5.01 - 4.92 (m, 3H, BnCH2, H1
1, 
H16), 4.92 - 4.80 (m, 3H, BnCH2), 4.80 - 4.73 (m, 2H, BnCH2, H3
5), 4.68 (dd, J=11.6, 3.3, 2H, 
BnCH2), 4.64 - 4.45 (m, 9H, H1
2, BnCH2), 4.45 - 4.16 (m, 13H, H2
5, H24, H23, BnCH2, H1
3), 4.13 
(dd, J=10.2, 1.9, 2H, H26, BnCH2), 4.11 - 4.01 (m, 2H, H2
1, H6a1), 4.01 - 3.83 (m, 6H, BnCH2, 
H6b1, H36, H31, H41, H45), 3.83 - 3.71 (m, 3H, H55, H6a5, BnCH2), 3.71 - 3.57 (m, 4H, H6b
5, H52, 
H43, H14), 3.56 - 3.26 (m, 10H, H6a4, H6a3, H44, H51, H46, H32, H34, H6a2, H6b3, H33), 3.25 - 
3.09 (m, 5H, H6b4, H6a6, H6b6, H42, H54), 2.86 (d, J=10.1, 2H, H6b2, H53), 2.10 (d, J=6.7, 1H, 
H56). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 168.96 (Phth C=O), 168.04 (Phth 
C=O), 167.13, 166.32 (benzoyl C=O), 139.63, 139.37, 139.32, 139.23, 139.03, 138.85, 138.80, 
138.61, 138.40, 138.32, 138.26, 138.11, 137.36 (139.6 - 137.4 benzyl), 133.93 (Phth), 133.65 
(Phth), 133.37 (Phth), 132.21, 131.83, 131.68, 130.51, 129.50, 128.92, 128.87, 128.76, 
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128.71, 128.63, 128.59, 128.50, 128.42, 128.39, 128.37, 128.30, 128.23, 128.14, 127.94, 
127.92, 127.78, 127.73, 127.67, 127.64, 127.58, 127.55, 127.48, 127.28, 127.20 (129.5 - 
127.2 aromatic), 123.19, 102.08 (C14), 100.69 (C13), 99.58 (C15), 97.74 (C11), 97.46 (C16), 
97.26 (C12), 82.19 (C32), 80.51 (C33), 80.31 (C34), 79.48 (C45), 79.31 (C46), 78.98 (C35), 78.61 
(C36), 78.09 (C41), 76.76 (C31), 76.06 (C54), 75.45 (BnCH2), 75.38 (BnCH2), 75.34 (C4
2), 75.17 
(C53), 74.99 (C55), 74.63 (BnCH2), 74.49 (C4
3, BnCH2), 74.37 (BnCH2), 74.28 (BnCH2), 74.15 
(C44, C51), 74.07 (BnCH2), 73.77 (C5
6, C52), 73.68 (BnCH2), 73.58 (BnCH2), 72.56 (C2
3), 70.85 
(C62), 70.77 (BnCH2), 70.30 (C2
4), 69.93 (C22, BnCH2), 69.79 (C6
1), 69.68 (BnCH2), 68.91 (C6
6), 
68.37 (C65), 63.24 (C63), 62.92 (C64), 56.88 (C25), 56.57 (C26), 56.13 (C21). 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-ben 
zyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-di-O-benzyl-α-D-mannopyranosyl
-(1→3)-{3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-b
enzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→6)]-3,4-di-O-benzyl-α-D-mannopyrano
syl-(1→6)}-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranoside (98) 
Compounds 55 (485 mg, 0.72 mmol, 4.0 eq), 97 (495 
mg, 0.18 mmol, 1.0 eq), N-iodosuccinimide (162 mg, 
0.72 mmol, 4.0 eq) and 4 Å molecular sieves (0.5 g) in 
dry dichloromethane (10 mL) were stirred at room 
temperature for 30 min under argon atmosphere. 
Then the suspension was cooled to 0 °C followed by slow addition of 
trifluoromethanesulfonic acid (16.4 μL, 0.12 mmol, 0.25 eq). After stirring for 0.5 h at 0 °C, 
the reaction was quenched by dilution with more DCM (20 mL). The molecular sieves were 
removed by filtration and the filtrate was washed with 1 M Na2S2O3 (15 mL×3), brine (30 
mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(toluene-ethyl acetate 5% to 11%) to give 98. Yield: 74% (545 mg, 0.13 mmol). Rf = 0.4 
(CHex/EtOAc 2:1). *α+D
20 = -2° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1951.2720 ([M+2NH4]
2+, calc. 1951.2906), 1953.7541 ([M+Na+NH4]
2+, 
calc. 1953.7683), 1962.2458 ([M+Na+NH3+NH4]
2+, calc. 1962.2816). 1H-NMR (600 MHz, CDCl3, 
gCOSY, gHSQC, gHMBC), δ (ppm): 8.21 (d, J=7.9, 2H, benzoyl), 7.78 (d, J=6.4, 1H, Phth), 7.69 
(d, J=6.5, 1H, Phth), 7.65 - 6.82 (m, 110H, aromatic), 6.82 - 6.74 (m, 5H, aromatic), 6.71 (d, 
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 J=6.8, 2H, aromatic), 6.63 (t, J=7.3, 1H, aromatic), 6.41 (t, J=7.4, 2H, aromatic), 6.34 (d, J=7.3, 
3H, aromatic), 5.49 (d, J=8.5, 1H, H15), 5.24 - 5.20 (m, 2H, H16, BnCH2), 5.19 (d, J=3.2, 1H, 
H22), 5.10 - 5.05 (m, 2H, H17, BnCH2), 4.98 (d, J=8.4, 1H, H1
1), 4.97 - 4.90 (m, 5H, H18, H35, 
BnCH2), 4.88 (d, J=9.1, 1H, BnCH2), 4.86 - 4.77 (m, 6H, BnCH2), 4.74 - 4.65 (m, 6H, BnCH2), 
4.63 - 4.54 (m, 4H, BnCH2), 4.53 - 4.48 (m, 4H, BnCH2), 4.48 - 4.40 (m, 8H, H1
2, H36, BnCH2), 
4.40 - 4.36 (m, 3H, H25, BnCH2), 4.33 (d, J=12.2, 1H, BnCH2), 4.30 - 4.24 (m, 6H, H1
3, H38, H23, 
H24, H26, BnCH2), 4.24 - 4.16 (m, 3H, H2
8, H6a1, BnCH2), 4.15 - 4.06 (m, 5H, H4
5, H21, H6b1, 
BnCH2), 4.06 - 3.99 (m, 4H, H3
7, H41, H31, BnCH2), 3.96 (d, J=9.7, 1H, H5
5), 3.89 - 3.79 (m, 5H, 
H48, H46, H42, H6a4, H6a6), 3.79 - 3.72 (m, 3H, H6a3, H6b6, H6a5), 3.72 - 3.66 (m, 4H, H32, H14, 
H54, H6a8), 3.65 - 3.59 (m, 4H, H47, H6a2, H6b5, H6b8), 3.50 - 3.43 (m, 3H, H34, H56, H51), 3.42 
- 3.37 (m, 2H, H52, H58), 3.35 - 3.32 (m, 3H, H44, H6b4, H6b3), 3.25 (t, J=9.4, 1H, H43), 3.17 (dd, 
J=9.2, 2.4, 1H, H33), 3.14 (dd, J=10.5, 2.8, 1H, H6a7), 3.10 (d, J=10.2, 1H, H6b2), 3.02 (d, J=10.0, 
1H, H6b7), 2.99 - 2.96 (m, 1H, H53), 2.14 (d, J=9.3, 1H, H57). 13C-NMR (150.9 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 168.64, 168.34, 168.28, 167.96, 167.66, 167.40, 166.91, 166.66 
(168.6 - 166.7 Phth C=O), 166.08 (benzoyl C=O), 139.70, 139.43, 139.25, 139.19, 138.87, 
138.80, 138.78, 138.64, 138.47, 138.31, 138.24, 138.13, 138.07, 138.04, 138.00, 137.84, 
137.24, 136.78, 133.77, 133.54, 133.47, 133.43, 133.22 (133.8 - 133.2 Phth), 132.45, 131.89, 
131.84, 131.53, 131.48, 131.18, 130.22, 130.05, 129.80, 129.18, 129.04, 128.72, 128.64, 
128.48, 128.40, 128.35, 128.28, 128.24, 128.21, 128.15, 128.12, 128.10, 128.07, 128.05, 
128.00, 127.98, 127.95, 127.93, 127.88, 127.83, 127.76, 127.70, 127.64, 127.62, 127.56, 
127.51, 127.49, 127.39, 127.36, 127.30, 127.25, 127.17, 127.12, 126.95, 126.91, 126.88, 
126.83, 126.76, 126.62 (129.2 - 126.6 aromatic), 123.59, 123.46, 123.31, 123.16, 122.93, 
122.84, 102.21 (C14), 99.97 (C16), 99.46 (C15), 99.30 (C18), 99.18 (C13), 97.54 (C17), 97.24 
(C11), 96.63 (C12), 80.93 (C32), 80.76 (C33), 80.52 (C34), 79.52 (C46), 79.39 (C36), 79.37 (C38), 
79.16 (C48), 79.04 (C45), 78.74 (C47), 78.55 (C35), 78.49 (C37), 77.04 (C41), 76.90 (C54), 76.36 
(C53), 76.13 (C31), 75.12 (BnCH2), 75.07 (BnCH2), 74.96 (BnCH2), 74.89 (C5
6), 74.83 (C44), 
74.81 (C58), 74.72 (C52), 74.68 (C55), 74.60 (C43), 74.46 (C51), 74.21 (BnCH2), 74.11 (BnCH2), 
74.03 (BnCH2), 73.91 (BnCH2), 73.81 (C5
7), 73.71 (BnCH2), 73.68 (BnCH2), 73.51 (C4
2), 73.29 
(BnCH2), 73.24 (BnCH2), 73.18 (BnCH2), 72.45 (C6
2), 72.20 (C23), 72.14 (C61), 70.61 (C63), 
70.48 (BnCH2), 70.23 (C2
4, BnCH2), 69.75 (BnCH2), 69.62 (BnCH2), 69.59 (C6
1), 69.54 (C22), 
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68.58 (C66), 68.48 (C65), 68.33 (C67), 66.78 (C68), 56.21 (C25), 56.17 (C27), 55.90 (C28), 55.85 
(C21), 55.78 (C26).  
Benzyl 2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetami 
do-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→6)+-3,4-di-O-benzyl-α-D-mannopyran
osyl-(1→3)-{2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acet
amido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→6)+-3,4-di-O-benzyl-α-D-mannopy
ranosyl-(1→6)}-2-O-acetyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-3,6-di-O-
benzyl-2-deoxy-β-D-glucopyranoside (99) 
To a heated solution of 94 (515 mg, 133 μmol) in Tol / 
EtOH 1:1 (20 mL) at 80 °C, hydrazine monohydrate (4 
mL) was added. The reaction was kept at 80 °C for 10 
days, the solvent was then removed and 
coevaporated with toluene (20 mL×3). The residue 
was taken up in pyridine / acetic anhydride 2:1 (20 mL) and stirred at r.t. for 2 days. 
Evaporation and co-evaporation three times with toluene was followed. Purification by 
column chromatography (cyclohexane-ethyl acetate 5:1 to 1:3) gave 99. Yield: 72% (322 mg, 
96 μmol). Rf = 0.7 (Tol/EtOAc 1:1). MALDI-TOF-MS (Bruker autoflex II MALDI spectrometer): 
3388.168 ([M+Na]+, calc. 3387.512), 3404.361 ([M+K]+, calc. 3403.486). 1H-NMR (600 MHz, 
CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.48 – 7.15 (benzyl aromatics), 5.42 (H2
2), 5.04 (H16), 
5.02 (H18), 4.88 (H35), 4.85 (H11), 4.78 (H15), 4.75 (H12), 4.55 (H17), 4.52 (H13), 4.39 (H23), 
4.24 (H37), 4.21 (H27), 4.20 (H28), 5.06 – 4.15 (benzyl CH2), 4.07 (H1
4), 4.01 (H24), 3.98 (H41), 
3.91 (H42), 3.90 (H43), 3.75 (H44), 3.59 (H32), 3.55 (H63), 3.46 (H64), 3.97 – 3.66 (H6s), 3.29 
(H53), 3.11 (H26), 3.10 (H25), 2.95 (H54), 2.38, 2.17, 2.12, 2.07, 2.04, 1.79 (Acetyl CH3). 
13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 173.85, 172.51, 172.10, 170.54, 
169.67, 168.55 (acetyl C=O), 139.22, 138.72, 138.66, 138.54, 138.38, 138.22, 138.16, 138.12, 
138.10, 137.88, 137.81, 137.79, 137.75, 135.27, 134.05, 133.97, 133.49, 132.62, 131.87, 
129.04, 128.76, 128.57, 128.56, 128.51, 128.48, 128.45, 128.44, 128.40, 128.37, 128.34, 
128.25, 128.20, 128.14, 128.06, 128.04, 127.94, 127.90, 127.86, 127.83, 127.68, 127.66, 
127.61, 127.55, 127.48, 127.44, 127.39 (139.22 – 127.39 benzyl aromatics), 102.28 (C17), 
101.27 (C14), 101.08 (C15), 100.68 (C16), 100.54 (C18), 99.34 (C11), 98.87 (C12), 98.24 (C13), 
83.00, 80.59, 80.28 (C32), 79.81, 79.62 (C35), 79.26, 79.20, 78.60, 78.34 (C37), 77.92 (C41), 
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 76.53 (C4
2), 75.34 (C53), 75.21, 75.10, 75.01, 74.77, 74.67, 74.64, 74.47 (C54), 74.42, 74.26, 
74.10, 73.60, 73.53 (C24), 73.46, 73.41, 72.31 (C44), 72.24 (C43), 71.26 (C23), 70.98, 69.93, 
69.69, 69.51 (C63), 69.42 (C64), 69.12, 69.08, 68.60, 68.11 (C22), 67.17, 66.57, 59.57 (C25), 
59.19 (C26), 55.26 (C28), 55.65 (C27), 25.04, 24.06, 23.89, 23.11, 21.39, 20.83 (25.04- 20.83 
acetyl CH3). 
2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetamido-3,4,6-
tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→6)]-3,4-di-O-acetyl-α-D-mannopyranosyl-(1→3
)-{2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetamido-3,4,
6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→6)]-3,4-di-O-acetyl-α-D-mannopyranosyl-(1
→6)}-2,4-di-O-acetyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-1,3,6-di-O-acetyl-2-deoxy-
β-D-glucopyranose (100) 
Compound 99 (447 mg, 133 μmol) and 10% Pd(C) 
(300 mg) was suspended in MeOH / acetic acid 30:2 
(22.4 mL). The suspension was stirred under argon 
and flushed with H2 gas. The reaction was stirred 
under hydrogen atmosphere for 15 days and after 
completion flushed with argon again. The suspension was filtered through Celite and the 
filtrate concentrated and co-concentrated three times with toluene. The residue was 
dissolved in pyridine / acetic anhydride 2:1 (15 mL) and stirred at room temperature for 3 
days. The solvent was removed and co-evaporated three times with toluene, purified by 
column chromatography (cyclohexane-ethyl acetate 1:1 to MeOH-ethyl acetate 5%) to give 
100. Yield: 58% (186 mg, 77 μmol). Rf = 0.3 (EtOAc/MeOH/AcOH/H2O 60:3:3:2). *α+D
20 = -42° 
(c = 0.8, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1202.4050 
([M+2H]2+, calc. 1202.4034), 1210.9251 ([M+H+NH4]
2+, calc. 1210.9167), 1221.8867 
([M+Na+NH4]
2+, calc. 1221.9077). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
6.86 (s, 1H, NH7), 6.57 (d, J=5.3, 1H, NH8), 6.40 (d, J=8.1, 1H, NH6), 6.16 (d, J=3.1, 1H, H11), 
6.04 (t, J=9.8, 1H, H35), 5.66 (d, J=8.3, 1H, NH1), 5.44 - 5.34 (m, 4H, H15, H37, H38, H22), 5.31 
(t, J=9.9, 1H, H33), 5.22 (t, J=9.9, 1H, H34), 5.18 - 5.10 (m, 2H, H36, H31), 5.04 (t, J=9.5, 1H, 
H46), 4.99 - 4.89 (m, 3H, H12, H48, H47), 4.86 (t, J=9.5, 1H, H45), 4.79 (dd, J=10.3, 2.7, 1H, H44), 
4.73 - 4.66 (m, 4H, H17, H43, H42, H6a1), 4.55 (s, 1H, H13), 4.49 - 4.46 (m, 4H, H18, H14, H6a6, 
H6a7), 4.36 (d, J=2.6, 1H, H23), 4.34 - 4.30 (m, 3H, H6b6, H6b7, H21), 4.29 - 4.20 (m, 5H, H24, 
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H6a5, H6b1, H6a8, H26), 4.19 - 4.11 (m, 3H, H16, H6a3, H6a4), 4.10 - 4.04 (m, 2H, H41, H6b8), 
3.98 - 3.91 (m, 3H, H52, H32, H6b5), 3.89 - 3.79 (m, 3H, H51, H56, H6a2), 3.79 - 3.74 (m, 1H, 
H27), 3.73 - 3.63 (m, 3H, H56, H58, H28), 3.60 - 3.56 (m, 1H, H57), 3.53 - 3.45 (m, 2H, H54, 
H6b2), 3.39 (d, J=9.5, 1H, H53), 3.27 (d, J=11.0, 1H, H6b4), 3.19 (d, J=11.3, 1H, H6b3), 3.07 (d, 
J=6.0, 1H, H25), 2.20 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H), 2.14 (s, 3H), 2.13 (s, 3H), 2.10 (s, 3H), 
2.10 (s, 3H), 2.08 (s, 3H), 2.07 (s, 6H), 2.06 - 2.03 (m, 15H), 2.00 (t, J=8.1, 24H), 1.94 (s, 6H), 
1.85 (s, 3H) (2.20 - 1.85 Ac). 13C-NMR (150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.94, 
171.70, 171.57, 171.20, 170.84, 170.75, 170.68, 170.54, 170.48, 170.45, 170.36, 170.18, 
170.03, 170.00, 169.68, 169.59, 169.57, 169.38, 168.78 (171.94 - 168.78 C=O), 103.03 (C16), 
101.24 (C18), 99.54 (C14), 99.34 (C17), 99.21 (C13), 98.45 (C15), 97.75 (C12), 90.19 (C11), 77.88 
(C32), 75.04 (C41), 72.91 (C54), 72.74 (C53), 72.55 (C38, C37), 72.51 (C52), 72.23 (C36), 72.17 
(C58), 72.02 (C43), 71.73 (C57), 71.71 (C44), 71.62 (C56), 71.35 (C31), 71.28 (C23), 71.13 (C55), 
71.07 (C51), 70.90 (C24), 70.72 (C35), 70.08 (C45), 69.33 (C47), 69.17 (C48), 68.99 (C22), 68.74 
(C46), 68.36 (C62), 68.08 (C42), 67.77 (C63), 67.07 (C64), 65.39 (C33), 65.27 (C34), 63.05 (C65), 
62.37 (C61), 62.15 (C66), 62.12 (C67), 62.02 (C68), 56.91 (C25), 55.01 (C27), 54.82 (C28), 53.56 
(C26), 51.29 (C21), 23.48, 23.41, 23.16, 22.81, 22.68, 21.49, 21.16, 21.05, 21.02, 20.95, 20.91, 
20.89, 20.85, 20.73, 20.69, 20.63, 20.59, 20.52 (23.48 - 20.52 CH3).  
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 7.17 Synthesis of a 2,4-OAc-3,6-OBn mannosyl donor building block 
Allyl 2,4-di-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranoside (101)[283] 
Compound 30 (4.69 g, 11.7 mmol) was dissolved in pyridine / acetic 
anhydride 2:1 (45 mL) and stirred at r.t. for 24 h. Then concentrated, coevaporated with 
toluene (50 ml×3) and purified by column chromatography (cyclohexane-ethyl acetate 10:1 
to 2:1) to give 101 in 99% yield (5.65 g, 11.7 mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = +12° (c 
= 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 485.3472 
([M+H]+, calc. 485.2175), 502.2441 ([M+NH4]
+, calc. 502.2435), 507.1988 ([M+Na]+, calc. 
507.1995). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.36 - 7.23 (m, 10H, 
aromatic), 5.90 (dddd, J=21.8, 10.4, 6.1, 5.2, 1H, CH2CH=CH2), 5.37 (dd, J=3.3, 1.8, 1H, H2), 
5.32 - 5.18 (m, 3H, CH2CH=CH2, H4), 4.89 (d, J=1.6, 1H, H1), 4.65 (d, J=12.1, 1H, 3-BnCH2), 
4.58 - 4.50 (m, 2H, 6-BnCH2), 4.42 (d, J=12.1, 1H, 3-BnCH2), 4.19 (ddt, J=12.9, 5.2, 1.4, 1H, 
CH2CH=CH2), 4.01 (ddt, J=12.9, 6.2, 1.3, 1H, CH2CH=CH2), 3.92 - 3.84 (m, 2H, H3, H5), 3.61 - 
3.52 (m, 2H, H6a, H6b), 2.13 (s, 3H, Ac), 1.91 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.63 (CO2CH3), 170.00 (CO2CH3), 138.21, 138.11, 133.54 (CH2CH=CH2), 
128.53, 128.50, 127.95, 127.91, 127.80 (128.5 - 127.8 aromatic), 118.10 (CH2CH=CH2), 97.02 
(C1), 74.97 (C3), 73.73 (6-BnCH2), 71.56 (3-BnCH2), 70.25 (C5), 69.69 (C6), 68.59 (C2), 68.52 
(C4, CH2CH=CH2), 21.26 (CO2CH3), 21.08 (CO2CH3). 
2,4-di-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranose (102)[283] 
Compound 101 (4.82 g, 9.95 mmol, 1.0 eq) was dissolved in Tol/EtOAc/H2O 
20:10:1 (62 mL) and Wilkinson’s catalyst (920 mg, 0.99 mmol, 0.1 eq) was added. After 
refluxing for 24 h, the reaction mixture was cooled to r.t., filtered through a layer of Celite 
and concentrated. The residue was dissolved in THF/H2O 4:1 (50 mL) followed by addition of 
I2 (10.2 g, 39.8 mmol, 4.0 eq). The reaction was kept stirring at r.t. for 2 h and neutralized 
with 1 M Na2S2O3. The suspension was concentrated to removed most of the THF and then 
diluted with DCM (100 mL), washed with 1 M Na2S2O3 (50 mL×2), H2O (50 mL×2), brine (50 
mL×1), dried over MgSO4, the solvent was removed and the crude product was purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) to give 102, yield 68% (3.02 
g, 6.79 mmol). Rf = 0.3 (
CHex/EtOAc 2:1). *α+D
20 = -13° (c = 1.0, CHCl3). HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 462.2124 ([M+NH4]
+, calc. 462.2128), 
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467.1676 ([M+Na]+, calc. 467.1682). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.37 - 7.21 (m, 10H, aromatic), 5.32 (dd, J=3.2, 1.9, 1H, H2), 5.17 (d, J=1.6, 1H, H1), 
5.10 (t, J=9.9, 1H, H4), 4.64 (d, J=12.2, 1H, 3-BnCH2), 4.50 (s, 2H, 6-BnCH2), 4.40 (d, J=12.2, 1H, 
3-BnCH2), 4.09 (ddd, J=10.0, 7.2, 2.5, 1H, H5), 3.90 (dd, J=9.7, 3.3, 1H, H3), 3.56 (dd, J=10.5, 
7.2, 1H, H6a), 3.45 (dd, J=10.5, 2.6, 1H, H6b), 2.12 (s, 3H, Ac), 1.91 (s, 3H, Ac). 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.71 (CO2CH3), 170.20 (CO2CH3), 138.08, 
137.67, 128.61, 128.58, 128.55, 128.34, 128.31, 128.03, 127.96, 127.94 (128.6 - 127.9 
aromatic), 92.52 (C1), 74.35 (C3), 73.73 (6-BnCH2), 71.53 (3-BnCH2), 69.87 (C6), 69.82 (C5), 
68.97 (C2), 68.54 (C4), 21.29 (CO2CH3), 21.07 (CO2CH3). 
2,4-di-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranosyl trichloroacetimidate (103)[300] 
A solution of 102 (3.0 g, 6.75 mmol, 1.0 eq) and trichloroacetonitrile 
(1.35 mL, 13.5 mmol, 2.0 eq) in anhydrous DCM (30 mL) was stirred 
under Ar at 0 °C, DBU (0.20 mL, 1.35 mmol, 0.2 eq) was added. After 
stirring at 0 °C for 3 h, the reaction mixture was concentrated and purified by column 
chromatography (cyclohexane-ethyl acetate 5:1 to 1:1) to give 103, yield 79% (3.16 g, 5.37 
mmol). Rf = 0.5 (
CHex/EtOAc 2:1). *α+D
20 = +25° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo 
LTQ-Orbitrap mass spectrometer), m/z: 605.4454 ([M+NH4]
+, calc. 605.1224), 610.1842 
([M+Na]+, calc. 610.0778). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.73 (s, 
1H, NH), 7.38 - 7.21 (m, 10H, aromatic), 6.30 (d, J=1.5, 1H, H1), 5.52 - 5.48 (m, 1H, H2), 5.38 
(t, J=10.0, 1H, H4), 4.67 (d, J=12.2, 1H, 3-BnCH2), 4.59 - 4.43 (m, 3H, 3-BnCH2, 6-BnCH2), 4.04 
(dt, J=8.5, 4.0, 1H, H5), 3.93 (dd, J=9.8, 3.3, 1H, H3), 3.58 (d, J=4.0, 2H, H6a, H6b), 2.17 (s, 3H, 
Ac), 1.94 (s, 3H, Ac). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.26 (CO2CH3), 
169.85 (CO2CH3), 159.92 (C=NH), 138.07, 137.51, 128.64, 128.51, 128.32, 128.19, 128.13, 
128.06, 127.84 (128.6 - 127.8 aromatic), 95.25 (C1), 73.99 (C3), 73.70 (6-BnCH2), 73.03 (C5), 
71.75 (3-BnCH2), 69.27 (C6), 67.77 (C4), 66.98 (C2), 21.15 (CO2CH3), 21.07 (CO2CH3). 
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 7.18 Synthesis of a complex type 2,4 branched octasaccharide 
Benzyl 2,4-di-O-acetyl-3,6-di-O-benzyl-α-D-mannopyranosyl-(1→3)-[2,4-di-O-acetyl-3,6-di- 
O-benzyl-α-D-mannopyranosyl-(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)
-3,6-di-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranoside(104)  
The trichloroacetimidate donor 103 (2.49 mg, 4.23 mmol, 3.0 
eq) and acceptor 26 (1.33 g, 1.42 mmol, 1.0 eq) was dissolved in 
dry DCM (30 mL) and 4 Å molecular sieves (3 g) was added. The 
suspension was stirred under argon at r.t. for 30 min and cooled 
to 0 °C, trimethylsilyl trifluoromethanesulfonate (TMSOTf) (77.3 μL, 0.43 mmol, 0.3 eq) was 
added. The reaction was kept stirring at 0 °C for 2 h, then quenched with triethylamine (0.1 
mL). The molecular sieves were removed by filtering over a layer of Celite. The filtrate was 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) 
to give 104. Yield 91% (2.32 g, 1.30 mmol). Rf = 0.2 (
CHex /EtOAc 2:1). *α+D
20 = +9° (c = 1.0, 
CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1789.6967 ([M+H]
+, 
calc. 1789.6986), 1806.7173 ([M+NH4]
+, calc. 1806.7251), 906.3388 ([M+Na+H]2+, calc. 
906.3442), 914.8286 ([M+Na+NH4]
2+, calc. 914.8575). 1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 8.23 - 8.14 (m, 2H, benzoyl), 7.63 (s, 2H, Phth), 7.57 - 6.98 (m, 35H, 
aromatic), 6.70 - 6.51 (m, 5H, aromatic), 5.69 (d, J=2.9, 1H, H22), 5.48 (dd, J=3.0, 1.8, 1H, H24), 
5.38 (dd, J=2.7, 1.4, 1H, H23), 5.32 (dd, J=10.0, 4.7, 1H, H44), 5.29 (dd, J=9.9, 4.7, 1H, H43), 
5.21 (s, 1H, H13), 5.01 (d, J=8.5, 1H, H11), 5.00 (d, J=1.4, 1H, H14), 4.80 (d, J=11.5, 1H, H12), 
4.77 - 4.62 (m, 4H, BnCH2), 4.61 - 4.50 (m, 5H, BnCH2), 4.49 - 4.38 (m, 3H, BnCH2), 4.38 - 4.27 
(m, 4H, H53, BnCH2), 4.18 - 4.11 (m, 2H, H2
1), 4.05 (dd, J=10.3, 8.5, 1H, H41), 3.95 - 3.77 (m, 
7H, H42, H32, H34, H33, H54, H6a2, H6b2), 3.73 - 3.68 (m, 2H, H6a4, H6b4), 3.68 - 3.62 (m, 2H, 
H6a3, H6b3), 3.55 (dd, J=11.0, 4.7, 1H, H6a1), 3.49 - 3.41 (m, 2H, H6b1, H51), 3.22 (dd, J=9.1, 
3.2, 1H, H52), 2.09 (s, 3H, Ac), 1.98 (s, 3H, Ac), 1.95 (s, 3H, Ac), 1.88 (s, 3H, Ac). 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.31, 170.20, 170.15, 170.12 (CO2CH3), 
167.61 (Phth C=O), 165.89 (benzoyl C=O), 138.51, 138.43, 138.35, 138.27, 137.98, 137.91, 
137.83, 137.38 (138.5 - 137.4 benzyl), 133.62 (Phth), 130.12 (benzoyl), 129.26, 129.01, 
128.87, 128.63, 128.50, 128.44, 128.42, 128.38, 128.30, 128.13, 128.05, 128.00, 127.98, 
127.88, 127.84, 127.76, 127.72, 127.68, 127.63, 127.05 (129.3 - 127.1 aromatic), 123.23, 
99.48 (C13), 98.63 (C12), 98.41 (C14), 97.53 (C11), 78.62 (C41), 77.39 (C32), 76.32 (C31), 75.57 
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(C42), 75.21 (C33, BnCH2), 74.88 (C5
2), 74.72 (C51), 74.66 (C34), 74.57 (BnCH2), 73.78 (BnCH2), 
73.68 (BnCH2), 73.62 (BnCH2), 72.04 (BnCH2), 71.14 (C2
2), 70.93 (C53), 70.64 (BnCH2), 69.57 
(C54), 69.40 (C63), 68.86 (C61), 68.63 (C23), 68.54 (C62), 68.05 (C43, C44), 67.88 (C24), 66.28 
(C62), 55.90 (C21), 21.18 (CO2CH3), 21.15 (CO2CH3), 20.90 (CO2CH3). 
Benzyl 3,6-di-O-benzyl-α-D-mannopyranosyl-(1→3)-[3,6-di-O-benzyl-α-D-mannopyranosyl- 
(1→6)]-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-pht
halimido-β-D-glucopyranoside (105) 
To a solution of 104 (2.15 g, 1.20 mmol) in MeOH / DCM 5:1 (60 
mL), NaOMe (100 mg) was added to reach pH 9.5. The reaction 
was kept at r.t. for 12 days and quenched with Dowex 50WX8 ion-exchanger (1 g, prewashed 
with MeOH), concentrated and coevaporated with toluene (50 mL×3). Then purified by 
column chromatography (cyclohexane-ethyl acetate 10:1 to 1:2) and recrystallized from 
cyclohexane - EtOAc to give 105, yield 75% (1.46 g, 0.90 mmol). Rf = 0.6 (Tol/EtOAc 1:1). 
*α+D
20 = +17° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 
1621.6588 ([M+H]+, calc. 1621.6563), 1638.6880 ([M+NH4]
+, calc. 1638.6829), 1643.6425 
([M+Na]+, calc. 1643.6383), 828.3586 ([M+2NH4]
2+, calc. 828.3586), 830.3058 ([M+Na+NH4]
2+, 
calc. 830.3347). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.11 (d, J=7.3, 
2H, benzoyl), 7.60 (s, 2H, Phth), 7.46 - 7.16 (m, 36H, aromatic), 7.09 - 6.96 (m, 5H, aromatic), 
6.61 (dq, J=8.1, 4.0, 1H, aromatic), 6.47 (d, J=4.4, 4H, aromatic), 5.65 (d, J=2.9, 1H, H22), 5.17 
(s, 1H, H13), 5.06 (s, 1H, H14), 5.01 (d, J=8.5, 1H, H11), 4.78 (s, 1H, H12), 4.75 - 4.66 (m, 5H, 
BnCH2), 4.65 - 4.53 (m, 5H, BnCH2), 4.52 - 4.47 (m, 3H, BnCH2), 4.43 (dd, J=12.2, 6.7, 2H, 
BnCH2), 4.28 (d, J=13.1, 1H, BnCH2), 4.20 - 4.11 (m, 3H, H4
1, H21), 4.09 - 4.03 (m, 2H, H54, 
H32), 4.03 - 3.99 (m, 1H, H31), 3.98 - 3.88 (m, 4H, H6a2, H43, H44, H34), 3.85 - 3.65 (m, 12H, 
H6b2, H53, H6a1, H6b1, H6a3, H6b3, H6a4, H6b4, H32, H42, H34), 3.51 (dd, J=9.1, 3.2, 1H, H33), 
3.46 (d, J=10.0, 1H, H51), 3.39 - 3.33 (m, 1H, H52). 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 167.75 (Phth C=O), 165.70 (benzoyl C=O), 138.48, 138.45, 138.36, 138.18, 
138.06, 137.78, 137.42 (138.5 - 137.4 benzyl), 133.56 (Phth), 133.44, 131.83, 130.15 
(benzoyl), 130.13 (benzoyl), 128.90, 128.83, 128.78, 128.70, 128.68, 128.61, 128.49, 128.42, 
128.30, 128.26, 128.18, 128.17, 128.11, 128.07, 128.06, 127.91, 127.90, 127.87, 127.78, 
127.76, 127.68, 127.66, 127.04 (128.9 - 127.0 aromatic), 123.31, 101.78 (C13), 99.42 (C14), 
98.39 (C12), 97.47 (C11), 79.84 (C34), 79.37 (C33), 78.98 (C32), 78.31 (C41), 76.21 (C31), 76.13 
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 (C4
2), 75.48 (BnCH2), 74.78 (C5
2), 74.68 (C51), 74.46 (BnCH2), 73.80 (BnCH2), 73.77 (BnCH2), 
72.65 (BnCH2), 72.55 (BnCH2), 72.17 (C2
2), 71.66 (C33), 71.57 (C34), 70.79 (C63, BnCH2), 70.64 
(C64), 68.65 (C53), 68.50 (C54, C61), 68.31 (C43, C44), 66.01 (C62), 55.90 (C21). 
Benzyl 3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-ben 
zyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)]-3,4-di-O-benzyl-α-D-mannopyranosyl
-(1→3)-{3,4,6-tri-O-benzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→2)-[3,4,6-tri-O-b
enzyl-2-deoxy-2-phthalimido-β-D-glucopyranosyl-(1→4)]-3,4-di-O-benzyl-α-D-mannopyrano
syl-(1→6)}-2-O-benzoyl-4-O-benzyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-2-
phthalimido-β-D-glucopyranoside (106)  
Compounds 55 (2.92 g, 4.35 mmol, 6.0 eq), 105 (1.18 
g, 0.73 mmol, 1.0 eq), N-iodosuccinimide (1.31 g, 5.83 
mmol, 8.0 eq) and 4 Å molecular sieves (1.5 g) in dry 
dichloromethane (15 mL) were stirred at room 
temperature for 30 min under argon atmosphere. 
Then the suspension was cooled to 0 °C followed by slow addition of 
trifluoromethanesulfonic acid (49.8 μL, 0.36 mmol, 0.5 eq). After stirring for 0.5 h at 0 °C, the 
reaction was quenched by diluting with more DCM (50 mL). The molecular sieves were 
removed by filtration and the filtrate was washed with 1 M Na2S2O3 (30 mL×3), brine (50 
mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(toluene-ethyl acetate 5% to 11%) to give 106. Yield: 58% (1.62 g, 0.42 mmol). Rf = 0.3 
(Tol/EtOAc 6:1). *α+D
20 = +10° (c = 1.0, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1942.7640 ([M+H+NH4]
2+, calc. 1942.7773), 1951.2735 ([M+2NH4]
2+, calc. 
1951.2906). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.16 (d, J=7.3, 2H, 
benzoyl), 7.77 (d, J=7.0, 2H, Phth), 7.68 - 6.85 (m, 114H, aromatic), 6.68 (d, J=6.8, 3H, 
aromatic), 6.58 - 6.44 (m, 5H, aromatic), 5.38 (d, J=8.4, 1H, H16), 5.32 (d, J=8.3, 1H, H18), 5.15 
(s, 1H, H22), 4.94 (d, J=8.5, 1H, H11), 4.89 - 4.82 (m, 3H, H14, H17, BnCH2), 4.82 - 4.77 (m, 3H, 
H15, BnCH2), 4.77 - 4.64 (m, 10H, BnCH2), 4.59 - 4.52 (m, 4H, BnCH2), 4.52 - 4.45 (m, 5H, H1
3, 
BnCH2), 4.45 - 4.38 (m, 5H, BnCH2), 4.38 - 4.31 (m, 4H, H3
8, BnCH2), 4.28 - 4.22 (m, 7H, H3
6, 
H28, H12, BnCH2), 4.21 - 4.13 (m, 3H, H2
6, H27, BnCH2), 4.13 - 4.11 (m, 2H, H2
5, BnCH2), 4.11 - 
4.05 (m, 2H, H37, H21), 3.99 (d, J=12.2, 2H, BnCH2), 3.92 - 3.84 (m, 6H, H3
5, H31, H41, H48, 
BnCH2), 3.82 - 3.70 (m, 7H, H4
6, H42, H33, H34, H23, H24, BnCH2), 3.69 (s, 2H, H6a
1, H6b1), 
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3.63 - 3.54 (m, 5H, H47, H45, H32, H44, H43), 3.54 - 3.44 (m, 3H, H58, H53, H6a3), 3.42 - 3.29 (m, 
5H, H6a8, H6b8, H6a7, H6b7, H6b3), 3.28 - 3.20 (m, 5H, H51, H54, H6a2, H6a5, H6a4), 3.15 - 3.06 
(m, 2H, H56, H6b5), 3.00 (d, J=10.5, 1H, H6b4), 2.80 (d, J=11.4, 1H, H6a6), 2.78 - 2.70 (m, 2H, 
H6b2, H6b6), 2.70 - 2.66 (m, 1H, H52), 2.33 (s, 1H, H55), 2.16 (d, J=6.6, 1H, H57). 13C-NMR 
(150.9 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 168.26, 167.98, 167.82, 167.51, 167.18 (168.3 - 
167.2 Phth C=O), 164.74 (BzC=O), 139.23, 138.88, 138.84, 138.73, 138.71, 138.64, 138.53, 
138.41, 138.37, 138.35, 138.25, 138.21, 138.18, 138.08, 138.03, 137.95, 137.91, 137.18 
(139.2 - 137.2 aromatics), 133.37, 133.26, 133.08, 132.08 (133.4 - 132.1 Phth), 131.93, 
131.75, 131.62, 131.48, 131.38, 130.44, 130.32, 130.19 (Benzoyl), 129.80, 129.09, 129.06, 
129.02, 128.95, 128.87, 128.73, 128.59, 128.41, 128.36, 128.35, 128.30, 128.28, 128.27, 
128.24, 128.20, 128.16, 128.11, 128.03, 128.01, 127.99, 127.94, 127.91, 127.87, 127.83, 
127.82, 127.79, 127.77, 127.72, 127.67, 127.65, 127.61, 127.53, 127.47, 127.42, 127.40, 
127.36, 127.33, 127.31, 127.27, 127.22, 127.13, 126.94, 126.88, 126.79, 126.73, 126.07, 
125.96, 125.35 (129.8 - 125.4 aromatics), 123.24, 123.07, 122.88 (123.2 - 122.9 Phth), 99.47 
(C16), 98.60 (C14, C12), 98.06 (C13), 97.91 (C18), 97.39 (C15), 97.02 (C11), 95.69 (C17), 79.61 
(C48), 79.36 (C46), 79.16 (C38), 79.09 (C36, C47, C32), 78.93 (C47), 78.77 (C37), 78.68 (C35), 
77.33 (C42), 74.99 (C31), 74.77 (C58, C53, BnCH2), 74.69 (C3
3, C56, BnCH2), 74.53 (BnCH2), 
74.41 (C55, BnCH2), 74.32 (BnCH2), 74.23 (C5
7), 74.14 (C51), 73.95 (C43), 73.83 (C44), 73.58 
(C34), 73.40 (BnCH2), 73.34 (BnCH2), 73.19 (BnCH2), 73.14 (BnCH2), 73.11 (BnCH2), 73.00 
(BnCH2), 72.91 (C5
2), 72.82 (BnCH2), 72.70 (BnCH2), 72.26 (BnCH2), 71.82 (C2
2, C68), 71.72 
(C23), 71.57 (C24), 71.40 (C41), 71.19 (C54), 70.72 (BnCH2), 70.64 (BnCH2), 70.19 (C6
2), 69.64 
(BnCH2), 68.55 (C6
5), 68.13 (C61), 67.93 (C67), 67.65 (C66), 67.13 (C64), 66.69 (C63), 56.95 
(C26), 56.67 (C28), 55.60 (C21), 55.50 (C27, C25). 
Benzyl 2-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetami 
do-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucopyranosyl-(1
→4)]-3,4-di-O-benzyl-α-D-mannopyranosyl-(1→3)-{2
-N-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-glucop
yranosyl-(1→2)-[2-N-acetamido-3,4,6-tri-O-benzyl-2
-deoxy-β-D-glucopyranosyl-(1→4)]-3,4-di-O-benzyl-α
-D-mannopyranosyl-(1→6)}-2-O-acetyl-4-O-benzyl-β-
D-mannopyranosyl-(1→4)-2-N-acetamido-3,6-di-O-b
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 enzyl-2-deoxy-β-D-glucopyranoside (107)  
To a heated solution of 106 (1.54 g, 398 μmol) in Tol / EtOH 1:1 (40 mL) at 80 °C, hydrazine 
monohydrate (8 mL) was added. The reaction was kept at 80 °C for 4 days, the solvent was 
removed and coevaporated with toluene (40 mL×3). The residue was taken up in pyridine / 
acetic anhydride 2:1 (30 mL) and stirred at r.t. for 2 days. Evaporation and co-evaporation 
three times with toluene was followed. Purification by column chromatography 
(cyclohexane-ethyl acetate 5:1 to 1:3) gave 107. Yield: 97% (1.31 g, 388 μmol). Rf = 0.4 
(Tol/EtOAc 1:1). *α+D
20 = +17° (c = 1.2, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1683.2711 ([M+2H]2+, calc. 1683.2689), 1691.7825 ([M+H+NH4]
2+, calc. 
1691.7822), 1122.1886 ([M+3H]3+, calc. 1122.1808), 1128.2035 ([M+2H+NH4]
3+, calc. 
1128.1907). 1H-NMR (600 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.45 -7.07 (benzyl 
aromatics), 5.37 (H22), 5.04 (H11), 4.97 (H13), 4.87, 4.81 (H14), 4.72, 4.69, 4.67, 4.60 (4.87 – 
4.60, H1s), 4.35 (H3), 4.31 (H2-NHAc), 4.23 (H3), 4.92 – 4.22 (benzyl CH2), 3.86 (H2-NHAc), 
3.82 (C32), 3.72 (H2-NHAc), 3.53 (H2-NHAc), 3.77- 3.35 (H6s), 3.17 (H2-NHAc), 2.94 (H6b2), 
1.95, 1.91, 1.79, 1.77, 1.62, 1.61 (1.95 – 1.61 acetyl CH3). 
13C-NMR (150.9 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 171.72, 171.43, 170.73, 170.54, 169.95 (171.72 – 169.95 acetyl C=O), 
139.31, 139.03, 138.68, 138.63, 138.49, 138.44, 138.39, 138.29, 138.24, 138.13, 138.08, 
138.02, 137.92, 137.82, 128.80, 128.73, 128.69, 128.60, 128.55, 128.52, 128.46, 128.44, 
128.40, 128.36, 128.34, 128.26, 128.19, 128.17, 128.15, 128.10, 128.00, 127.90, 127.88, 
127.84, 127.83, 127.81, 127.71, 127.63, 127.60, 127.57, 127.45, 127.42, 127.40, 127.38, 
127.33, 127.23, 127.09 (139.31 – 127.09 benzyl aromatics), 101.09, 100.30, 99.91 (C13), 
99.71 (C11), 97.52, 97.40, 97.38 (101.09 – 97.38 H1s), 97.28 (C14), 82.35, 82.14, 80.08 (C3), 
79.85 (C32), 78.82 (C3), 78.63, 78.37, 78.15, 76.41, 75.14, 74.96, 74.85, 74.79, 74.72, 74.66, 
74.55, 74.38, 74.21, 74.10, 73.51, 73.39, 73.36, 73.32, 73.28, 73.17, 72.95, 72.03, 71.84, 
71.58, 71.28 (C22), 71.01, 70.62, 69.37 (C62), 69.20, 69.03, 68.88, 67.16 (70.62 – 67.16 C6s), 
57.46, 57.03, 56.29, 55.75, 53.82 (57.46 – 53.82 C2-NHAc), 23.51, 23.45, 23.27, 23.19, 20.96, 
20.83 (23.51 – 20.86 acetyl CH3). 
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2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetamido-3,4,6-
tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→4)]-3,4-di-O-acetyl-α-D-mannopyranosyl-(1→3
)-{2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-[2-N-acetamido-3,4,
6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→4)]-3,4-di-O-acetyl-α-D-mannopyranosyl-(1
→6)}-2,4-di-O-acetyl-β-D-mannopyranosyl-(1→4)-2-N-acetamido-1,3,6-tri-O-acetyl-2-deoxy
-α/β-D-glucopyranose (108)  
Compound 107 (1.23 g, 364 μmol) and 10% Pd(C) (700 
mg) was suspended in MeOH / acetic acid 30:2 (44.8 
mL). The suspension was stirred under argon and 
flushed with H2 gas. The reaction was stirred under 
hydrogen atmosphere for 12 days and after 
completion flushed with argon again. The suspension was filtered through Celite and the 
filtrate concentrated and co-concentrated three times with toluene. The residue was 
dissolved in pyridine / acetic anhydride 2:1 (30 mL) and stirred at room temperature for 3 
days. The solvent was removed and co-evaporated three times with toluene, purified by 
column chromatography (cyclohexane-ethyl acetate 1:1 to MeOH-ethyl acetate 5%) to give a 
α/β (2:1) mixture of 108. Yield: 55% (480 mg, 200 μmol). Rf = 0.3 (EtOAc/MeOH/AcOH/H2O 
60:3:3:2). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1202.4022 
([M+2H]2+, calc. 1202.4034), 1210.9191 ([M+H+NH4]
2+, calc. 1210.9167), 1213.3974 
([M+H+Na]2+, calc. 1213.3944), 801.6074 ([M+3H]3+, calc. 801.6037), 807.6151 
([M+2H+NH4]
3+, calc. 807.6137), 809.2631 ([M+2H+Na]3+, calc. 809.2670), 601.4722 
([M+4H]4+, calc. 601.4548), 605.6893 ([M+3H+NH4]
4+, calc. 605.7114). 1H-NMR (600 MHz, 
DMSO -d3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.11 – 7.76 (NHs), 5.86 (d, J=3.2, H1
1α), 5.74 (d, 
J=8.6, 1H, H11β), 5.31 (d, J=6.4, H22), 5.20 (H31β), 5.08 (H31α), 4.97 (H42), 4.96 (H13), 4.88 
(H12), 4.84 (H14), 4.80, 4.76, 4.66, 4.43 (4.80 – 4.43 H1s from terminal GlcNAc), 5.18 – 4.64 
(H33, H34 and H3s, H4s from terminal GlcNAc), 4.13 (H21α), 4.07 (H32), 3.91 (H51α), 4.40 – 
3.83 (H6s), 3.82 (H41), 3.79 (H51β), 3.76 (H6a2), 3.70 (H21β), 3.87 – 3.63 (H2s from terminal 
GlcNAc) 3.58 (H52), 3.92 – 3.57 (H23, H43, H24, H44, H53, H54 and H5s from terminal GlcNAc), 
3.48 (H6b2), 2.16 – 1.68 (acetyl CH3). 
13C-NMR (150.9 MHz, DMSO -d3, gHSQC, gHMBC), δ 
(ppm): 170.75, 170.66, 170.63, 170.56, 170.48, 170.27, 170.11, 170.02, 169.91, 169.85, 
169.81, 169.73 (170.75 – 169.73 ), 100.87, 100.73, 100.56, 100.47 (100.87 – 100.47 H1s from 
terminal GlcNAc), 99.61 (C13), 97.90 (C14), 97.72 (C12), 92.02 (C11β), 90.07 (C11α), 77.56 
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 (C3
2α/β), 77.42 (C32α/β), 74.56, 74.45, 74.29, 74.20, 73.76 (C41), 73.14, 72.81 (C31α), 72.73, 
72.55, 72.39 (C31β), 72.12, 71.88, 71.60 (C52), 71.40 (C51β), 71.33, 71.09, 70.82 (C51α), 70.73, 
70.45 (C42), 70.46 (C22), 70.19, 69.24 (C62), 69.06, 69.02, 68.96, 68.88, 68.82, 68.55, 68.40, 
62.86, 62.59, 62.54, 62.40, 61.94 (62.86 – 61.94 C6s), 54.02, 53.80 (C21β), 53.03, 52.88, 
52.70 (54.02 – 52.70 C2s from terminal GlcNAc), 50.35 (C21α), 23.16, 23.03, 22.97, 22.92, 
22.71, 21.36, 21.21, 21.16, 21.13, 21.06, 21.00, 20.95, 20.89, 20.86, 20.82, 20.80, 20.77, 
20.67 (23.16 – 20.67 acetyl CH3). 
 
  
217 
 
EXPERIMENTAL PART 
7.19 Synthesis of oxazoline donor 
2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl-(1→3)-[2,3,4,6-tetra-O-acetyl-α-D-mannopyran
osyl-(1→6)+-2,4-di-O-acetyl-β-D-mannopyranosyl-(1→4)-3,6-di-O-
acetyl-1,2-dideoxyl-α-D-glucopyrano-[2,1-d]-2-oxazoline (109)[200] 
A solution of 89 (350 mg, 279.1 µmol, 1.0 eq) and tri-tert-butyl 
pyrimidine (972 mg, 3.91 mmol, 14 eq) in freshly distilled DCE (5 
mL) was stirred under Ar atmosphere, then bromotrimethylsilane (441 µL, 3.34 mmol, 12 eq) 
and BF3 etherate (414 µL, 3.34 mmol, 12 eq) was added. The reaction was kept at 40 °C for 4 
– 6 h, until TLC indicated that a faster product was formed, then the mixture was neutralized 
by addition of a few drops of Et3N. The crude mixture was diluted with DCM (30) and washed 
with Sat. NaHCO3 (15 mL×2), brine (15 mL×1) and dried over MgSO4. The solvent was 
removed under reduced pressure without heating and the residue was purified by column 
chromatography (cyclohexane-ethyl acetate 1:1 to ethyl acetate-MeOH 100:10) to give 109, 
yield 93% (310 mg, 269.6 µmol). Rf = 0.6 (Pure EtOAc). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap 
mass spectrometer), m/z: 1194.3733 ([M+H]+, calc. 1194.3724). 1H-NMR (600 MHz, DMSO-d6, 
gCOSY, gHSQC, gHMBC), δ (ppm): 5.97 (d, J=7.3, 1H, H11), 5.33 (d, J=3.3, 1H, H22), 5.33 - 5.31 
(m, 1H, H31), 5.19 - 5.11 (m, 4H, H23, H24, H43, H44), 5.04 - 4.96 (m, 3H, H13, H42, H34), 4.96 - 
4.92 (m, 2H, H12, H33), 4.87 (s, 1H, H14), 4.22 - 4.02 (m, 8H, H32, H21, H6a1, Hb1, H6a3, H6b3, 
H6a4, H6b4), 4.00 - 3.94 (m, 2H, H53, H54), 3.76 - 3.67 (m, 3H, H41, H52, H6a2), 3.54 (dd, 
J=10.6, 3.4, 1H, H6b2), 3.39 (ddd, J=8.9, 6.1, 2.7, 1H, H51), 2.13 (s, 3H), 2.12 (s, 3H), 2.12 (s, 
3H), 2.07 (s, 3H), 2.05 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 
1.95 (s, 6H), 1.94 (s, 3H) (2.13 - 1.94 Ac, CH3). 
13C-NMR (150.9 MHz, DMSO-d6, gHSQC, 
gHMBC), δ (ppm): 170.64, 170.52, 170.47, 170.36, 170.26, 170.20, 170.02, 170.01, 169.97, 
169.94, 169.91, 169.56 (170.6- 169.6 CO2CH3), 165.23 (C=N), 99.21 (C1
1), 98.84 (C12), 98.45 
(C13), 97.26 (C14), 75.91 (C32), 75.77 (C41), 72.03 (C52), 70.61 (C22), 70.46 (C31), 69.36 (C33), 
69.13 (C23), 69.10 (C24), 68.94 (C53), 68.64 (C42), 68.44 (C34), 68.34 (C54), 68.17 (C51), 66.98 
(C62), 65.70 (C44), 65.40 (C43), 64.79 (C21), 63.78 (C61), 62.28 (C63), 62.01 (C64), 21.25, 21.08, 
21.05, 20.99, 20.97, 20.94, 20.89, 20.87 (21.3 - 20.9 CO2CH3), 13.81 (N=CCH3). 
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 α-D-mannopyranosyl-(1→3)-*α-D-mannopyranosyl-(1→6)+-β-D-mannopyranosyl-(1→4)-1,2-
dideoxyl-α-D-glucopyrano-[2,1-d]-2-oxazoline (110)[200] 
Compound 109 (28 mg, 23.4 µmol) was dissolved in anhydrous 
MeOH (10 mL) and stirred under Ar atmosphere. NaOMe (8 mg, 
148.1 µmol) was added in portions to keep the reaction pH around 9.5 - 10. After 24 h, the 
reaction was checked by MALDI MS, indicating that all acetyl groups were removed. The 
reaction was neutralized by addition of 3-5 µL 10% AcOH solution in MeOH to reach a pH of 
7.5. The solvent was removed and the residue freeze dried to give the deacetylated product 
110 (28 mg, containing 12 mg NaOAc, 146.3µmol, 16 mg product, 23.2 µmol) in 99% yield. 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 690.2446 ([M+H]+, calc. 
690.2457), 712.2279  ([M+Na]+, calc. 712.2276).1H-NMR (600 MHz, DMSO-d6, gCOSY, 
gHSQC, gHMBC), δ (ppm): 5.91 (d, J=7.3, 1H, H11), 4.84 (s, 2H, H13), 4.65 (d, J=1.2, 1H, H14), 
4.50 (s, 1H, H12), 4.12 - 4.09 (m, 1H, H31), 3.92 (d, J=7.2, 1H, H21), 3.89 (d, J=2.3, 1H, H22), 
3.76 - 3.74 (m, 1H, H23), 3.68 - 3.58 (m, 7H, H43, H44, H24, H6a2, H6b2, H6a3, H6b3), 3.58 - 
3.47 (m, 4H, H41, H33, H6a4, H6b4), 3.47 - 3.40 (m, 5H, H34, H52, H53, H6a1, H6b1), 3.39 - 3.34 
(m, 2H, H32, H54), 3.30 - 3.25 (m, 1H, H42), 3.18 - 3.15 (m, 1H, H51), 1.92 (s, 3H, CH3). 
13C-NMR (150.9 MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 164.21 (C=N), 102.44 (C1
3), 
101.18 (C12), 99.57 (C11, C14), 81.15 (C32), 78.86 (C41), 75.27 (C42), 73.91 (C43), 73.62 (C34), 
70.88 (C51), 70.82 (C33), 70.61 (C44), 70.24 (C23), 70.19 (C24), 69.74 (C22, C31), 67.47 (C21), 
67.25 (C54), 66.97 (C53), 65.95 (C62), 65.57 (C52), 61.31 (C61), 61.20 (C64), 61.09 (C63), 13.62 
(N=CCH3). 
2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→2)-3,4,6-tri-O-acetyl-α-D-
mannopyranosyl-(1→3)-[2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl-(1→
2)-3,4,6-tri-O-acetyl-α-D-mannopyranosyl-(1→6)]-3,6-di-O-acetyl-1,2-dideoxyl-α-D-glucopyr
ano-[2,1-d]-2-oxazoline (111)[203] 
A solution of 96 (52 mg, 28.7 µmol, 1.0 eq) with tri-tert-butyl 
pyrimidine (61.4 mg, 247.2 µmol, 8.6 eq) in freshly distilled 
DCE (1 mL), was stirred under Ar atmosphere, then 
bromotrimethylsilane (28 µL, 211.9 µmol, 7.4 eq) and BF3 
etherate (26 µL, 211.9 µmol, 7.4 eq) was added. The reaction 
was kept at 40 °C for 4 - 6 h and then neutralized by addition of a few drops of Et3N. The 
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crude mixture was diluted with DCM (10 mL) and washed with Sat. NaHCO3 (10 mL×2), brine 
(10 mL×1), dried over MgSO4. The solvent was removed by evaporation under reduced 
pressure without heating and the residue was purified by column chromatography 
(cyclohexane-ethyl acetate 1:3 to ethyl acetate-MeOH 100:10) to give 111, yield 93% (47 mg, 
26.8 µmol). Rf = 0.3 (EtOAc/MeOH 100:5). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 884.7939 ([M+2H]2+, calc. 884.7907), 893.3070 ([M+NH4+H]
2+, calc. 
893.3039), 895.7838 ([M+Na+H]2+, calc. 895.7816), 903.7695 ([M+K+H] 2+, calc. 903.7686), 
906.7763 ([M+2Na] 2+, calc. 906.7726). 1H-NMR (600 MHz, DMSO-d6, gCOSY, gHSQC, gHMBC), 
δ (ppm): 7.87 (d, J=9.0, 1H, NH5), 7.81 (d, J=9.5, 1H, NH6), 5.97 (d, J=7.2, 1H, H11), 5.36 - 5.34 
(m, 1H, H31), 5.32 (d, J=3.0, 1H, H22), 5.12 - 5.07 (m, 1H, H35), 5.07 - 5.01 (m, 4H, H43, H44, 
H42, H36), 5.01 - 4.96 (m, 2H, H12, H13), 4.88 (s, 1H, H14), 4.87 - 4.81 (m, 3H, H45, H43, H46), 
4.72 (dd, J=10.3, 3.3, 1H, H34), 4.59 (d, J=8.5, 1H, H16), 4.57 (d, J=8.4, 1H, H15), 4.21 - 4.11 (m, 
3H, H6a6, H6a5, H6a1), 4.09 - 3.96 (m, 8H, H613, H6b3, H6b6, H6b5, H6b1, H21, H24, H32), 3.93 
(d, J=10.4, 2H, H6a4, H6b4), 3.90 - 3.87 (m, 1H, H23), 3.86 - 3.81 (m, 3H, H26, H53, H56), 3.79 
(dd, J=9.8, 2.7, 1H, H54), 3.76 - 3.72 (m, 1H, H6a2), 3.72 - 3.62 (m, 4H, H25, H52, H55, H41), 
3.44 (dd, J=10.0, 4.0, 1H, H6b2), 3.36 (s, 1H, H51), 2.18 (s, 3H), 2.10 (s, 3H), 2.06 (s, 3H), 2.04 
(s, 3H), 2.04 (s, 3H), 2.02 (s, 3H), 2.02 (s, 3H), 2.01 (s, 3H), 2.01 (s, 3H), 2.00 (s, 6H), 1.98 (s, 
3H), 1.97 (s, 3H), 1.95 (s, 3H, N=CCH3), 1.94 (s, 3H), 1.93 (s, 3H), 1.92 (s, 3H) (2.18 - 1.92 OAc), 
1.76 (s, 3H, NHAc), 1.75 (s, 3H, NHAc). 13C-NMR (150.9 MHz, DMSO-d6, gHSQC, gHMBC), δ 
(ppm): 170.20, 170.14, 170.12, 169.81, 169.80, 169.68, 169.65, 169.61, 169.58, 169.30, 
169.26, 169.24 (170.2 - 169.3 C=O), 164.89 (C=N), 99.82 (C16), 99.45 (C15), 98.86 (C12), 98.72 
(C13), 98.66 (C11), 97.38 (C14), 76.10 (C32), 75.49 (C41), 73.81 (C24, C23), 72.12 (C36), 71.83 
(C35), 71.31 (C52), 71.06 (C55), 70.81 (C56), 70.24 (C22), 70.18 (C31), 69.82 (C46), 69.28 (C34), 
68.81 (C33), 68.62 (C42, C45, C53), 67.90 (C54), 67.56 (C51), 67.41 (C62), 64.80 (C44), 64.59 
(C43), 64.21 (C21), 63.40 (C61), 62.16 (C65), 61.99 (C64), 61.75 (C66), 61.52 (C63), 53.07 (C25), 
52.46 (C26), 22.62, 22.54, 20.85, 20.84, 20.78, 20.62, 20.57, 20.55, 20.53, 20.49, 20.45, 20.43, 
20.41, 20.39, 20.37, 20.34 (22.6 - 20.3 Ac), 13.35 (N=CCH3). 
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 2-N-acetamido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→3)-[2-N-aceta
mido-2-deoxy-β-D-glucopyranosyl-(1→2)-α-D-mannopyranosyl-(1→6)]-1,2-dideoxyl-α-D-glu
copyrano-[2,1-d]-2-oxazoline (112)[203] 
Compound 111 (47 mg, 26.6 µmol) was dissolved in 
anhydrous MeOH (10 mL) and stirred under Ar atmosphere. 
NaOMe (18 mg, 0.33 mmol) was added in portions to keep 
the reaction pH around 9.5 - 10. After 24 h, the completion of 
the reaction was checked by MALDI MS, which indicated that 
all acetyl groups were removed. The reaction was neutralized by addition of 3-5 µL 10% 
AcOH solution in MeOH to reach pH 7.5. The solvent was removed and the residue freeze 
dried to give the deacetylated product 112 (46 mg, containing 23 mg NaOMe, 0.26 mmol and 
23.4 mg product, 21.3 µmol) in 80% yield. HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1096.4073 ([M+H]+, calc. 1096.4044), 1118.3892 ([M+Na]+, calc. 
1118.3864), 1136.4008 ([M+NH3+Na]
 2+, calc. 1136.4163). 1H-NMR (600 MHz, DMSO-d6, 
gCOSY, gHSQC, gHMBC), δ (ppm): 7.99 (d, J=9.0, 1H, NH5), 7.87 (d, J=9.0, 1H, NH6), 5.93 (d, 
J=7.3, 1H, H11), 4.98 (s, 1H, H13), 4.78 (s, 1H, H14), 4.53 (s, 1H, H12), 4.39 (d, J=8.4, 1H, H16), 
4.37 (d, J=8.0, 1H, H15), 4.14 (s, 1H, H31), 3.93 (d, J=6.7, 1H, H21), 3.90 (s, 1H, H22), 3.86 (s, 1H, 
H23), 3.79 - 3.74 (m, 1H, H24), 3.69 - 3.62 (m, 10H, H6a5, H6b5, H6a4, H6b4, H6a2, H6b2, H45, 
H46, H33, H41), 3.50 - 3.40 (m, 9H, H25, H26, H6a6, H6b6,H6a1, H6b1, H52, H34, H32), 3.38 - 3.25 
(m, 5H, H53, H54, H36, H35, H42), 3.19 - 3.12 (m, 2H, H43, H54), 3.12 - 3.05 (m, 3H, H44, H51, 
H55), 1.93 (d, J=1.5, 3H, N=CCH3), 1.83 (s, 3H, NHAc), 1.81 (s, 3H, NHAc). 
13C-NMR (150.9 
MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 169.88 (C=O), 169.75 (C=O), 164.40 (C=N), 101.49 
(C15), 101.41 (C16), 101.22 (C12), 99.75 (C13), 99.57 (C11), 97.26 (C14), 81.31 (C32), 79.06 (C23), 
78.92 (C41), 78.72 (C14), 77.11 (C55), 77.03 (C56), 75.24 (C42), 74.13 (C33), 73.97 (C35), 73.87 
(C34), 73.79 (C36), 70.83 (C43), 70.53 (C44, C51), 69.87 (C46), 69.72 (C31), 69.63 (C32), 69.55 
(C45), 67.49 (C54), 67.44 (C21), 66.98 (C53), 66.31 (C62), 65.45 (C52), 61.37, 61.19, 60.95 (61.4 
- 61.0 C61, C63, C64, C65, C66), 55.59 (C26), 55.44 (C25), 23.25 (NHAc), 23.24 (NHAc), 13.60 
(N=CCH3). 
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7.20 Synthesis of Gal-GlcNAc-Man/GlcNAc-Man glycosylated amino acid 
N-tert-butyloxycarbonyl-O-(2-O-acetyl-3,4,6-O-benzyl-α-D-mannopy
ranosyl)-L-threonine-tert-butylester (113)[301] 
The trichloroacetimidate donor 76 (11.31 g, 17.8 mmol, 1.0 eq) and 
Boc-Thr-OtBu (4.97 g, 18.1 mmol, 1.02 eq) was dissolved in dry DCM 
(150 mL) and 4 Å molecular sieves (15 g) was added. The suspension 
was stirred under argon at room temperature for 30 min and then cooled to -40 °C followed 
by dropwise addition of trimethylsilyl-trifluoromethanesulfonate (TMSOTf) (0.807 ml, 4.4 
mmol, 0.25 eq). The reaction was stirred at -40 °C for 2 h, then quenched with triethylamine 
(2 mL). The molecular sieves were removed by filtering over a layer of Celite. The filtrate was 
concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 3:1) 
to give 113. Yield 67% (8.90 g, 11.9 mmol). Rf = 0.6 (
CHex/EtOAc 2:1). *α+D
20 = +23° (c = 0.7, 
CHCl3). HR-ESI-MS (pos), m/z: 750.3847 ([M+H]
+, calc. 750.3853), 767.4113 ([M+NH4]
+, calc. 
767.4119), 772.3665 ([M+Na]+, calc. 772.3673). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.30 - 7.03 (m, 15H, CH2Ph), 5.15 (s, 1H, H2), 4.95 (d, J=9.7, 1H, NH), 4.83 
(d, J=1.5, 1H, H1), 4.77 (d, J=10.6, 1H, 4-CH2Ph), 4.62 (d, J=2.6, 1H, 3-CH2Ph), 4.59 (d, J=3.6, 
1H, 6-CH2Ph), 4.45 (d, J=11.3, 1H, 3-CH2Ph), 4.42 (d, J=12.5, 1H, 6-CH2Ph), 4.38 (d, J=10.6, 1H, 
4-CH2Ph), 4.20 (ddd, J=12.4, 6.0, 1.8, 1H, Thr-Hβ), 4.11 (dd, J=9.8, 2.0, 1H, Thr-Hα), 3.81 (d, 
J=2.8, 1H, H3), 3.79 (s, 1H, H4), 3.77 (s, 1H, H5), 3.74 - 3.67 (m, 1H, H6a), 3.63 - 3.57 (m, 1H, 
H6b), 2.05 (s, 3H, CH3CO), 1.41 - 1.39 (m, 9H, CO2C(CH3)3), 1.35 (s, 9H, CO2C(CH3)3), 1.21 (d, 
J=6.3, 3H, Thr-CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.3 (COCH3), 
169.7 (CHCO2tBu), 156.2 (NHCO2tBu), 138.4, 138.0, 128.7, 128.6, 128.5, 128.3, 128.1, 127.9, 
127.8 (138.4-127.9, CH2Ph), 99.7 (C1), 82.6 (CCH3), 80.1 (CCH3), 78.0 (Thr-Cβ), 77.8 (C3), 75.6 
(4-CH2Ph), 74.5 (C4), 73.7 (6-CH2Ph), 72.1 (C5), 71.9 (3-CH2Ph), 69.0 (C6), 68.8 (C2), 59.0 
(Thr-Cα), 28.6, 28.2, 28.1, 27.1 (28.6-27.1, C(CH3)3), 21.2 (COCH3), 18.5 (Thr-CH3).  
N-tert-butyloxycarbonyl-O-(3,4,6-O-benzyl-α-D-mannopyranosyl)-L-t
hreonine-tert-butylester (114)[301] 
Compound 113 (6.48 g, 8.6 mmol) was dissolved in MeOH (68 ml) 
followed by addition of NaOMe (294 mg, 5.4 mmol, 0.08 M) in small 
portions over 2 h to reach pH 9.0-9.5. The reaction mixture was stirred overnight at room 
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 temperature and then neutralized by a small amount of Dowex 50WX8 ion-exchanger, 
filtered and concentrated. The residue was purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 5:1) to give 114. Yield: 72% (4.42 g, 6.3 mmol). Rf = 0.4 
(CHex/EtOAc 2:1). *α+D
20 = +55° (c = 0.8, CHCl3). HR-ESI-MS (pos), m/z: 708.3736 ([M+H]
+, calc. 
708.3748), 725.4005 ([M+NH4]
+, calc. 725.4013), 730.3560 ([M+Na]+, calc. 730.3567). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm):  7.38 - 7.26 (m, 13H, CH2Ph), 
7.19-7.16 (m, 2H, CH2Ph), 5.05 (d, J=9.8, 1H, NH), 4.95 (s, 1H, H1), 4.82 (d, J=10.7, 1H, CH2Ph), 
4.70 (s, 2H, CH2Ph), 4.65 (d, J=12.2, 1H, CH2Ph), 4.54 (d, J=12.23, 1H, CH2Ph), 4.49 (d, J=10.72, 
1H, CH2Ph), 4.31 (dd, J=6.3, 2.1, 1H, Thr-CHβ), 4.18 (dd, J=9.9, 2.1, 1H, Thr-CHα), 3.89 (s, 1H, 
H2), 3.83 (m, 3H, H5, H4, H3), 3.78 - 3.73 (m, 1H, H6a), 3.68 (d, J=10.1, 1H, H6b), 1.49-1.47 (s, 
18H, CO2C(CH3)3), 1.29 (d, J=6.2, 3H, Thr-CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), 
δ (ppm): 169.9 (CHCO2tBu), 156.1 (NHCO2tBu), 138.3, 137.9, 128.7, 128.5, 128.4, 128.1, 
128.0, 127.9, 127.9, 127.7 (128.7-127.7, CH2Ph), 101.3 (C1), 82.3 (CCH3), 80.0 (CCH3), 79.8 
(C3), 77.6 (Thr-Cβ), 75.4 (CH2Ph), 74.4 (C4), 73.6 (CH2Ph), 72.1 (CH2Ph), 71.6 (C5), 69.0 (C6), 
68.5 (C2), 59.0 (Thr-Cα), 28.5, 28.2, 27.0 (28.5-27.0, C(CH3)3), 18.7 (Thr-CH3).  
Phenyl 2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl-(1→4)-3,6-di-O-benzyl-2-deoxy-1-thio- 
2-N-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranoside (115)[301] 
Compound 43 (14.35 g, 15.74 mmol) was dissolved in MeOH 
(215 ml) followed by addition of hydrazine hydrate (86.10 mL, 
1.76 mmol). The reaction mixture was stirred at 70°C for 2 h, 
and then the solvent was removed under reduced pressure. The residue was diluted with 
ethyl acetate (150 ml) and filtered over Celite. The filtrate was washed with saturated 
NaHCO3 (50 ml×3), brine (100 ml×1) and dried over MgSO4. The organic solvent was 
evaporated to give the deprotected disaccharide in 62% yield (6.00 g, 9.78 mmol). The crude 
material was taken up in 1,4-dioxane (60 ml) and a solution of NaHCO3 (1.89 g, 22.5 mmol) in 
H2O (20 ml) was added. The mixture was stirred at room temperature for 15 min followed by 
slow addition of TrocCl (1.97 ml, 14.7 mmol). After 2 h TLC (DCM/MeOH 9:1, Rf = 0.5) 
indicated full conversion to the desired product. The reaction mixture was concentrated and 
coevaporated with toluene (50 ml×3) and was then dissolved pyridine / acetic anhydride 2:1 
(18 mL). After 24 h the solvent was removed and again coevaporated with toluene (50 ml×3). 
Purification by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) gave 115 in 
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75% yield (6.88 g, 7.20 mmol). Rf = 0.4 (
CHex/EtOAc 2:1). *α+D
20 = -7 (c = 0.7, CHCl3). 
HR-ESI-MS (pos), m/z: 956.1891 ([M+H]+, calc. 956.1888). 1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 7.54 - 7.44 (m, 2H, Ph), 7.41 - 7.18 (m, 13H, Ph), 5.32 (d, J=8.0, 1H, 
NH), 5.26 (d, J=3.4, 1H, H4’), 5.12 (dd, J=10.4, 8.0, 1H, H2’), 4.95 (d, J=10.0, 1H, H1), 4.91 - 
4.82 (m, 2H, H3’, PhCH2), 4.81 - 4.64 (m, 3H, TrocCH2, PhCH2), 4.60 (m, 2H, H1’, PhCH2), 4.50 
(d, J=11.9, 1H, PhCH2), 3.99 (m, 2H, H4, H6a’), 3.88 (m, J=11.0, 6.0, 1H, H6b’), 3.83 (m, 1H, 
H3), 3.78 - 3.70 (m, 2H, H6ab), 3.60 (t, J=6.9, 1H, H5’), 3.47 (m, 1H, H5), 3.41 (m, 1H, H2), 
2.07 (s, 3H), 2.02 (s, 3H), 1.97 (s, 3H), 1.95 (s, 3H) (2.07-1.95 COCH3). 
13C-NMR (100.6 MHz, 
CDCl3, gHSQC, gHMBC), δ (ppm): 171.3, 170.4, 170.4, 170.2, 169.5 (171.3-169.5 COCH3), 
154.0, 138.4, 138.1, 132.8 (138.4 - 132.8 CH2Ph), 100.3 (C1’), 95.7 (Troc-CCl3), 85.9 (C1), 79.7 
(C3), 79.3 (C5), 76.5 (C4), 74.7 (CH2Ph), 73.8 (CH2Ph), 71.1 (C3’), 70.8 (C5’), 69.7 (C2’), 68.2 
(C6), 67.0 (C4’), 60.9 (C6’), 56.3 (C2), 23.2, 21.2, 20.9, 20.8 (21.2-20.8 COCH3). 
Phenyl 3,4,6-tri-O-benzyl-2-deoxy-1-thio-2-N-(2,2,2-trichloroethoxycarbonylamino)-β-D-glu 
copyranoside (116)[301] 
Compound 55 (8.9 g, 13.2 mmol) was dissolved in Tol/EtOH 2:3 (300 mL) 
followed by addition of hydrazine hydrate (10 mL, 204 mmol). The reaction mixture was 
refluxed at 105 °C for 72 h, and then the solvent was removed under reduced pressure. The 
residue was diluted with DCM (150 ml) and washed with saturated NaHCO3 (50 mL×3), brine 
(100 mL×1) and dried over MgSO4. The organic solvent was evaporated and the crude 
material was taken up in 1,4-dioxane (90 ml) and a solution of NaHCO3 (2.56 g, 30.5 mmol, 
2.3 eq) in H2O (30 mL) was added. The mixture was stirred at r.t. for 15 min followed by slow 
addition of TrocCl (2.74 mL, 19.9 mmol, 1.5 eq). After 2 h TLC indicated full conversion to the 
desired product. The reaction mixture was concentrated and coevaporated with toluene (50 
ml×3) and purification by column chromatography (cyclohexane-ethyl acetate 10:1 to 2:1) 
gave 116 in 76% yield (7.2 g, 10.0 mmol). Rf = 0.7 (Tol/EtOAc 4:1). *α+D
20 = +11 (c = 1.2, CHCl3). 
ESI-MS (pos), m/z: 732.73 ([M+NH4]
+, calc. 733.17), 1451.07 ([2M+NH4]
+, calc. 1450.30). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.57 - 7.53 (m, 2H), 7.39 - 7.20 
(m, 18H), 5.13 (d, J=8.1, 1H, NH), 4.95 (d, J=10.1, 1H, H1), 4.86 - 4.79 (m, 2H, BnCH2), 4.78 - 
4.70 (m, 3H, BnCH2), 4.65 - 4.52 (m, 3H, TrocCH2, BnCH2), 3.89 (t, J=8.9, 1H, H3), 3.81 (d, 
J=10.8, 1H, H6a), 3.76 (dd, J=10.8, 4.4, 1H, H6b), 3.67 (t, J=9.0, 1H, H4), 3.59 (d, J=7.2, 1H, 
H5), 3.50 (dd, J=18.7, 9.5, 1H, H2). 13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 
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 154.05 (TrocC=O), 138.47, 138.17, 138.10, 132.69, 129.16, 128.72, 128.70, 128.60, 128.30, 
128.14, 128.12, 128.10, 128.03, 127.91, 127.83 (129.2 - 127.8, aromatic), 95.74 (CCl3), 86.02 
(C1), 82.53 (C3), 79.53 (C5), 78.70 (C4), 75.46 (CH2Ph), 75.1 (CH2Ph)1, 74.73 (CH2Ph), 73.70 
(TrocCH2), 69.22 (C6), 56.90 (C2). 
N-tert-butoxycarbonyl-O-{3,4,6-O-benzyl-2-O-[3,6-O-benzyl-2-deoxy-2-N-(2,2,2-trichloroet
hoxycarbonylamino)-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-
α-D-mannopyranosyl}-L-threonine-tert-butylester (117)[301] 
Compounds 114 (2.37 g, 3.35 mmol, 1.0 eq), 115 (3.85 g, 
4.02 mmol, 1.2 eq) and 4 Å molecular sieves (3 g) in dry 
dichloromethane (35 mL) were stirred at room 
temperature for 30 min under argon atmosphere. Then the 
suspension was cooled to -18 °C followed by slow addition of N-iodosuccinimide (1.51 g, 6.71 
mmol, 2.0 eq) and trifluoromethanesulfonic acid (0.059 mL, 0.67 mmol, 0.2 eq). After stirring 
for 2 h at -18 °C, the reaction was quenched by addition of Et3N (0.5 mL). The molecular 
sieves were removed by filtration and the filtrate was concentrated. Purification by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 5:1) gave 117. Yield: 78% (4.08 g, 2.63 
mmol).  Rf = 0.4 (
CHex/EtOAc 3:2). *α+D
20 = +12° (c = 0.9, CHCl3). HR-ESI-MS (pos), m/z: 
1553.3979 ([M+H]+, calc. 1553.5368). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ 
(ppm): 7.42 - 7.15 (m, 25H, CH2Ph), 5.36 (d, J=6.0, 1H, GlcNH), 5.24 (d, J=3.4, 1H, H4’’), 5.12 
(dd, J=10.3, 8.0, 1H, H2’’), 4.99 (d, J=8.0, 1H, ThrNH), 4.93 - 4.86 (m, 2H, H1’, PhCH2×1), 4.86 - 
4.77 (m, 4H, H3’’, H1, PhCH2×2), 4.71 - 4.56 (m, 6H, TrocCH2, H1’’, PhCH2×3), 4.56 - 4.41 (m, 
3H, PhCH2×3), 4.36 (d, J=12.0, 1H, PhCH2×1), 4.21 - 4.07 (m, 2H, Thr-CHβ, Thr-CHα), 4.05 - 
3.92 (m, 4H, H2, H3’, H6a’’, H3), 3.92 - 3.80 (m, 3H, H6b’’, H4’, H4), 3.77 - 3.65 (m, 4H, H5, 
H6ab, H6a’), 3.62 (d, J=8.8, 1H, H6b’), 3.55 (t, J=7.0, 1H, H5’’), 3.43 - 3.33 (m, 1H, H5’), 3.28 - 
3.12 (m, 1H, H2’), 2.09 (s, 3H, Ac), 2.00 (s, 3H, Ac), 1.97 (s, 6H, Ac), 1.47 (s, 18H, Boc, tBu), 
1.25 (d, J=6.9, 3H, Thr-CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.4, 
170.4, 170.3, 170.1, (170.4-170.1 Ac), 169.4 (CHCO2tBu), 156.1 (NHCO2tBu), 154.2 
(NHCOTroc), 138.9, 138.7, 138.5, 138.2, 138.0, 137.6, 128.9, 128.8, 128.7, 128.6, 128.6, 
128.5, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.9, 127.8, 127.7, 127.6 (138.9-127.6, 
CH2Ph), 100.4 (C1’’), 99.3 (C1), 98.7 (C1’), 95.9 (CCl3), 82.2 (CCH3), 80.2 (CCH3), 78.2 (C3’), 
77.5 (Thr-Cβ), 77.4 (C4), 77.1 (C3), 75.2 (CH2Ph), 74.9 (C4’), 74.9 (C5’), 74.5 (CH2Ph), 74.4 
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(TrocCH2), 73.9 (C2), 73.9 (CH2Ph), 73.5 (CH2Ph), 72.5 (C5), 71.3 (C3’’), 71.2 (CH2Ph), 70.8 
(C5’’), 69.9 (C2’’), 69.6 (C6’), 68.5 (C6), 67.1 (C4’’), 61.1 (C6’’), 58.8 (Thr-Cα), 57.9 (C2’), 29.9, 
28.6, 28.3, 27.1 (29.9-27.1, C(CH3)3), 20.9, 20.9, 20.8, 20.8 (20.9-20.8 Ac), 18.5 (Thr-CH3).  
N-tert-butoxycarbonyl-O-{3,4,6-O-benzyl-2-O-[2-N-acetamido-3,6-O-benzyl-2-deoxy-4-O-(2,
3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-mannopyranosyl}-L-thre
onine-tert-butylester (118)[301] 
Zinc powder was activated by treatment with 1 M HCl aq. 
for 20 min, washed with H2O, MeOH, Et2O and dried under 
reduced pressure for 30 min. Compound 117 (4.30 g, 2.77 
mmol) was dissolved in glacial acetic acid (60 mL) followed 
by addition of the activated Zn powder (5.50 g, 84.6 mmol, 30 eq). The reaction mixture was 
stirred at room temperature for 36 h and was then filtered through a thin layer of Celite. The 
filtrate was concentrated and coevaporated 3 times with toluene. The residue was dissolved 
in pyridine / acetic anhydride 2:1 (15 mL) and stirred at room temperature overnight. Then 
the reaction mixture was concentrated and coevaporated three times with toluene. 
Purification by column chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) gave 118. 
Yield: 69% (2.70 g, 1.91 mmol). Rf = 0.3 (
CHex/EtOAc 3:2). *α+D
20 = +8° (c = 0.7, CHCl3). 
HR-ESI-MS (pos), m/z: 1421.6392 ([M+H]+, calc. 1421.6431). 1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 7.42 - 7.17 (m, 25H, CH2Ph), 5.68 (d, J=5.4, 1H, GlcNH), 5.27 (d, J= 
3.4, 1H, H4’’), 5.12 (dd, J=10.4, 8.0, 1H, H2’’), 5.03 (d, J=7.3, 1H, H1’), 4.99 (d, J=9.8, 1H, 
ThrNH), 4.89 - 4.79 (m, 4H, H3’’, H1, PhCH2×2), 4.78 - 4.75 (m, 1H, PhCH2), 4.67 - 4.55 (m, 4H, 
H1’’, PhCH2×3), 4.55 - 4.48 (m, 2H, PhCH2×2), 4.47 - 4.39 (m, 2H, PhCH2×2), 4.36 (d, J=11.9, H, 
PhCH2), 4.27 (t, J=8.5, 1H, H3’), 4.20 (d, J=6.2, 1H, Thr-CHβ), 4.17 - 4.14 (m, 1H, Thr-CHα), 
4.04 - 3.96 (m, 2H, H2, H6a’’), 3.96 - 3.86 (m, 3H, H6b’’, H3, H4’), 3.85 - 3.79 (m, 1H, H4), 3.76 
- 3.68 (m, 3H, H6ab, H5), 3.68 - 3.63 (m, 1H, H6a’), 3.61 - 3.54 (m, 2H, H6b’, H5’’), 3.50 - 3.42 
(m, 1H, H5’), 3.25 - 3.16 (m, 1H, H2’), 2.09 (s, 3H, Ac), 2.04 (s, 3H, Ac), 1.99 (s, 3H, Ac), 1.97 (s, 
3H, Ac), 1.96 (s, 3H, Ac), 1.46 (s, 18H, Boc, tBu), 1.26 (d, J=7.1, 3H, Thr-CH3). 
13C-NMR (100.6 
MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 171.5, 170.4, 170.3, 170.0, (171.5-170.0 Ac), 169.5 
(CHCO2tBu), 139.3, 138.6, 138.5, 138.2, 128.7, 128.6, 128.4, 128.1, 128.0, 127.9, 127.7, 127.6, 
127.6 (139.3-127.6 CH2Ph), 100.4 (C1’’), 99.4 (C1), 97.8 (C1’), 82.1 (CCH3), 80.1 (CCH3), 77.9 
(Thr-Cβ), 77.4 (C3’), 77.4 (C4), 77.1 (C3), 75.4 (CH2Ph), 74.8 (C5’), 74.6 (C4’), 74.1 (CH2Ph), 
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 73.8 (C2), 73.8 (CH2Ph), 73.5 (CH2Ph), 72.2 (C5), 71.2 (C3’’), 71.0 (CH2Ph), 70.8 (C5’’), 69.8 
(C2’’), 69.5 (C6’), 69.0 (C6), 67.1 (C4’’), 61.1 (C6’’), 59.0 (Thr-Cα), 57.1 (C2’), 28.6, 28.3, 27.1 
(28.6-27.1, C(CH3)3), 23.5, 21.3, 21.0, 20.9, 20.8, 20.8 (21.3-20.8 Ac), 18.6 (Thr-CH3).  
N-tert-butoxycarbonyl-O-{3,4,6-O-acetyl-2-O-[2-N-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,
3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-mannopyranosyl}-L-thre
onine-tert-butylester (119)[301] 
Compound 118 (2.50 g, 1.76 mmol) was dissolved in 
MeOH / acetic acid 30:2 (85 mL). The solution was added 
to a suspension of 10% Pd(C) (2.67 g) in MeOH (80 mL), 
stirred under argon. The reaction mixture was then stirred 
under hydrogen atmosphere for 48 h. After flushing the mixture with argon, the suspension 
was filtered through Celite and the filtrate concentrated and co-concentrated three times 
with toluene. The residue was dissolved in pyridine / acetic anhydride 2:1 (25 mL) and stirred 
at room temperature overnight. Evaporation and co-evaporation three times with toluene 
was followed. Purification by column chromatography (cyclohexane-ethyl acetate 1:1 to 1:5) 
finally gave 119. Yield: 53% (1.10 g, 0.93 mmol). Rf = 0.3 (Tol/EtOAc 1:5). *α+D
20 = +3° (c = 0.7, 
CHCl3). HR-ESI-MS (pos), m/z: 1181.4589 ([M+H]
+, calc. 1811.4612), 1203.4422 ([M+Na]+, calc. 
1203.4431). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 5.83 (d, J=9.2, 1H, 
NH), 5.32 (d, J=3.4, 1H, H4’’), 5.20-5.05 (m, 3H, H4, H3’, H2’’), 4.99 (dd, J=9.7, 3.4, 1H, H3), 
4.94 (dd, J=10.5, 3.4, 1H, H3’’), 4.84 (s, 1H, H1), 4.46-4.48 (m, 2H, H1’, H1’’), 4.35 (dd, J=11.8, 
2.6, 1H, H6a’), 4.26 - 4.17 (m, 2H, Thr-CHβ, Thr-CHα), 4.13 - 4.02 (m, 5H, H6b’, H6ab’’, H6ab), 
3.98 - 3.95 (m, 1H, H2), 3.91 (m, 1H, H2’), 3.87 (m, 1H, H5), 3.85 (m, 1H, H5’’), 3.71 (t, J=8.6, 
1H, H4’), 3.51 (m, 1H, H5’), 2.12 (s, 3H, Ac), 2.09 (s, 3H, Ac), 2.06 (s, 3H, Ac), 2.05 (s, 3H, Ac), 
2.03 (s, 3H, Ac), 2.01 (m, 6H, Ac), 1.96 (s, 3H, Ac), 1.94 (s, 3H, Ac), 1.92 (s, 3H, NHAc), 1.47 (s, 
9H, tBu), 1.44 (s, 9H, tBu), 1.27 - 1.24 (m, 3H, Thr-CH3).
 13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.8, 170.5, 170.5, 170.4, 170.4, 170.3, 170.2, 170.1, 169.9, 169.4 
(170.8-169.4 Ac), 169.3 (CHCO2tBu), 156.0 (NHCO2tBu), 101.1 (C1’’), 99.7 (C1’), 98.8 (C1), 
82.5 (CCH3), 80.3 (CCH3), 77.4 (Thr-Cβ), 76.1 (C4’), 74.6 (C2), 72.7 (C5’), 72.1 (C3’), 70.9 (C3’’), 
70.9 (C5’’), 70.1 (C3), 69.2 (C2’’), 69.2 (C5), 66.8 (C4’’), 66.2 (C4), 62.8 (C6), 62.5 (C6’), 60.9 
(C6’’), 58.5 (Thr-Cα), 53.6 (C2’), 29.7, 28.8, 28.4, 28.1 (29.7-28.1, C(CH3)3), 23.2, 21.1, 20.9, 
20.8, 20.8, 20.7, 20.7, 20.7, 20.6 (21.1-20.6 Ac), 17.9 (Thr-CH3).  
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N-9-Fluorenylmethoxycarbonyl-O-{3,4,6-O-acetyl-2-O-[2-N
-acetamido-3,6-O-acetyl-2-deoxy-4-O-(2,3,4,6-tetra-O-acet
yl-β-D-galactopyranosyl)-β-D-glucopyranosyl]-α-D-mannopy
ranosyl}-L-threonine (120)[301] 
Compound 119 (1.04 g, 0.88 mmol) was dissolved in 
TFA/DCM/anisole 3:1:0.4 (34 mL) and was stirred at room 
temperature overnight. The solution was then concentrated and coevaporated three times 
with toluene. The residue was dissolved in a mixture of Dioxane / H2O 1:1 (40 mL) followed 
by addition of Na2CO3 (224 mg, 2.67 mmol 3.0 eq). The mixture was cooled to 0°C and 
Fmoc-OSu (357 mg, 1.06 mmol, 1.2 eq) was slowly added. After stirring the reaction mixture 
for 4 h at room temperature, dioxane was removed by evaporation followed by addition of 5 
M HCl until pH reached 1.5. The residue was diluted with H2O /DCM (100 mL each) and after 
extraction, the organic layer was dried, filtered and concentrated. Purification by silica 
column chromatography (DCM-MeOH 100:1 to 10:1) gave 120. Yield: 91% (1.00 g, 0.8 mmol). 
Rf = 0.1 (EtOAc/MeOH/AcOH/H2O 60:3:3:2). *α+D
20 = +11° (c = 0.8, CHCl3). HR-ESI-MS (pos), 
m/z: 1247.4121 ([M+H]+, calc. 1247.4142). 1H-NMR (600 MHz, DMSO-d6, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.87 (d, J=7.5, 2H, Fmoc), 7.81 - 7.66 (m, 4H, Fmoc, NH×2), 7.39 (q, J=7.2, 
2H, Fmoc), 7.36 - 7.27 (m, 2H, Fmoc), 5.21 (d, J=3.6, 1H, H4’’), 5.16 (dd, J=10.1, 3.6, 1H, H3’’), 
5.02 (m, 2H, H1, H3), 4.94 (m, 1H, H4), 4.92 - 4.79 (m, 2H, H3’, H2’’), 4.75 (d, J=8.0 1H, H1’’), 
4.39 (d, J=8.5, 1H, H1’), 4.33 - 4.26 (m, 2H, FmocCH2), 4.24 (m, 2H, FmocCH, H6a’), 4.20 (m, 
3H, Thr-CHβ, Thr-CHα, H5’’), 4.08 - 3.91 (m, 6H, H5, H6b’, H6ab, H6ab’’), 3.83 (s, 1H, H2), 3.79 
- 3.68 (m, 2H, H2’, H4’), 3.62 - 3.49 (m, 1H, H5’), 2.08 (s, 3H, Ac), 2.04 (s, 3H, Ac), 2.01 - 1.94 
(m, 15H, Ac), 1.88 (s, 6H, Ac), 1.73 (s, 3H, Ac), 1.23 (d, J=5.8, 3H, Thr-CH3). 
13C-NMR (150.9 
MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 171.5, 170.3, 170.1, 169.8, 169.5, 169.5, 169.4, 
169.3, 169.1 (171.5-169.1 Ac), 156.58 (NHCOFmoc), 143.8, 143.7, 140.7, 137.3, 128.9, 128.2, 
127.6, 127.0, 125.3, 125.3, 120.1 (128.9-120.1 Fmoc aromatic), 100.1 (C1’), 100.0 (C1’’), 98.2 
(C1), 76.3 (C4’), 76.2 (Thr-Cβ), 75.0 (C2), 72.7 (C3’), 72.0 (C5’), 70.3 (C3’’), 69.6 (C3), 69.6 
(C5’), 69.0 (C2’’), 67.9 (C5), 67.0 (C4’’), 65.9 (FmocCH2), 65.7 (C4), 62.3 (C6’), 62.1 (C6), 60.8 
(C6’’), 58.6 (Thr-Cα), 52.6 (C2’), 46.7 (FmocCH), 22.5, 21.0, 20.5, 20.5, 20.4, 20.3, 20.3 
(22.5-20.3 Ac), 17.5 (Thr-CH3).  
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 N-tert-butoxycarbonyl-O-{3,4,6-O-benzyl-2-O-[3,4,6-O-benzyl-2-deoxy-2-N-(2,2,2-trichloroe
thoxycarbonylamino)-β-D-glucopyranosyl]-α-D-mannopyranosy
l}-L-threonine-tert-butylester (121)[301] 
Compounds 114 (3.11 g, 4.40 mmol, 1.0 eq), 116 (5.04 g, 7.03 
mmol, 1.6 eq), N-iodosuccinimide (2.37 g, 10.5 mmol, 2.4 eq) 
and 4 Å molecular sieves (5 g) in dry dichloromethane (50 mL) 
were stirred at room temperature for 30 min under argon 
atmosphere. Then the suspension was cooled to -40 °C followed by slow addition of 
trifluoromethanesulfonic acid (0.078 mL, 0.87 mmol, 0.2 eq). After stirring for 30 min at 
-40 °C, the reaction was quenched by addition of Et3N (0.5 mL). The molecular sieves were 
removed by filtration and the filtrate was concentrated. Purification by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 4:1) gave 121. Yield: 57% (3.28 g, 2.50 
mmol).  Rf = 0.7 (Tol/EtOAc 4:1). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.29 (m, 30H, CH2Ph), 5.29 (bs, 1H, GlcNH), 4.95 (d, J=8.7, 1H, ThrNH), 4.92 (d, J=8.1, 1H, H1’), 
4.86 - 4.76 (m, 5H, H1’, PhCH2×4), 4.73 - 4.63 (m, 3H, TrocCH2, PhCH2×2), 4.61 - 4.55 (m, 3H, 
TrocCH2, PhCH2×2), 4.55 - 4.42 (m, 4H, PhCH2×4), 4.18 (d, J=5.9, 1H, Thr-CHβ), 4.15 (m, 2H, 
Thr-CHα, H3’), 4.04 (t, J=2.4, 1H, H2), 3.89 (d, J=7.8, 1H, H4), 3.83 (dd, J=8.0, 2.5, 1H, H3), 
3.72 (m, 4H, H5, H6a, H6b, H6a’), 3.61 (m, 2H, H6b’, H4’), 3.50 (dt, J=9.7, 3.3, 1H, H5’), 3.25 
(d, J=7.6, 1H, H2’), 1.47 (s, 9H, tBu), 1.47 (s, 9H, Boc), 1.25 (d, J=6.2, 3H, Thr-CH3).
 13C-NMR 
(100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.2 (CHCO2tBu), 156.1 (CHCO2tBu), 154.3 
(NHCOTroc), 138.9, 138.5, 138.5, 138.2, 138.2, 128.6, 128.6, 128.5, 128.5, 128.3, 128.2, 
128.1, 127.9, 127.9, 127.8, 127.5 (138.8 - 127.6, CH2Ph), 99.6 (C1), 98.4 (C1’), 95.9 (CCl3), 
82.2 (CCH3), 80.6 (C3’), 80.1 (CCH3), 78.9 (C4’), 77.4 (Thr-Cβ), 77.0 (C3), 75.2 (C5’, CH2Ph), 
75.1 (CH2Ph), 75.1 (C4, CH2Ph), 74.4 (TrocCH2), 73.7 (C2, CH2Ph), 73.4 (CH2Ph), 72.4 (C5), 71.2 
(CH2Ph), 69.7 (C6’), 69.4 (C6), 58.8 (Thr-Cα), 58.4 (C2’), 28.5 (C(CH3)3), 28.3 (C(CH3)3), 18.6 
(Thr-CH3). HR-ESI-MS (pos), m/z: 1313.4928 ([M+H]
+, calc. 1313.4886), 1330.5157 ([M+NH4]
+, 
calc. 1330.5155). 
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N-tert-butoxycarbonyl-O-{3,4,6-O-benzyl-2-O-[2-N-acetamido-3,4,6-O-benzyl-2-deoxy-β-D-g
lucopyranosyl]-α-D-mannopyranosyl}-L-threonine-tert-butylester (122)[301] 
Zinc powder was activated by treatment with 1 M HCl aq. for 20 
min, washed with H2O, MeOH, Et2O and dried under reduced 
pressure for 30 min. Compound 121 (2.87 g, 2.18 mmol) was 
dissolved in glacial acetic acid (50 mL) followed by addition of 
the activated Zn powder (2.84 g, 43.7 mmol, 20 eq). The 
reaction mixture was stirred at room temperature for 36 h and 
was then filtered through a thin layer of Celite. The filtrate was concentrated and 
coevaporated 3 times with toluene. The residue was dissolved in pyridine / acetic anhydride 
2:1 (15 mL) and stirred at room temperature overnight. Then the reaction mixture was 
concentrated and coevaporated three times with toluene. Purification by column 
chromatography (cyclohexane-ethyl acetate 10:1 to 1:1) gave 122. Yield: 67% (1.74 g, 1.47 
mmol). Rf = 0.2 (
CHex/EtOAc 3:2). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 
7.44 - 7.16 (m, 30H, CH2Ph), 5.57 (bs, 1H, GlcNH), 5.07 (d, J=8.3, 1H, H1’), 4.92 (t, J=11.1, 
PhCH2×1), 4.87 - 4.75 (m, 4H, H1, PhCH2×3), 4.67 - 4.46 (m, 7H, PhCH2×7), 4.43 (m, 2H, H 3’, 
PhCH2×1), 4.21 (d, J=6.4, 1H, Thr-CHβ), 4.15 (d, J=7.2, 1H, Thr-CHα), 4.03 (t, J=2.3, 1H, H2), 
3.99 (d, J=9.1, 1H, H4), 3.83 (dd, J=8.9, 2.6, 1H, H3), 3.76 - 3.68 (m, 4H, H5, H6a, H6b, H6a’), 
3.60 (m, 1H, H6b’), 3.55 (m, 2H, H4’, H5’), 3.10 (dd, J=16.6, 8.2, 1H, H2’), 1.72 (s, 3H, NHAc), 
1.48 (s, 9H, tBu), 1.47 (s, 9H, Boc), 1.24 (d, J=6.2, 3H, Thr-CH3). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 171.8 (NHAc), 169.9 (CHCO2tBu), 156.1 (NHCO2tBu), 138.9, 138.6, 
138.4, 138.3, 138.1, 128.9, 128.6, 128.6, 128.5, 128.5, 128.5, 128.4, 128.2, 128.0, 127.9, 
127.8, 127.8, 127.7, 127.6 (138.9 - 127.6, CH2Ph), 99.5 (C1), 97.4 (C1’), 82.1 (CCH3), 80.3 (C3’), 
80.0 (CCH3), 79.2 (C4’), 78.1 (Thr-Cβ), 77.0 (C3), 75.3 (CH2Ph), 75.2 (C5’), 75.0 (CH2Ph), 75.0 
(CH2Ph), 74.4 (C4), 73.7 (CH2Ph), 73.4 (CH2Ph), 73.1 (C2), 72.1 (C5), 70.7 (CH2Ph), 69.7 (C6), 
69.5 (C6’), 59.0 (Thr-Cα), 58.9 (C2’), 28.5 (C(CH3)3), 28.3 (C(CH3)3), 23.6 (Ac), 18.6 (Thr-CH3). 
HR-ESI-MS (pos), m/z: 1181.5978 ([M+H]+, calc. 1811.5950), 1198.6211 ([M+NH4]
+, calc. 
1198.6215). 
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 N-tert-butoxycarbonyl-O-{3,4,6-O-acetyl-2-O-[2-N-acetamido-3,4,6-O-acetyl-2-deoxy-β-D-gl
ucopyranosyl]-α-D-mannopyranosyl}-L-threonine-tert-butylester (123)[301] 
Compound 122 (1.70 g, 1.40 mmol) was dissolved in MeOH / 
acetic acid 30:2 (64 mL). The solution was added to a 
suspension of 10% Pd(C) (1.88 g) in MeOH (60 mL), stirred 
under argon. The reaction mixture was then stirred under 
hydrogen atmosphere for 48 h. After flushing the mixture with 
argon, the suspension was filtered through Celite and the 
filtrate concentrated and co-concentrated three times with toluene. The residue was 
dissolved in pyridine / acetic anhydride 2:1 (30 mL) and stirred at room temperature 
overnight. Evaporation and co-evaporation three times with toluene was followed. 
Purification by column chromatography (cyclohexane-ethyl acetate 1:1 to 1:5) finally gave 
123. Yield: 90% (1.15 g, 1.29 mmol). Rf = 0.2 (Tol/EtOAc 1:5). 
1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 5.74 (d, J=7.9, 1H, GlcNH), 5.37 (t, J=10.0, 1H, H3’), 5.16 (t, J=9.8, 
1H, H4), 5.11 (d, J=9.5, 1H, BocNH), 4.97 (m, 2H, H3, H4’), 4.81 (s, 1H, H1), 4.78 (d, J=8.1, 1H, 
H1’), 4.22 (m, 3H, H6a’, Thr-CHβ, Thr-CHα), 4.14 (d, J=12.4, 6.1, 1H, H6a), 4.06 (d, J=2.5, 1H, 
H6b), 4.06 - 3.99 (m, 1H, H2), 3.67 - 3.63 (m,1H, H2), 3.58 - 3.54 (m, 1H, H5’), 2.05 (s, 3H, Ac), 
2.05 (s, 3H, Ac), 2.02 (s, 3H, Ac), 2.01 (s, 3H, Ac), 1.98 (s, 6H, Ac×2), 1.92 (s, 3H, NHAc), 1.48 (s, 
9H, tBu), 1.45 (s, 9H, Boc), 1.26 (d, J=6.2, 3H, Thr-CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, 
gHMBC), δ (ppm): 170.8, 170.8, 170.7, 170.4, 169.9, 169.6, 169.5 (170.8 - 169.5 Ac, 
CHCO2tBu), 156.1 (NHCO2tBu), 99.2 (C1’), 99.1 (C1), 82.5 (CCH3), 80.3 (CCH3), 77.4 (Thr-Cβ), 
74.4 (C2), 72.0 (C5’), 71.9 (C3’), 70.1 (C3), 69.3 (C5), 68.9 (C4’), 66.4 (C4), 63.0 (C6), 62.2 (C6’), 
58.6 (Thr-Cα), 55.3 (C2’), 28.5 (C(CH3)3), 28.2 (C(CH3)3), 23.4 (NHAc), 21.2, 20.9, 20.9, 20.8, 
20.8, 20.8 (21.2 - 20.8 Ac), 18.0 (Thr-CH3). HR-ESI-MS (pos), m/z: 893.3779 ([M+H]
+, calc. 
893.3767), 910.4025 ([M+NH4]
+, calc. 910.4032), 915.3567 ([M+Na]+, calc. 915.3586).  
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N-9-Fluorenylmethoxycarbonyl-O-{3,4,6-O-acetyl-2-O-[2-N-acetamido-3,6-O-acetyl-2-deoxy
-β-D-glucopyranosyl]-α-D-mannopyranosyl}-L-threonine (124)[301] 
Compound 123 (1.11 g, 1.24 mmol) was dissolved in TFA/DCM 
3:1 (40 mL) and was stirred at room temperature for 3 hours. The 
solution was then concentrated and coevaporated three times 
with toluene. The residue was dissolved in a mixture of Dioxane / 
H2O 1:1 (60 mL) followed by addition of Na2CO3 (316 mg, 2.98 
mmol, 2.4 eq). The mixture was cooled to 0°C and Fmoc-OSu (503 mg, 1.49 mmol, 1.2 eq) 
was slowly added. After stirring the reaction mixture for 4 h at room temperature, dioxane 
was removed by evaporation followed by addition of 5 M HCl until pH reached 1.5. The 
residue was diluted with H2O /DCM (100 mL each) and after extraction, the organic layer was 
dried, filtered and concentrated. Purification by silica column chromatography (DCM-MeOH 
100:1 to 10:1) gave 124. Yield: 99% (1.20 g, 1.24 mmol). Rf = 0.5 (EtOAc/MeOH/AcOH/H2O 
60:3:3:2). 1H-NMR (400 MHz, DMSO-d6, gCOSY, gHSQC, gHMBC), δ (ppm): 7.88 (d, J=7.5, 2H, 
Fmoc), 7.84 - 7.70 (m, 4H, Fmoc, NH×2), 7.40 (t, J=7.4, 2H, Fmoc), 7.32 (dd, J=7.4, 6.3, 2H, 
Fmoc), 5.09 - 4.90 (m, 4H, H4, H3’, H1, H3), 4.84 (t, J=9.7, 1H, H4’), 4.48 (d, J=8.5, 1H, H1’), 
4.32 - 4.26 (m, 2H, FmocCH2), 4.26 - 4.16 (m, 3H, FmocCH, Thr-CHβ, Thr-CHα), 4.13 (dd, 
J=12.3, 4.8, 1H, H6a’), 4.06 - 3.86 (m, 5H, H6a, H2, H6b, H5, H6b’), 3.80 (dd, J=19.4, 9.4, 1H, 
H2’), 3.75 - 3.66 (m, 1H, H5’), 1.99 (s, 3H, Ac), 1.97 (d, J=3.9, 6H, Ac×2), 1.96 (s, 3H, Ac), 1.93 
(s, 3H, Ac), 1.90 (s, 3H, Ac), 1.75 (s, 3H, NHAc), 1.24 (d, J=5.8, 3H, Thr-CH3). 
13C-NMR (150.9 
MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 172.2, 170.7, 170.7, 170.4, 170.3, 170.1, 170.0, 
169.8 (172.2 - 169.8 Ac), 157.2 (NHCOFmoc), 144.4 (Fmoc-quaternary carbon), 141.3 
(Fmoc-quaternary carbon), 128.3, 127.7, 126.0, 120.7 (128.3 - 120.7 Fmoc aromatic), 100.9 
(C1’), 98.8 (C1), 76.9 (Thr-Cβ), 75.7 (C5), 72.7 (C3’), 71.5 (C5’), 70.2 (C4), 69.1 (C4’), 68.6 (C2), 
67.0 (FmocCH2), 66.6 (C3), 62.8 (C6), 62.5 (C6’), 59.2 (Thr-Cα), 53.2 (C2’), 47.3 (FmocCH), 
23.2 (NHAc), 21.1, 21.1, 21.0 (21.18 - 21.05 Ac), 18.2 (Thr-CH3). HR-ESI-MS (pos), m/z: 
959.3311 ([M+H]+, calc. 959.3297), 959.3297 ([M+NH4]
+, calc. 976.3563), 981.3098 ([M+Na]+, 
calc. 981.3117). 
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 7.21 Synthesis of Fmoc protected threonine tert-butylester 
N-9-Fluorenylmethoxycarbonyl-L-threonine (125)[302] 
To a stirring mixture of Thr (17.7 g, 148.5 mmol, 1.0 eq) and NaHCO3 (12.5 g, 
148.6 mmol, 1.0 eq) in acetone/H2O 1:1 (800 mL), Fmoc-OSu (50 g, 148.2 
mmol, 1.0 eq) was added in portion. The reaction was stirred at r.t. for 24 h. Then the 
mixture was acidified by conc. HCl until pH reach 2.0, acetone was removed under reduced 
pressure and the aqueous layer was then extracted with DCM (200 mL×3). The DCM layer 
was washed with 1 M HCl (100 mL×2), H2O (100 mL×2), brine (150 mL×1), dried over MgSO4, 
and the solvent was removed to give 125, yield 88% (44.6 g, 131 mmol). 1H-NMR (400 MHz, 
CDCl3), δ (ppm): 7.62 (d, J=7.6, 2H, Fmoc), 7.47 (m, 2H, Fmoc), 7.23 (t, J=7.2, 2H, Fmoc), 7.16 
(dd, J=7.3, 6.2, 2H, Fmoc), 5.99 (d, 1H, J=7.2, NH), 4.26 - 4.07 (m, 5H, FmocCH2, FmocCH, 
Thr-CHβ, Thr-CHα), 1.13 (d, J=5.6, 3H, Thr-CH3). 
N-9-Fluorenylmethoxycarbonyl-L-threonine-tert-butylester (126)[303] 
A mixture of tert-butanol (11.3 g, 14.5 mL, 152 mmol, 2.3 eq) with CuCl 
(0.6 g, 6 mmol, 0.09 eq) in DCC (55.35 g, 41.8 mL, 268 mmol, 4.0 eq) was stirred in the 
darkness under Ar for 72 h, the deep green solution was diluted with DCM (20 mL) and a 
solution of 125 (22.5 g, 66 mmol, 1.0 eq) in DCM (50 mL) was added dropwise over 1 h. The 
mixture was then stirred at r.t. for 2 h, filtered through a layer of Celite, washed with sat. 
NaHCO3 (100 mL×2), H2O (100 mL×2), brine (150 mL×1), dried over MgSO4 and concentrated. 
The residue was dissolved in EtOAc (200 mL), stored in freezer at -20 °C for 24 h, and filtered 
through a layer of Celite. The EtOAc solution was concentrated and the residue was purified 
by column chromatography (cyclohexane-ethyl acetate 4:1 to 3:1) to give 126 yield 83% (21.7 
g, 54.6 mmol). Rf = 0.4 (
CHex/EtOAc 3: 1). 1H-NMR (400 MHz, CDCl3), δ (ppm): 7.68 (d, J=7.7, 
2H, Fmoc), 7.53 (d, J=7.5 2H, Fmoc), 7.31 (t, J=7.2, 2H, Fmoc), 7.22 (dd, J=7.3, 6.2, 2H, Fmoc), 
5.53 (d, 1H, J=7.6, NH), 4.33 (d, 2H, J=7.2, FmocCH2), 4.21 - 4.15 (m, 3H, FmocCH, Thr-CHβ, 
Thr-CHα), 1.41 (s, 9H, C(CH3)3), 1.16 (d, J=5.8, 3H, Thr-CH3). 
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7.22 Synthesis of 2,6-OAc mannosyl donor for further elongation 
Allyl 2,6-di-O-acetyl-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyranoside (127) 
Compound 31 (6.93 g, 20.7 mmol) was dissolved in pyridine/acetic 
anhydride 2:1 (85 ml) and stirred at r.t. for 24 h. The solvent was then 
removed and the residue was coevaporated three times with toluene. 
Purification by column chromatography (cyclohexane-ethyl acetate 10:1 to 6:1) gave 127 
yield 93% (8.10 g, 19.4 mmol). Rf = 0.8 (
CHex/EtOAc 1:1). *α+D
20 = +137° (c = 1.0, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 436.2179 ([M+NH4]
+, calc. 
436.2183), 441.1729 ([M+Na]+, calc. 441.1737). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 5.87 (dddd, J=15.7, 10.4, 6.2, 5.3, 1H, CH2CH=CH2), 5.25 (ddd, J=17.2, 3.1, 
1.5, 1H, CH2CH=CH2), 5.18 (ddd, J=10.4, 2.7, 1.2, 1H, CH2CH=CH2), 5.04 (dd, J=3.3, 1.5, 1H, 
H2), 4.82 (d, J=1.4, 1H, H1), 4.32 (dd, J=12.0, 1.4, 1H, H6a), 4.27 - 4.20 (m, 1H, H6b), 4.18 - 
4.10 (m, 2H, H3, CH2CH=CH2), 3.99 (dt, J=6.5, 1.3, 1H, CH2CH=CH2), 3.98 - 3.93 (m, 2H, H4, 
H5), 3.24 (s, 3H, OCH3), 3.21 (s, 3H, OCH3), 2.12 (s, 3H, Ac), 2.07 (s, 3H, Ac), 1.25 (s, 3H, CH3), 
1.25 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.96 (CO2CH3), 
170.68 (CO2CH3), 133.52 (CH2CH=CH2), 118.13 (CH2CH=CH2), 100.44 (COCH3(CH3)), 100.09 
(COCH3(CH3)), 97.51 (C1), 70.67 (C2), 68.89 (C4), 68.67 (CH2CH=CH2), 66.16 (C3), 63.81 (C5), 
62.90 (C6), 48.27 (OCH3), 48.02 (OCH3), 21.34 (CO2CH3), 20.99 (CO2CH3), 17.95 (CH3), 17.83 
(CH3). 
2,6-di-O-acetyl-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyranoside (128) 
Compound 127 (8.02 g, 19.2 mmol, 1.0 eq) was dissolved in Tol/EtOAc/H2O 
20:10:1 (248 mL) and Wilkinson’s catalyst (2.66 mg, 2.9 mmol, 0.15 eq) was 
added. After refluxing for 24 h, the reaction mixture was cooled to r.t., 
filtered through a layer of Celite and concentrated. The residue was dissolved in THF/H2O 4:1 
(375 mL) followed by addition of I2 (19.4 g, 76.8 mmol, 4.0 eq). The reaction was kept stirring 
at r.t. for 2 h and neutralized with 1 M Na2S2O3. The suspension was concentrated to remove 
the THF and then diluted with DCM (100 mL), washed with 1 M Na2S2O3 (50 mL×2), H2O (50 
mL×2), brine (50 mL×1) and dried over MgSO4. The solvent was removed and the crude 
product was purified by column chromatography (cyclohexane-ethyl acetate 6:1 to 1:1) to 
give 128, yield 92% (6.67 g, 17.6 mmol). Rf = 0.4 (
CHex/EtOAc 1:1). *α+D
20 = +94° (c = 1.0, 
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 CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 396.1865 ([M+NH4]
+, 
calc. 396.1870), 401.1416 ([M+Na]+, calc. 401.1424). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 5.19 (s, 1H, H1), 5.06 - 5.03 (m, 1H, H2), 4.31 (d, J=11.5, 1H, H6a), 4.23 - 
4.17 (m, 3H, H6b, H3), 4.15 (t, J=4.5, 1H, H5), 3.97 (t, J=10.0, 1H, H4), 3.24 (s, 3H, OCH3), 3.21 
(s, 3H, OCH3), 2.12 (s, 3H, Ac), 2.05 (s, 3H, Ac), 1.25 (s, 6H, CH3). 
13C-NMR (100.6 MHz, CDCl3, 
gHSQC, gHMBC), δ (ppm): 171.17 (CO2CH3), 170.87 (CO2CH3), 100.43 (COCH3(CH3)), 100.09 
(COCH3(CH3)), 93.02 (C1), 71.21 (C2), 68.69 (C3), 65.69 (C5), 63.85 (C4), 63.08 (C6), 48.26 
(OCH3), 48.01 (OCH3), 21.39 (CO2CH3), 21.02 (CO2CH3), 17.97 (CH3), 17.85 (CH3). 
2,6-di-O-acetyl-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyranosyl trichloroaceti 
midate (129)  
A solution of 128 (6.67 g, 17.6 mmol, 1.0 eq) and trichloroacetonitrile 
(5.29 mL, 53.0 mmol, 3.0 eq) in anhydrous DCM (80 mL) was stirred 
under Ar at 0 °C and DBU (0.53 mL, 3.53 mmol, 0.2 eq) was added. After stirring at 0 °C for 3 
h, the reaction mixture was concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 2:1) to give 129, yield 78% (7.2 g, 13.8 mmol). Rf = 0.8 
(CHex/EtOAc 1:1). *α+D
20 = +98° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 539.1441 ([M+NH4]
+, calc. 539.0966), 544.0520 ([M+Na]+, calc. 
544.0520). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 8.72 (s, 1H, NH), 6.25 
(s, 1H, H1), 5.32 - 5.19 (m, 1H, H2), 4.37 (dd, J=12.1, 1.8, 1H, H6a), 4.23 (dd, J=12.0, 5.2, 1H, 
H6b), 4.19 (dd, J=9.9, 3.2, 1H, H3), 4.14 (ddd, J=10.3, 5.1, 1.4, 1H, H5), 4.13 - 4.02 (m, 1H, H4), 
3.24 (s, 3H, OCH3), 3.23 (s, 3H, OCH3), 2.16 (s, 3H, Ac), 2.05 (s, 3H, Ac), 1.27 (s, 3H, CH3), 1.26 
(s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.88 (CO2CH3), 170.23 
(CO2CH3), 160.09 (C=NH), 100.44 (COCH3(CH3)), 100.17 (COCH3(CH3)), 95.49 (C1), 71.79 (C5), 
68.86 (C2), 66.17 (C3), 63.19 (C4), 62.45 (C6), 48.17 (OCH3), 48.11 (OCH3), 21.18 (CO2CH3), 
20.96 (CO2CH3), 17.94 (CH3), 17.79 (CH3). 
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7.23 Synthesis of a 2,6-branched GlcNAc2-Man glycosylated amino acid 
N-9-Fluorenylmethoxycarbonyl-O-[2,6-di-O-acetyl-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-
α-D-mannopyranosyl]-L-threonine-tert-butylester (130)  
The trichloroacetimidate donor 129 (3.96 g, 7.58 mmol, 1.2 eq) 
and the protected amino acid 126 (2.51 g, 6.32 mmol, 1.0 eq) was 
dissolved in dry Et2O (50 ml) and 4 Å molecular sieves (2.5 g) was 
added. The suspension was stirred under argon at r.t. for 30 min 
and trimethylsilyl -trifluoromethanesulfonate (TMSOTf) (0.23 mL, 1.27 mmol, 0.2 eq) was 
added. The reaction was kept stirring at r.t. for 30 min, then quenched with triethylamine 
(0.23 mL). The molecular sieves were removed by filtering over a layer of Celite. The filtrate 
was concentrated and purified by column chromatography (cyclohexane-ethyl acetate 10:1 
to 3:1) to give 130. Yield 84% (4.02 g, 5.30 mmol). Rf = 0.8 (DCM/MeOH 95:5). *α+D
20 = +91° (c 
= 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 758.3380 
([M+H]+, calc. 758.3388), 775.3658 ([M+NH4]
+, calc. 775.3653), 780.3216 ([M+Na]+, calc. 
780.3207), 712.2744 ([M+K]+, calc. 712.2735). 1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, 
gHMBC), δ (ppm): 7.77 (d, J=7.4, 2H, Fmoc), 7.68 - 7.61 (m, 2H, Fmoc), 7.40 (t, J=7.2, 2H, 
Fmoc), 7.33 (dd, J=12.9, 7.1, 2H, Fmoc), 5.40 (d, J=9.4, 1H, NH), 4.96 (s, 1H, H2), 4.88 (s, 1H, 
H1), 4.45 - 4.37 (m, 2H, FmocCH2), 4.35 - 4.18 (m, 5H, Thr-CHβ, H6a, H6b, Thr-CHα, FmocCH), 
4.09 - 4.02 (m, 2H, H3, H5), 4.01 - 3.93 (m, 1H, H4), 3.30 (s, 3H, OCH3), 3.23 (s, 3H, OCH3), 
2.13 (s, 3H, Ac), 2.06 (s, 3H, Ac), 1.49 (s, 9H, tBu), 1.33 (d, J=6.3, 3H, Thr-CH3), 1.30 (s, 3H, 
CH3), 1.28 (s, 3H, CH3).
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.91, 170.30, 
169.23, 156.88 (NHCOFmoc), 144.12 (Fmoc quaternary), 144.03 (Fmoc quaternary), 141.51 
(Fmoc quaternary), 127.93, 127.30, 125.40, 120.19 (127.9-120.2 Fmoc aromatic), 100.50 
(OC(CH3)OCH3), 100.18 (OC(CH3)OCH3), 99.80 (C1), 82.99 (CCH3), 77.98 (Thr-Cβ), 70.55 (C2), 
69.37 (C5), 67.60 (FmocCH2), 66.14 (C3), 63.90 (C4), 62.94 (C6), 59.35 (Thr-Cα), 48.45 (OCH3), 
48.11 (OCH3), 47.40 (FmocCH), 28.20 (CCH3), 27.13, 21.25 (Ac), 20.95 (Ac), 18.36 (Thr-CH3), 
17.99 (CH3), 17.85 (CH3). 
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 N-9-Fluorenylmethoxycarbonyl-O-[3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyra
nosyl]-L-threonine-tert-butylester (131) 
Compound 130 (10.3 g, 13.6 mmol, 1.0 eq) was dissolved in MeOH 
(270 ml) followed by dropwise addition of a 1% solution of NaOMe 
in MeOH until pH 9.0-9.5. The reaction mixture was stirred 24 h at 
r.t. and then neutralized by a small amount of Dowex 50WX8 ion-exchanger, filtered and 
concentrated. The residue was dissolved in 1,4-dioxane/H2O 1:1 (100 mL) with NaHCO3 (1.49 
g, 17.7 mmol, 1.3 eq), and Fmoc-OSu (4.59 g, 13.6 mmol, 1.0 eq) was added in portions. The 
reaction was stirred at r.t. for 2 h. Then the dioxane was removed under reduced pressure 
and the residue was extracted with DCM (100 mL×3). The DCM layer was washed with brine 
(200 mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:3) to give 131. Yield: 78% (7.2 g, 10.7 mmol). Rf = 0.4 
(CHex/EtOAc 1:2). *α+D
20 = +114° (c = 1.1, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 674.3180 ([M+H]+, calc. 674.3177), 691.3443 ([M+NH4]
+, calc. 691.3442), 
696.3003 ([M+Na]+, calc. 696.2996), 1347.6301 ([2M+H]+, calc. 1347.6275), 1364.6555 
([2M+NH4]
+, calc. 1364.6540), 1369.6130 ([2M+Na]+, calc. 1369.6094). 1H-NMR (400 MHz, 
DMSO-d6, gCOSY, gHSQC, gHMBC), δ (ppm): 7.87 (d, J=7.5, 2H, Fmoc), 7.74 (d, J=7.5, 2H, 
Fmoc), 7.64 (d, J=8.4, 1H, NH), 7.40 (t, J=7.4, 2H, Fmoc), 7.31 (td, J=7.5, 1.0, 2H, Fmoc), 5.05 
(d, J=5.2, 1H, OH), 4.73 (s, 1H, H1), 4.54 (dt, J=11.7, 6.1, 1H, OH), 4.32 - 4.25 (m, 2H, 
FmocCH2), 4.25 - 4.20 (m, 1H, FmocCH), 4.09 (d, J=6.8, 2H, Thr-CHβ, Thr-CHα), 3.80 - 3.72 (m, 
2H, H4, H3), 3.67 - 3.57 (m, 3H, H6a, H5, H2), 3.49 - 3.42 (m, 1H, H6b), 3.14 (s, 3H, OCH3), 
3.11 (s, 3H, OCH3), 1.41 (d, J=10.1, 9H, tBu), 1.19 (s, 3H, Thr-CH3), 1.15 (m, 6H, CH3×2). 
13C-NMR (100.6 MHz, DMSO-d6, gHSQC, gHMBC), δ (ppm): 170.98, 169.89, 157.18, 144.45 
(Fmoc quaternary), 144.43( Fmoc quaternary), 141.38 (Fmoc quaternary), 128.34, 127.73, 
126.04, 120.77 (128.3-120.8 Fmoc aromatic), 102.59 (C1), 100.03 (OC(CH3)OCH3), 99.57 
(OC(CH3)OCH3), 81.61 (CCH3), 75.43 (Thr-Cβ), 72.64 (C2), 68.85 (C5), 68.38 (C3), 66.65 
(FmocCH2), 63.66 (C4), 60.92 (C6), 59.73 (Thr-Cα), 47.97 (OCH3), 47.87, (OCH3) 47.34 
(FmocCH), 31.99, 28.32 (CCH3), 21.42, 19.51, 18.61 (Thr-CH3), 18.48 (CH3), 18.35, (CH3) 14.76, 
14.44. 
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N-9-Fluorenylmethoxycarbonyl-O-{2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2-N-(2,2,2-trichlor
oethoxycarbonylamino)-β-D-glucopyranosyl-(1→2)-[2-deoxy-3,4,6-tri-O-p-methoxybenzyl-2
-N-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl]-(1→6)-3,4-O-(2’,3’-dimethoxy
butane-2’,3’-diyl)-α-D-mannopyranosyl}-L-threonine-tert-butylester (132) 
Compounds 54 (3.60 g, 4.46 mmol, 3.0 eq), 131 (1.00 g, 
1.48 mmol, 1.0 eq), N-iodosuccinimide (1.00 g, 4.46 mmol, 
3.0 eq) and 4 Å molecular sieves (1.5 g) in dry 
dichloromethane (15 mL) were stirred at room temperature 
for 30 min under argon atmosphere. Then the suspension 
was cooled to -50 °C followed by slow addition of 
trifluoromethanesulfonic acid (6.6 μL, 0.074 mmol, 0.05 eq). After stirring for 4 h at -40 to - 
50 °C, the reaction was quenched by diluting with more DCM (60 mL). The molecular sieves 
were removed by filtration and the filtrate was washed with 1 M Na2S2O3 (50 mL×3), brine 
(100 mL×1), dried over MgSO4, concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 1:3) to give 132. Yield: 90% (2.78 g, 1.34 mmol). Rf = 0.6 
(CHex/EtOAc 2:1).  
The trichloroacetimidate donor 62 (731 mg, 0.40 mmol, 1.0 eq) and the protected amino 
acid 126 (317 mg, 0.80 mmol, 2.0 eq) was dissolved in dry DCM (10 ml) and 4 Å molecular 
sieves (1 g) was added. The suspension was stirred under argon at r.t. for 30 min and 
trimethylsilyl -trifluoromethanesulfonate (TMSOTf) (14.5 μL, 0.08 mmol, 0.2 eq) was added 
under cooling with an ice bath. The reaction was kept stirring at 0 °C for 2 h, then neutralized 
with triethylamine (0.14 mL). The molecular sieves were removed by filtering over a layer of 
Celite. The filtrate was concentrated and purified by column chromatography 
(cyclohexane-ethyl acetate 10:1 to 3:2) to give 132. Yield 82% (672 mg, 0.33 mmol). Rf = 0.3 
(DCM/MeOH 95:5). *α+D
20 = +32° (c = 1.3, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1044.7902 ([M+H+Na]2+, calc. 1044.7978), 1050.8342 ([M+2NH4]
2+, calc. 
1050.8334), 1053.2823 ([M+Na+NH4]
2+, calc. 1053.3111). 1H-NMR (400 MHz, CDCl3, gCOSY, 
gHSQC, gHMBC), δ (ppm): 7.76 (d, J=7.5, 2H, Fmoc), 7.63 - 7.56 (m, 2H, Fmoc), 7.39 (t, J=7.4, 
2H, Fmoc), 7.34 - 7.15 (m, 10H, Fmoc, Ph), 7.08 (d, J=8.2, 4H, Ph), 6.84 (m, 12H, Ph), 6.39 (s, 
1H, NH’), 5.44 (s, 1H, NH), 5.31 (s, 1H, NH’’), 5.01 (d, J=8.0, 1H, H1’), 4.97 (d, J=12.7, 1H, 
CH2Ph), 4.91 (s, 1H, H1), 4.81 - 4.63 (m, 8H, TrocCH2×2, CH2Ph×6), 4.61 - 4.52 (m, 3H, 
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 CH2Ph×3), 4.51 - 4.42 (m, 4H, TrocCH2×2, CH2Ph×2), 4.39 (d, J=7.2, 3H, FmocCH2, H3’), 4.33 - 
4.21 (m, 3H, Thr-CHβ, Thr-CHα, FmocCH), 4.17 - 4.09 (m, 1H, H6a), 4.04 - 3.96 (m, 2H, H2, 
H3), 3.93 (d, J=4.4, 2H, H4, H5), 3.81 - 3.74 (m, 18H, PMBCH3×6), 3.72 - 3.66 (m, 2H, H6a’, 
H6a’’), 6.66 - 3.54 (m, 5H, H6b’, H6b’’, H6b, H2’’, H4’’), 3.54 - 3.44 (m, H4’, H5’, H5’’), 3.28 (s, 
3H, OCH3), 3.21 (s, 3H, OCH3), 1.46 (s, 9H, tBu), 1.33 (s, 3H, CH3), 1.30 (d, J=6.1, 3H, Thr-CH3), 
1.28 (s, 3H, CH3). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 159.44 (PhCOCH3), 
159.40 (PhCOCH3), 144.08 (Fmoc quaternary), 141.50 (Fmoc quaternary), 130.73, 130.54, 
130.48, 130.41, 129.80, 129.72, 129.66, 129.56, 127.92 (130.7-127.9 aromatic), 127.33, 
125.44, 125.39, 120.18 (127.3-120.2 Fmoc aromatic), 114.03, 114.01, 113.98, 113.96 
(114.0-113.9 aromatic), 100.78 (C1’’), 100.37 (OC(CH3)OCH3), 99.84 (OC(CH3)OCH3), 99.56 
(C1), 97.30 (C1’), 82.57 (CCH3), 79.53 (C3’), 78.52 (C4’), 78.37 (C4’’), 75.95 (C3’), 75.69 (C5’), 
75.25 (C5’’), 74.77 (PMBCH2), 74.69 (PMBCH2), 74.62 (PMBCH2), 74.54 (TrocCH2), 74.48 
(TrocCH2), 74.26 (PMBCH2), 73.34 (PMBCH2), 73.27 (PMBCH2), 71.87 (C2), 71.25 (C5), 68.76 
(C6’), 68.56 (C6’’), 67.55 (FmocCH2), 67.08 (C6, C3), 63.71 (C4), 58.82 (Thr-Cα), 58.00 (C2’), 
57.78 (C2’’), 55.49, 55.47, 55.42 (55.5-55.4 PMBCH3), 48.44 (OCH3), 48.20 (OCH3), 47.38 
(FmocCH), 28.35 (CCH3), 18.36 (Thr-CH3), 18.05 (CH3), 17.97 (CH3). 
N-9-Fluorenylmethoxycarbonyl-O-{3,4,6-tri-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroethoxycar
bonylamino)-β-D-glucopyranosyl-(1→2)-[ 3,4,6-tri-O-acetyl-2-deoxy-2-N-(2,2,2-trichloroeth
oxycarbonylamino)-β-D-glucopyranosyl]-(1→6)-3,4-O-(2’,3’-dimethoxybutane-2’,3’-diyl)-α-D
-mannopyranosyl}-L-threonine-tert-butylester (133) 
To a stirring solution of 132 (1.59 g, 0.77 mmol, 1.0 eq) in 
MeCN/H2O 9:1 (30 mL), cerium ammonium nitrate (5.04 g, 
9.20 mmol, 12.0 eq) was added. The reaction was stirred at 
r.t. for 30 min and quenched with Sat. NaHCO3 until the 
orange color was removed. The mixture was filtered through 
a layer of Celite, washed with EtOAc (20 mL ×2), H2O (20 mL ×2), MeOH (20 mL ×2) and DCM 
(20 mL ×2). The filtrate was combined and concentrated to remove the organic solvent, and 
the residue was extracted with DCM (20 mL ×3). The organic layer was then washed with 
brine (30 mL) and concentrated to dryness. The crude product was acetylated with 
pyridine/acetic anhydride 2:1 (15 mL) for 24 h, concentrated and coevaporated with toluene 
(15 mL ×3), and purified by column chromatography (cyclohexane-ethyl acetate 10:1 to 3:2) 
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to give 133. Yield 91% (1.12 g, 0.70 mmol). Rf = 0.5 (Tol/EtOAc 1:1). *α+D
20 = +19° (c = 1.2, 
CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1600.3180 ([M+H]
+, 
calc. 1600.3212), 1634.3535 ([M+NH3+NH4]
+, calc. 1634.37743). 1H-NMR (400 MHz, CDCl3, 
gCOSY, gHSQC, gHMBC), δ (ppm): 7.75 (d, J=7.5, 2H, Fmoc), 7.61 (d, J=7.3, 2H, Fmoc), 7.38 (t, 
J=7.4, 2H, Fmoc), 7.29 (dd, J=13.2, 5.9, 2H, Fmoc), 6.30 (d, J=3.3, 1H, NH’), 5.83 (t, J=9.3, 1H, 
H3’), 5.67 (d, J=8.6, 1H, NH’’), 5.61 (d, J=7.3, 1H, NH), 5.32 - 5.22 (m, 1H, H3’’), 5.18 (d, J=8.0, 
1H, H1’), 5.03 (dd, J=19.8, 10.0, 2H, H4’’, H4’), 4.84 (d, J=10.9, 3H, H1, TrocCH2), 4.70 (d, J=7.8, 
1H, H1’’), 4.68 - 4.56 (m, 2H, TrocCH2), 4.45 (d, J=7.2, 1H, FmocCH2), 4.36 (d, J=7.2, 1H, 
FmocCH2), 4.34 - 4.27 (m, 3H, Thr-CHβ, H6a’, Thr-CHα), 4.26 - 4.20 (m, 2H, H6a’’, FmocCH), 
4.14 - 4.08 (m, 2H, H6b’, H6b’’), 4.06 (d, J=12.1, 1H, H6a), 3.98 (d, J=8.2, 2H, H2, H3), 3.88 (d, 
J=7.0, 2H, H4, H5), 3.78 - 3.71 (m, 2H, H5’ H2’’), 3.71 - 3.63 (m, 2H, H5’’, H6b), 3.45 (dd, J=7.9, 
5.6, 1H, H2’), 3.30 (s, 3H, OCH3), 3.23 (s, 3H, OCH3), 2.06 (s, 3H, Ac), 2.05 (s, 3H, Ac), 2.01 (s, 
3H, Ac), 1.99 (s, 6H, Ac×2), 1.94 (s, 3H, Ac), 1.48 (s, 9H, tBu), 1.31 (d, J=5.6, 3H, Thr-CH3), 1.27 
(s, 6H, CH3×2). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 170.88, 169.99, 169.63 
(170.9-169.6 Ac), 156.72 (NHCOFmoc), 154.29, 144.10, 144.00, 141.51, 141.49 (144.1 - 141.5 
Fmoc quaternary), 127.92, 127.28, 125.34, 120.19 (127.9-120.2 Fmoc aromatic), 100.95 
(C1’’), 100.29 (OC(CH3)OCH3), 100.00 (OC(CH3)OCH3), 99.42 (C1), 97.02 (C1’), 82.69 (CCH3), 
75.48 (Thr-Cβ), 74.63 (TrocCH2), 74.40 (TrocCH2), 72.46 (C5’), 72.33 (C3’’), 71.94 (C2, C5’’), 
71.29 (C5), 70.85 (C3’), 69.34 (C4’), 68.95 (C4’’), 67.41 (C6, FmocCH2), 66.99 (C3), 63.56 (C4), 
62.29 (C6’), 62.18 (C6’’), 58.63 (Thr-Cα), 56.48 (C2’’, C2’), 48.52 (OCH3), 48.26 (OCH3), 47.39 
(FmocCH), 28.27 (CCH3), 20.95, 20.92, 20.87, 20.84, 20.82, 20.77 (21.0 - 20.8 Ac), 18.44 
(Thr-CH3), 17.96 (CH3), 17.82 (CH3), 14.40, 14.11. 
N-9-Fluorenylmethoxycarbonyl-O-{2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyra
nosyl-(1→2)-[2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl]-(1→6)-3,4-O-(2
’,3’-dimethoxybutane-2’,3’-diyl)-α-D-mannopyranosyl}-L-threonine-tert-butylester (134) 
Zinc powder was activated by treatment with 1 M HCl aq. for 
20 min, washed with H2O, MeOH, Et2O and dried under 
reduced pressure for 30 min. Compound 133 (1.22 g, 0.76 
mmol, 1.0 eq) was dissolved in glacial acetic acid (12 mL) 
followed by addition of the activated Zn powder (1 g, 15.4 
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 mmol, 20 eq). The reaction mixture was stirred at room temperature for 96 h and was then 
filtered through a thin layer of Celite. The filtrate was concentrated and coevaporated with 
toluene (15 mL×3). The residue was dissolved in pyridine / acetic anhydride 2:1 (15 mL) and 
stirred at r.t. overnight. Then the reaction mixture was concentrated and coevaporated three 
times with toluene. Purification by column chromatography (cyclohexane-ethyl acetate 10:1 
to 1:1) gave 134. Yield: 85% (0.87 g, 0.65 mmol). Rf = 0.2 (EtOAc). *α+D
20 = +22° (c = 0.9, CHCl3). 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1332.5401 ([M+H]+, calc. 
1332.5398), 1349.5706 ([M+NH4]
+, calc. 1349.5663), 1354.5251 ([M+Na]+, calc. 1354.5217). 
1H-NMR (400 MHz, CDCl3, gCOSY, gHSQC, gHMBC), δ (ppm): 7.69 (d, J=7.5, 2H, Fmoc), 7.59 - 
7.50 (m, 2H, Fmoc), 7.32 (t, J=7.4, 2H, Fmoc), 7.28 - 7.19 (m, 2H, Fmoc), 6.91 (d, J=7.0, 1H, 
NH’), 6.11 (d, J=9.1, 1H, NH’’), 5.77 (t, J=9.8, 1H, H3’), 5.50 (d, J=9.2, 1H, NH), 5.23 - 5.14 (m, 
2H, H3’’, H1’), 5.01 - 4.91 (m, 2H, H4’’, H4’), 4.85 (s, 1H, H1), 4.54 (d, J=8.2, 1H, H1’’), 4.33 (m, 
2H, FmocCH2), 4.26 - 4.10 (m, 5H, Thr-CHβ, H6a’, H6a’’, Thr-CHα, FmocCH), 4.04 (d, J=12.1, 
2H, H6b’, H6b’’), 3.99 - 3.82 (m, 4H, H6a, H3, H4, H2’’), 3.81 - 3.67 (m, 2H, H2, H5), 3.65 - 3.57 
(m, 2H, H5’, H5’’), 3.57 - 3.50 (m, 1H, H6b), 3.21 (m, 4H, H2’, OCH3), 3.14 (s, 3H, OCH3), 1.98 (s, 
3H, Ac), 1.97 (s, 3H, Ac), 1.96 (s, 3H, Ac), 1.94 (s, 3H, Ac), 1.93 (s, 6H, Ac×2), 1.91 (s, 3H, 
NHAc), 1.90 (s, 3H, NHAc), 1.43 (s, 9H, tBu), 1.25 (d, J=6.3, 3H, Thr-CH3), 1.23 - 1.16 (m, 6H, 
CH3×2). 
13C-NMR (100.6 MHz, CDCl3, gHSQC, gHMBC), δ (ppm): 172.11, 171.13, 170.89, 
170.83, 170.77, 170.30, 169.95, 169.57 (172.1-169.6 Ac), 156.72 (NHCOFmoc), 144.09 (Fmoc 
quaternary), 143.96 (Fmoc quaternary), 141.48 (Fmoc quaternary), 127.93, 127.30, 125.34, 
120.20 (127.9-120.2 Fmoc aromatic), 101.22 (C1’’), 100.40 (OC(CH3)OCH3), 99.94 
(OC(CH3)OCH3), 99.44 (C1), 97.42 (C1’), 82.57 (CCH3), 76.58 (Thr-Cβ), 74.04 (C2), 72.56 (C3’’), 
72.17 (C5’), 71.93 (C5’’), 71.26 (C3’), 70.56 (C5), 69.49 (C4’), 68.91 (C4’’), 67.45 (FmocCH2), 
67.02 (C3), 66.60 (C6), 62.90 (C4), 62.42 (C6’’), 62.28 (C6’), 59.07 (Thr-Cα), 56.28 (C2’), 54.70 
(C2’’), 48.36 (OCH3), 48.28 (OCH3), 47.38 (FmocCH), 28.29 (CCH3), 23.69 (NHAc), 21.06, 20.98, 
20.93, 20.89, 20.85, 20.81 (21.1 - 20.8 Ac), 18.45 (Thr-CH3), 18.15 (CH3), 18.01 (CH3). 
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N-9-Fluorenylmethoxycarbonyl-O-{2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyra
nosyl-(1→2)-[2-N-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-glucopyranosyl]-(1→6)-α-D-ma
nnopyranosyl}-L-threonine (135) 
Compound 134 (766 mg, 0.57 mmol) was dissolved in TFA/DCM 
3:1 (10 mL) and was stirred at r.t. for 24 h. The solution was 
then concentrated and coevaporated with toluene (10 mL×3), 
purification by silica column chromatography (DCM-MeOH 
100:1 to 10:1) gave 135. Yield: 62% (415 g, 0.33 mmol). Rf = 0.2 (EtOAc/MeOH/AcOH/H2O 
60:3:3:2). *α+D
20 = +79° (c = 0.9, CHCl3). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass 
spectrometer), m/z: 1162.4094 ([M+H]+, calc. 1162.4091), 1179.4368 ([M+NH4]
+, calc. 
1179.4357), 1184.3928 ([M+Na]+, calc. 1184.3910). 1H-NMR (600 MHz, DMSO-d6, gCOSY, 
gHSQC, gHMBC), δ (ppm): 7.88 (dd, J=20.1, 8.3, 2H, Fmoc), 7.77 (dd, J=6.7, 4.4, 2H, Fmoc), 
7.43 (t, J=7.4, 2H, Fmoc), 7.35 (t, J=7.2, 2H, Fmoc), 5.19 (t, J=9.9, 1H, H3’), 5.12 (t, J=9.9, 1H, 
H3’’), 4.85 (m, 4H, NH, H1, H4’’, H4’), 4.67 (d, J=8.2, 1H, H1’), 4.62 (d, J=8.3, 1H, H1’’), 4.34 - 
4.22 (m, 4H, NH, FmocCH2, FmocCH), 4.20 (m, 2H, 6a’, 6a’’), 4.14 (m, 2H, Thr-CHβ, Thr-CHα), 
4.00 (t, J=9.8, 2H, 6a, 6b’’), 3.96 (d, J=10.7, 1H, 6b’), 3.85 - 3.80 (m, 1H, H5’’), 3.80 - 3.76 (m, 
1H, H5’), 3.76 - 3.56 (m, 5H, H2, H2’’, H2’, H3, H4), 3.41 (m, 1H, 6b), 3.19 (dd, J=14.8, 9.4, 1H, 
H5), 2.02 (s, 3H, Ac), 1.99 (s, 3H, Ac), 1.97 (s, 6H, Ac), 1.95 (s, 3H, Ac), 1.92 (s, 3H, Ac), 1.81 (s, 
3H, NHAc), 1.78 (d, J=11.3, 3H, NHAc), 1.19 (d, J=5.8, 3H, Thr-CH3). 
13C-NMR (150.9 MHz, 
DMSO-d6, gHSQC, gHMBC), δ (ppm): 172.38, 170.57, 170.54, 170.37, 170.15, 170.12, 169.77, 
169.74 (172.4-169.7 Ac), 157.03 (NHCOFmoc), 144.27 (Fmoc quaternary), 141.16 (Fmoc 
quaternary), 129.36, 128.67, 128.15, 127.58, 125.90, 125.84, 121.84, 120.57, 120.49 
(129.4-120.6 Fmoc aromatic), 101.45 (C1’’), 99.96 (C1’), 99.00 (C1), 78.49 (C2), 76.04 
(Thr-Cβ), 73.06 (C4), 72.96 (C3’’), 72.63(C3’), 71.39 (C5’), 71.06 (C5’’), 70.57 (C6), 69.64 (C3), 
69.13 (C4’,C4’’), 67.58 (C5), 66.46 (FmocCH2), 62.27 (C6’, C6’’), 59.38 (Thr-Cα), 53.89 (C2’’), 
53.78 (C2’), 47.13 (FmocCH), 46.13, 23.41, 23.18, 20.97, 20.94, 20.87, 20.82 (23.41-20.82 Ac), 
18.62 (Thr-CH3). 
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 7.24 Synthesis of N-GlcNAc peptides 
The N-glycopeptides 136 - 163 were synthesized by stepwise solid-phase peptide synthesis 
using the Fmoc strategy and starting with preloaded PHB Fmoc-Arg (Pbf) resin or tentagel 
PHB Fmoc-Lys (Boc) resin (12.5 μmol scale). The glycopeptide synthesis performed using 1.5 
eq of the protected N-glycosylated building block 6, which was pre-activated manually using 
1.5 eq HATU/HOAt and 3.0 eq of DIPEA (8 h coupling time). The standard Fmoc amino acids 
were coupled automatically on a Multisyntech peptide synthesizer using 8 eq of the amino 
acid, 8 eq of the HBTU/HOBt reagents and 16 eq of DIPEA (40 min). Fmoc deprotection was 
done according to standard conditions, 20% piperidine in DMF. For peptides 150 - 163, 
assembly of the peptide backbone was followed by coupling of a triethyleneglycol amino acid 
spacer to the N-terminus and then Fmoc deprotection. The obtained peptides were then 
released from the resin, and all acid sensitive side-chain protecting groups were 
simultaneously removed using TFA/TIPS/H2O 15:0.9:0.9 for 3 h, followed by solvent 
concentration, lyophilization and purification using a C-18 cartridge (1 g of C-18 material, 
Waters). For saccharide deprotection, the O-acetyl groups were removed by 
transesterification in methanol using catalytic amounts of NaOMe at pH 9-9.5 for 24 h (the 
deprotection was followed by analytical HPLC) to yield glycopeptides 136 - 163 which were 
purified by preparative HPLC. 
Sequence: NH2-IN*TTADEKDPTNPFR, *=GlcNAc (136) 
Yield: 73% (17.5 mg, 9.11 μmol). Analytical HPLC Rt= 23.01 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.92 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(75:25), 35 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 961.4615 ([M+2H]2+, calc. 961.4611), 
972.4557 ([M+Na+H]2+, calc. 972.4521), 641.3091 ([M+3H]3+, calc. 641.3100), 648.9727 
([M+Na+2H]3+, calc. 648.9718), 654.2944 ([M+Na+NH4+H]
3+, calc. 654.3128). 
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Sequence: NH2-AN*HSGAVVLLKR, *=GlcNAc (137) 
Yield: 83% (15.2 mg, 10.36 μmol). Analytical HPLC Rt= 22.25 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.58 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(75:25), 35 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1467.8326 ([M+H]+, calc. 1467.8283), 
734.4180 ([M+2H]2+, calc. 734.4181), 745.4097 ([M+Na+H]2+, calc. 745.4091), 489.9470 
([M+3H]3+, calc. 489.9480)，502.9314 ([M+Na+NH4+H]
3+, calc. 502.9508), 367.7123 ([M+4H]4+, 
calc. 367.7129). 
Sequence: NH2-VVN*STTGPGEHLR, *=GlcNAc (138) 
Yield: 82% (16.0 mg, 10.19 μmol). Analytical HPLC Rt= 17.34 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 10.23 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 785.3972 ([M+2H]2+, calc. 785.3975), 
796.3912 ([M+Na+H]2+, calc. 796.3885), 523.9336 ([M+3H]3+, calc. 523.9343), 536.9182 
([M+Na+NH4+H]
3+, calc. 536.9371). 
Sequence: NH2-WVSN*KTEGR, *=GlcNAc (139) 
Yield: 88% (14.0 mg, 10.94 μmol). Analytical HPLC Rt= 14.65 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 9.27 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 640.3170 ([M+2H]2+, calc. 640.3180), 
651.3103 ([M+Na+H]2+, calc. 651.3090), 427.2140 ([M+3H]3+, calc. 427.2146), 440.1982 
([M+Na+NH4+H]
3+, calc. 440.2175). 
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 Sequence: NH2-LRPDDSKN*FSIQVR, *=GlcNAc (140) 
Yield: 86% (20.1 mg, 10.70 μmol). Analytical HPLC Rt= 24.09 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 13.22 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(75:25), 35 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 939.4904 ([M+2H]2+, calc. 939.4899), 
950.4831 ([M+Na+H]2+, calc. 950.4809), 626.6616 ([M+3H]3+, calc. 626.6625), 639.6468 
([M+Na+NH4+H]
3+, calc. 639.6654), 470.2486 ([M+4H]4+, calc. 470.2489). 
Sequence: NH2-GEYFVN*VTTR, *=GlcNAc (141) 
Yield: 7.5% (1.3 mg, 0.94 μmol). Analytical HPLC Rt= 24.82 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.09 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1388.6814 ([M+H]+, calc. 1388.6697), 
694.8384 ([M+2H]2+, calc. 694.8388), 705.8313 ([M+Na+H]2+, calc. 705.8298), 476.5459 
([M+Na+NH4+H]
3+, calc. 476.5646). 
Sequence: NH2-AYSWN*ISR, *=GlcNAc (142) 
Yield: 64% (9.6 mg, 8.00 μmol). Analytical HPLC Rt= 25.14 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.19 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 600.2878 ([M+2H]2+, calc. 600.2887), 
611.2804 ([M+Na+H]2+, calc. 611.2797), 413.5121 ([M+Na+NH4+H]
3+, calc. 413.5313). 
Sequence: NH2-N*LTALPPDLPK, *=GlcNAc (143) 
Yield: 62% (10.7 mg, 7.74 μmol). Analytical HPLC Rt= 27.37 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 15.08 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
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MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1381.7710 ([M+H]+, calc. 1381.7578), 
691.3824 ([M+2H]2+, calc. 691.3828), 702.3757 ([M+Na+H]2+, calc. 702.3738), 474.2422 
([M+Na+NH4+H]
3+, calc. 474.2607). 
Sequence: NH2-LQN*LTLPTNASIK, *=GlcNAc (144) 
Yield: 57% (11.5 mg, 7.12 μmol). Analytical HPLC Rt= 26.71 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.51 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 808.4493 ([M+2H]2+, calc. 808.4492), 
819.4442 ([M+Na+H]2+, calc. 819.4402), 539.3034 ([M+3H]3+, calc. 539.3021), 552.2873 
([M+Na+NH4+H]
3+, calc. 552.3049). 
Sequence: NH2-SN*YSSPSNISK, *=GlcNAc (145) 
Yield: 51% (8.8 mg, 6.35 μmol). Analytical HPLC Rt= 15.58 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 9.38 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1386.6535 ([M+H]+, calc. 1386.6388), 
693.8231 ([M+2H]2+, calc. 693.8233), 704.8163 ([M+Na+H]2+, calc. 704.8143), 475.8693 
([M+Na+NH4+H]
3+, calc. 475.8877). 
Sequence: NH2-ELISN*ASDALDK, *=GlcNAc (146) 
Yield: 34% (6.6 mg, 4.46 μmol). Analytical HPLC Rt= 23.12 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.99 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 739.8649 ([M+2H]2+, calc. 739.8652), 
750.8583 ([M+Na+H]2+, calc. 750.8562), 506.5637 ([M+Na+NH4+H]
3+, calc. 506.5822). 
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 Sequence: NH2-LLDLSGNN*LTHLPK, *=GlcNAc (147) 
Yield: 60% (13.0 mg, 7.48 μmol). Analytical HPLC Rt= 30.21 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 16.00 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 869.4743 ([M+2H]2+, calc. 869.4732), 
880.3617 ([M+Na+H]2+, calc. 880.4642), 579.9839 ([M+3H]3+, calc. 579.9847). 
Sequence: NH2-LQNLTLPTN*ASIK, *=GlcNAc (148) 
Yield: 60% (12.0 mg, 7.43 μmol). Analytical HPLC Rt= 26.99 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.66 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 808.4482 ([M+2H]2+, calc. 808.4492), 
819.4434 ([M+Na+H]2+, calc. 819.4402), 539.3030 ([M+3H]3+, calc. 539.3021). 
Sequence: NH2-SNYSSPSN*ISK, *=GlcNAc (149) 
Yield: 74% (12.9 mg, 9.30 μmol). Analytical HPLC Rt= 15.40 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 9.16 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1386.6539 ([M+H]+, calc. 1386.6388), 
693.8233 ([M+2H]2+, calc. 692.8233), 704.8167 ([M+Na+H]2+, calc. 704.8143), 475.8694 
([M+Na+NH4+H]
3+, calc. 475.). 
Sequence: NH2-Spacer-IN*TTADEKDPTNPFR, *=GlcNAc (150) 
Yield: 66% (17.5 mg, 8.23 μmol). Analytical HPLC Rt= 23.56 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(35:65), 30 min, wavelength=214 
nm). Preparative HPLC Rt= 13.72 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
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(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1063.0251 ([M+2H]2+, calc. 1063.0190), 
1074.0178 ([M+Na+H]2+, calc. 1074.0100), 1082.5016 ([M+Na+NH4]
2+, calc. 1082.5233), 
709.0148 ([M+3H]3+, calc. 709.0152), 716.6787 ([M+Na+2H]3+, calc. 716.6770), 722.0003 
([M+Na+NH4+H]
3+, calc. 722.0181). 
Sequence: NH2-Spacer-AN*HSGAVVLLKR, *=GlcNAc (151) 
Yield: 85% (17.8 mg, 10.63 μmol). Analytical HPLC Rt= 23.56 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.79 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm);  
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 835.9766 ([M+2H]2+, calc. 
835.9760), 846.9685 ([M+Na+H]2+, calc. 846.9670), 557.6522 ([M+3H]3+, calc. 557.6532), 
716.6787 ([M+Na+2H]3+, calc. 716.6770), 570.6370 ([M+Na+NH4+H]
3+, calc. 570.6561). 
Sequence: NH2-Spacer-VVN*STTGPGEHLR, *=GlcNAc (152) 
Yield: 86% (19.0 mg, 10.70 μmol). Analytical HPLC Rt= 21.13 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 11.71 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 886.9564 ([M+2H]2+, calc. 886.9554), 
897.9493 ([M+Na+H]2+, calc. 897.9564), 591.6386 ([M+3H]3+, calc. 591.6395), 599.3019 
([M+Na+2H]3+, calc. 599.3013), 604.6232 ([M+Na+NH4+H]
3+, calc. 604.6424). 
Sequence: NH2-Spacer-WVSN*KTEGR, *=GlcNAc (153) 
Yield: 51% (9.43 mg, 6.36 μmol). Analytical HPLC Rt= 20.62 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 11.80 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1482.7529 ([M+H]+, calc. 1482.7440), 
741.8753 ([M+2H]2+, calc. 741.8759), 752.8684 ([M+Na+H]2+, calc. 752.8669), 494.9190 
([M+3H]3+, calc. 494.9199), 507.9036 ([M+Na+NH4+H]
3+, calc. 507.9227). 
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 Sequence: NH2-Spacer-LRPDDSKN*FSIQVR, *=GlcNAc (154) 
Yield: 41% (10.7 mg, 5.14 μmol). Analytical HPLC Rt= 36.37 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 13.91 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1041.0495 ([M+2H]2+, calc. 1041.0478), 
1052.0402 ([M+Na+H]2+, calc. 1052.0388), 694.3674 ([M+3H]3+, calc. 694.3678), 702.0306 
([M+Na+2H]3+, calc. 702.0296), 707.3524 ([M+Na+NH4+H]
3+, calc. 707.3707), 521.0270 
([M+4H]4+, calc. 521.0278). 
Sequence: NH2-Spacer-GEYFVN*VTTR, *=GlcNAc (155) 
Yield: 23% (4.65 mg, 2.92 μmol). Analytical HPLC Rt= 27.09 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.81 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 796.3961 ([M+2H]2+, calc. 796.3967), 
807.3904 ([M+Na+H]2+, calc. 807.3877), 544.2515 ([M+Na+NH4+H]
3+, calc. 544.2699). 
Sequence: NH2-Spacer-AYSWN*ISR, *=GlcNAc (156) 
Yield: 58% (10.2 mg, 7.24 μmol). Analytical HPLC Rt= 26.99 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.74 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 701.8464 ([M+2H]2+, calc. 701.8466), 
712.8390 ([M+Na+H]2+, calc. 712.8376), 481.2177 ([M+Na+NH4+H]
3+, calc. 481.2365). 
Sequence: NH2-Spacer-N*LTALPPDLPK, *=GlcNAc (157) 
Yield: 64% (12.7 mg, 8.02 μmol). Analytical HPLC Rt= 28.87 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 15.35 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
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MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1584.8936 ([M+H]+, calc. 1584.8736), 
792.9407 ([M+2H]2+, calc. 792.9407), 803.9349 ([M+Na+H]2+, calc. 803.9317), 528.9644 
([M+3H]3+, calc. 528.9631), 541.9481 ([M+Na+NH4+H]
3+, calc. 541.9659), 396.9659 ([M+4H]4+, 
calc. 396.9743). 
Sequence: NH2-Spacer-LQN*LTLPTNASIK, *=GlcNAc (158) 
Yield: 64% (14.7 mg, 8.06 μmol). Analytical HPLC Rt= 30.26 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 15.89 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 910.0074 ([M+2H]2+, calc. 910.0071), 
921.0021 ([M+Na+H]2+, calc. 920.9981), 607.0094 ([M+3H]3+, calc. 607.0073), 614.6717 
([M+Na+2H]3+, calc. 614.6691), 619.9931 ([M+Na+NH4+H]
3+, calc. 620.0102), 455.5122 
([M+4H]4+, calc. 455.5075). 
Sequence: NH2-Spacer-SN*YSSPSNISK, *=GlcNAc (159) 
Yield: 37% (7.45 mg, 4.69 μmol). Analytical HPLC Rt= 17.54 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 9.98 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); 
/HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 795.3810 ([M+2H]2+, calc. 
795.3812), 806.3755 ([M+Na+H]2+, calc. 806.3722), 543.5750 ([M+Na+NH4+H]
3+, calc. 
543.5929). 
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 Sequence: NH2-Spacer-ELISN*ASDALDK, *=GlcNAc (160) 
Yield: 64% (13.35 mg, 7.94 μmol). Analytical HPLC Rt= 26.57 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.34 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1681.8656 ([M+H]+, calc. 1681.8383), 
841.4237 ([M+2H]2+, calc. 841.4237), 852.4162 ([M+Na+H]2+, calc. 852.4242), 568.9490 
([M+Na+2H]3+, calc. 568.9464), 574.2704 ([M+Na+NH4+H]
3+, calc. 574.2875), 421.2193 
([M+4H]4+, calc. 421.2154). 
Sequence: NH2-Spacer-LLDLSGNN*LTHLPK, *=GlcNAc (161) 
Yield: 75% (18.3 mg, 9.43 μmol). Analytical HPLC Rt= 33.32min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 17.23 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 971.0352 ([M+2H]2+, calc. 971.0311), 
982.0268 ([M+Na+H]2+, calc. 982.0221), 647.6894 ([M+3H]3+, calc. 647.6900), 655.3526 
([M+Na+2H]3+, calc. 655.3518), 660.6743 ([M+Na+NH4+H]
3+, calc. 660.6929). 
Sequence: NH2-Spacer-LQNLTLPTN*ASIK, *=GlcNAc (162) 
Yield: 66% (15.0 mg, 9.43 μmol). Analytical HPLC Rt= 30.57 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 16.05 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1819.0355 ([M+H]+, calc. 1819.0064), 
910.0078 ([M+2H]2+, calc. 910.0071), 921.0024 ([M+Na+H]2+, calc. 920.9981), 607.0099 
([M+3H]3+, calc. 607.0073), 614.6719 ([M+Na+2H]3+, calc. 614.6691), 619.9933 
([M+Na+NH4+H]
3+, calc. 620.0102). 
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Sequence: NH2-Spacer-SNYSSPSN*ISK, *=GlcNAc (163) 
Yield: 48% (9.6 mg, 6.04 μmol). Analytical HPLC Rt= 17.06 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 9.93 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 795.3813 ([M+2H]2+, calc. 795.3912), 
806.3755 ([M+Na+H]2+, calc. 806.3722), 530.5915 ([M+3H]3+, calc. 530.5901), 538.24483 
([M+Na+2H]3+, calc. 538.2519), 543.5752 ([M+Na+NH4+H]
3+, calc. 534.5929). 
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 7.25 Enzymatic coupling of oxazoline to N-glycopeptides 
Sequence: NH2-IN*TTADEKDPTNPFR, *= Man3GlcNAc2 (164) 
The tetrasaccharide oxazoline 110 (0.39 mg, 0.56 µmol 8.0 eq) and the GlcNAc-peptide 136 
(0.13 mg, 0.07 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 6.25 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC. The reaction finished in 1 h 
and a faster product was observed on HPLC with full conversion. The crude product was 
diluted with H2O and purified by semi-prep HPLC directly to give product glycopeptide 164, 
yield 54% (0.10 mg, 0.038 µmol). Analytical HPLC Rt= 22.42 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(35:65), 30 min, wavelength=214 
nm). Semi-preparative HPLC Rt= 22.33 min (Thermo Hypersil GOLD, 5 μm, 4.6x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 nm); 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1306.6200 ([M+2H]2+, calc. 
1306.5817), 871.3962 ([M+3H]3+, calc. 871.3904), 663.2904 ([M+K+3H]4+, calc. 663.2837). 
Sequence: NH2-Spacer-VVN*STTGPGEHLR, *= Man3GlcNAc2 (165) 
The tetrasaccharide oxazoline 110 (1.03 mg, 1.49 µmol, 6.3 eq) and the GlcNAc-peptide 152 
(0.42 mg, 0.24 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 7.75 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC. The reaction finished in 1 h 
and a faster product was observed on HPLC with full conversion. The crude product was 
diluted with H2O and purified by semi-prep HPLC directly to give product glycopeptide 165, 
yield 55% (0.32 mg, 0.13 µmol). Analytical HPLC Rt= 15.36 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (10:90)->(40:60), 30 min, 
wavelength=214 nm). Semi-preparative HPLC Rt= 15.50 min (Thermo Hypersil GOLD, 5 μm, 
4.6x250mm, Grad: MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1232.0969 ([M+2H]2+, 
calc. 1232.0761), 821.7212 ([M+3H]3+, calc. 821.7200), 616.5465 ([M+4H]4+, calc. 616.5419), 
501.0277 ([M+K+4H]5+, calc. 501.0263). 
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Sequence: NH2-Spacer-WVSN*KTEGR, *= Man3GlcNAc2 (166) 
The tetrasaccharide oxazoline 110 (1.03 mg, 1.49 µmol, 5.3 eq) and the GlcNAc-peptide 153 
(0.42 mg, 0.28 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 7.75 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC. The reaction finished in 1 h 
and a faster product was observed on HPLC with full conversion. The crude product was 
diluted with H2O and purified by semi-prep HPLC directly to give product glycopeptide 166, 
yield 57% (0.35 mg, 0.16 µmol). Analytical HPLC Rt= 14.15 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (10:90)->(40:60), 30 min, 
wavelength=214 nm). Semi-preparative HPLC Rt= 14.63 min (Thermo Hypersil GOLD, 5 μm, 
4.6x250mm, Grad: MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1086.5079 ([M+2H]2+, 
calc. 1086.4949), 724.6675 ([M+3H]3+, calc. 724.6658), 553.2415 ([M+K+3H]4+, calc. 
553.2403). 
Sequence: NH2-Spacer-N*LTALPPDLPK, *= Man3GlcNAc2 (167) 
The tetrasaccharide oxazoline 110 (1.19 mg, 1.73 µmol, 8.2 eq) and the GlcNAc-peptide 157 
(0.42 mg, 0.21 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 7.75 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC. The reaction finished in 1 h 
and a faster product was observed on HPLC with full conversion. The crude product was 
diluted with H2O and purified by semi-prep HPLC directly to give product glycopeptide 167, 
yield 89% (0.42 mg, 0.18 µmol). Analytical HPLC Rt= 21.99 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (10:90)->(40:60), 30 min, 
wavelength=214 nm). Semi-preparative HPLC Rt= 22.41 min (Thermo Hypersil GOLD, 5 μm, 
4.6x250mm, Grad: MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1138.0721 ([M+2H]2+, 
calc. 1138.0614), 759.0502 ([M+3H]3+, calc. 759.0435), 579.0296 ([M+K+3H]4+, calc. 
579.0236). 
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 Sequence: NH2-Spacer-LQNLTLPTN*ASIK, *= Man3GlcNAc2 (168) 
The tetrasaccharide oxazoline 110 (1.03 mg, 1.49 µmol, 6.8 eq) and the GlcNAc-peptide 162 
(0.40 mg, 0.22 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 7.75 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC. The reaction finished in 1 h 
and a faster product was observed on HPLC with full conversion. The crude product was 
diluted with H2O and purified by semi-prep HPLC directly to give product glycopeptide 168, 
yield 70% (0.35 mg, 0.15 µmol). Analytical HPLC Rt= 23.50 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (10:90)->(40:60), 30 min, 
wavelength=214 nm). Semi-preparative HPLC Rt= 23.57 min (Thermo Hypersil GOLD, 5 μm, 
4.6x250mm, Grad: MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1255.1527 ([M+2H]2+, 
calc. 1255.1278), 837.0907 ([M+3H]3+, calc. 837.0878), 637.5616 ([M+K+3H]4+, calc. 
637.5568). 
Sequence: NH2-IN*TTADEKDPTNPFR, *= Man3GlcNAc4 (169) 
The hexasaccharide oxazoline 112 (0.61 mg, 0.56 µmol 8.0 eq) and the GlcNAc-peptide 136 
(0.13 mg, 0.07 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 6.25 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC for a few hours. The reaction 
was stopped after 4 h and a faster product was observed on HPLC with 20% conversion and 
longer reaction times only resulted back-hydrolysis of the obtained product. The crude 
product was diluted with H2O and purified by semi-prep HPLC directly to give product 
glycopeptide 169. Analytical HPLC Rt= 22.42 min (Phenomenex Luna C18 (2), 2.0 x 150 mm, 3 
μm, Grad: MeCN/water + 0.1% TFA (5:95)->(35:65), 30 min, wavelength=214 nm). 
Semi-preparative HPLC Rt= 21.72 min (Thermo Hypersil GOLD, 5 μm, 4.6x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 nm); 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1509.6645 ([M+2H]2+, calc. 
1509.6611), 1006.7768 ([M+3H]3+, calc. 1006.7766), 764.8211 ([M+K+3H]4+, calc. 764.8234). 
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Sequence: NH2-Spacer-N*LTALPPDLPK, *= Man3GlcNAc4 (170) 
The hexasaccharide oxazoline 112 (0.92 mg, 0.84 µmol 8.0 eq) and the GlcNAc-peptide 157 
(0.17 mg, 0.10 µmol 1.0 eq) were dissolved in a phosphate buffer (50 mM, pH 7.1, 6.25 µL) 
and mixed with the enzyme solution, Endo-M-N175Q (TCI chemistry, 12.5 milli-units in 6.25 
µL buffer), incubated at 25 °C and followed by analytical HPLC for a few hours. The reaction 
was stopped after 3.5 h and a faster product was observed on HPLC with 21% conversion and 
longer reaction times only resulted back-hydrolysis of the obtained product. The crude 
product was diluted with H2O and purified by semi-prep HPLC directly to give product 
glycopeptide 170. Analytical HPLC Rt= 22.20 min (Phenomenex Luna C18 (2), 2.0 x 150 mm, 3 
μm, Grad: MeCN/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 nm). 
Semi-preparative HPLC Rt= 23.08 min (Thermo Hypersil GOLD, 5 μm, 4.6x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (10:90)->(40:60), 30 min, wavelength=214 nm); 
HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1341.1621 ([M+2H]2+, calc. 
1371.1407), 894.4315 ([M+3H]3+, calc. 894.4297), 680.5668 ([M+K+3H]4+, calc. 680.5632). 
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 7.26 Mass fragmentation analysis of selected N-glycopeptides 
Multistage CID-MSn 
For the CID-MSn experiments (n=2-4), a HR-ESI-FTICR-MS (Thermo LTQ-FT Ultra) operated in 
positive ion mode and coupled to a nano-LC system was used. Precursor ion scans were 
acquired over the m/z range 300-2000 at a resolution setting of 50,000. CID-MS2 spectra 
were recorded for the most intense precursor ion in each full scan, at a normalised collision 
energy (NCE) level of 30% and an isolation width of 5 m/z units. An ion product list 
containing the m/z 366.14 and m/z 204.08 ions were used for the MS3 selection, and the 
seven most intense ions from each MS3 scan were selected for consecutive MS4 events. 
HCD experiments 
HCD fragmentation at the levels of 10 to 50% NCE in steps of 5% were performed on an 
Orbitrap Fusion Tribrid mass spectrometer interfaced to an Easy-nLC II (Thermo Fisher 
Scientific). Glycopeptides were separated using an analytical column (300x0.075 mm I.D.) 
packed with 3 μm Reprosil-Pur C18-AQ particles (Dr. Maisch, Germany), using a mobile phase 
of 0.2% formic acid in water and a gradient of 0.2% formic acid in acetonitrile for 30 min. 
Positive ions were injected into the mass spectrometer under a spray voltage of 1.6 kV. MS 
scans was performed at 120,000 resolution, m/z range 400-1,200 in the Orbitrap, followed 
by nine scan events of MS/MS analysis during a top speed cycle of 3s and precursor ion 
isolation in the quadrupole with a 1.6 m/z window. The nine individual consecutive MS/MS 
HCD fragmentation scans used 10, 15, 20, 25, 30, 35, 40, 45 and 50% NCE with detection in 
the Orbitrap at 60,000 resolution and m/z starting at 50. 
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7.27 Synthesis of O-mannosyl peptides 
General procedure glycopeptide synthesis 
The O-Mannosylated peptides 171 - 173, 180 - 183 and 190 - 195 were synthesized by 
stepwise solid-phase peptide synthesis using the Fmoc strategy and starting with preloaded 
tentagel S RAM Fmoc-Gly resin or tentagel R Trt Fmoc-Gly or Fmoc-Arg resin (12.5 μmol 
scale). The glycopeptide synthesis performed using 2.0 eq of the protected O-Mannosyl 
amino acid building blocks 120, 124 and 135, which were pre-activated manually using 2.0 
eq HATU/HOAt and 4.0 eq of DIPEA (8 h coupling time). The standard Fmoc amino acids were 
coupled automatically on a Multisyntech peptide synthesizer using 8 eq of the amino acid 
and the HBTU/HOBt reagents (40 min). Fmoc deprotection was done according to standard 
conditions, 20% piperidine in DMF. After assembly of the peptide backbone:  
i) peptide 171 - 173 and 190 - 195 were coupled with a triethyleneglycol amino acid spacer 
to the N-terminus followed by Fmoc deprotection. The obtained peptides were then released 
from the resin, and all acid sensitive side-chain protecting groups were simultaneously 
removed using TFA/TIPS/H2O 15:0.9:0.9 for 2.5 h followed by solvent concentration, 
lyophilization and purification using a C-18 cartridge (1g of C-18 material, Waters). For 
saccharide deprotection, the O-acetyl groups were cleaved by transesterification in methanol 
using catalytic amounts of NaOMe at pH 9-9.5 for 24 h (deprotection followed by analytical 
HPLC) to yield glycopeptides 171 - 173 and 190 - 195 which were purified by preparative 
HPLC. 
ii) peptide 180 - 183 were capped with an N-terminal acetyl group using a solution of 0.015 
M HOBt, 0.5 M Ac2O, 0.125 M DIPEA in NMP on N-terminus for 45 min. The obtained peptide 
was then released from the resin, and all acid sensitive side-chain protecting groups were 
simultaneously removed using TFA/TIPS/H2O 15:0.9:0.9 for 2.5 h followed by solvent 
concentration, lyophilization and purification using a C-18 cartridge (1g of C-18 material, 
Waters). The C-terminal was then extended with N-Boc-4,7,10-trioxa-1,13-tridecanediamine 
spacer (1.5 eq), catalyzed by HATU/HOAt (1.25 eq) and DIPEA (2.5 eq) in DMF (200 µL per 
12.5 mmol batch) for 8 h. The coupling product was diluted by H2O and the solvent was 
removed by lyophilization. The Boc protection group was then removed by using DCM/TFA 
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 3:1 solution (1.6 mL/10 mg peptide) in 3 h followed by solvent concentration, lyophilization 
and purification using a C-18 cartridge (500 mg of C-18 material, Waters). For saccharide 
deprotection, the O-acetyl groups were cleaved by transesterification in methanol (10 mL/10 
mg peptide) using catalytic amounts of NaOMe at pH 9-9.5 for 24 h (deprotection followed 
by analytical HPLC) to yield glycopeptides 180 - 183 which were purified by preparative HPLC. 
The GlcNAc-Man and 2,6-GlcNac2-Man glycopeptides loading on BSA and CRM-conjugates 
186 - 189 were measured by MALDI. The spectra were listed in section 10 and the loading 
equivalence were calculated. 
Sequence: NH2-Spacer-GT*G, *= GalGlcNAcMan: (171) 
Yield: 37% (4.8 mg, 4.63 μmol). Analytical HPLC Rt= 8.20 min (Phenomenex Luna C18 (2), 
3μm, 2.0 x 150 mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(50:50), 45 min, 
wavelength = 214 nm). Preparative HPLC Rt= 5.99 min (Phenomenex Luna C18 (2), 10 μm, 
21.2x250mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+H] +: 
963.4258, found: 963.4247. 
Sequence: NH2-Spacer-GT*G, *= GlcNAcMan: (172) 
Yield: 64% (5.2 mg, 6.49 μmol). Analytical HPLC Rt= 8.17 min (Phenomenex Luna C18(2), 3μm, 
2.0 x 150 mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(35:65), 30 min, wavelength=214 
nm). Preparative HPLC Rt= 6.07 min (Phenomenex Luna C18 (2), 21.2x250mm, 10 μm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm). HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+H] +: 801.3729, found: 
801.3721. 
Sequence: NH2-Spacer-GTG: (173) 
Yield: 43% (3.6 mg, 5.38 μmol). Analytical HPLC Rt= 7.07 min (Phenomenex Luna C18 (2), 
2.00x150mm, 3μm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(35:65), 30 min, 
wavelength=214 nm). Preparative HPLC Rt= 5.88 min (Phenomenex Luna C18 (2), 
21.2x250mm, 10 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(55:45), 25 min, 
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wavelength=214 nm). HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. 
for [M+H] +: 436.2407, found: 436.2398. 
Sequence: Squarate-NH-Spacer-GT*G, *= GalGlcNAcMan: (174) 
Peptide 171 (6.1 mg, 6.33 μmol) was dissolved in a 1:1 solution of EtOH / H2O (6 mL) and 
3,4-Diethoxy-3-cyclobuten-1,2-dione (1.03 μL, 6.96 μmol) was added. Then small portions of 
Sat. Na2CO3 solution (2.5 μL) was added every 5 min until pH reached 8.0. The reaction 
mixture was stirred at room temperature and after 2h HPLC showed complete conversion to 
the desired product. To quench the reaction AcOH (5 μL) was added, the solvent was then 
removed under reduced pressure and the residue was purified by HPLC to give 174. Yield: 70% 
(4.4 mg, 4.43 μmol). Analytical HPLC Rt= 17.52 min (Phenomenex Luna C18 (2), 2.0 x 150 mm, 
3 μm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(75:25), 70 min, wavelength=214 nm). 
Preparative HPLC Rt= 17.58 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+Na] +: 1109.4232, found: 
1109.4253. [M+2Na]2+: 556.2068, found: 556.2070 
Sequence: Squarate-NH-Spacer-GTG: (175) 
Peptide 173 (6.8 mg, 15.6 μmol, 1.0 eq) was dissolved in a 1:1 solution of EtOH / H2O (16 mL) 
and 3,4-Diethoxy-3-cyclobuten-1,2-dione (2.54 μL, 17.2 μmol, 1.1 eq) was added. Then small 
portions of Sat. Na2CO3 solution (2.5 μL) was added every 5 min until pH reached 8.0. The 
reaction mixture was stirred at room temperature and after 2h HPLC showed complete 
conversion to the desired product. To quench the reaction AcOH (5 μL) was added, the 
solvent was then removed under reduced pressure and the residue was purified by HPLC to 
give 175. Yield: 56% (4.9 mg, 8.73 μmol). 
BSA-conjugate of peptide sequence: -Spacer-GT*G, *= GalGlcNAcMan: (176) 
The squarate monoamide 174 (2.18 mg, 2.0 μmol) and BSA (6.67 mg, 0.1 μmol, 1/20 eq) was 
dissolved in a 60 mM Na2HPO4 buffer (0.5 mL, pH 9.5). The solution was stirred at room 
temperature and at pH 9.5 for 3 days. By passing the reaction mixture through an amicon 
filter (10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted glycopeptide 
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 material was removed from the obtained BSA conjugate product 176. The protein conjugate 
in the amicon filter was then washed 5 times with H2O (0.4 mL, centrifugation at 1000 g for 2 
min each time) followed by lyophilization to give 176 (5.0 mg, 5 mol/ mol BSA determined by 
MALDI). 
BSA-conjugate of peptide sequence: -Spacer-GTG: (177) 
The squarate monoamide 175 (1.12 mg, 2.0 μmol) and BSA (6.67 mg, 0.1 μmol, 1/20 eq) was 
dissolved in a 60 mM Na2HPO4 buffer (0.5 mL, pH 9.5). The solution was stirred at room 
temperature and at pH 9.5 for 3 days. By passing the reaction mixture through a amicon filter 
(10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted glycopeptide material 
was removed from the obtained BSA conjugate product 177. The protein conjugate in the 
amicon filter was then washed 5 times with H2O (0.4 mL, centrifugation at 1000 g for 2 min 
each time) followed by lyophilization to give 177 (5.0 mg). 
KLH-conjugate of peptide sequence: -Spacer-GT*G, *= GalGlcNAcMan: (178) 
The squarate monoamide 174 (2.18 mg, 2.0 μmol) and KLH (5 mg, 1.67-12.5 nmol, 
1/160-1200 eq, average mass 400-3000 kDa given by Sigma Aldrich) was dissolved in a 60 
mM Na2HPO4 buffer (0.5 mL, pH 9.5). The solution was stirred at room temperature and at 
pH 9.5 for 3 days. By passing the reaction mixture through a amicon filter (30 kDa cut-off, 
centrifugation at 14000 g for 15 min) the unreacted glycopeptide material was removed from 
the obtained KLH conjugate product 178. The protein conjugate in the amicon filter was then 
washed 5 times with H2O (0.4 mL, centrifugation at 1000 g for 2 min each time) followed by 
lyophilization to give 178 (3.07 mg). 
KLH-conjugate of peptide sequence: -Spacer-GTG: (179) 
The squarate monoamide 175 (1.12 mg, 2.0 μmol) and KLH (0.6 mg, 0.20-1.5 nmol, 
1/1333-10000 eq, average mass 400-3000 kDa given by Sigma Aldrich) was dissolved in a 60 
mM Na2HPO4 buffer (0.5 mL, pH 9.5). The solution was stirred at room temperature and at 
pH 9.5 for 3 days. By passing the reaction mixture through a amicon filter (30 kDa cut-off, 
centrifugation at 14000 g for 15 min) the unreacted glycopeptide material was removed from 
the obtained KLH conjugate product 179. The protein conjugate in the amicon filter was then 
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washed 5 times with H2O (0.4 mL, centrifugation at 1000 g for 2 min each time) followed by 
lyophilization to give 179 (0.5 mg). 
Sequence: AcHN-GT*T*G-Spacer-NH2, *= GlcNAcMan (180) 
Yield: 28% (9.0mg, 6.95 μmol). Analytical HPLC Rt= 8.97 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 5.12 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+2H]2+: 655.3038, found: 
655.3064. 
Sequence: AcHN-GT*T*G-Spacer-NH2, *= GlcNAc2Man (181) 
Yield: 3.6% (2.3 mg, 1.34 μmol). Analytical HPLC Rt= 9.07 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 6.28 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 869.3735 ([M+Na+H]2+, calc. 869.3742), 
880.3651 ([M+2Na]2+, calc. 880.3653). 
Sequence: AcHN-T*G-Spacer-NH2, *= GlcNAc2Man (182) 
Yield: 1.9% (0.7 mg, 0.71 μmol). Analytical HPLC Rt= 10.43 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 7.15 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 989.4817 ([M+H]+, calc. 989.4778), 
1011.4631 ([M+Na]+, calc. 1011.4597), 506.2328 ([M+Na+H]2+, calc. 506.2338), 517.2244 
([M+2Na]2+, calc. 517.2248). 
Sequence: AcHN-GTTG-Spacer-NH2: (183) 
Yield: 24% (3.4 mg, 5.88 μmol). Analytical HPLC Rt= 12.20 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
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 nm). Preparative HPLC Rt= 6.92 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 579.3340 ([M+H]+, calc. 579.3354), 
601.3174 ([M+Na]+, calc. 601.3173), 290.1737 ([M+2H]2+, calc. 290.1716). 
Sequence: AcHN-GT*T*G-Spacer-NH-Squarate, *= GlcNAcMan (184) 
Peptide 180 (8.2 mg, 6.33 μmol, 1.0 eq) was dissolved in a 1:1 solution of EtOH / H2O (11 mL) 
and 3,4-Diethoxy-3-cyclobuten-1,2-dione (1.03 μL, 6.96 μmol, 1.1 eq) was added. Then small 
portions of Sat. Na2CO3 solution (1.0 μL) was added every 5 min until pH reached 8.0. The 
reaction mixture was stirred at room temperature and after 2h HPLC showed complete 
conversion to the desired product. To quench the reaction AcOH (1 μL) was added, the 
solvent was then removed under reduced pressure and the residue was purified by HPLC to 
give 184. Yield: 63% (5.5 mg, 3.96 μmol). Analytical HPLC Rt= 19.74 min (Phenomenex Luna 
C18 (2), 2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(75:25), 70 min, 
wavelength=205nm). Preparative HPLC Rt= 11.99 min (Phenomenex Luna C18 (2), 10 μm, 
21.2x250mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 1433.6269 ([M+H]+, 
calc. 1433.6158), 1455.6099 ([M+Na]+, calc. 1455.5977), 717.3111 ([M+2H]2+, calc. 717.3118), 
728.3042 ([M+Na+H]2+, calc. 728.3028), 736.7886 ([M+Na+NH4]
2+, calc. 736.8161), 748.2696 
([M+2Na+NH3]
2+, calc. 748.3087). 
Sequence: AcHN-GT*T*G-Spacer-NH-Squarate, *= GlcNAc2Man (185) 
Peptide 181 (1.50 mg, 0.87 μmol, 1.0 eq) was dissolved in a 1:1 solution of EtOH / H2O (1 mL) 
and 3,4-Diethoxy-3-cyclobuten-1,2-dione (0.14 μL, 0.96 μmol, 1.1 eq) was added. Then small 
portions of Sat. Na2CO3 solution (1.0 μL) was added every 5 min until pH reached 8.0. The 
reaction mixture was stirred at room temperature and after 2h HPLC showed complete 
conversion to the desired product. To quench the reaction AcOH (1 μL) was added, the 
solvent was then removed under reduced pressure and the residue was purified by HPLC to 
give 185. Yield: 52% (0.85 mg, 0.46 μmol). Analytical HPLC Rt= 17.93 min (Phenomenex Luna 
C18 (2), 2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, 
wavelength=214 nm). Preparative HPLC Rt= 10.87 min (Phenomenex Luna C18 (2), 10 μm, 
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21.2x250mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: 942.3747 ([M+2Na]2+, 
calc. 943.3732). 
BSA-conjugate of peptide sequence: AcHN-GT*T*G-Spacer-, *= GlcNAcMan (186) 
The squarate monoamide 184 (2.00 mg, 1.40 μmol) and BSA (5.25 mg, 0.079 μmol, 1/17.7 eq) 
was dissolved in a 200 mM Na2HPO4 buffer (0.25 mL, pH 9.5). The solution was stirred at 
room temperature and at pH 9.5 for 3 days. By passing the reaction mixture through an 
amicon filter (10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted 
glycopeptide material was removed from the obtained BSA conjugate product 186. The 
protein conjugate in the amicon filter was then washed 5 times with H2O (0.4 mL, 
centrifugation at 1000 g for 2 min each time) followed by lyophilization to give 186 (6.5 mg). 
The average mass was measured around 85.5k as pure BSA for 66.4k. The loading of 
glycopeptide 184 (MS 1433.4) was calculated for 13.3 eq. See section 10. 
CRM-conjugate of peptide sequence: AcHN-GT*T*G-Spacer-, *= GlcNAcMan (187) 
The squarate monoamide 184 (0.6 mg, 0.419 μmol) and CRM (1.0 mg, 0.016 μmol, 1/26.4 eq) 
was dissolved in a 200 mM Na2HPO4 buffer (0.25 mL, pH 9.5). The solution was stirred at 
room temperature and at pH 9.5 for 3 days. By passing the reaction mixture through an 
amicon filter (10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted 
glycopeptide material was removed from the obtained BSA conjugate product 187. The 
protein conjugate in the amicon filter was then washed 5 times with H2O (0.4 mL, 
centrifugation at 1000 g for 2 min each time) followed by lyophilization to give 187 (1.2 mg). 
The average mass was measured around 72k as pure CRM for 63k. The loading of 
glycopeptide 184 (MS 1433.4) was calculated for 6.3 eq. See section 10. 
BSA-conjugate of peptide sequence: AcHN-GT*T*G-Spacer-, *= GlcNAc2Man (188) 
The squarate monoamide 185 (0.4 mg, 0.22 μmol) and BSA (0.5 mg, 0.0075 μmol, 1/30 eq) 
was dissolved in a 100 mM Na2HPO4 buffer (0.10 mL, pH 9.5). The solution was stirred at 
room temperature and at pH 9.5 for 3 days. By passing the reaction mixture through an 
amicon filter (10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted 
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 glycopeptide material was removed from the obtained BSA conjugate product. The protein 
conjugate in the amicon filter was then washed 5 times with H2O (0.4 mL, centrifugation at 
1000 g for 2 min each time) followed by lyophilization to give 188 (0.6 mg). The 
BSA-conjugate was compared with pure BSA, see section 10. The zoom in spectrum showed 
clearly only 1-3 eq glycopeptide 185 (MS 1839.8) were loaded on the carrier protein. 
CRM-conjugate of peptide sequence: AcHN-GT*T*G-Spacer-, *= GlcNAc2Man (189) 
The squarate monoamide 185 (0.80 mg, 0.44 μmol) and CRM (1.0 mg, 0.016 μmol, 1/28 eq) 
was dissolved in a 75 mM Na2HPO4 buffer (0.10 mL, pH 9.5). The solution was stirred at room 
temperature and at pH 9.5 for 3 days. By passing the reaction mixture through an amicon 
filter (10 kDa cut-off, centrifugation at 14000 g for 15 min) the unreacted glycopeptide 
material was removed from the obtained CRM conjugate product. The protein conjugate in 
the amicon filter was then washed 5 times with H2O (0.4 mL, centrifugation at 1000 g for 2 
min each time) followed by lyophilization to give 189 (1.1 mg). The CRM-conjugate was 
compared with pure CRM, see section 10. The zoom in spectrum showed clearly only 2-3 eq 
glycopeptide 185 (MS 1839.8) were loaded on the carrier protein. 
Sequence: NH2-Spacer-PVPGKPT*VTIR, *= GalGlcNAcMan (190) 
Yield: 70% (16.5 mg, 8.75 μmol). Analytical HPLC Rt= 21.01 min (Phenomenex Luna C18 (2), 
3μm, 2.0 x 150 mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(35:65), 30 min, 
wavelength=214 nm). Preparative HPLC Rt= 11.95 min (Phenomenex Luna C18 (2), 10 μm, 
21.2x250mm, Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 
nm); HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+2H]2+: 
948.0096, found: 948.0098. 
Sequence: NH2-Spacer-RGAIIQT*PTLG, *= GalGlcNAcMan (191) 
Yield: 21% (4.9 mg, 2.56 μmol). Analytical HPLC Rt= 23.84 min (Phenomenex Luna C18 (2), 
2.0 x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(50:50), 45 min, wavelength=214 
nm). Semi-preparative HPLC Rt= 13.82 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, 
Grad: MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); 
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HR-ESI-TOF-MS (Thermo LTQ-Orbitrap mass spectrometer), m/z: calc. for [M+2H]2+: 928.9835, 
found: 928.9837. 
Sequence: NH2-Spacer-PVPGKPT*VTIR, *= GlcNAcMan (192) 
Yield: 62% (15.5 mg, 7.8 μmol). Analytical HPLC Rt= 22.25 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.53 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 866.9857 ([M+2H]2+, calc. 866.9872), 
877.9768 ([M+H+Na]2+, calc. 877.9782), 578.3239 ([M+3H]3+, calc. 578.3274). 
Sequence: NH2-Spacer-RGAIIQT*PTLG, *= GlcNAcMan (193) 
Yield: 18% (4.3 mg, 2.2 μmol). Analytical HPLC Rt= 25.35 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 14.45 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 1694.9332 ([M+H]+, calc. 1694.9064), 
847.9578 ([M+2H]2+, calc. 847.9571), 578.6265 ([M+H+Na+NH4]
3+, calc. 578.6435). 
Sequence: NH2-Spacer-PVPGKPT*VTIR, *= GlcNAc2Man (194) 
Yield: 21% (5.2 mg, 2.69 μmol). Analytical HPLC Rt= 23.29 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 12.12 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 968.5279 ([M+2H]2+, calc. 968.5269), 
979.5183 ([M+H+Na]2+, calc. 979.5179), 987.5007 ([M+Na+NH4]
2+, calc. 987.5295), 646.0179 
([M+3H]3+, calc. 646.0205). 
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 Sequence: NH2-Spacer-RGAIIQT*PTLG, *= GlcNAc2Man (195) 
Yield: 5% (1.2 mg, 0.63 μmol). Analytical HPLC Rt= 22.09 min (Phenomenex Luna C18 (2), 2.0 
x 150 mm, 3 μm, Grad: MeCN/water + 0.1% TFA (5:95)->(45:55), 40 min, wavelength=214 
nm). Preparative HPLC Rt= 13.01 min (Phenomenex Luna C18 (2), 10 μm, 21.2x250mm, Grad: 
MeCN (84%)/water + 0.1% TFA (5:95)->(55:45), 25 min, wavelength=214 nm); HR-ESI-TOF-MS 
(Thermo LTQ-Orbitrap mass spectrometer), m/z: 949.4967 ([M+2H]2+, calc. 949.4968), 
960.4914 ([M+H+Na]2+, calc. 960.4878), 633.3360 ([M+3H]3+, calc. 633.3338), 640.6636 
([M+2H+Na]3+, calc. 640.6611), 646.3197 ([M+H+Na+NH4]
3+, calc. 646.3366). 
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7.28 Determination glycopeptide loading on KLH-conjugate 
To determine the glycopeptide loading on the glycopeptide-KLH conjugate 178, 
monosaccharides were released from the peptide backbone by acid hydrolysis, derivatized 
and analyzed by HPLC in accordance with a previously published procedure. The KLH 
conjugate 178 (0.18 mg) was dissolved in 4 M trifluoroacetic acid  (300 μL) and hydrolyzed 
for 3 h at 100 °C. The solvent was then removed using a speedvac, and the residue was 
dissolved in H2O (10 μL) and mixed with Anthranilic acid (AA) reagent solution (20 μL) (AA 
regent solution = 3 mg of AA and 30 mg of sodium cyanoborohydride in 1 mL of 2% (w/v) 
boric acid in methanol) and incubated for 1 h at 80 °C. Then an aliquot of the reaction 
mixture (1 μL) was diluted with 0.1% TFA-H2O (36 μL) and of the diluted sample 30μL was 
injected into the analytical HPLC. Measuring the UV absorbance at 214 nm a peak area of 
83.549 mAu was detected for the combined galactose and mannose peaks (the combined 
area was used due to AA-derived mannose/galactose peak overlap). Using the AA-derived 
galactose/mannose calibration curve described below, it was concluded that the measured 
peak area was corresponding to 0.818 nmol of galactose and mannose respectively. Based on 
the obtained amount of released monosaccharides, the dilution of the KLH conjugate 178, 
and the molecular weight of KLH (400-3000 kDa, given by Sigma-Aldrich), the glycopeptide to 
KLH ratio was determined to 65 (400 kDa KLH) - 491 (3000 kDa KLH) mol glycopeptide / mol 
KLH. 
HPLC calibration curve of an AA derivatized 1:1 galactose-mannose mixture 
Galactose (3.24 mg, 0.018 mmol) and mannose (3.24 mg, 0.018 mmol) was dissolved in H2O 
(1 mL) and an aliquot (10 μL, 0.18 μmol) of the galactose/mannose 1:1 mixture was treated 
with 20 μL Anthranilic acid (AA) labeling solution at 80 °C for 1 h.  Then an aliquot (1 μL) of 
the reaction mixture was diluted with 100 μL, 150 μL, 200 μL and 600 μL 0.1% TFA-H2O and 
of the diluted sample 30μL was injected into the analytical HPLC. Measuring the UV 
absorbance at 214 nm the combined galactose and mannose peak area was detected and a 
calibration curve was plotted for the corresponding dilutions. 
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Calibration curve peak area absorbance at 214 nm versus dilution in nmol of the 1:1 
galactose/mannose mixture.   
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1:100 1.8 187.43 
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1:200 0.9 93.48 
1:600 0.3 33.86 
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7.29 Immunization of rabbit sera 
For antibody induction against the Galβ1-4GlcNAcβ1-2Manα glycopeptide, two rabbits 
21390 and 21391 were immunized with the KLH vaccine 178 together with Freunds complete 
adjuvant (CFA). Six booster immunizations were carried out over 8 weeks. Immunizations 
were carried out by Biogenes GmbH, Berlin, Germany. 
For antibody induction against the GlcNAcβ1-2Manα glycopeptide, two rabbits 23803 and 
23804 were immunized with the CRM vaccine 187 together with Freunds complete adjuvant 
(CFA). Six booster immunizations were carried out over 8 weeks. Immunizations were carried 
out by Biogenes GmbH, Berlin, Germany. 
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 7.30 ELISA experiments 
ELISA of Rabbit sera 21390 and 21391 in Figure 19 A 
ELISA experiments performed according to a standard protocol. BSA conjugate 176 was 
coated on the ELISA plate (96-well, Maxisorb, nunc), 50 μL (10 μg/mL) substrate per well and 
incubation at 4 °C overnight. Coating buffer: 0.1 M Na2HPO4, pH 9.4. The coated plate was 
washed 3 times with PBST buffer followed by blocking of the surface using PBST buffer with 1% 
BSA (100 μL/well). The blocking buffer was removed and titration with the rabbit sera 
followed. 50 μL blocking buffer was added to each well and in the first row 50 μL pre-diluted 
serum was added followed by 1:2 dilution in each well. Incubation performed for 60 min at 
37 °C. Rabbit sera 21390 and 21391, pre-immune, first-bleed and final bleed were incubated 
in 12 dilutions starting from 1:1000. After incubation three PBST washing steps followed. 
Incubation with secondary antibody (anti-rabbit IgG biotin, Invitrogen, 1:200 dilution, 50 
μL/well) in blocking buffer were done for 60 min at 37 °C. Thereafter washing and incubation 
with 50 μL streptavidin-horseradish peroxidase (1:2000, SA-HPO, Sigma-Aldrich), 37 °C for 30 
min. Additional washing and incubation with 50 μL/well ABTS (1 mg/mL, Sigma-Aldrich) and 
H2O2 (30%, 1:4000 dilution) in citrate buffer (40 mM citric acid and 60 mM Na2PO4) was 
followed. After 5 min the UV absorbance at 410 nm was detected (Tecan infinity 700 
scanner).  
Glycopeptide ELISA neutralization experiments for analysis of antibody binding specificity 
of Rabbit serum 21390 in Figure 19 B and C 
The ELISA neutralization experiments performed in accordance to the normal ELISA protocol 
with minor differences in the incubation step with the primary antibody. The ELISA plate was 
coated with BSA conjugate 176 followed by BSA blocking. 40 μL blocking buffer was added to 
each well and in the first row 40 μL pre-diluted serum (Rabbit sera 21390 final bleed, 1:4000, 
6 dilutions) was added followed by 1:2 dilution in each well. Then 10 μL neutralization 
substance was added to each well (neg. contrl. and peptides 171 - 173, 190, 191) and the mix 
incubation performed for 60 min at 37 °C. Incubation with secondary antibody, SA-HPO and 
ABTS-H2O2 and detection followed according to the ELISA protocol described above. 
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ELISA of Rabbit sera 23803 and 23804 in Figure 21 
ELISA experiments performed according to a standard protocol. BSA conjugate 186 was 
coated on the ELISA plate (96-well, Maxisorb, nunc), 50 μL (10 μg/mL) substrate per well and 
incubation at 37 °C 1 h. Coating buffer: 0.1 M Na2HPO4, pH 9.4. The coated plate was washed 
3 times with PBST buffer followed by blocking of the surface using PBST buffer with 1% BSA 
(100 μL/well). The blocking buffer was removed and titration with the rabbit sera followed. 
50 μL blocking buffer was added to each well and in the first row 50 μL pre-diluted serum 
was added followed by 1:2 dilution in each well. Incubation performed for 60 min at 37 °C. 
Rabbit sera 23803 and 23804, pre-immune, first bleed, second bleed and final bleed were 
incubated in 12 dilutions starting from 1:1000. After incubation three PBST washing steps 
followed. Incubation with secondary antibody (anti-rabbit IgG biotin, Invitrogen, 1:200 
dilution, 50 μL/well) in blocking buffer were done for 60 min at 37 °C. Thereafter washing 
and incubation with 50 μL streptavidin-horseradish peroxidase (1:2000, SA-HPO, 
Sigma-Aldrich), 37 °C for 30 min. Additional washing and incubation with 50 μL/well ABTS (1 
mg/mL, Sigma-Aldrich) and H2O2 (30%, 1:4000 dilution) in citrate buffer (40 mM citric acid 
and 60 mM Na2PO4) was followed. After 5 min the UV absorbance at 410 nm was detected 
(Tecan infinity 700 scanner).  
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 7.31 Microarray experiments 
On-slide enzymatic coupling of tetrasaccharide oxazoline 110 to N-GlcNAc peptides and 
examining binding efficiency using the lectin ConA in Figure 13 
Two microarray slides (Slide H, Schott-Nexterion, Jena, Germany) were immobilized with 
N-GlcNAc peptides 150 - 163 as well as pre-synthesized pentasaccharide N-glycopeptides 165 
- 168 with 50 µM/100 µM concentration (in 150 mM phosphate buffer pH 8.5, 0.005% 
Tween-20, 85 picoL spots) using a piezo-driven non-contact spotter (iTWO200, 
M2-automation, Berlin, Germany). The spotting were performed in a 16 array (well) format 
with 9 spot replicates for each peptides. The printed peptides were allowed to react in a 
humidity chamber (75% humidity) for 24 h and unreacted NHS-esters were capped with 1 
mM ethanolamine at pH 9 for 1 h. The slides were washed with phosphate buffered saline 
(PBS), 0.05% Tween-20 buffer (PBST) and water and then dried with a stream of argon for 
storage. A solution of 1.5 mg oxazoline donor 110 with 12.5 mU Endo-M-N175Q (TCI 
chemistry) in 30 µL phosphate buffer (50 mM, pH 7.1) was added in one well and incubated 
at 25 °C for 1 h followed by washing 3 times for 10 min with PBST buffer. For recognition, 
another well without enzyme treatment was also included as blank control. The two wells 
were incubated with biotin labeled ConA (0.1 mg/mL in PBST buffer) for 1 h followed by 
washing 3×10 min with PBST buffer. For readout the slides were incubated with Cy5 
streptavidin (Invitrogen, diluted 1/1000 in PBST buffer), washed 3 times for 10 min with PBST 
buffer, water, and dried. Fluorescence was detected on a Typhoon Trio+ scanner (General 
Electrics) and the signals were analyzed and quantified by means of the Image quant 
software. 
O-Mannosyl glycopeptide microarrays for analysis of antibody binding specificity of Rabbit 
sera 21390 and 21391 in Figure 20 
The synthesized peptides 171 - 173, 190 and 191 (0.25 mM of peptide in 150 mM phosphate 
buffer pH 8.5, 0.005% Tween-20, 85 picoL spots) were immobilized on amino reactive and 
biocompatible hydrogel slides with a surface functionalized with carboxylic acids activated as 
N-hydroxysuccinimide esters (Slide H, Schott-Nexterion, Jena, Germany). Using a piezo-driven 
non-contact spotter (iTWO200, M2-automation, Berlin, Germany) the spotting performed in 
a 16 array (well) format. Every well contained a spotting field divided into four blocks. In 
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every block glycopeptides 171 - 173, 190 and 191 were printed with 10 spot replicates. The 
printed peptides were allowed to react in a humidity chamber (75% humidity) for 2.5 h and 
unreacted NHS-esters were trapped with 1 mM ethanolamine at pH 9 for 30 min. The slides 
were washed with phosphate buffered saline (PBS), 0.05% Tween-20 buffer (PBST) and water 
and then dried with a stream of argon for storage or directly incubated with primary 
antibodies. The slides were incubated with rabbit sera 21390 and 21391 (diluted 1/ 100 or 
1/1000 in PBST buffer) for 45 min followed by washing 3 times for 10 min with PBST buffer. 
For readout the slides were subsequently incubated with a 488 fluorescent labeled 
secondary anti-rabbit antibody (Invitrogen, diluted 1/5000 in PBST buffer), washed 3 times 
for 10 min with PBST buffer, washed with water and dried. Fluorescence was detected on a 
Typhoon Trio+ scanner (General Electrics) and the signals were analyzed and quantified by 
means of the Image quant software. 
O-Mannosyl glycopeptide microarrays for analysis of antibody binding specificity of Rabbit 
sera 23803 and 23804 Figure 22 
The synthesized peptides  171- 173, 182, 183 and 190 - 195 (0.25 mM of peptide in 150 mM 
phosphate buffer pH 8.5, 0.005% Tween-20, 85 picoL spots), 180 and 181 at different 
concentration (0.1 mM, 0.05 mM, 0.01 mM, 2 µM and 0.5 µM of peptide in 150 mM 
phosphate buffer pH 8.5, 0.005% Tween-20, 85 picoL spots), were spotted and immobilized 
on amino reactive and biocompatible hydrogel slides with a surface functionalized with 
carboxylic acids activated as N-hydroxysuccinimide esters (Slide H, Schott-Nexterion, Jena, 
Germany). Using a piezo-driven non-contact spotter (iTWO200, M2-automation, Berlin, 
Germany) the spotting performed in a 8 array (well) format with 6 replicates for each 
glycopeptides in every block. The printed peptides were allowed to react in a humidity 
chamber (75% humidity) for 24 h and unreacted NHS-esters were trapped with 1 mM 
ethanolamine at pH 9 for 1 h. The slides were washed with phosphate buffered saline (PBS), 
0.05% Tween-20 buffer (PBST) and water and then dried with a stream of argon for storage 
or directly incubated with primary antibodies. The slides were incubated with rabbit sera 
23803, 23804 (diluted 1/25 in PBST buffer) and ConA (0.1 mg/mL in PBST buffer) for 45 min 
followed by washing 3 times for 10 min with PBST buffer. For readout the slides were 
subsequently incubated with a 488 fluorescent labeled secondary anti-rabbit antibody 
(Invitrogen, diluted 1/5000 in PBST buffer) or Cy5 streptavidin (Invitrogen, diluted 1/1000 in 
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 PBST buffer), washed 3 times for 10 min with PBST buffer, washed with water and dried. 
Fluorescence was detected on a Typhoon Trio+ scanner (General Electrics) and the signals 
were analyzed and quantified by means of the Image quant software. 
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Compound 110 
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9 Appendix 2: HPLC chromatograms 
9.1 HPLC Chromatogram N-glycosylated peptides 
Compound 136, ADAM10, Sequence: IN*TTADEKDPTNPFR. 
 
Compound 137, Integrin alpha-6, Sequence: AN*HSGAVVLLKR. 
 
Compound 138, Trombospondin-1, Sequence: VVN*STTGPGEHLR. 
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 Compound 139, Antithrombin III, Sequence: WVSN*KTEGR. 
 
Compound 140, Integrin beta-3, Sequence: LRPDDSKN*FSIQVR. 
 
Compound 141, Integrin alpha-2, Sequence: GEYFVN*VTTR. 
 
Compound 142, P-Selectin, Sequence: AYSWN*ISR. 
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Compound 143, Platelet glycoprotein 1b alpha, Sequence: N*LTALPPDLPK. 
 
Compound 144, Multimerin 1, Sequence: LQN*LTLPTNASIK. 
 
Compound 145, Coagulationfactor V, Sequence: SN*YSSPSNISK. 
 
Compound 146, Endoplasmin, Sequence: ELISN*ASDALDK. 
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 Compound 147, Platelet glycoprotein V, Sequence: LLDLSGNN*LTHLPK. 
 
Compound 148, Multimerin 1, Sequence: LQNLTLPTN*ASIK. 
 
Compound 149, Coagulationfactor V, Sequence: SNYSSPSN*ISK. 
 
Compound 150, Sequence: Spacer-IN*TTADEKDPTNPFR. 
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Compound 151, Sequence: Spacer-AN*HSGAVVLLKR. 
 
Compound 152, Sequence: Spacer-VVN*STTGPGEHLR. 
 
Compound 153, Sequence: Spacer-WVSN*KTEGR. 
 
Compound 154, Sequence: Spacer-LRPDDSKN*FSIQVR. 
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-200
250
500
750
1.000
JIN #148 14030603 RF UV_VIS_1
mAU
min
1 - 21,127
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
500
1.000
1.500
2.000
JIN #149 14030604 RF UV_VIS_1
mAU
min
1 - 20,623
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
250
500
750
1.000
JIN #150 14030605 RF UV_VIS_1
mAU
min
1 - 26,273
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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 Compound 155, Sequence: Spacer-GEYFVN*VTTR. 
 
Compound 156, Sequence: Spacer-AYSWN*ISR. 
 
Compound 157, Sequence: Spacer-N*LTALPPDLPK. 
 
Compound 158, Sequence: Spacer-LQN*LTLPTNASIK. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
250
500
900
JIN #151 14030606 RF UV_VIS_1
mAU
min
1 - 27,087
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-500
1.000
2.500
JIN #152 14030607 RF UV_VIS_1
mAU
min
1 - 26,990
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
200
400
700
JIN #153 14030608 RF UV_VIS_1
mAU
min
1 - 28,873
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
200
400
700
JIN #154 14030609 RF UV_VIS_1
mAU
min
1 - 30,260
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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Compound 159, Sequence: Spacer-SN*YSSPSNISK. 
 
Compound 160, Sequence: Spacer-ELISN*ASDALDK. 
 
Compound 161, Sequence: Spacer-LLDLSGNN*LTHLPK. 
 
Compound 162, Sequence: Spacer-LQNLTLPTN*ASIK. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
500
1.000
1.400
JIN #155 14030610 RF UV_VIS_1
mAU
min
1 - 17,540
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
200
400
600
JIN #156 14030611 RF UV_VIS_1
mAU
min
1 - 26,573
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
250
500
800
JIN #157 14030612 RF UV_VIS_1
mAU
min
1 - 33,323
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
250
500
800
JIN #158 14030613 RF UV_VIS_1
mAU
min
1 - 30,567
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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 Compound 163, Sequence: Spacer-SNYSSPSN*ISK. 
 
  
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
500
1.000
1.600
JIN #159 14030614 RF UV_VIS_1
mAU
min
1 - 17,063
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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9.2 HPLC Chromatogram O-glycosylated peptides 
Compound 171, Sequence: NH2-Spacer-GT*G-NH2, *=Gla-GlcNAc-Man. 
 
Compound 172, Sequence: NH2-Spacer-GT*G-NH2, *=GlcNAc-Man. 
 
Compound 173, Sequence: NH2-Spacer-GTG-NH2. 
 
  
0,1 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 57,2
-24
0
50
101
VC_ANA #12 JIN GTG UV_VIS_1
mAU
min
1 - 8,197
WVL:214 nm
Flow: 200 µl/min
%B: 5,1 %
50,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0
-100
125
250
375
500
JIN #46 GTGK39Spacer UV_VIS_1
mAU
min
1 - 8,167
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
35,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0
-150
0
125
250
350
JIN #47 GTGSpacer UV_VIS_1
mAU
min
1 - 7,070
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
35,0
90,0
5,0
%C: 0,0 %
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 Compound 174, Sequence: Linker-NH-Spacer-GT*G-NH2, *=Gla-GlcNAc-Man. 
 
Compound 175, UV channel 280 nm. 
 
Compound 180, Sequence: AcNH-GT*T*G-Spacer-NH2, *=GlcNAc-Man. 
 
Compound 181, Sequence: AcNH-GT*T*G-Spacer-NH2, *=2,6 GlcNAc-Man. 
 
0,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 84,0
-6,2
10,0
20,0
30,0
39,9
JIN #18 YU120213-1 recover UV_VIS_1
mAU
min
1 - 17,517
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
75,0
90,0
5,0
%C: 0,0 %
0,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 84,0
-20
50
100
160
JIN #18 YU120213-1 recover UV_VIS_3
mAU
min
1 - 17,517
WVL:280 nm
Flow: 200 µl/min
%B: 5,0 %
75,0
90,0
5,0
%C: 0,0 %
0,1 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 48,1
-4,4
0,0
5,0
9,2
JIN #180 130531-5 UV_VIS_3
mAU
min
1 - 8,967
WVL:280 nm
Flow: 200 µl/min
%B: 5,1 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-11,9
20,0
40,0
60,0
83,9
JIN #144 14040601 RF UV_VIS_1
mAU
min
1 - 9,070
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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Compound 182, Sequence: AcNH-T*G-Spacer-NH2, *=2,6 GlcNAc-Man. 
 
Compound 183, Sequence: AcNH-GTTG-Spacer-NH2. 
 
Compound 184, Sequence: AcNH-GT*T*G-Spacer-NH-Linker, *=GlcNAc-Man. 
 
Compound 185, Sequence: AcNH-GT*T*G-Spacer-NH-Linker, *=2,6 GlcNAc-Man. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-6,4
12,5
25,0
37,5
49,4
JIN #145 14040602 RF UV_VIS_1
mAU
min
1 - 10,433
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-23
50
100
150
217
JIN #146 13110603 RF UV_VIS_1
mAU
min
1 - 12,203
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 10,0 20,0 30,0 40,0 50,0 60,0 70,0 84,0
-100
0
100
200
345
JIN #13 YuPep130531 coupling to linker 1 UV_VIS_3
mAU
min
1 - 19,743
WVL:205 nm
Flow: 200 µl/min
%B: 5,0 %
75,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-26
50
100
183
JIN #181 14040601Linker RF UV_VIS_1
mAU
min
1 - 17,927
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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 Compound 185, UV channel 280 nm. 
 
Compound 190, Sequence: NH2-Spacer-PVPGKPT*VTIR, *=Gla-GlcNAc-Man. 
 
Compound 191, Sequence: NH2-Spacer-RGAIIQT*PTLG, *=Gla-GlcNAc-Man. 
 
Compound 192, Sequence: NH2-Spacer-PVPGKPT*VTIR, *= GlcNAc-Man. 
 
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-100
200
400
600
800
JIN #181 14040601Linker RF UV_VIS_3
mAU
min
1 - 17,930
WVL:280 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0
-200
500
1.200
JIN #48 12112401 UV_VIS_1
mAU
min
1 - 21,007
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
35,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 57,0
-100
200
400
600
VC_ANA #11 JIN 12122701 UV_VIS_1
mAU
min
1 - 23,840
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
50,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
250
500
800
JIN #139 13040901 RF UV_VIS_1
mAU
min
1 - 22,247
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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Compound 193, Sequence: NH2-Spacer-RGAIIQT*PTLG, *=GlcNAc-Man. 
 
Compound 194, Sequence: NH2-Spacer-PVPGKPT*VTIR, *=2,6 GlcNAc-Man. 
 
Compound 195, Sequence: NH2-Spacer-RGAIIQT*PTLG, *=2,6 GlcNAc-Man. 
  
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
200
400
600
JIN #140 13040902 RF UV_VIS_1
mAU
min
1 - 25,350
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
0
200
400
700
JIN #143 13051101 UV_VIS_1
mAU
min
1 - 23,287
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
0,0 5,0 10,0 15,0 20,0 25,0 30,0 35,0 40,0 45,0 50,0 54,1
-200
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1.000
JIN #142 13051102 RF UV_VIS_1
mAU
min
1 - 22,087
WVL:214 nm
Flow: 200 µl/min
%B: 5,0 %
45,0
90,0
5,0
%C: 0,0 %
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 9.3 HPLC Chromatogram Monosaccharide Analysis (determination 
glycopeptide loading on KLH) 
Chromatogram for calibration curve, integration of combined galactose/mannose peak after 
AA derivatization, R stands for reagent (Anthranilic acid, AA): 
HPLC of dilution series of 1:1 Gal:Man mixture for calibration 
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APPENDIX 2: HPLC CHROMATOGRAMS 
 
Chromatogram after hydrolysis of glycopeptide-KLH conjugate 178 and monosaccharide AA 
derivatization, R stands for reagent (Anthranilic acid, AA):  
HPLC of labeled glycans cleaved from KLH conjugate 
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10 Appendix 3: MS spectra 
10.1 MS2 fragmentation of enzymatically extended N-glycopeptides 
MS2 fragmentation of the pentasaccharide core glycopeptide 164. 
 
MS2 fragmentation of the pentasaccharide core glycopeptide 165. 
 
 
  
NMFT3484 #15-519 RT: 0,23-2,98 AV: 84 NL: 3,34E5
T: ITMS + c NSI d Full ms2 871,40@cid35,00  [225,00-2000,00]
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NMFT3473 #18-570 RT: 0,30-2,99 AV: 90 NL: 8,48E6
T: ITMS + c NSI d Full ms2 821,72@cid35,00  [215,00-2000,00]
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MS2 fragmentation of the pentasaccharide core glycopeptide 166. 
 
MS2 fragmentation of the pentasaccharide core glycopeptide 167. 
 
 
NMFT3474 #22-580 RT: 0,32-3,00 AV: 93 NL: 4,69E6
T: ITMS + c NSI d Full ms2 725,00@cid35,00 [185,00-2000,00]
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NMFT3475 #11-449 RT: 0,25-2,98 AV: 71 NL: 3,51E4
T: ITMS + c NSI d Full ms2 759,05@cid35,00  [195,00-2000,00]
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 MS2 fragmentation of the pentasaccharide core glycopeptide 168. 
 
MS2 fragmentation of the heptasaccharide N-glycopeptide 169. 
 
 
NMFT3476 #15-429 RT: 0,30-3,00 AV: 70 NL: 2,84E4
T: ITMS + c NSI d Full ms2 837,09@cid35,00  [220,00-2000,00]
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T: ITMS + c NSI d Full ms2 1006,77@cid35,00  [265,00-2000,00]
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MS2 fragmentation of the heptasaccharide N-glycopeptide 170. 
 
 
  
NMFT3478 #19-565 RT: 0,30-3,00 AV: 92 NL: 7,07E3
T: ITMS + c NSI d Full ms2 894,43@cid35,00  [235,00-2000,00]
400 600 800 1000 1200 1400 1600
m/z
0
10
20
30
40
50
60
70
80
90
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
667,4187
793,1855
423,2460
1239,3321537,2724
876,5932
1431,54371158,3162951,5129
 
 
2+ 
 
  
 
 
 
2+ 
 
 
 
 
 
2+ 
 
 
2+ 
 
 
 
3+ 
 
 
 
m/z 894,43 
3+ 
 
  
  
322 
 
APPENDIX 3: MS SPECTRA 
 10.2 CID-MSn and HCD measurements of N- and O- mannosyl glycopeptides 
 
Figure 27. LC-MS/MS of the synthetic N-glycopeptide 165. A) Precursor MS1 scan of 165 showing in source 
fragmentation. B) Full HCD spectrum of 165. C) The oxonium ion m/z region of the HCD spectrum for the 
GlcNAc-N- substituted peptide. 
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Figure 28. LC-MS/MS of the synthetic N-glycopeptide 166. A) Precursor MS1 scan of 166 showing in source 
fragmentation. B) Full HCD spectrum of 166 and C) the oxonium ions of the m/z 50-220 region. D) The 
oxonium ion m/z region of the HCD spectrum for the GlcNAc-N- substituted peptide generated via the in 
source fragmentation. 
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Figure 29. CID-MSn and HCD of Gal4GlcNAc terminated glycopeptides 190. A) The CID-MS2 spectrum of 
the Gal4GlcNAc2Man1-O- substituted peptide showed glycosidic fragmentation and formation of 
[Gal4GlcNAc]+ (m/z 366.1). B) CID-MS3 at m/z 366. C) Further CID-MS4 at m/z 168 to demonstrate the 
selective formation of the m/z 138 ion. D) The HCD spectrum at the 25% NCE level and the m/z 100-220 
region. The peptide sequence is PVPGKPT*VTIR. Yellow circle is Gal (162 amu); green circle is Man (162 
amu); blue square is GlcNAc (203 amu). 
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Figure 30. CID-MSn and HCD of GlcNAc terminated glycopeptides 192. A) The CID-MS2 spectrum of the 
GlcNAc2Man1-O- substituted peptide showed glycosidic fragmentation and formation of [GlcNAc]+ 
(m/z 204.1). B) CID-MS3 at m/z 204. C) The HCD spectrum at the 25% NCE level and the m/z 100-220 
region. The peptide sequence is PVPGKPT*VTIR. Green circle is Man (162 amu); blue square is GlcNAc (203 
amu). 
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 10.3 MALDI measurements of glycopeptide-protein conjugates 
MALDI spectrum of BSA-conjugate 186 
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MALDI spectrum of CRM-conjugate 187 
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 MALDI spectrum of BSA-conjugate 188 (top) compared with pure BSA (bottom) 
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MALDI spectrum of CRM-conjugate 189 (top) compared with pure CRM (bottom) 
 
 
 
  
 
ZUSAMMENFASSUNG 
Diese Dissertation beinhaltet die Synthese von Glykanen sowie glykosylierten Aminosäuren zu 
Herstellung verschiedener Glykopeptide. Anhand dieser wurden Interaktionen zwischen Proteinen und 
N- und O-Glykosylierung untersucht, sowie Tools zur Strukturanalyse entwickelt. Der Fokus lag dabei auf 
verschiedenen N-Glykanstrukturen sowie O-Mannosylierung. Diese Strukturen weisen eine strukturelle 
Ähnlichkeit auf. Komplexe N-Glykane und die verlängerten O-Mannosylierten Aminosäuren weisen 
gleiche terminale Struktureinheiten auf und wurden daher ausgehend von gemeinsamen Bausteinen 
hergestellt. Darüber hinaus ähnelt die mannosereiche N-Glykosylierung, der üblicherweise in Hefe 
vorkommenden  O-Mannosylierung. Dagegen ähnelt die komplexe N-Glykosylierung der verlängerten O-
Mannosylierung, welche Proteine in eukaryotischem Gehirngewebe modifiziert.  
Zur Erstellung der N-Glykan-Oligosaccharide, welche einen gemeinsamen asparagingebundenen 
Pentassacharidkern aufweisen, wurde zunächst eine Manβ1-4GlcNAc Disaccharid Kerneinheit 26 
synthetisiert. Verschiedene Untereinheiten 76, 58, 103 und 55 wurden symmetrisch und schrittweise  an 
den Mannosekern gekuppelt. Vier komplexe N-Glykanstrukturen 89, 96, 100  und 108 wurden 
synthetisiert. Zwei davon wurden zu den Oxazolin-Donatoren 110 und 112 umgesetzt und in 
enzymatischen Endoglycosidse-Kupplungen mit einer synthetischen N-GlcNAc-Peptidbibliothek 
verwendet. 
Die enzymatischen Endoglycosidasekupplungen des Tetrasaccharidoxazolins 110 an verschiedene N-
GlcNAc-Peptide waren erfolgreich und alle Kupplungen in Lösung waren innerhalb von 0,5 h bei voller 
Umsetzung abgeschlossen. Dies wurde mittels HPLC und hochauflösendem ESI-MS verifiziert. Zur 
effizienten Erstellung einer N-Glykopeptidblibliothek mit homogener komplexer Glykosylierung wurden - 
anstelle von sequenziellen  enzymatischen Kupplungen in Lösung – verschiedene N-GlcNAc-Peptide 
mittels on-slide enzymatischer Glykosylierung verlängert. Im Prinzip wurden N-GlcNAc-Peptide auf einen 
Microarrayslide gespottet und immobilisiert, gefolgt von einer enzymatischen einschritt-on-slide-N-
Glykanverlängerung durch Nutzung von synthetischen Oxazolindonorbausteinen. Durch Vergleich der 
on-slide-Reaktionen mit vorsynthetisierten internen Peptidstandards wurde geschlussfolgert, dass die 
on-slide Kupplungen mit Endoglycosidase innerhalb einer Stunde abgeschlossen waren. Darüber hinaus 
wiesen die Ergebnisse darauf hin, dass die Position des N-GlcNAc-Asn-Restes im Peptidrückgrat keinen 
großen Einfluss auf die on-slide-Kupplung  hat, obwohl die N-GlcNAc-Peptide durch einen N-terminalen 
Spacer an den Microarryslide gekoppelt waren. Zusammenfassend nachweisen die Experimente, dass es 
möglich ist eine N-Glykopeptidbibliothek mit komplexer Glykosylierung effizient auf einem 
Microarrayslide zu erzeugen. Die erhaltene Hepta- und Pentasaccharid-N-Glykopeptidbibliothek wurde 
im Rahmen dieser Arbeit in ersten Microarraystudien verwendet, um die Bindungsinteraktionen mit 
dem Lektin Concanavalin A (ConA) zu untersuchen. Zudem wurden ausgewählte Peptide zur ESI-MS-
Fragmentierung verwendet, um die Methoden zur Strukturaufklärung von N-Glycopeptiden zu 
verbessern.  
 
Einige der Bausteine aus der N-Glykansynthese wurden auch in der Synthese von O-mannosylierten 
Aminosäuren verwendet um die Bausteine 120, 124 und 135 herzustellen. Proteine, welche an Ser- und 
Thr-Seitenketten O-mannosyliert sind, sind an wichtigen Funktionen in der Gehirn- und 
Muskelglykobiologie beteiligt. Trotz der klaren Bedeutung der O-Mannosylierung, existieren bislang 
keine Werkzeuge zur spezifischen Detektion, Anreicherung und Identifizierung von Proteinen, welche 
die Modifikation tragen. Um diese Prozesse zu studieren, wurde ein Projekt initiiert, um glykan- und 
glykopeptidspezifische Antikörper, welche nützliche Werkzeuge zur Detektion und Anreicherung von O-
mannosylierten Proteinen darstellen könnten, zu generieren.  
Vakzinkonstrukte wurden ausgehend von Glykopeptiden, welche diese verlängerten Mannoseeinheiten 
enthielten, hergestellt.  Diese stellen eine Voraussetzung für die Studien an O-Mannosylierung dar. Die 
Fmoc-O-mannosylierten Aminosäuren 120, 124 und 135 wurden hergestellt und zur 
Glykopeptidsynthese genutzt, um 171, 180 und 181 mit angekuppelten Spacern zu erhalten. Diese 
Glykopeptide wurden dann in Glykopeptid-Immuncarrier zur Antikörperinduktion in Kaninchen 
eingebaut. Zur Bewertung der Antikörper wurden zusätzliche Glykopeptide generiert und in ELISA-
Neutralisationsexperimenten sowie in Glykopeptidmicroarrays verwendet. Weiter wurde die erhaltene 
O-Mannosylglykopeptidbibliothek verwendet, um Interaktionen mit glykanbindenden Lektinen zu 
untersuchen. Diese Lektine wurden hinsichtlich ihres Potentials als analytische Tools für die Detektion 
und Anreicherung spezifischer O-Mannosylglykoproteine oder -glykopeptide bewertet.  
 
Das Antigenpeptid 171 mit einem Gal-GlcNAc-Man Trisaccharid wurde mit monovalenter Glykosylierung 
am Peptid und N-terminalem Spacer zur Proteinkonjugation synthetisiert. Das an den KLH-Immuncarrier 
Glycan structure      /     Antigen peptides 
135 
120 
124 
171 
180 
181 
konjugierte Gal-GlcNAc-Man Antigenpeptid 171 wurde Kaninchen verabreicht. Das erhaltene 
Antikörperserum wurde mittels normalem ELISA, ELISA-Neutralisationsexperimenten sowie 
Glykopeptid-Microarrayanalyse analysiert. Es wurde ein starker Antikörpertiter, welcher das 
Antigenpeptid 171 erkannte detektiert. Die Microarrayanalyse zeigte, dass Peptid 171, welches das 
kürzere, auf demselben Peptidrückgrat wie das Antigen präsentierte, GlcNAc-Man enthielt, zu einem 
gewissen Grad von den Antikörpern erkannt wurde. Des Weiteren war die Antikörperspezifität zur 
Antigenstruktur extrem hoch, sodass wenn die O-Mannosylglykane an andere Peptidsequenzen wie 
Glykopeptid 190 und 191 präsentiert wurden, die Antikörpererkennung vollständig oder teilweise 
verloren war.  
Um die Spezifität der induzierten Antikörper zur Glykanstruktur zu erhöhen und die Erkennung der 
darunterliegenden Peptidsequenz zu reduzieren wurde ein zweites Antigenpeptid 180 mit dem GlcNAc-
Man-Disaccharid hergestellt, welches divalent am Peptidrückgrat glykosyliert war. Der N-Terminus 
wurde mit einer Acetylkappe und der C-Terminus mit einem Spacer zur Proteinkonjugation versehen. 
Nach der Immunisierung wurde das erhaltene Antikörperserum erneut mittels ELISA und 
Glykopeptidmikroarryexperimenten analysiert. Die Antigenglycopeptid-gerichtete Immunantwort war 
sehr stark. Die erhaltenen Antikörper erkannten zudem andere Glykopeptidsequenzen, welche die 
gleiche GlcNAc-Man-Thr-O-Glykosylierung aufwiesen, wie Peptid 192, 193 und 172. Cluster-
Glykanpräsentation am Peptidrückgrat begünstigte die Antikörpererkennung dramatisch. 
Zusammenfassend wurden Antikörper mit sehr hoher Spezifität gegenüber der O-
Mannosylglykanstruktur sowie der darunterliegenden Peptidsequenz erhalten. Präsentation mit höherer 
Glykandichte am Peptidrückgrat würde die Antikörperspezifität gegenüber der Glykanstruktur erhöhen. 
Die O-Mannosylglykopeptidbibliothek wurde zudem verwendet, um Interaktionen mit bestimmten 
Lektinen zu untersuchen. Eine Analyse des glykanbindenden Lektins Concanavalin A (ConA), welches 
bekanntlich α-Mannosereste erkennt zeigte, dass einzigartige strukturelle Glykan- und 
Glykopeptidbindungsepitope erkannt wurden. Während monoglykosylierte Peptide, welche die simplere 
GlcNAc-Man-Disaccharidstruktur enthielten, stark erkannt wurden, war die Reaktivität gegenüber der 
2,6-verzweigten GlcNAc2-Man-Thr- oder der linearen Gal-GlcNAc-Man-Thr-Struktur eher schwach. Die 
Präsentation von geclusterten Glykanen ergab keine Erkennung von ConA. Diese Ergebnisse werden 
einen Impact auf die Strukturanalyse von O-Mannosylglykoproteinen haben. Zusätzlich wurden ESI-MS-
Fragmentierungsexperimente an ausgewählten O-Mannosylpeptiden durchgeführt, um die Methodik für 
die O-Glykopeptid-Strukturanalyse zu verbessern. 
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